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Background material                                                                                          Abstract 
Anu Jalanko, Marjo Kestilä, Ismo Ulmanen, Matti Jauhiainen, Vesa Olkkonen, Janna Saarela, 
Juha Saharinen, Jussi Taipale, Markus Perola, Pekka Ellonen, Matti Lukka, Leena Peltonen  
National Public Health Institute 
Department of Molecular Medicine 
Background Material for the International Evaluation 
 
Abstract 
 
This review includes the material for the evaluation of the work of the National Public Health 
Institute (KTL, www.ktl.fi), the Department of Molecular Medicine (MLO, 
www.ktl.fi/portal/404) in 1997-2007. The main purpose of the evaluation is to guide the 
Ministry of Social Affairs and Health for the strategic management of KTL. A panel has been 
nominated to implement the evaluation. The panel members are Professor Albert Hofman 
(Erasmus MC, Rotterdam, The Netherlands), Professor Alan Wright (MRC, Edinburgh, UK), 
Professor Mart Saarma (University of Helsinki, Helsinki, Finland) and Chancellor Eero Vuorio 
(University of Turku, Turku, Finland). The evaluation panel will scrutinize the functions, 
strategic importance, scientific merits and the value for money of the scientific and expert work 
undertaken, and make proposals for future. In addition, a special attention is paid to the 
relevance and effectiveness of the work and of its impact on the health of Finnish people.  
 
The goals of MLO are characterization of the molecular background of human diseases and 
producing of new data on the relationship between the genetic and life style risk factors that 
result in the health problems of Finns. Our internationally recognized research programs are 
focused towards the characterization of the molecular background of the Finnish disease 
heritage, cardiovascular diseases and neuropsychiatric diseases. Research data and expertise is 
provided for the national and international scientific community, for health care officials, for 
decision makers and for the general public. In addition, MLO produces novel knowledge of 
wide-scale genomic and biocomputational analyses for other investigators and research groups. 
 
In 2006, MLO had personnel of 142 employees, out of which 43 with governmental funding and 
99 with competitive external funding. The operating costs from the government budget has been 
1.6–2.7 million Euros in 1997-2007. In 1997-2007 the competitive external funding has varied 
between 0.6–2.7 million Euros per year (25-56% of the total funding), being on an average 1.6 
million Euros per year (44% of the total funding) during this same period. Within this decade 
MLO has produced 623 international peer reviewed articles, 65 international review articles and 
17 articles in Finnish journals. In addition, 21 international and 10 domestic book chapters have 
been produced. Total of 61 Ph.D. theses have been compeleted during this period. 
 
MLO has three research programs: 1) Genetic epidemiology, 2) Molecular biology of 
cardiovascular diseases and 3) Finnish disease heritage. The department also houses three core 
facilities or technology platforms that serve the wider research community: Bioinformatics core, 
Biotechnology core and Large Scale DNA Extraction and Storage Facility/National Biobank of 
Finland. Additionally, the Paternity Testing Laboratory has performed a legally determined 
function by offering the nationwide DNA-based paternity testing on a full cost-benefit basis.  
 
Since June 1st 2007 the research programs and core facilities of MLO were strategically joined 
as a part of the Institute for Molecular Medicine Finland (FIMM). The Paternity Testing 
Laboratory was integrated into the Department of Research and Expertise Support Services 
(TASO). 
 
Key words: molecular medicine, molecular genetics, Finnish disease heritage, coronary heart 
diseases, neuropsychiatric diseases, cellular biochemistry, bioinformatics, chip technologies, 
sequencing, paternity testing 
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Anu Jalanko, Marjo Kestilä, Ismo Ulmanen, Matti Jauhiainen, Vesa Olkkonen, Janna Saarela, 
Juha Saharinen, Jussi Taipale, Markus Perola, Pekka Ellonen, Matti Lukka, Leena Peltonen  
Kansanterveyslaitos 
Molekyylilääketieteen osasto 
Kansainvälisen arvioinnin taustamateriaali 
 
Tiivistelmä 
 
Tämä yhteenveto sisältää kansainvälistä arviointia varten kootun materiaalin Kansanterveys-
laitoksen (KTL, www.ktl.fi) Molekyylilääketieteen osaston (MLO, www.ktl.fi/mlo) toiminnasta 
vuosina 1997-2007. Sosiaali- ja terveysministeriö odottaa saavansa arvioinnista tukea Kansan-
terveyslaitoksen strategiseen ohjaukseen. Arvioinnin tekevät professori Albert Hofman 
(Erasmus MC, Rotterdam, Alankomaat), professori Alan Wright (MRC, Edinburgh, Iso-
Britannia), professori Mart Saarma (Helsingin yliopisto, Helsinki) ja kansleri Eero Vuorio 
(Turun yliopisto, Turku). Arviointipaneelin tehtävänä on tarkastella osaston toimintaa, 
strategista tärkeyttä, tieteellisiä saavutuksia, tieteellisen työn ja asiantuntijatyön 
kustannusvastaavuutta sekä tehdä ehdotuksia tulevaisuutta varten. Lisäksi kiinnitetään erityistä 
huomiota työn kohdentamiseen ja tehokkuuteen sekä sen vaikutukseen suomalaisten terveyteen.  
 
MLO:n tavoitteena on selvittää kansantautien geneettistä taustaa ja tautien molekyylipato-
geneesiä sekä tuottaa uutta tietoa, johon pohjaavat tulevaisuuden kansantautien diagnostiikka ja 
interventiostrategiat. Osaston tutkimus hyödyntää suomalaisväestön erityispiirteitä ja laitoksen 
keräämiä kansallisia erityisaineistoja. Osaston tieteellinen tutkimustoiminta liittyy KTL:n 
strategiassa määritetyille painoalueille, jollaisia ovat sydän- ja verisuonitaudit, metabolinen 
oireyhtymä, neuropsykiatriset sairaudet sekä suomalaisen tautiperimän sairaudet. Tutkimus- ja 
asiantuntijatietoa tuotetaan kansalliselle ja kansainväliselle tiedeyhteisölle, terveydenhuollon 
toimijoille ja päättäjille sekä suurelle yleisölle. Lisäksi MLO tarjoaa genomitietoon perustuvaa 
analytiikkaa sekä biolaskentaa muille tutkijoille ja tutkimusryhmille. 
 
Vuonna 2006 MLO:lla työskenteli 142 henkilöä, joista 43 valtion budjettirahoituksella ja 99 
kilpaillulla ulkopuolisella rahoituksella. Osaston vuosittainen budjettirahoitus on ollut 1.6–2.7 
miljoonaa euroa vuosina 1997-2007. Vastaavana aikana vuosittainen kilpaillun ulkopuolisen 
rahoituksen määrä on vaihdellut 0.6 miljoonasta 2.7 miljoonaan euroon (25-56% kokonais-
rahoituksesta) ollen keskimäärin 1.6 miljoonaa euroa vuodessa (44% kokonaisrahoituksesta). 
Kuluneen vuosikymmenen aikana MLO on tuottanut 623 kansainvälisen tieteellisen arviointi-
käytännön läpäissyttä artikkelia, 65 kansainvälistä katsausartikkelia sekä 17 kotimaista julkaisua. 
Lisäksi on tuotettu 21 ulkomaista ja 10 kotimaista kirjan kappaletta. Samana ajanjaksona 
MLO:ssa tehdyn työn tuloksena on valmistunut 61 väitöskirjaa. 
 
MLO:lla toimii kolme tutkimusyksikköä, jotka ovat 1) Sydän- ja verisuonitautien molekyyli-
biologia, 2) Geneettinen epidemiologia, 3) Suomalainen tautiperintö sekä kolme tutkimuksen 
tukiyksikköä: Biologisten näytteiden logistiikkayksikkö/Kansallinen biopankki, Bioteknologia-
yksikkö ja Genomi-informaatioyksikkö (yhteinen Suomen Genomikeskuksen kanssa). Lisäksi 
Isyystutkimuslaboratorio on suorittanut palvelutoimintana lakisääteisiä DNA-tutkimukseen 
perustuvia isyystutkimuksia.  
 
1.6.2007 alkaen MLO:n tutkimus- ja teknologiset osaamisyksiköt liittyivät osaksi Suomen 
molekyylilääketieteen instituuttia (FIMM) ja Isyystutkimuslaboratorio siirtyi Tutkimus- ja 
asian-tuntijatyön tukiosastoon (TASO).  
 
Avainsanat: molekyylilääketiede, molekyyligenetiikka, suomalainen tautiperintö, sydän- ja 
verisuoni-taudit, neuropsykiatriset taudit, biokemia, solubiologia, bioinformatiikka, 
geenisiruanalyysit, sekvenointi, isyystutkimus 
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Anu Jalanko, Marjo Kestilä, Ismo Ulmanen, Matti Jauhiainen, Vesa Olkkonen, Janna Saarela, 
Juha Saharinen, Jussi Taipale, Markus Perola, Pekka Ellonen, Matti Lukka, Leena Peltonen  
Folkhälsoinstitutet 
Avdelningen för molekylärmedicin 
Bakgrundsmaterial för internationell utvärdering 
   
Sammandrag 
 
Detta sammandrag innehåller materialet som är samlat för den internationella utvärderingen av 
verksamheten på Folkhälsoinstitutets (KTL, www.ktl.fi) avdelning för molekylärmedicin (MLO, 
www.ktl.fi/portal/3480) under åren 1997-2007. Utvärderingens syfte är att fungera som en 
vägledare för Social- och hälsoministeriet och planeringen av den strategiska förvaltningen av 
KTL. Följande personer har utnämnts till panelmedlemmar: professor Albert Hofman (Erasmus 
MC, Rotterdam, Nederländerna), professor Alan Wright (MRC, Edinburgh, Storbritannien), 
professor Mart Saarma (Helsingfors universitet, Helsingfors, Finland) och kansler Eero Vuorio 
(Turun yliopisto, Åbo, Finland). Utvärderingspanelens uppgift är att granska avdelningens 
verksamhet, strategiska relevans, veteskapliga meriter och kostnadsmotsvarighet för 
vetenskapligt och specialistarbete, samt framställa förslag för framtiden. Speciell tonvikt läggs 
på arbetets inriktning och effektivitet samt dess påverkan på finländarnas hälsa. 
 
MLO strävar efter att klarlägga folksjukdomars genetiska bakgrund, samt att producera ny 
information som diagnostiken och interventionsstrategierna för framtidens folksjukdomar 
baserar sig på. Avdelningens forskning utnyttjar den finländska befolkningens särdrag och de 
nationella specialmaterial institutet inhämtat. Avdelningens vetenskapliga forskningsverksamhet 
hör till de prioriterade områden som definieras i KTL:s strategi, såsom  hjärt- och kärlsjukdomar, 
metaboliska syndrom, neuropsykiatriska sjukdomar samt finländska ärftliga sjukdomar. 
Forskningsmaterial och expertis produceras för att användas inom nationell och internationell 
forskning, inom hälsovården, samt av beslutsfattare och allmänheten. Dessutom erbjuder MLO 
genombaserad analytik och bioberäkning för andra forskare och forskningsgrupper. 
 
År 2006 sysselsatte MLO 142 personer varav 43 med statens budjetfinansiering och 99 med 
utomstående finansiering. Avdelningens årliga budjetmedel har under åren 1997-2007 varierat 
mellan 1.6–2.7 miljoner euro, och den konkurenssatta utomstående finansieringens årliga 
belopp har varierat mellan 0.6-2.7 miljoner euro (25–56% av totalfinansieringen), vilket utgör i 
medeltal 1.6 miljoner euro per år (44% av totalfinansieringen). Under de senaste tio åren har 
MLO producerat 623 internationella artiklar med peer review, 65 internationella 
översiktsartiklar, samt 17 inhemska publikationer. Därtill har 21 utländska och 10 inhemska 
bokkapitel publicerats. Sammanlagt 61 doktorsavhandlingar har producerats under denna period. 
 
MLO har tre forskningsenheter, 1) Enheten för hjärt- och kärlsjukdomarnas molekylärbiologi, 2) 
Enheten för genetisk epidemiologi och 3) Enheten för det finländska sjukdomsarvet, samt tre 
enheter som stöder forskningsarbetet: Logistikenheten för biologiska prov/Nationell biobank, 
Enheten för bioteknologi och Enheten för genominformation (gemensamt med Finlands 
Genomcenter). Dessutom Laboratoriet för faderskapsundersökningar har utfört faderskaps-
undersökningar som en avgiftsbelagd service. 
 
Från och med 1.6.2007 anslöts MLO:s forsknings- och teknologienheter till Institutet för 
molekylärmedicin i Finland och Laboratoriet för faderskapsundersökningar till Service-
avdelningen för forsknings och specialistarbete. 
 
Ämnesord: molekylärmedicin, molekylärgenetik, finländska sjukdomsarvet, hjärt- och kärl-
sjukdomar, biokemi, neuropsykiatriska sjukdomar, bioinformatik, array teknologi, 
faderskapsunder-sökningar 
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PREAMBLE  
In the early 1990s the Science and Technology Policy Council in Finland encouraged 
the Ministries to evaluate research institutions in their jurisdiction. In accordance to this 
policy, the Medical Research Council of the Academy of Finland carried out an 
evaluation of the research activities of KTL in 1994–1995, in response to a proposal put 
forward by the Finnish National Public Health Institute (KTL) and the Ministry of 
Social Affairs and Health (STM). The objective of this evaluation was to provide 
information on the public health functions, strategic importance, scientific merit and 
value for money of the scientific work undertaken and to make proposals for future 
work.  
 
The international Evaluation Panel, chaired by Dr. David Evered of the UK Medical 
Research Council, prepared an evaluation Report to the Academy in October 1995. For 
the evaluation, KTL prepared a report describing the work in the Institute. The 
Evaluation Panel worked via internal meetings, discussions with important stakeholders 
of KTL, and through site visits to the three divisions of KTL. On the basis of their 
evaluation, the Panel made 35 major recommendations for further development of the 
organization, management and work of the Institute. Overall, the evaluation of the 
Department of Molecular Genetics and related operations of KTL were extremely 
favorable. The Panel made also some suggestions concerning the organization of the 
Departments and setting distinct priorities for the research so that they would be 
harmonized with the mission of KTL.  
 
Over the past 10 years, most of the recommendations made by the Panel have been 
implemented: the organization of KTL has been changed, several areas of research and 
public health work have been directed towards new priorities, and more emphasis has 
been put on the public health impact of the work of KTL. In addition, a renewed 
strategy was prepared for the Institute in 2001 during a thorough process involving the 
whole organization. At the end of 2003, a new Director General was appointed to KTL.  
 
Based on these developments, and on changes in the environment, time is ripe for a new 
evaluation of KTL. The purpose of such an evaluation would be to evaluate the 
effectiveness of the work and assess the scientific and societal impact of the Institute. 
 
 
KTL IN BRIEF  
 
Strategy and functions 
The mission of KTL is to protect and promote the health of the Finnish people. As a 
research and expert institute belonging to the Ministry of Social Affairs and Health, 
KTL is responsible for providing decision-makers, professionals and citizens with the 
best possible health-related information for their choices. A general strategy for the 
Institute was prepared in 2001, while detailed objectives for the work are agreed upon 
annually with the Ministry. 
 
The three main areas of work in KTL have traditionally been: 1) infectious diseases and 
immunizations, 2) chronic diseases and health promotion, and 3) environmental health. 
In all these areas, both research and public health functions are carried out. Activities of 
the Institute include basic research, ranging from the detailed analysis of the molecular 
Background material                         1 DEPARTMENT OF MOLECULAR MEDICINE 
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mechanisms of pathogenesis to large scale epidemiological and preventive studies and 
research into factors influencing health. 
 
KTL monitors public health, diseases and their determinants through surveys and 
registers. Research and expert information is transferred into action by developing 
health-promoting and preventive measures and by advising and collaborating with 
various stakeholders. National vaccine service, many centralized laboratory functions 
and forensic medicine investigations are some of KTL’s service functions. 
 
Several of KTL’s functions are based on laws, such as surveillance of infectious 
diseases and protection from communicable diseases by vaccinations. In the prevention 
of chronic diseases KTL works in close collaboration with various Non-Governmental 
Organizations. In promoting healthy environment and preventing diseases KTL 
collaborates with environmental authorities and municipalities. A strong presence in the 
media is a way to reach the people. The ultimate goal is to reduce the human suffering 
and economic cost caused by illness and to help people enhance their quality of life. 
 
Organization, personnel and budget 
KTL’s main facilities are located in Helsinki and three other facilities in Kuopio, Oulu 
and Turku. The Institute has 11 departments, each of which is built of various 
laboratories and units. Ultimate responsibility of leading and managing the whole 
Institute rests on the Director General of KTL. He is assisted by the Deputy Director 
General, the Administrative Director and the Steering Group, consisting of the Directors 
of Departments. The Director General is also advised by a Scientific Council of KTL, 
where representatives of most important stakeholders are present.  
 
At the end of 2006, KTL had a staff of 980 persons, of whom 450 were scientists or 
experts. Women make up 73% of the staff. In addition to the permanent or temporary 
staff, KTL is also a working place for non-paid students or scientists who pursue their 
studies and research together with the staff of KTL. Altogether, there were 158 Ph.D. 
students working at KTL in 2006. 
 
The total expenditure of KTL was 66 million euros in 2006, and the operating expenses 
were 54 million euros when the acquisition of vaccines is excluded. Most part (62%) of 
the operational funding comes from the national budget, 29% from external sources like 
the Academy of Finland, the European Union, US National Institutes of Health, or 
various Foundations supporting scientific research. The rest 8% of KTL’s budget is 
covered through income from chargeable services and from miscellaneous other funding. 
 
 
EVALUATION PROCESS 
 
Scope and purpose of evaluation  
The objective of the review is to provide an evaluation of the work of KTL for the 
Ministry of Social Affairs and Health. The evaluation should examine the functions, 
strategic importance, scientific merits and value for money of the scientific and expert 
work undertaken, and to make proposals for future work. A special emphasis will be 
placed on the evaluation of the relevance and effectiveness of the work and of its impact 
on the health of Finnish people. 
Background material                         1 DEPARTMENT OF MOLECULAR MEDICINE 
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The evaluation and the Evaluation Report should address the following main issues: 
 
a. National relevance and effectiveness of the activities 
b. Appropriateness and adequacy of the research, expert functions and services  
c. Output and quality of research activities 
d. National and international co-operation  
e. Resource allocation 
f. Research fund raising 
g. Development needs, especially regarding processes and organization 
  
The main purpose of the evaluation is to guide the Ministry of Social Affairs and Health 
so that they can use them for the strategic management of KTL. The practical 
implementation of the results, based on the decisions made at the Ministry, is the 
responsibility of the Director General of KTL.  
 
Entities to be evaluated 
The first round of detailed evaluations consists of four separate, partly parallel 
evaluations covering the main functional areas of KTL: 
 
a. Environmental health  
b. Chronic disease prevention and health promotion  
c. Infectious diseases  
d. Molecular medicine  
 
After the first round has been completed, the entire Institute will be evaluated. This 
evaluation will focus merely on the general strategy, function and management of the 
Institute, with less emphasis on the evaluation of individual research and expert 
functions. 
 
Information sources for the evaluation 
KTL will provide the Panels following information: 
Published documents concerning the whole Institute: 
 
a. Annual Report 2006 
b. Kansanterveyslaitoksen toimintakertomus ja tilinpäätöslaskelmat 2006 
(available only in Finnish) 
c. Evaluation of the National Public Health Institute of Finland. Report of 
the Evaluation Panel 1995 
 
A document prepared by the Director of each relevant Department involved in the 
evaluation, will be provided for the evaluation. These documents describe 1) a report on 
progress in research over period 1997-2007 and research plans for the period 2007-2011, 
2) the arrangement for governance and management, and 3) allocation of staff and 
resources, and 4) his/her plans for the future development of the Department. 
 
Each Department involved in the evaluation will also provide the Panel a self evaluation 
of 1) the appropriateness of its work to the national public health needs, 2) its role in the 
dissemination of research results and knowledge and technology transfer, 3) a 
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description of the interfaces between the Department and the key players in Finland and 
abroad. 
 
Evaluation of the Department of Molecular Medicine 
The evaluation process was initiated in the Department of the Molecular Medicine 
(MLO) in 2006 after discussions in KTL’s Steering Group and with the group leaders 
and core unit heads of the Department. The panel consists of two members, two from 
abroad and two from Finland. All the panelists are familiar to governmental health 
research, and the Finnish members will provide to the panel especially the knowledge of 
the national needs. Professor Albert Hofman from the University of Amsterdam, 
Netherlands, Professor Alan Wright from MRC center, Edinburgh, UK, Chancellor Eero 
Vuorio from the University of Turku, Finland and Professor Mart Saarma, Director 
from the Institute of Biotechnology, University of Helsinki, Finland were invited to 
conduct the evaluation.  
 
The next step of the evaluation is based on the review of the documents provided by the 
Department. During the site visit in September 2007, the panel members will have an 
opportunity to interview group leaders, investigators and the staff of MLO and discuss 
with representatives of key stakeholders and collaborators in relevant Ministries and 
University of Helsinki. Based on the review of the obtained documents, discussions, and 
site visit, the Panel will prepare a Report to the Ministry of Social Affairs and Health 
and to the Director General of KTL. 
 
 
1 DEPARTMENT OF MOLECULAR MEDICINE (MLO)  
 
1.1. Background 
The current department of Molecular Medicine is a result of a merge of two previous 
departments of KTL: Department of Human Molecular Genetics and Department of 
Biochemistry. This administrative reconstruction was based on the recommendation by 
the previous international evaluation and took place in 2001. 
 
Department of Human Molecular Genetics (founded in 1988, Director Professor 
Leena Peltonen) exploited the unique opportunities of the genetic isolation of Finland to 
analyse the genetic background of human disease. The main goal of the department was 
to characterize the molecular background of the diseases of Finnish disease heritage and 
via this effort to develop tools and analytical strategies for the identification of genetic 
and life style risk profiles in common multifactorial diseases, representing public health 
problems. Additionally, the department developed specific DNA test panels of disease 
mutations based on research findings for population based studies. The department 
served both researchers within the KTL and investigators nationwide as knowledge 
centre for human genetics-related molecular biology techniques. The main mission of 
the Department of Human Molecular Genetics was research and it had no public health 
responsibilities beyond being in charge for the DNA-based national paternity testing. 
Concerning the Evaluation of the National Public Health Institute of Finland, the Report 
of the Evaluation Panel 1995 concluded that the department had exploited effectively 
the Finnish disease heritage and in the field of common diseases had produced studies 
of the highest standard, especially in MS and bipolar disease. Specifically, the good 
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collaborations with the FINRISK study and the Department of Mental Health were 
attributed. The research in human genetics was considered of major potential 
significance for public health. The panel recommended that (i) there should be further 
investment in this group in view of the potential public health importance of research in 
human genetics, (ii) the KTL should consider developing mechanisms through further 
investment an collaboration to extend the range of studies on the structure and function 
of gene products, including the use of transgenic animals and (iii) these studies should 
be developed further through the development of screening and other programmes – 
particularly through collaborations with other groups in KTL which have the necessary 
skills in epidemiology and behavioural sciences. 
 
Department of Biochemistry (Director Professor Christian Ehnholm) concentrated on 
three major research topics: Lipoprotein metabolism, lipoprotein genetics and cell 
biology. The major focus was on lipoprotein metabolism and genetic factors influencing 
the risk of cardiovascular disease. The cell biology research was directed to the study of 
intracellular membrane traffic and microsomal triglyceride transfer. The department was 
specialized also in extensive biomarker analyses of lipid metabolism supporting 
research projects nationwide. Concerning the Report of the Evaluation panel 1995, the 
research on lipoprotein metabolism was considered of high quality and the lipoprotein 
genetics of good quality. The quality of the cell biology research was considered 
impressive. The panel recommended that (i) a strategic reappraisal of the role of the 
KTL in cardiovascular research should be undertaken covering particularly the 
departments Epidemiology and Health Promotion, Human Molecular Genetics, 
Nutrition and Biochemistry with possibly some reconfiguration of departmental 
boundaries to meet the needs of the strategy more effectively and enhance critical mass 
in the key areas (ii) the professional staff of the Department should be encouraged to 
develop their own high quality research programmes with an overall strategic 
framework; (iii) the cell biology group should be strengthened. 
 
Department of Molecular Medicine (MLO) was founded in 2001 by merging the 
Departments of Human Molecular Genetics and Biochemistry. The MLO moved to the 
new biomedical research building: Biomedicum Helsinki, located on the Meilahti 
medical campus, next to the University Hospital. The research activities of the MLO 
have been since organized into the major programmes that were identified as most 
relevant areas from the public health and scientific point of view.  
 
 
1.2. Objectives and organization 
Goals 
The Department of Molecular Medicine (MLO) is dedicated to use the unique Finnish 
study samples and population cohorts to characterize the molecular background of 
human diseases. This includes efforts to produce new data on the relationship between 
the genetic and life style risk factors that result in public health problems. The obtained 
genome-wide information is further utilized to develop intervention strategies and more 
biology-related classification for diseases, potentially valuable to develop diagnostics. 
Our research programs are especially focused in characterization of the molecular 
background of Finnish disease heritage, cardiovascular diseases and neuropsychiatric 
diseases. The Department provides expertise in a wide scale of genomic and 
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biocomputational analyses for the national and international scientific community, for 
national health care officials, for decision makers and for general public. 
 
Means 
To guarantee the top level of expertise in modern genetic and biological analyses, MLO 
has built an infrastructure that facilitates the collection of genome-wide information on 
the genetic background of diseases as well as functional information on the molecules 
that are critical in the disease process. Furthermore, we have established necessary 
database and computational resources for the expert analyses of the massive amount of 
collected biological information. Our scientific expertise, technology platforms and 
large nationwide sample collections facilitate a highly competitive environment for 
research and education in molecular medicine of the 21st century. 
 
Organization 
The directors of the department of Molecular Medicine have been Christian Ehnholm 
(2001-2002), Leena Peltonen (2002-2004) and Anu Jalanko (2004-). The department 
consists of three research programs, three research infrastructure core facilities and the 
Paternity Testing Laboratory (until 31.5.2007) which provides a legally determined 
nationwide service function. 
 
 
 
 
Figure 1. The organization of MLO in 2007.  
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1.3. Staff and resources  
The staff of the department represents the personnel of the two departments: Human 
Molecular Genetics and Biochemistry during the years 1997-2000. In the year 2001 as 
the MLO was founded, the resources were combined to be exploited by the new 
department, with the exception of the Laboratory of Analytical Biochemistry that was 
allocated to the Department of Health Promotion. In the year 2005 the Research Unit of 
Immunology was transferred to the department of Virology and Immunological 
Diseases (VIMO) and is not included in this report. 
 
The development of personnel of the MLO from 1997 to 2007 is presented in Table 1. 
The annual governmental budget has been varying between 1.6-2.7 million euros during 
the last ten years (Table 2.) and the external funding has increased from 0.6 million 
euros to a quite stable 2.6 million euros, e.g. 55% (year 2007) of the total funding 
including rents and equipments (Table 3.). Internal services (management help, animal 
facility support, media kitchen, library services) are not included in the sum.  
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Table 1. Development of personnel of the Department of Molecular Medicine* from 
1997 to 2007.  
 1997
 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Permanent 
 
Head of  
research group 
or laboratory 
6 7 6 5 5 6 8 8 9 10 10 
Senior  
researchers 
2 2 2 3 3 3 3 2 0 0 0 
Researchers 
 
2 2 2 2 2 2 2 2 2 2 2 
Administrative 
staff 
2 2 3 3 3 3 2 2 4 5 6 
IT personnel 0 
 
0 0 0 1 1 1 1 1 2 2 
Technical  
assistants 
16 16 16 16 19 19 21 21 23 24 24 
Together 
 
28 29 29 29 33 34 37 36 39 43 44 
External funded 
 
Head of  
research group 
or laboratory 
1 1 2 1 2 2 2 2 2 2 3 
Senior  
researchers 
1 1 1 2 4 4 7 9 10 11 9 
Postdoctoral 
researchers 
4 4 11 10 4 4 6 4 3 6 7 
Administrative 
staff 
0 0 0 0 0 0 0 0 1 2 2 
IT personnel 
 
1 1 1 1 1 2 2 2 7 7 6 
Students 
 
28 29 25 25 25 25 47 55 64 65 61 
Technical  
assistants 
2 2 2 2 3 4 4 5 4 6 7 
Together 
 
37 38 42 41 39 41 68 77 91 99 95 
 
TOTAL 
 
 
65 
 
67 
 
71 
 
70 
 
72 
 
75 
 
105 
 
113 
 
130 
 
142 
 
139 
* In 2001 two departments - Department of Biochemistry (BIOS) and the Department of Human 
Molecular Genetics (LMGO) - were merged and the Department of Molecular Medicine was 
established. 
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Table 2. Governmental budget (k€) of the Department of Molecular Medicine from 
1997 to 2007 (not corrected for inflation). 
 1997
 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Salaries of 
permanent 
personnel 
758 780 803 826 822 822 1083 1083 1083 1083 1083
Funding for 
running costs 
385 385 385 385 385 385 385 385 385 385 385 
Equipment 
and  
biobanking 
759 781 803 374 202 200 200 786 874 809 200 
Rent 
 
- - - - 384 384 384 384 384 384 384 
 
TOTAL 
 
 
1902
 
1946 
 
1991
 
1585
 
1793
 
1791
 
2052
 
2638
 
2726 
 
2661 
 
2052
 
 
Table 3. External funding (k€) of the research programs from 1997 to 2007. The figures 
show the total amount of competitive external funding obtained in that year (one grant is 
typically for two to four years). 
 1997
 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Finnish 
disease  
heritage 
159 159 290 483 507 478 343 715 850 821 556 
Genetic 
epidemiology 
 
158 231 181 355 278 642 826 953 1424 1653 1600
Mol. biol. of 
cardio-
vascular 
diseases 
315 315 432 516 420 480 436 427 377 267 421 
 
TOTAL 
 
 
632 
 
705 
 
903 
 
1354
 
1205
 
1600
 
1605
 
2095
 
2651 
 
2741 
 
2577
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Figure 2. Total annual budget of the Department of Molecular Medicine* in 1997-2007. 
*1997-2001 Department of Biochemistry and Department of Human Molecular 
Genetics 
 
1.4. Research areas  
The research programs (www.ktl.fi/portal/405) of the MLO utilize our internationally 
unique study samples, the Finnish health care system and our accumulated expertise in 
genetics, biostatistics and molecular analyses to tackle the genetic background of 
diseases important for the public health. The research programs focus in cardiovascular 
diseases, neuropsychiatric diseases and the Finnish disease heritage. The research 
programs of MLO utilize methods of molecular genetics, genetic epidemiology, 
biochemical analyses of cellular and animal models, bioinformatics and systems biology 
to investigate molecular background of human health and disease. 
 
Genetic epidemiology 
The research of genetic epidemiology is based on our access to well defined Finnish 
study samples including large pedigrees of specific diseases and nationwide 
epidemiological cohorts. The major research projects involve molecular characterization 
of hyperlipidemias, metabolic syndrome, multiple sclerosis and severe psychiatric 
disorders. Utilization of genome-wide marker maps, transcript analyses combined with 
new tools of biocomputing and biostatistics has resulted in the initial identification of 
numerous genes and loci associated with common diseases. This success is based on the 
efficient use of special population structure of Finland and actually provided new 
paradigms of the use of founder populations in disease gene identification. This research 
area has also remarkably contributed to the development of new technology for the 
collection and analysis of massive genome-wide information. 
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Systems biology 
The systems biology research area was initiated in MLO with the recruitment of 
Professor Jussi Taipale in 2005. The research of his group aims at understanding of 
disease mechanisms and development of high content screening methods facilitating the 
identification of new disease genes and characterization of functions of genes and their 
regulatory elements. Development of novel methodology has already resulted in 
internationally recognized success. 
 
Molecular biology of cardiovascular diseases 
The genetic findings in lipid metabolism constitute the basis for the functional analyses 
aimed at understanding the molecular mechanisms behind cardiovascular diseases. This 
research area utilizes biochemical, cellular and animal models to tackle the basic lipid 
metabolism. Life style and nutritional risk factors are tackled utilizing nationwide 
sample cohorts and functional analyses. 
 
Finnish disease heritage 
The Finnish disease heritage consists of over 30, typically recessive inherited diseases, 
enriched in this founder population. They have provided a proof of principle of the 
efficient use of the unique population structure and sample resources in identification 
and characterization of disease genes, development of DNA-based diagnostics and 
revealing of metabolic pathways important for human health in general. This research 
utilizes cell and animals models and genome-wide functional analyses to follow the 
disease process in cells and tissues.  
 
Research infrastructure: Core facilities and technology platforms 
The bioinformatics unit (www.giu.fi) utilizes and develops genome-wide 
computational analyses for the research purposes of molecular medicine. 
The biotechnology core facility (www.ktl.fi/portal/9086) develops and provides easy 
access for investigators to genome-wide methods in transcript profiling and 
characterization of copy-number and functional variations.  
The DNA sequencing facility (www.ktl.fi/portal/10917) is a part of the biotechnology 
core offering high quality sequencing and genotyping services for the research 
community. 
Large Scale DNA Extraction and Storage Facility/National Biobank of Finland  
(www.ktl.fi/portal/3416 (in Finnish), www.nationalbiobanks.fi) serves the research 
groups of KTL and universities in DNA biobanking. It is equipped with state of the art 
sample tracking system, automated DNA extraction equipment, liquid handling robots, 
storage facilities and data management tools for sample logistics and optimal 
confidentiality and quality control. 
 
Paternity testing laboratory 
The paternity testing laboratory (www.ktl.fi/isyys (in Finnish)) is a national service 
laboratory providing legally determined paternity-testing based on DNA-analyses. 
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1.5. Strategic planning and management  
The Director General of the KTL distributes the overall resources between departments 
after acceptance of the annual strategic plan of each department. The steering group of 
MLO (program leaders and core facility leaders) meets the Director General once a year 
to present the yearly achievements and strategic plans for the next year. The internal 
allocation of the resources takes place upon the acceptance of the strategic plan and the 
Director General does not interfere with the internal allocation of resources. In the 
beginning of each year the director of department makes a proposal for the allocation of 
the institutional funds to the steering group of the Department that provides the 
feedback and then the budget is finalized by the department director. The Paternity 
Testing Laboratory (ITL) works on a full-cost basis. Once a year, the steering group of 
MLO holds a strategic brainstorming session to discuss future developmental needs of 
the Department. All research programs have their own strategy days also at least once a 
year. The Paternity Testing Laboratory is an accredited laboratory and they have several 
management meetings during the year and face a yearly assessment by the Finnish 
Accreditation Service (FINAS). 
 
The steering group of the Department meets once a week to discuss urgent matters and 
plans. The information from these meetings is further distributed to the personnel and 
staff by the program leaders. MLO has a weekly department meeting for the whole 
personnel, where the director of department shortly informs about timely important 
matters. Three times monthly the department meeting contains a presentation by a) 
Invited lecturer of public health or nationally/internationally important research areas, b) 
Postdoctoral researcher of the MLO, c) Junior researcher of the MLO and d) Once a 
month the department meeting is devoted to general business matters presented by the 
director of the department (including meetings with the KTL board) and the department 
is introduced with latest scientific accomplishments: new publications in press, new 
grants and other celebrations involving the researchers of the MLO. This monthly 
meeting ends with free discussion and questions of important matters. The meetings are 
held in English to guarantee the participation of the non-Finnish scientists and students. 
 
Each research program has a weekly meeting on managerial subjects. In these meetings 
the research progress of each project is followed thoroughly. Research core facilities 
usually have their meetings once a month, assessing mostly managerial issues. Each 
core facility also has a supervision group of scientists and stake holders that meets at 
least once a year. Additionally, graduate students and postdoctoral researchers have 
regular strategic planning meetings with the supervisors and members of collaborating 
research groups.  
 
Every employee has a discussion once a year with his/her supervisor where they discuss 
about personal achievements, future plans, needs for further education etc. This is a part 
of the KTL salary and support system. Additionally, salary agreement is discussed once 
a year between each employee and the immediate supervisor or unit head, within the 
limitations coming from the general rules of KTL and the budget available. To make the 
process transparent, the overall ranking of the different personnel groups are discussed 
in the Department board meeting.  The flow of the strategic management is presented in 
Figure 3. 
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Figure 3. Strategic management of the MLO 
 
 
1.6. Scientific impact of research 
The MLO builds on the existing and integrated strengths of Finnish molecular genetics, 
epidemiology, biochemical expertise and biostatistics. The key investigators of the 
MLO include scientists with a worldwide recognized expertise and a strong track record 
in disease genetics, genetic epidemiology, systems biology, lipid biochemistry, cell 
biology, mouse models and biomathematics. Based on our expertise accumulated 
during research on the molecular basis of rare Finnish diseases, we have utilized the 
special Finnish population resources and established research programs in complex 
diseases affecting central nervous (CNS) and cardiovascular (CVS) system. These 
projects have produced new insights and understanding of the role of genetic profiles in 
human disease processes also more generally. The Department has a long tradition on 
tight national and international collaboration and the senior investigators are in the 
leading positions in many peer-reviewed prestigous research programs and networks 
including the Centre of Excellence in Complex Disease Genetics of the Academy of 
Finland, Nordic Centre of Excellence in Disease Genetics, Biomedicum Helsinki 
Research Programme on Molecular Medicine, Biocentrum Helsinki as well as in many 
EU projects and international networks.  
Background material                         1 DEPARTMENT OF MOLECULAR MEDICINE 
 
 23
The research programs of MLO capitalize on the possibilities provided by the special 
study samples collected by the MLO investigators and by KTL: The large pedigrees 
ascertained for familial types of common diseases, twin cohorts and epidemiological 
study samples collected from the Finnish population and representing a non-ascertained 
population sample facilitate both case cohort studies and longitudinal data analyses for 
quantitative traits. Detailed analyses of these study samples in an efficient way requires 
the most updated high-throughput genotyping, sequencing and transcript profiling 
methodology. The integrated expertise of the investigators at the participating umbrella 
organizations is critical for the application and further developments of high-throughput 
technologies. Finally, the integrated data analyses in these large study samples require 
construction and harmonization of databases and development of novel 
biocomputational and biostatistical strategies. Again, the pooled expertise of our 
national and international networks provide a solid basis for detailed genetic analyses of 
the large study samples and the necessary infrastructure for extensive genetic studies 
accessible to other investigators not only in Finland but also in other countries. The 
research tradition and research infrastructure of MLO has recruited numerous foreign 
students and scientists to Finland, most recently, the only Finnish Distinguished 
Professor of the Academy in Meilahti campus, Professor Joe Terwilliger. Research 
programs of MLO have also been the driving force behind the foundation of the 
Institute for Molecular Medicine Finland (FIMM). The FIMM, founded in September 
2006 by the University of Helsinki (UH), the Hospital District of Helsinki and Uusimaa 
(HUS) and KTL is expected to further increase the visibility of genetic, epidemiological 
and translational research in Finland and strengthen recruitment of scientists around 
Europe. 
 
Staff competence  
We consider that the competence of the research staff in general has further improved 
during the last ten years. The number of citations of our publications has increased 
notably towards the end of the evaluation period. The increase is likely due to the fact 
that scientific requirements of KTL have been driven by a strong strategic vision of the 
institutional leadership. The best investigators in critical new fields are recruited and 
KTL has actively supported research careers and research training as an essential part of 
the departmental strategy. Importantly, we have focused on the increasing demands to 
train scientists in new skills of genome wide analyses, including high throughput 
screening, bioinformatics and systems biology. The total number of supervised Ph.D. 
theses was 61 during the past ten years, this would mean 8-10% of the Ph.D. theses of 
the Medical Faculty annually. The number of post doctoral researchers and senior 
scientists within the research groups has increased from 5 to 17 during the ten year 
period. Also, the number of junior investigators has increased remarkably since 2002 
(Table 1.). The staff including technicians has also been offered systematic training 
programs in developing methodology and modern equipments involved in the analyses 
of modern genetics and biochemistry. Additionally, the competitive research 
environment in Biomedicum Helsinki has created pressure to develop the research 
careers for laboratory staff as well. The research infrastructure core unit concept, 
introduced by Professor Peltonen after her UCLA years (1998-2002) has generated 
novel working careers for bioanalytists and scientists as core facility leaders and 
laboratory project managers. The advancement of modern genetics has necessitated the 
recruitment of high level IT personnel, funded mainly from research grants and this has 
been a major contributor to our success in genetic epidemiology. 
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Investigators of MLO have succeeded very well in the highly competitive calls of 
research positions of the Academy of Finland. Two of the research group leaders are 
Academy professors (L.Peltonen (1.8.2003-31.7.2008) and J.Taipale (1.1.2008-
31.12.2012)), the most prestigious academic position in Finland. In addition, during 
past 10 years two group leaders have been Academy Research Fellows, six investigators 
have been postdoctoral researchers and three group leaders have had a senior scientist 
grant of Academy. 
 
Scientific productivity 
The number of scientific articles in international peer review journals and domestic 
articles are shown in Table 4. If one article has authors from several research programs 
of the department, the article is counted to the most relevant unit based on subject. Thus, 
the sum numbers in Table 4. show the total numbers of articles published in MLO in 
each year.  
 
Table 4. International peer review articles, reviews, book chapters and domestic articles 
and book chapters within different research units at the Department of Molecular 
Medicine published in years 1997-2007.  
International 
peer review 
articles 1
99
7 
19
98
 
19
99
 
20
00
 
20
01
 
20
02
 
20
03
 
20
04
 
20
05
 
20
06
 
20
07
  
Sum 
Finnish disease 
heritage 
18 25 17 11 15 17 10 18 12 15 7 165 
Genetic  
epidemiology 
15 18 16 18 25 25 34 33 24 28 21 257 
Mol. biol. of  
CV diseases 
22 22 22 21 23 22 14 12 16 11 16 201 
 
TOTAL  
 
 
55 
 
65 
 
55 
 
50 
 
63 
 
64 
 
58 
 
63 
 
52 
 
54 
 
44 
 
623 
 
Review 
articles and 
book chapters 1
99
7 
19
98
 
19
99
 
20
00
 
20
01
 
20
02
 
20
03
 
20
04
 
20
05
 
20
06
 
20
07
  
Sum 
Finnish disease 
heritage 
3 4 3 1 4 2   2 2 2 23 
Genetic  
epidemiology 
4  1 3 2 2 1 2 2 4 6 27 
Mol. biol. of  
CV diseases 
4 2 3 7 3 3 3 5 1 3 2 36 
 
TOTAL 
 
 
11 
 
6 
 
7 
 
11 
 
9 
 
7 
 
4 
 
7 
 
5 
 
9 
 
10 
 
86 
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Domestic 
articles and 
book chapters 19
97
 
19
98
 
19
99
 
20
00
 
20
01
 
20
02
 
20
03
 
20
04
 
20
05
 
20
06
 
20
07
  
Sum 
Finnish disease 
heritage 
2      1 1   1 5 
Genetic  
epidemiology 
 6  2 2 1 3 1  2 1 18 
Mol. biol. of  
CV diseases 
1   1  1   1   4 
 
TOTAL 
 
 
3 
 
6 
 
0 
 
3 
 
2 
 
2 
 
4 
 
2 
 
1 
 
2 
 
2 
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The mean impact factors of peer review articles per year are shown in Figure 4. The 
mean impact factor of all journals is 6.28 and 34 % of the all references present with 
impact factors over 7.  
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Figure 4. The mean impact factors in 1997-2007 
 
Our researchers are actively supervising doctoral students working at the Department. 
Altogether 61 doctoral dissertations have been finished (the work done at MLO, see 
appendixes 1-3) during the last 10 years (Figure 5.). On average six Ph.D. dissertations 
have been completed annually. 
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Figure 5. Number of doctoral dissertations at the Department of Molecular Medicine in 
1997–2007. Upcoming dissertations are marked in purple.  
 
 
1.7. Public health and expert functions 
The main mission of the Department of Molecular Medicine is to perform top level 
research in the areas relevant for medicine and public health. Our goal is to collect new 
information and produce innovations that will guide public health decisions in future. 
The researchers of MLO participate in numerous national and international expert 
functions. At international level the most important current expert functions include the 
position of HUGO president held by Leena Peltonen, who also acts as the chair of the 
Strategic group of epidemiological research by Wellcome Trust. Leena Peltonen further 
acts as a board member of the European Research Council and as a chair of the 
governance body of the ESFRI Biobank initiative. She is also the only Finnish member 
of the Medical Institute of the National Academy of the USA. Research program leaders 
of the department have further held expert functions as evaluators in the 6th Framework 
Programme of the European Commission. At the national level, the researchers of the 
MLO have provided expert functions in the preparation of paternity and biobank law 
initiatives as well as given expert statements to the Board of Gene Technology. 
 
The researchers of the MLO have further contributed to the production of the mission 
statement, strategy and founding documents of the Institute for Molecular Medicine 
Finland (FIMM). They have contributed to guidelines and quality control design 
strategies of biobank efforts nationally and internationally as well as to the development 
of ethical guidelines of the use of genetic information (e.g. Dr. Peltonen being a 
member of the UNESCO Bioethics Committee in years 1996-2002). In the local 
research committee the MLO investigators have contributed to the development of the 
Animal Centre of the University of Helsinki and strategic planning of the future fusion 
of the KTL animal facility to the Animal Centre of the UH. The main expert functions 
of the researchers of the MLO include pre-evaluations of several doctoral theses of 
different universities as well as acting as a dissertation opponent. As a major public 
health function, the researchers of the MLO regularly produce publications and give 
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oral presentations in meetings and congresses aimed to public health experts, 
researchers, patient organizations and general public. MLO investigators are frequently 
interviewed in radio and TV for their expert opinions in molecular medicine. The 
Finnish KTL Journal (www.ktl.fi/portal/12059 (in Finnish)) with a wide distribution 
among the Finnish biomedical community, has published articles presenting the EU 
projects of MLO as well as the research programmes of Finnish Disease Heritage, 
Genetic epidemiology, Systems biology and Molecular Biology of Cardiovascular 
Diseases. 
 
 
1.8. Public health impact 
The public health impact of the MLO is “future building”, based on the enormous 
potential of modern human genetics and national sample cohorts to dissect the 
molecular background of common diseases. We recognize that there are major issues to 
be addressed prior to transferring new genetic or molecular discoveries to the health 
care system. These issues range from the essential step of validating the initial findings 
in multiple populations to the dissection of the genetic effect in relation to disease 
manifestations. Joint effects of genes, life style and environment, the cost implications 
of genetic testing and data delivery for the public in relation to benefits that could be 
obtained by the institution of traditional disease prevention measures, as well as the 
establishment of appropriate guidelines to inform health ministries, health care workers, 
patients and their relatives are also cited. Although it is acknowledged that several 
approaches are needed to discover and characterize every disease-susceptibility gene, 
there is a growing realization that the primary resource needed to address most of the 
above-mentioned issues are large collections of samples from human populations that 
include extensive clinical information (F. Collins, Nature, July 27, 2004). The common 
diseases studied by the MLO are major burdens to health care and society with 
prevalence figures for each selected target diseases being in the 2-10% range. 
Quantitative phenotype traits and mild subcomponents of the traits are even more 
common. MLO has identified and further aims at identifying susceptibility genes in all 
disorders under study by a combination of family- and population based genetic analysis 
in human study samples and to characterize some molecular mechanisms in detail using 
vast amount of genome tools available for mouse strains. Further, we are in the process 
to define the size of the genetic impact of identified allelic variants as well as to create 
some understanding of the tissue-and developmental stage character of the disease 
phenotype (e.g. characterization of specific triggers in molecular subtypes of disease).  
 
The MLO utilizes the unique Finnish resources collected by highly professional Finnish 
clinicians and epidemiologists for the initial identification of genes and their specific 
alleles associated with specific complex diseases and their QTL component traits (often 
representing intermediate phenotypes). We further aim to obtain some understanding 
how alleles of various genes contribute to the genetic risk of these phenotypes. This 
novel information will be crucially important for future efforts toward more specific 
“molecular” diagnosis and improved treatment and care of these diseases. The data will 
produce accurate estimates for the prevalence, the distribution pattern and the effect of 
frequent gene variants (and combinations of gene variants) in the population 
contributing to biological diversity, health and disease (susceptibility and protection). It 
will also contribute to the understanding of the effect of frequent gene variants (and 
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combination of gene variants) on environmental exposure or life habits (such as diet, 
sedentary life style and smoking). 
 
Inventions and innovations in this particular field are likely to result in new strategies in 
medical practice including new tools of diagnostics, treatment and intervention. The 
Nordic societies with their national health care system are in an excellent position to 
deliver the new possibilities of health care to individuals and the whole society. Thus 
the research carried out within the MLO will benefit not only the biotechnology and 
health care industry in Finland and other Nordic countries, but also European societies 
more broadly.  
 
 
1.9. Participation in umbrella organizations and Centres of Excellence 
Finnish Centres of Excellence (Academy of Finland) 
Finnish centres of excellence are research units or researcher training units which 
comprise one or more high-level research teams that are at or near the international 
cutting edge of research in their field. These Centers are selected based on the 
international reviews of top experts in extremely competitive calls. In biomedicine there 
are total of 27 Centers of Excellence in Finland. The centre groups share a common set 
of objectives and work under the same leadership. Funding for centres of excellence 
comes not only from the Academy of Finland, but also from the host organisations of 
the units concerned. A centre of excellence may be a unit of research teams working at 
both universities and research institutes. 
 
Center of Excellence in Disease Genetics (Academy of Finland, 2000-2005) was 
established to facilitate the maximal use of the potential of Finnish study resources and 
population structure in genetic research. The aim of this center was to utilize the 
specific features of the Finnish population:  isolation, the small original population and 
the excellent health care system. In particular, the research carried out at the Center 
focused at understanding the function of the disease genomes damaging the central 
nervous system and at identifying the genetic component in diseases of Finnish disease 
heritage and common Finnish diseases with special competitive niche (families with 
multiple affecteds) such as multiple sclerosis, colon cancer and asthma. The Center was 
directed by Leena Peltonen (KTL) and other participating groups included: Lauri 
Aaltonen (UH), Anu Jalanko (KTL), Juha Kere (UH and Karolinska Institute) and 
Anna-Elina Lehesjoki (FH). Numerous disease genes were identified and the functional 
defects involved characterized by the investigators of this Center. 
 
Center of Excellence in Complex Disease Genetics (Academy of Finland 2006-2011) 
(CoECDG, www.ktl.fi/diseasegenetics) aims to dissect genetic background of common 
diseases and their trait components by integrating special expertise and sample 
resources accessible to center investigators. The Center builds on accomplishments of 
the Center of Excellence in Disease Genetics of the Academy of Finland (years 2000-
2005) but has a more extended research program to reflect the development of the field 
as well as its own research progress: from Mendelian diseases to complex traits. The 
major goal is to identify predisposing genes and their risk alleles for asthma, major 
cardiovascular and neuropsychiatric diseases. The center aims to capitalize the 
possibilities of the special population and epidemiological study sample resources of 
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Finland in genome-wide analyses using molecular methods, across species comparisons 
and biocomputational strategies.  
 
The Center combines diverse expertise of eight group leaders across three academic 
institutes in Finland and one in Sweden: Leena Peltonen, (Director, UH and KTL), 
Jaakko Kaprio (Vice director, Department of Public Health, UH and KTL), Anu Jalanko 
(KTL), Juha Kere (Karolinska Institute and UH), Kimmo Kontula (Department of 
Medicine, UH), Anna-Elina Lehesjoki (FH and Neuroscience Center, UH), Aarno 
Palotie (Finnish Genome Center, UH), Joseph Terwilliger (Columbia University and 
Finnish Genome Center, UH). 
 
Center of Excellence in Translational Genome-Scale Biology (Academy of Finland 
2006-2011) (CoE in TGSB, www.tgsb.fi) has set itself the goal of studying the impacts 
of human genes on cell growth and premature ageing. The CoE in TGSB developes and 
applies high-throughput technologies to discover genes and signalling events that are 
responsible for cancer initiation, progression and for key cancer cell phenotypes. It 
translates the discoveries towards clinical and industrial applications. Finally, an 
important mission is the training of post-genome era young scientists. This CoE is a 
multidisciplinary effort that integrates biosciences, medicine, technology and 
informatics. It consists of six independently recognised research groups from the 
Universities of Helsinki and Turku and from the VTT Technical Research Centre of 
Finland.  
 
The project is coordinated by Academy Professor Olli Kallioniemi (VTT Medical 
Biotechnology Centre, Turku). The other participating research groups include: Lauri 
Aaltonen (UH), Tomi Mäkelä (UH), Jussi Taipale (UH and KTL), Päivi Ojala (UH), 
Marko Kallio (University of Turku). 
 
Nordic Center of Excellence in Disease Genetics (Nordiska ministerrådet 2005-
2009) 
The Nordic Centre of Excellence Programme in Molecular Medicine is a joint venture 
between the Joint Committee of the Nordic Medical Research Councils (NOS-M), the 
Nordic Council of Ministers and the Nordic Research Board (NordForsk). During 2005-
2009, the Programme will support three new Nordic Centres of Excellence, NCoEs - 
networks of established Nordic researchers working together with common goals.  
 
In the Nordic Center of Excellence in Disease Genetics (NCoEDG) (www.ncoedg.org)  
investigators from Denmark, Finland and Sweden, working in five Nordic Universities 
have pooled their expertise, methodological power and study sample resources to study 
the genetic background of metabolic syndrome, autoimmune and inflammatory diseases 
and colon cancer. The goal of the NCoEDG is to capitalize on unique resources of 
Nordic countries: Advanced molecular technologies, many developed by partners of 
NCoEDG, and advanced biocomputational analyses will be efficiently used to analyze 
large pedigrees of humans, ascertained for familial types of common diseases, the 
outbred stocks of farm animals and rodent strains produced for numerous complex 
diseases.  
 
The detailed analyses of these study samples require updated high-throughput 
genotyping, sequencing and transcript profiling methodology. The collected expertise in 
clinical and molecular medicine and data analyses of the NCoEDG investigators is 
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critical for the next generation studies addressing the genetic etiology of common 
diseases. The most critical component for integration and analysis of these large study 
samples requires construction and harmonization of databases and development of novel 
biocomputational and biostatistical strategies. The pooled expertise of the NCoEDG and 
the complementary grant from Wallenberg Foundation to NCoEDG provides a solid 
basis for development of these critical infrastructure elements, not achievable by any 
group alone. The Nordic Center works like one integrated research group being linked 
virtually and via multiple annual workshops. Students and scientists visit other Nordic 
laboratories and the training program educates a generation of young scientists in new 
genome-wide approaches. The Center aims to create a unique scientific environment 
which could attract scientists and students also from outside Nordic countries. This 
would maximize our possibilities to solve the molecular background of these common 
diseases and use the inventions for the betterment of Nordic societies and health care. 
The NCoEDG comprises five Nordic centres with their repesctive leaders: University of 
Helsinki-Leena Peltonen (Coordinator), University of Uppsala-Ulf Landegren and Leif 
Andersson, Karolinska Institutet-Juha Kere, University of Lund/Malmö-Leif Groop and 
University of Århus-Torben Årntoft. A total of 21 research groups participate in this 
umbrella organization, three from the MLO: Peltonen, Jalanko and Taipale. The 
database structure of the Nordic Center has obtained substantial funding from the 
Wallenberg Foundation. 
 
Biomedicum Helsinki Research Programme of Molecular Medicine (2001-2005 
and 2006-2010) 
The Faculty of Medicine has based on the competitive search and external evaluation 
selected total of six research programs to represent the flagships of it’s research. 
Program of Molecular Medicine integrating basic genetic science discoveries with 
clinical medical research (and ultimate public health) is one of the original Programs in 
Biomedicum Helsinki. The first period of the program constituted years 2001-2005 and 
based on the evaluation of the international advisory board (headed by Erkki Ruoslahti) 
the programme was recommended to continue for the period of 2006-2011. The goal is 
to capitalize on the population-based, public health-based infrastructure in Finland to 
identify relationships between genomic composition of individuals and 
environmental/life style factors so as to define the molecular pathogenesis of common 
human diseases including the responses to intervention. 
 
The Program of Molecular Medicine, led by Professor Leena Peltonen and Professor 
Kimmo Kontula interfaces and synergizes with the National Public Health Institute, 
Folkhälsan Institute, Finnish Genome Center, and Helsinki University Central Hospital. 
Core laboratories of international stature and utilizing state-of-the-art methodologies 
have been developed for (1) DNA-biobanking, (2) DNA sequencing, (3) microarrays, (4) 
bioinformatics. 
 
The Program of Molecular Medicine is composed of ten interactive research groups, for 
the most part co-located within Biomedicum Helsinki:  
Professor Leif Groop:Genetic complexity of type 2 diabetes and the metabolic syndrome  
Dr. Päivi Holopainen: Molecular genetics of immunological diseases  
Professor Juha Kere: Genetic research of complex diseases  
Professor Kimmo Kontula: Molecular background of cardiac arrhythmias, essential 
hypertension, obesity and inflammatory bowel diseases  
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Professor Anna-Elina Lehesjoki: Mechanisms of neurologic disease: from gene mutation to 
molecular pathogenesis  
Dr. Hannes Lohi: Canine models of human inherited diseases  
Professor Aarno Palotie: Molecular genetics of migraines  
Academy Professor Leena Peltonen: Genetic profiles of common diseases  
Professor Marja-Riitta Taskinen: Cardiometabolical and genetical risk factors  
Docent Tiinamaija Tuomi: Genetic complexity of diabetes 
 
Biocentrum Helsinki 
Biocentrum Helsinki is a large umbrella organization at the University of Helsinki, with 
some 530 people being engaged in research in biotechnology and molecular biology. 
The 26 member groups, selected based on the international evaluation, are located on 
two separate campuses of the University: Meilahti; Biomedicum Helsinki and Haartman 
Institute, and Viikki; Viikki Biocenter including Institute of Biotechnology and 
Neuroscience Center and Faculty of Agriculture and Forestry. The research activities at 
Biocentrum Helsinki range from human molecular genetics to plant biotechnology. Its 
purpose is to improve cooperation among the well-established research groups at the 
University of Helsinki, not only in conducting scientific research in the fields of 
biotechnology and molecular biology, but also in providing joint graduate training 
programs. The member groups in Biocentrum Helsinki have been selected by 
international experts strictly on the basis of their scientific accomplishments, providing 
that the work of the group is related to the fields of biotechnology and molecular 
biology. Professors Peltonen and Taipale from the MLO are members of this 
organization. 
 
 
1.10. Research training and scientific meetings  
Activity in teaching, training of graduate students and postdoctoral fellows  
Each group of the Department has accumulated extensive experience in training of 
graduate students and postdoctoral fellows and the group leaders are all involved in one 
or several graduate schools. Professor Leena Peltonen has served as a member for the 
steering group of Helsinki Biomedical Graduate School (HBGS) in 1996-1998 and for 
the steering group of Helsinki Graduate school of Biotechnology and Molecular 
Biology (GSBM) since 2002. She established the graduate program in human genetics 
at UCLA in 1999 and was the member of the steering group of the campus-wide 
graduate program in genetics at UCLA in 1998-2002. Professor Peltonen serves on the 
Board of ComBi (Graduate School of Computational Biology) and GSBM (Helsinki 
Graduate School in Biotechnology and Molecular Biology). Drs Anu Jalanko, Matti 
Jauhiainen, Marjo Kestilä, Vesa Olkkonen, Markus Perola and Ismo Ulmanen have 
served as regular lecturers and experts in these graduate schools. Drs Aija Kyttälä (from 
Dr. Jalanko’s group), Anu Loukola and Kaisa Silander (from Professor Peltonen’s 
group) have been working as part-time coordinators in this Graduate School. The total 
number of supervised P.D. theses by the group leaders in 1997-2007 is 61. Our training 
is closely integrated with training provided by graduate schools. 30% of the graduate 
students of the MLO have been supported by one of the different graduate schools of 
the University of Helsinki. However, each graduate student of the Department has a 
possibility to apply to teaching events and courses arranged by graduate schools. Each 
student of the MLO has his/her thesis committee that meets annually to monitor the 
progress of the work. The Department maintains a continuous training program, 
involving weekly journal club sessions together with the Biomedicum Research 
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Programme of Molecular Medicine and Departmental research seminars. Additional 
method training sessions have been organized once month, featuring invited speakers 
from different core facilities and researchers mastering specific technologies.  
 
Our international collaborations facilitate exchange both graduate and postgraduate 
students with other research institutes: Graduate training with UCLA became a tradition 
during Professor Peltonen’s time there (total of 12 graduate students have experienced 
some time in UCLA and four UCLA graduate students have spent more than a year in 
MLO). Similarly, the exhange of postdoctoral fellows and junior scientists is taking 
place with the Broad Institute where Professor Peltonen holds a 18% visiting 
professorship. Total of six advanced graduate students or postdoctoral fellows have 
spents weeks or months at Broad and three postdoctoral fellows and junior scientists 
from Broad have spent various periods at MLO. Also via our EU supported integrated 
programs like GenomEUtwin and NCL-models as well as via the Nordic Center of 
Excellence special funds are targeted to the training of graduate and postgraduate 
students to guarantee the international links of our training program. MLO investigators 
have also organized two EMBO Practical courses in SNP genotyping and HapMap in 
2005 and 2007. These international courses have been heavily oversubscribed and 
attracted a high number of students, postdoctoral fellows and junior scientists.  
 
For postdoctoral students a more tailor-made training rotation to learn different methods 
within the Department is designed based on their expertise and research projects. The 
postdoctoral students are responsible for organizing and running the weekly journal 
clubs of complex diseases. They give their contribution to weekly seminars of the 
Department as well as in annual retreats in the form of scientific presentations 
describing their project. Each postdoctoral student will have in addition to his/her 
supervisor also a senior mentor from another group within the Department.   
 
Scientific meetings and courses 
The department has been a key contributor or the responsible organizer to 34 
scientific meetings and workshops and seven training courses: 
 
Scientific Meetings and Workshops: 
• 5th International Symposium on the Marfan Syndrome, August 7-10, 1998, 
Helsinki, Finland 
• The 69th European Atherosclerosis Society Meeting, May 24-26, 1998, Helsinki, 
Finland 
• Scandinavian Society for Electron Microscopy, 50th annual meeting, June 7-10, 
1998, Espoo-Helsinki, Finland 
• Satellite symposium of the XIIth International Symposium on Atherosclerosis: 
High density lipoproteins and atherosclerosis, June 30-July 3, 2000, Helsinki, 
Finland 
• The Annual Scandinavian Society for Atherosclerosis Research (SSAR) Meeting, 
May 30-June 2, 2002, Humlebaek, Denmark 
• GenomEUtwin Phenotype Workshop: harmonization and better definition of the 
phenotypes. Statistical Genetics Short Course: state-of-the-art statistical genetics 
methods for detection of susceptibility loci for complex traits March 24-25, 2003, 
Helsinki, Finland 
• HGM2003 – Human Genome Meeting, April 27-30, 2003, Cancun, Mexico 
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• The Annual Scandinavian Society for Atherosclerosis Research (SSAR) Meeting, 
May 22-25, 2003, Humlebaek, Denmark 
• DNA 50 years Biomedicum Symposium, August 25, 2003, Helsinki 
• HGM2004 – Human Genome Meeting, April 4-7 2004, Berlin, Germany  
• 1st Millennium Technology Prize Symposium, June 13-16, 2004, Espoo, Finland 
• GenomEUtwin: 1st Workshop on Logical Reasoning in Human Genetics, 
September 19-23, 2004, Helsinki, Finland 
• GenomEUtwin Junior Investigators Workshop, December 13-14, 2004, Rome, 
Italy 
• Public Population Project in Genomics (P3G), June 1-4, 2004, Helsinki and 
Tallin Workshop 
• 11th International Symposium on Neuronal Ceroid Lipofuscinoses, June 5-8, 
2005, Helsinki  
• World Congress on Psychiatric Genetics XIII, October 14-18, 2005, Boston, 
USA  
• NCoEDG - database expert meeting and student training, March 30 - 31, 2006, 
Lund, Sweden 
• HGM2006 – Human Genome Meeting, May 31– June 3, 2006, Helsinki, Finland 
• The English Speaking Working Group of International Society for Forensic 
Genetics, June 8-11, 2006, Tuusula, Finland 
• 5th European Research Council Meeting, July 3-4, 2006, Helsinki, Finland 
• GenomEUtwin 2nd Workshop Logical reasoning in genetics and genetic 
epidemiology, August 14-18, 2006, Helsinki, Finland  
• NCoEDG database and bioinformatics experts meeting, August 24, 2006,
 Stockholm, Sweden   
• Round table workshop on clinical experts and Intranet training of site experts, 
August 28, 2006, Uppsala, Sweden  
• 1st Nordic Meeting on Genetic and Pathogenesis Immunological Diseases, 
September 4-5, 2006, Helsinki, Finland 
• World Congress on Psychiatric Genetics XIV, October 28 – November 1, 2006, 
Cagliari, Italy 
• Nordic Centre of Excellence in Disease Genetics (NCoEDG), Junior scientist 
meeting, November 16-17, 2006, Malmö, Sweden 
• XV Paavo Nurmi Symposium, December 13-15, 2006, Oulu, Finland 
• GenomEUtwin Scientific Meeting, European network of twin registers and 
MORGAM cohorts, December 14-15, 2006, Rome, Italy  
• NCoEDG database and Informatics meeting: Towards a Nordic Federated 
Network in Disease Genetics, March 6, 2007, Uppsala, Sweden 
• European Research Infrastructure - Bio-Banking and Biomolecular Resources, 
Partner and Stakeholder Meeting, Vienna, March 17, 2007, Vienna, Austria 
 
• HGM2007 – Human Genome Meeting, May 21-24, 2007, Montreal, Canada 
• 3rd International Meeting on Genetics of Complex Diseases and Isolated 
Populations, May 26 – 29, 2007, Turin, Italy  
• High Density Lipoproteins and Atherosclerosis, Satellite Symposium of the EAS 
Congress, June 7-9, 2007, Helsinki, Finland 
• EAS 76th Annual Congress, June 10-13, 2007, Helsinki, Finland  
 
Background material                         1 DEPARTMENT OF MOLECULAR MEDICINE 
 
 34 
Training courses: 
• EMBO Practical course on SNP genotyping and haplotype analysis, August 21-
27, 2005, Helsinki, Finland  
• Advanced Techniques in Molecular Medicine, co-sponsored by EMBO, June 
15-22, 2005, Uppsala, Sweden  
• Applied bioinformatics and methodologies for SNP genotyping, November 12-
18, 2005, Uppsala, Sweden  
• Statistical Genetics Course, July 23-28, 2006, Stockholm, Sweden  
• Logical Reasoning in Human Genetics and Epidemiology, August 14-18, 2006, 
Helsinki, Finland  
• Applied bioinformatics and methodologies in SNP genotyping, March 10-15, 
2007, Uppsala, Finland 
• Course on RNA interference, June 6-12, 2007, Heidelberg, Germany  
 
Upcoming meetings and training courses 
• EMBO Practical Course on Genome-wide SNP Association Studies, August 27-
31, 2007, Helsinki, Finland 
• European Life Scientist Organization (ELSO) Meeting (Systems Biology co-
organizer/chair, speaker), September 1-4, 2007, Dresden, Germany  
• International Research Policy Conference – Excellence Stems from people, 
August 27-28, Turku, Finland  
• Marie Curie workshop: Array techniques to identify copy number variations, 
September 10-15, 2007, Helsinki, Finland 
• The 48th International Conference on the Bioscience of Lipids, September 4-8, 
2007, Turku, Finland 
• XVI International Symposium on Drugs Affecting Lipid Metabolism, October 
4-7, 2007, New York, USA 
• The International Atherosclerosis Society (IAS) Workshop on HDL, October 9-
12, 2007, Santorini, Greece 
 
 
1.11. Future directions and participation in the Finnish Institute of 
Molecular Medicine (FIMM) 
Strategic joining of expertise and resources is the critical key to success for a small 
country. Within FIMM, MLO will serve even more efficiently the Ministry of Social 
Affairs and Health (STM), the international scientific community, national health care 
officials and the general public in the area of molecular medicine. We will continue to 
perform high quality research that gives us the expertise and credibility to advise both 
the ministry and the public. Especially we will serve the goals of the Biotechnology 
Strategy of KTL and the recently developed programs of the decision makers, aiming at 
producing scientific excellence by a novel strategic alliance between ministries. 
 
We will challenge ourselves to maintain the international scientific excellence and the 
unique Finnish expertise in the analysis of environmental and genetic risk factors behind 
common diseases. The research will be based on the large national biobanks, 
representing a total of 200 000 samples representing population cohorts with detailed 
information of risk factors and traits of cardiovascular and neuropsychiatric diseases 
(www.nationalbiobanks.fi). The basis of the department will continue to be the 
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exploitation of new genome information and the built expertise in genetics, databases, 
biocomputing and functional analyses of disease mechanisms.  
 
The most important strategic decision affecting the future of MLO is the strategic 
alliance between KTL and FIMM. KTL acts as a founding partner of FIMM together 
with University of Helsinki and the Helsinki and Uusimaa Hospital District. 
Regulations of FIMM were approved by the Senate of the University of Helsinki in 
December 2006. The collaboration agreement between KTL and FIMM will be signed 
by the rector of the university and the director general of KTL in August 2007. With 
this agreement the MLO will be strategically joined to the FIMM while the permanent 
staff of MLO will retain their employment in KTL. 
 
FIMM aims at producing new information concerning the molecular mechanisms of 
disease development, taking advantage of clinical and epidemiological materials to 
detect, treat and prevent diseases and promote public health. An important mission of 
FIMM is to engage high-quality international research in clinical and molecular 
medicine, genetic epidemiology and to co-operate with national and international 
research centres. The FIMM aims at enhancing the research in the field and to develop 
infrastructure with universities, university hospitals, research departments and industry 
to create an internationally visible, multidisciplinary environment of excellence in 
science and technology. Furthermore, FIMM aims to promote research training and 
exploitation of research findings.  The important added value of the FIMM is based on 
the strategic alliance between the university, state research centre and industry. It aims 
to network with centers of molecular medicine in Norway and Sweden and the final 
goal is to establish a Nordic node of EMBL in molecular medicine. 
 
The strategic value of MLO within the FIMM will be based on the scientific excellence 
in genetic epidemiology and utilization of the KTL biobank materials and study samples. 
The success of the alliance will depend on efficient utilization of the biobanks in genetic 
epidemiology. Additionally, the existing expertise of MLO in biocomputing and 
database construction will be utilized and further developed. The efficient development 
of the genomic research involving biobanks in Finland is tightly encoupled with the 
success of the recently funded new European biobank initiative (ESFRI Biobanks 
Initiative, BBMRI). The Ministry of Social Affairs and Health is acting as the Finnish 
state representative of this initiative. 
 
 
1.12. Facilities  
The MLO is housed in Biomedicum Helsinki 
(www.biomedicum.helsinki) (located next the to the Helsinki 
University Central Hospital), a five story 24 000 net m2 research 
building houses about 1200 research employees and over 200 research 
groups from several organizations (University of Helsinki (UH), 
National Public Health Institute (KTL), Folkhälsan (FH), Helsinki 
University Hospital). The Biomedicum Helsinki houses three centers 
of excellence of the Academy of Finland and investigators of 
Biomedicum direct of co-ordinate several EU projects and one Nordic 
Center of Excellence. This exceptional and interactive research 
environment is equipped with state of the art instrumentation which is 
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shared by groups. The department space of MLO contains 1322 net m2. To facilitate 
modern, cutting edge biomedical research, Biomedicum Helsinki has invested to core 
facilities with newest technology and professional expertise in the use and further 
development of these technologies. These include: 
 
1. Clinical data collection facilities: Immediate vicinity to the University Hospital 
and  equipped appointment rooms for research subject visits in the proximity of research 
laboratories  
2. A large scale DNA extraction and storage facility of KTL/MLO/National 
Biobank of Finland presently houses DNA from more than 200 000 individuals 
(www.nationalbiobanks.fi). It is equipped with state of the art liquid handling robots, 
storage facilities, an automated Gentra DNA extraction equipment and tailor made data 
management tools for optimal confidentiality and quality control and has a highly 
qualified, permanent staff of five technicians and a supervisor. The database 
management is harmonized between the DNA sample core, sequencing and genotyping 
units. It provides services on a subsidized recharge basis. 
3. The Finnish Genome Center (FGC, www.genome.helsinki.fi) is an intellectual 
core facility to promote genetic research in Finland by providing genotyping services 
for both genome-wide scans and fine-mapping analyses. Multi-allelic genotyping is 
performed using automated liquid handling equipment and the ABI3730 Capillary 
Sequencer. Locus-specific SNP genotyping of tens of markers is performed using a 
Sequenom iPLEX assays. Larger locus-specific or genome-wide SNP studies are 
primarily performed using the Illumina Golden Gate Assays. Genome-wide SNP 
genotyping can also be performed using Affymetrix platforms. The work flow and day 
to day quality control procedures are performed using a LIMS system and genotype 
storage and subsequent handling for statistical analysis is performed by a unique, tailor 
made data base system which is generated by the Genome Informatics Unit.  
4. The Genome Informatics Unit (GIU, www.giu.fi), a joint facility between the 
KTL/MLO and University of Helsinki, provides biocomputing expertise as well as 
computing resources for researchers in Biomedicum Helsinki and their collaborators to 
perform bioinformatics analysis in the areas of sequence analysis, gene expression 
analysis, genomic annotations as well as genetic linkage and association analysis. GIU 
provides its users the largest collection in Finland of the publicly available 
bioinformatics applications and databases in its focus areas and updates these frequently. 
These applications are generally available for MS Windows platforms as well as the 
traditional statistical data analysis packages, which are typically made for Linux/UNIX 
server environments. Since GIU has both the Linux and MS Windows Advanced server 
architectures, its users can employ the widest range of bioinformatics applications, 
made available over the Internet, using secure, graphical user interfaces.  
5. The Biomedicum Biochip Center (BBC, www.helsinki.fi/biochipcenter) 
provides microarray core facility services for both custom made and Affymetrix arrays. 
It serves annually 60 research projects and performs over 2000 hybridizations. It 
operates on either full service or walk in and training modes. The BBC involves 10 
scientists and technicians of whom two are full time for BBC. The core performs both 
service and research projects and provides hands on training in array technologies. 
6. The Sequencing Core (www.ktl.fi/portal/10917), a joint facility between 
KTL/MLO, HUS, FH and Biomedicum Research Programme on Molecular Medicine, 
provides low cost, high quality sequencing services for Biomedicum researchers using 
an ABI3730xl 96-capillary instrument. In addition, small to medium scale fragment 
analysis service is available. 
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7. The Protein Chemistry Core of Biomedicum provides modern microchemical 
protein analyses as well as small to medium scale protein purification and isolation 
(research.med.helsinki.fi/corefacilities/pcf/). Special services include identification and 
sequencing of proteins, characterization of protein interactions and proteomics-based 
analyses of the samples. The unit also provides training courses in modern protein 
purification. 
8. The Protein Interaction Facility of Biomedicum provides the yeast two-hybrid 
screening techniques to identify and clone interactive partners for proteins of interest 
(www.ltdk.helsinki.fi/res/makela/core/th.htm). The bacterial two-hybrid screenings are 
also being set up. The services include screening of appropriate cDNA libraries and the 
maintenance of several requisite cDNA libraries and cloning vectors. 
9. Transgenic Mouse Facility and Vivarium: The animal facility in Biomedicum 
can host up to 4000 mouse and 300 rat cages, has a barrier, a conventional area, and a 
room for experiments with replication deficient viral vectors. A second, new vivarium 
available is located across the street in the Haartman Institute and includes a P3 facility. 
The Biomedicum animal facility has long experience in production of transgenic 
animals. The animal facility at KTL has an SPF barrier, several rooms for 
experimentation and follow-up of the mouse strains, a separate BL3 area for 
experiments with viral vectors and an injection facility. The KTL animal facility has 
successfully produced both transgenic and knock-out animals. The KTL animal house 
has a long tradition for inbreeding of different mouse strains. The animals from KTL are 
allowed to Biomedicum for example, for MRI analyses. Additionally, the KTL animal 
house contains a separate department for production of rabbit antibodies. A current 
effort between KTL and UH aims at joining the KTL animal facility to the newly 
established University of Helsinki Animal Facility, including also the Biomedicum 
vivarium. This should promote integration and cost effectiveness of the animal facility. 
10. Functional MRI Unit of Biomedicum (www.miu.helsinki.fi): The 4.7 tesla 
fMRI equipment of this unit permits fast and accurate imaging of rodent organ structure 
and organ functions. The unit is a collaborative unit of the University Hospital and 
University. 
 
The Epidemiological units of the UH and of the KTL, including the Finnish Twin 
Cohort and their host departments are located just north of the Biomedicum facility, 
but joined by high-speed computer links and easily accessible by a short walk or car 
ride. The facilities contain up to date computing equipment, and support staff include 
both computer scientists and biostatisticians. There is also room for expansion, and 
current plans at the National Public Health Institute are to build in the very near future a 
new building to house both of these epidemiological units. The twin study has also 
extensively collaborated with other investigators to permit appropriate phenotyping of 
traits; in recent years imaging techniques (MRI, FMRI, PET etc), and clinical 
investigations have been integral parts of substudies of the most informative twin pairs 
and families. For these, subjects have attended facilities at different parts of the medical 
campus or elsewhere at the University. 
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2 BIOTECHNOLOGY 
 
2.1. Research area and its significance 
The Human Genome Project and the HapMap project have produced a high number of 
catalogued sequence variants enabling genome-wide studies of genetic loci behind 
common disease-related phenotypes. However, identification of genetic factors 
predisposing to these multifactorial diseases, like diabetes, cardiovascular disease, 
metabolic syndrome, neurological diseases and mental health problems, requires usage 
of genome-wide analysis methods in large sets of samples. Rapid development of 
genome wide analysis techniques during the last 10 years and requirement for 
substantial financial investment related to the high though-put technologies favors 
centralization of both the instruments and the special know-how to core facilities.  
 
The aim of the Biotechnology core facility is to develop and to provide easy access for 
investigators to genome wide methods in transcript profiling, sequencing and 
characterization of copy-number and functional variations. As mere service units 
seldom can operate in the international frontline of the technology development, the 
Biotechnology core is highly integrated into the scientific projects. This facility brings 
genome wide expertise to research projects nationwide and trains/educates researchers 
in utilizing genome wide methods: sequencing, genotyping and gene expression 
analysis on microarrays and other medium to high through-put platforms. The chip-
based operations of the Biotechnology core facility contribute to the functions of the 
Biomedicum Biochip Center core unit. Tight integrations and database harmonization 
with the Finnish Genome Center guarantee the seamless operations of these genome 
analysis units of Biomedicum. 
Background material                                                                      2 BIOTECHNOLOGY 
 
 39
 
 
Figure 1. Interactions of the biotechnology core operations 
 
Emerging new technologies need to be evaluated and certain supportive technologies 
and automation has to be developed/set up before even the commercially available 
methods can be adapted in large studies. The Biotechnology core develops and 
evaluates supportive techniques and provides expertise in setting up the automation for 
different platforms. Furthermore, genome-wide analysis methods create large amounts 
of data, thus the core works in close collaboration with the Bioinformatics core to 
develop software and database solutions for data storing and analysis. Rapidly 
increasing information of the structural or functional variability within the genome will 
greatly affect the interpretation of data.  
 
 
2.2. The main achievements 
Biotechnology core operations of MLO were initially established in the first quarter of 
2001 when the department moved to Biomedicum. The core facilities represent a natural 
extension to continuous method development process that has been a strong part of the 
department of Human Molecular Genetics since its foundation 1988. First task of the 
core during 2001-2002 was to set up a microarray facility for the Biomedicum research 
community. An Omnigrid microarrayer (GeneMachines) was acquired 2001 to enable 
construction of high-density SNP and expression microarrays. This allowed us to further 
develop the conversion of the classical SNP genotyping methods (minisequencing) into 
more high-throughput platforms (custom SNP microarrays), which had been initiated 
already in the previous facilities of KTL. The in-house developed allele-specific primer 
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extension on microarray method was further developed to a “mini-array” format, which 
allowed genotyping of 5-20 selected SNPs in one multiplex with minor assay 
optimization requirements. Eighty samples could be analyzed at the time. In close 
collaboration with the Bioinfomatics core we also developed the SNPSnapper software 
for semi-automated genotyping of the custom SNP arrays. These in-house developed 
custom SNP microarrays were successfully utilized in several research projects in our 
laboratory and this SNP genotyping platform was also brought into play in other 
laboratories (University of Tampere; Haartman Institute, Helsinki; University of 
Uppsala, Sweden). A next step forward in the SNP genotyping pipeline was the 
introduction of a common quality assessment system in all the genotyping projects. 
  
During 2002-2003 we increased the capacity in expression profiling and SNP 
genotyping by setting up the Affymetric GeneChip and the Sequenom MassArray 
platforms, which were acquired by targeted infrastructure funding (Academy of Finland, 
Juselius Foundation, EU, HUS EVO) and the latter was placed in the Finnish Genome 
Center. Full exploitation of the novel genotyping platform was enabled by 
implementing a large scale, partially automated DNA sample dilution and aliquoting 
process in 2002. This multi-step process, which utilizes Tecan Genesis 150 liquid 
handling automation and PicoGreen DNA quantification method, starts from the stock 
DNA tubes and provides quality-checked DNA in normalized concentration in 96-well 
format at the end. To assess the functionality of a DNA sample either a genetic tag via 
genotyping of a set of microsatellite markers or the gender of each sample is determined 
prior entering to the SNP genotyping pipeline. For low quality/low yield DNA samples 
a whole genome amplification protocol (WGA) was validated to complete the DNA 
sample pipeline. Figure 2. shows the growth of the production and the key investments 
in the DNA sequencing, genotyping and expression profiling pipelines during the years 
2001-2006.  
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In May 2003 Molecular Medicine Sequencing Laboratory was established to rationalize 
DNA sequencing services in Biomedicum. A jointly funded core laboratory (University 
of Helsinki, Folkhälsän and KTL) enables feasible sequencing for all research groups in 
KTL and Biomedicum research community. Since its foundation sequencing 
laboratory’s capacity has multiplied over the years resulting in 82 Mb of DNA sequence 
in 2006 (>220 000 reads of sequence). Small scale fragment analysis services are 
provided to complement services provided by the Finnish Genome Center. 
 
High number of catalogued sequence variants provided by the Human Genome and the 
HapMap projects and the recent technical development of highly-multiplexed 
microarray genotyping platforms has enabled conduction of genome wide association 
studies. The Biotechnology core has set up majority of the currently available genome 
wide association panels provided by Affymetrix and Illumina and worked in close 
collaboration with the Genome Informatics Unit of Biomedicum to create the pipeline to 
efficiently store and handle the large amount of data created in these experiments. Since 
2007 the core has provided mouse SNP genotyping services utilizing the Illumina SNP 
arrays to enable the mouse speed congenics, while management of the large genotyping 
projects is provided by the Finnish Genome Center/Institute of Molecular Medicine, 
Finland, for which the core provides technical expertise. 
 
 
2.3. Scientific impact  
Head of the Biotechnology core facility, Dr. Janna Saarela, operates also as a senior 
research scientist in projects listed under the Genetic Epidemiology research program. 
Thus the scientific impact is presented there based on the content.  
 
In addition to developing microarray based SNP genotyping methods and being a 
primary SNP genotyping center in international collaboration studies, such as 
MORGAM and EURODISC, the core has organized an international workshops on 
SNP genotyping technologies (MORGAM workshop in Sardinia, Italy, 2004) and the 
representatives of the core have given lectures as an invited speakers in national and 
international workshops on SNP genotyping technologies and have written book 
chapters on the data analysis of the Affymetrix GeneChip system, SNP genotyping on 
microarrays and whole-genome amplification of genomic DNA. The core also 
participated in the Nordic quality assessment survey of SNP genotyping laboratories. 
 
 
2.4. Societal impact 
The research infrastructure elements like biotechnology core facility of MLO are of the 
critical importance for the whole research community in the modern world of 
biomedical research relying on the high throughput technologies and massive data 
production units. They can only be successful if they are guided by the needs of top 
research and research groups, have excellent national and international collaborations 
and networks and are willing to train students and scientists. The Biotechnology core of 
MLO is a critical element of the research infrastructure in Biomedicum and at the 
Meilahti campus. It educates students and researches, nationally and internationally, in 
the use of genome wide technologies. The core has organized or participated in the 
organization of the following courses: 
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- Genome-wide strategies in biomedical research, 2002 
- Graduate School on Microarrays, 2003 
- Hands-on workshop on novel biotechnology – DNA sequencing, 2005 
- EMBO practical course on SNP genotyping and Haploblock analysis, 2005 
- Biology for methodological scientists: Microarrays, 2006, 2007 
- Biology for Methodological Scientists: Molecular Medicine, 2006, 2007 
- Measurement techniques for bioinformatics – Genotyping, 2007 
- EMBO Practical Course on Genome-wide SNP Association studies, 2007 
- Marie Curie workshop: Array techniques to identify copy number variations, 
2007 
 
Besides, representatives of the core have given lectures on microarray based methods 
and their usage in studies of complex diseases, in courses and hands-on workshops 
organized by medical and biological faculties of Universities of Helsinki, Kuopio, Oulu 
and Tampere.  
 
This core has been responsible for training all Ph.D. students utilizing the Affymetrix 
GeneChip system in their research projects during 2001-2003. Additionally, our core 
has trained most of the technicians currently working at the microarray core facility of 
the Helsinki region (Biomedicum Biochip Center). 
 
 
2.5. Research funding 
Majority of the project funding of this core comes from the specific research projects 
and is listed in elsewhere in this material.  
 
Molecular Medicine Sequencing laboratory, directed by biotechnology engineer Pekka 
Ellonen, operates as core service laboratory thus its main funding comes from selling 
the services. Major instrumentation investments have been supported by infrastructure 
funding from KTL, University of Helsinki and HUS EVO, namely the purchase and 
upgrade of the ABI3730xl DNA Analyzer. The operations, QC and databases systems 
are being harmonized with the operations of the Finnish Genome Center as a major 
technology platform of FIMM. 
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2.6. Scientific collaboration 
National 
Institute Department Research group (PI) Project type* 
Molecular Medicine Prof. C.Enholm 
Dr. A.Jalanko 
Dr. M.Jauhiainen 
Dr. M.Kestilä 
Dr. V.Olkkonen 
Dr. T.Paunio 
 
Prof. L.Peltonen 
 
Dr. M.Perola 
Prof J.Taipale 
Dr. I.Ulmanen 
SNP 
expr 
expr 
expr, seq 
expr 
SNP, expr, seq, 
custom 
SNP, expr, seq, 
custom 
SNP, seq 
expr 
SNP, expr, seq 
Health Promotion and 
Chronic Disease 
Prevention 
Dr. V.Salomaa 
Dr. K.Kuulasmaa 
SNP, expr 
SNP 
Paternity Testing 
Laboratory 
M.Sc. M.Lukka SNP, seq 
 
KTL - National 
Public Health 
Institute 
Infectious Disease 
Epidemiology 
Dr. K.Liitsola Seq 
Cancer research program Prof L.Aaltonen 
Prof K.Alitalo 
Prof M.Laiho 
SNP, seq 
expr 
expr 
Public Health Prof J.Kaprio SNP, seq 
Molecular Medicine 
research program 
Dr. H.Lohi 
Prof. A.Palotie 
Prof M-R.Taskinen 
SNP, seq 
expr, seq 
SNP, expr, seq 
Neuroscience program Dr. P.Tienari 
Prof A.Wartiovaara 
SNP 
SNP, seq 
Forensic Medicine Prof A.Sajantila Seq 
University of 
Helsinki 
Biomedicum Biochip 
Center 
Dr O.Monni SNP, expr 
Helsinki 
University of 
Technology 
Computer and 
Information Science 
Prof. H.Mannila 
Prof. J.Hollmen 
SNP, expr 
SNP, expr 
Helsinki 
University 
Central Hospital 
Clinical Chemistry Dr. A.Orpana SNP, expr, seq, 
custom 
Haartman 
Institute 
Virology Prof A.Vaheri SNP, custom 
University of 
Tampere 
Cancer Genetics Dr. J.Schleutker SNP 
University of 
Oulu 
Medical Biochemistry  Prof. T.Pihlajaniemi 
Prof. L.Ala-Kokko 
Dr. M.Männikkö 
expr 
SNP 
SNP 
 Microarray core unit Dr J.Vuoristo SNP, expr 
University of 
Jyväskylä 
Health Sciences Prof. U.Kujala 
Prof V.Kovanen 
SNP, seq 
expr 
Finnish Food 
Safety Authority 
EVIRA 
 Dr M.Tikkanen Seq 
This table does not list research groups for which the unit has provided sequencing purely as service. The 
sequencing facility has over 60 research groups as customers.  
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International 
Institute Department Research Group (PI) Project* 
University of 
Alberta, Canada 
Faculty of Rehabilitation 
Medicine 
Prof. T.Videman 
Prof. MC.Battie 
SNP 
Human Genetics Prof. S.Nelson 
Prof P.Pajukanta 
SNP 
SNP, expr 
University of 
California, Los 
Angeles, USA Chemistry and 
Biochemistry 
Prof C.Lee SNP 
McGill 
University, 
Quebec, Canada 
Génome Québec 
Innovation Center 
Prof TJ.Hudson SNP 
INSERM U525, 
Paris, France 
Médecine Pitié-
Salpêtrière 
Prof. F.Cambien SNP 
Queen's 
University 
Belfast, Ireland 
Epidemiology and Public 
Health 
Prof. A.Evans SNP 
Royal College of 
Surgeons in 
Ireland 
Clinical Pharmacology Dr D.Shields SNP 
Uppsala 
University 
Medical Sciences Prof. A-C.Syvänen SNP 
*Projects involving mainly SNP=SNP genotyping on microarray; expr=expression profiling; 
seq=sequencing; custom= method development. 
 
 
2.7. Proposal for the future work and expected (societal) benefits (next 
five years) 
As the operations of the Institute of Molecular Medicine Finland (FIMM) are planned to 
get started in the beginning of 2008, the Sequencing laboratory will move its operations 
into new FIMM facilities and integrate it’s operations and databases with the Finnish 
Genome Center (FGC). By this integration we plan to intensify the synergy in the 
structural analyses of genome. A major and constant challenge in genome analyses is 
the ever growing need of organized data storage and bioinformatics. In the FIMM 
environment we hope to benefit from FGC’s strong IT infrastructure and tight 
collaboration with Genome Informatics Unit (GIU). Biotechnology core already 
collaborates with the FGC in several areas, including method development and QC 
standards, thus we are convinced that the merge will create a major infrastructure 
platform for FIMM and the whole biomedical research community of Finland. 
 
A major enhancement in SeqLab’s service profile is to evaluate and acquire one of the 
ultra-high-throughput sequencing platforms for FIMM and Biomedicum research 
community. Evaluation process is already well on its way and acquisition hopefully 
takes place during 2007. Novel technology platform will provide powerful tool for 
targeted re-sequencing of human genome, both deep sequencing (e.g. cancer genomics) 
and broad sequencing such small RNAs and expression profiling. Due to the throughput 
and clonal nature of novel sequencing methods SeqLab/FGC enables the FIMM and 
Biomedicum research community to approach their research project from new aspects 
thus speeding up discoveries in medicine. The core also aims to adapt new core 
laboratory services which fit to our profile: A good example of such methodology is 
Illumina Golden Gate Mouse Arrays for speed congenics, which we have adapted 
during 2007. 
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In long term plans the Biotechnology core operations aim to quickly test and adapt 
novel high-throughput methods needed by the surrounding research community. The 
means for reaching such a goal are solid networking with other professionals 
(researchers, bioinformatics, administration) and educating the staff to be experts in 
high-throughput platforms in terms of technology, process oriented thinking and cost-
effectiveness. We also aim to work in close collaboration with GIU to develop 
methodology for data storage, handling, and analysis. 
 
 
2.8. Senior personnel 
Janna Saarela, MD, Ph.D., group leader 
Pekka Ellonen, B Eng, laboratory manager 
Kaisa Silander, Ph.D., senior scientist 
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3 BIOINFORMATICS 
 
3.1. Research area and its significance 
Bioinformatics has become an integral and essential part of life science research 
gradually since its emergence in 1980’s. Availability of all genome-wide data has 
facilitated the ongoing shift in molecular biology and molecular medicine to 
information based science. Accordingly the role of various interdisciplinary sciences, 
like bioinformatics, computational biology and biostatistics is being further emphasized. 
Generally no longer is molecular biology or molecular medicine performed only in the 
wet lab, but rather the integration of informatics techniques has become essential part of 
the research. In addition to the professionals in bioinformatics or in related areas, also 
scientists primarily working in the wet-lab are using more and more the various 
computational methods in their research. 
 
 
3.2. The main achievements 
The bioinformatics group in National Public Health Institute of Finland, Department of 
Molecular Medicine is the central part of an intellectual core facility, the Genome 
Informatics Unit GIU, www.giu.fi). The unit was established in 2002, as a collaborative 
project between the University of Helsinki and, Bioinformatics group and later fused 
with the bioinformatics group of the Finnish Genome Center, University of Helsinki in 
2006. The unit is directed by Dr. Juha Saharinen (National Public Health Institute). 
Since the KTL bioinformatics group is integrated as part of GIU, the rest of this 
evaluation report covers the acts of the whole GIU. 
 
The purpose of GIU is to provide scientific biocomputing expertise, high-performance 
computing resources and availability and own development of bioinformatics databases 
and software for researchers. The focus areas of GIU are sequence analysis, gene 
expression analysis, genomic annotations as well as genetic linkage and association 
analysis.  
 
Currently GIU has about 650 users from the different non-profit research organizations 
from University of Helsinki, KTL, other Finnish universities and non-profit 
organizations as well as from abroad. By measurement of the number users, GIU is by 
far the largest academic bioinformatics establishment in Finland. In addition, GIU is not 
acting just a bioinformatics oriented computational service provider, rather all the 
personnel in GIU are actively involved in various collaborative projects, requiring 
expertise in bioinformatics data analysis as well as in development of applications, 
algorithms and relational database structures for analysis and storage of biological data.  
 
High-performance computing Infrastructure: GIU has its own high-performance 
computing instrumentation, including Linux cluster, enterprise scale relational database 
servers, storage networks, terminal server farm etc. The annual CPU capacity usage is 
about 60 CPU years, corresponding to about 3.8 million Cray MP CPU hours per year, 
putting GIU as the most used bioinformatics computing center in Finland.  
 
Bioinformatics software and database development: GIU has made several 
bioinformatics applications and databases, which are used either in GIU own research, 
amongst GIU users, or in other universities in Finland and abroad. These applications 
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include enterprise scale relational database management systems for genetics and 
functional genomics data, namely including (see 
www.giu.fi/Core/Databaseandsoftwareprojects/tabid/73/Default.aspx for more complete 
list): GLIMS - complete laboratory information management system for 
genetic/genotyping laboratories; WebSaman - sample management and tracking LIMS 
system for high-volume laboratories (“BioBanks”); GenoFeno – genetic data: genotype, 
phenotype, pedigree and sample management system; GenoMart – high-volume whole 
genome association genotype and phenotype data warehouse (https://genomart.gu.fi); 
CanGEM – gene expression, aCGH and LOH database and data mining warehouse 
(www.cangem.org) as well as numerous other bioinformatics data management systems. 
Further GIU has been in a central role of multi-national scale data federation projects, 
where we have developed the database infrastructure, user interfaces, data federation 
concept as well as secured VPN connections for partnering centers to deposit, extract 
and analyze federated genetic data. These projects include the GenomEUtwin and 
Nordic Center of Excellence in Disease Genetics (see 
www.giu.fi/Core/Internationalcollaboration/tabid/80/Default.aspx) for more complete 
list). In addition to the bioinformatics databases and software developed in GIU, we 
provide our users the largest collection in Finland of the publicly available 
bioinformatics applications and databases in its focus areas and update these frequently 
(see https://apps.bioinfo.helsinki.fi/software/) for complete list of the public databases 
and software available in GIU). These allow fusion/linking of different data entities 
from both public as well as internal data repositories (like genotype, gene expression 
and molecular pathway data) and support systematic high-performance and high-
throughput analysis environment. We have also developed data analysis applications 
utilizing this concept and used them in multiple research projects. 
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Figure 1. Major bioinformatics  databases developed at GIU 2004-2007. 
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Figure 2. Bioinformatics database federation concept. The genetic data federation context,  
mainly developed in GIU is here illustrated as it is implemented in the GenomEUtwin  
project. The participating centers in different countries share their part of the data, which  
is federated via the data hub located in GIU, allowing all the participating centers to have  
a secured and controlled access to the data. 
 
 
3.3. Scientific impact  
The scientific impact of GIU can be categorized into three sections: 1) bioinformatics 
research originated/developed in GIU, 2) collaborative bioinformatics, statistical data 
analysis and data mining for research projects originated in other research groups and 3) 
teaching and advice on usage of bioinformatics, statistical and data mining tools, 
algorithms and databases. 
 
We have been collaborating in numerous studies providing expertise bioinformatics, 
statistics and data mining methods. Our primary focus areas have been in analysis of 
functional genomics and genetics data. Many of these projects are mentioned in the 
section 3.6. Scientific collaboration. In addition to collaboration/inclusion of authorship, 
we have been doing a lot of advising on how to design experiments and analyze the data, 
in cases where the researchers are able to self learn and conduct the data analysis and 
allowing the scientific personnel in GIU to focus on more demanding data analysis tasks. 
 
Another aspect of scientific impact involves teaching of the bioinformatics methods and 
resources. We have organized two extensive graduate student courses annually, one 
focusing on gene expression data analysis and the other on bioinformatics databases and 
data resources. In addition, we have organized each year a number of short term courses 
on various aspects of bioinformatics and high-performance computing related topics. 
 
Background material                                                                       3 BIOINFORMATICS 
 
 52 
The bioinformatics research originating mainly in GIU is a more nascent area and is to 
be increased in the future. Our research topics are in general based around the more 
efficient analysis of various high performance/high volume data sets, typically in a 
manner that is made possible by the strength of GIU of having also the high-
performance computing, software and database development and repositories within the 
group in addition to the scientific research interest.  
 
Here are listed the major scientific software applications developed in GIU during 2004-
2007 and excluding all GIU Core applications (i.e. non-scientific bioinformatics 
database and software). 
 
Name:  CanGEM Authors: Ilari Scheinin, Juha Saharinen 
Status:  In full production use 
Home page: www.cangem.org  
Description: CanGEM is a database service for storing detailed clinical information about tumor 
samples and microarray data. Main emphasis is on data mining studies. CanGEM is composed 
of custom made database/datawarehouse and a www interface partially using the latest Web 
2.0/AJAX technologies alleviating most of the limits of traditional www application interfaces. 
CanGEM can store gene expression, array CGH/copy number, sample and phenotype data as 
well as experimental protocol data from a variety of microarray platforms (Affymetrix, Agilent, 
cDNA arrays). CanGEM includes proper authentication and access rights management system, 
providing users with different access levels to different projects. 
 
 
Name:  LocusExpression  Author:  Juha Saharinen 
Status:  In production use and under further development 
Home page: None at the moment 
Description: LocusExpression is a genome-wide gene expression data analysis 
method/application for finding locus/loci of genes indicating coordinated expression regulation, 
deviating from a permuted empirical expression. The genes of a given locus may all need not to 
be regulated, LocusExpression is able to find any significant partial expression regulation 
patterns composed of combination of genes in the given locus. Also the genes may not need to 
have significant expression regulation p-values as individual genes. LocusExpression is a Linux 
command line application, utilizing the high performance computing power and genome 
databases publicly available at GIU. Thus far LocusExpression method has been successfully 
used in one submitted publication. 
 
 
Name:  ExpressionPathways   Author: Juha Saharinen 
Status:  In production use and under further development 
Home page: None at the moment 
Description: ExpressionPathways is a genome wide gene expression data analysis 
method/application for identifying coordinately regulated biological associations of genes 
(“pathways”). The genes of a given pathway may all need not to be regulated, 
ExpressionPathways is able to find any significant partial expression regulation patterns 
composed of combination of genes in the given pathway. Also the genes may not need to have 
significant expression regulation p-values as individual genes. ExpressionPathways is a Linux 
command line application, utilizing the high performance computing power and genome 
databases publicly available at GIU. ExpressionPathways method has been successfully used in 
several published or submitted publications. 
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Name:  WGAPathways   Authors: Juha Saharinen 
Status:  In late gamma-testing phase, estimated to be at version 1.0 level by end of Q2/2007 
Home page: None at the moment 
Description: WGAPathways is a genome wide SNP genotype association data analysis 
method/application for identifying coordinately regulated biological associations of genes 
(“pathways”) sharing association signal. The genes of a given pathway may all need not to be 
regulated, WGAPathways is able to find any significant partial expression regulation patterns 
composed of combination of genes in the given pathway. Also the SNP markers may not need 
to have significant association p-values as individual markers. WGAPathways is a Linux 
command line application, utilizing the high performance computing power and genome 
databases publicly available at GIU. WGAPathways method is under testing in five different 
WGA datasets for complex diseases. 
 
 
Name:  gwtf   Authors: Tommi Ripatti, Juha Saharinen 
Status:  In late beta-testing phase, under statistical performance evaluation 
Home page: None at the moment 
Description: Traditionally prediction of transcription factor binding sites form sequence, 
regulating gene expression has been immensely difficult task, producing typically ~10-fold false 
positive rate. Recent addition of using comparative genomics (phylogenetic footprinting) has 
increased the performance significantly, but still we are far from a robust and reliable method. 
Gwtf is an attempt to utilize other than linear sequence information for TFBS prediction, 
namely benefitting from spatial signals in the DNA/predicted TFBSes in addition to 
comparative genomics information. This and other information is then analyzed by machine 
learning methods, both by supervised and un-supervised manner, in an attempt to produce more 
reliable TFBS predictions which then are used to predict meaningful rSNPs. Some parts of gwtf 
system have been used in a published paper. 
 
 
Name:  GeneSOAP    Authors: Juha Saharinen, Teemu Perheentupa 
Status:  In late public gamma-testing phase  
Home page: www.giu.fi/Default.aspx?tabid=215  
Description: GeneSOAP provides a web services interface for execution of tens to hundreds of 
different bioinformatics applications and databases. GeneSOAP can distribute the execution of 
the applications to e.g. various servers/clusters in different institutions, providing a GRID 
middleware functionality. GeneSOAP provides a standard and secured WebServices/SOAP 
interface, usable in any modern programming language (Perl, Python, Java, C#, VB, Ruby, C++ 
etc.)  as well as  command line interface, native Windows graphical client and www interface 
(BioPortal). 
 
 
Name:  AffySNP    Author: Juha Saharinen 
Status:  In full production use 
Home page: None at the moment. 
Description: AffySNP is a program for handling Affymetrix WGA SNP genotyping data to be 
further analyzed for linkage multipoint lod scores in pedigrees with inbreeding loops. 
 
 
Name:  CartoGrapher   Authors: Juha Knuuttila, Juha Saharinen 
Status:  In full production use and under statistical testing for improvements 
Home page: www.giu.fi/Default.aspx?tabid=118  
Description: A properly-ordered marker map is essential for successful linkage analyses. 
Existing genetic marker maps have been shown to be inconsistent with the actual genome 
sequence, and manual construction of maps is time consuming and error prone. To solve this 
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problem, we have developed Cartographer, a method that automatically builds a physically-
ordered marker map, generated from a list of marker names, using the localization of full-
marker and marker-primer sequence data. Cartographer is provided also with a web interface in 
BioPortal (https://apps.bioinfo.helsinki.fi/software/cartographer.aspx
 
Name:  MPD – Multiplex Primer Designer Author: Juha Saharinen 
Status:  In full production use 
Home page: www.giu.fi/Default.aspx?tabid=199  
Description: Multiplex primer designer (MPD) is a program for designing primers for 
multiplexed PCR reactions such as multiplexed SNP genotyping assays. MPD designs PCR 
assays avoiding annealing of primers to the other products in the multiplexed reaction. MPD 
screens the generated primers for homology against other sequences within the multiplexed 
assay and rejects high homology candidates. In addition, Multiplex primer designer will use a 
Primer3 repeat masking library to prevent primer design within repeated genomic regions. 
Currently a human specific repeat library is used. MPD is provided also with a web interface in 
BioPortal (https://apps.bioinfo.helsinki.fi/software/mpd.aspx
 
Name:  siRNA designer   Author: Juha Saharinen 
Status:  In full production use 
Home page:  None at the moment 
Description: siRNA designer is a method/application for designing optimal siRNA/shRNA gene 
silencing targets/oligos. siRNA designer is based around the latest information of 
thermodynamic asymmetry in RNA strand specificity of RISC complex loading as well as a 
large number of experimentally deduced heuristical rules for optimal siRNA/shRNA targets. In 
addition, siRNA designer adds to the model the most probabilistic RNS secondary structure 
information, aiming to target siRNA/shRNA oligos to regions of low RNA strand dublex 
occupancy. Further, siRNA designer validates the uniqueness of the candidate probes by 
sequence level homology searches against target organism specific cDNA sequences. siRNA 
has been compared to other known siRNA/shRNA design tools/methods and successfully used 
in number of projects, including the Helsinki Biocentrum Systems Biology Initiative for making 
a library of hundreds-to-thousands siRNA/shRNA silencing constructs.  
 
 
Name:  SNPSnapper   Author: Juha Saharinen 
Status:  In full production use 
Home page: www.giu.fi/dnn/Default.aspx?tabid=179 
Description: SNPSnapper is a software package developed to produce accurate allele calling and 
genotyping of samples from custom SNP microarray data in semi-high-throughput genotyping 
facility. The raw data obtained from a microarray canner, containing intensity values of the 
localized spots, is first read and sorted according to SNPs and genotyped persons. Allelic pairs 
of each SNP for a given person are then sought and different graphical representations are 
drawn based on calculated data from the allelic pairs, in which the sample pairs are shown as 
dots. The allelic calls/genotypes assignments are done semi-automatically using unsupervised 
machine learning algorithm, possibly further tuned by the user. SNPSnapper is backed up by a 
custom made relational database for a LIMSS system containing experiments, projects, chips, 
subjects genotypes, array designs etc. and includes proper authentication and access rights 
management system, providing users with different access levels to different projects. SNP-
Snapper is in production use in multiples genotyping laboratories in many countries.  
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3.4. Societal impact 
Courses 
A significant part of the GIU efforts are devoted to educating the scientific society in 
key areas of bioinformatics, covering how to analyse data acquired through genome-
wide technologies, e.g. expression and SNP microarrays, and how to use biological 
information from public repositories (biodatabases), to yield more biologically relevant 
interpretation of the data. This is achieved by organising courses, seminars and one-on-
one consultations for scientists in, or associated with, research groups in Biomedicum. 
Courses are either organised on our own initiative, requested by researchers in need of 
tutoring in topics related to bioinformatics or arranged on behalf of other educational 
organisations. 
 
Courses organised on behalf of Helsinki Biomedical Graduate School, include the 
following: 
• Practical Bioinformatics - Microarray data processing, analysis and management, 
2006 
• Practical Bioinformatics - Biodatabases, 2006 
• Practical Bioinformatics - Microarray data analysis, 2007 
• Practical Bioinformatics - Biodatabases, 2007 
 
Courses organised on our own initiative, or by specific request from researchers, 
include the following:  
• Using GeneSpring for analysis of microarray data - basics, 2005 
• Using GeneSpring for analysis of microarray data - advanced, 2005 
• Using BRB Array Tools for microarray data analysis, 2005 
• Crash-course in basic microarray data analysis for Biomedicum researchers, 2006 
• Crash-course in basic microarray data analysis for NPHI/MLO researchers (29.9.2006) 
• Basic databases and SQL for Bioinformatics, 2007 
 
In addition to the above courses usually taught at class-room scale, a wealth of smaller 
scale courses, or tutorials, instructing researchers how to use the numerous 
bioinformatics tools developed by GIU have been given on request. Guidance in issues 
related to the analysis of large scale data sets as well as how to incorporate information 
from biodatabases into the analysis and/or the interpretation of the results have also 
been given to satisfy specific needs of research groups.  
 
GIU staff is also involved in teaching during courses organised by other organisations. 
Examples of this are the following courses given by the Finnish Centre for Scientific 
Computing (CSC); 
• GeneSpring basic course, 2003 
• GeneSpring basic course, 2006 
 
Impact on national bioinformatics ecosystem 
GIU provides several services nationally for life science researchers that are unique in 
Finland. These include various genetic data handling solutions (GenoMart, GenoFeno, 
CliniFeno etc. systems), computational resources (HPC Linux cluster, enterprise scale 
database servers, MS Windows server farm etc.) as well as collaboration on scientific 
projects. 
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In the very near future, GIU is planning too opening its bioinformatics database services 
to be openly accessibly directly from any Finnish research organization, without the 
need to log in to GIU system and thus being easier to integrate into institutes’ own data 
analysis pipelines. Further GIU will open its BioPortal WWW service for hundreds of 
bioinformatics applications and databases for open use (currently available for testing at 
https://apps.bioinfo.helsinki.fi/software). 
 
Collaboration in international bioinformatics service projects 
GIU has been actively collaborating and working with data integration systems and 
standards for genetic research. The work has been done in international research 
programs and consortiums like P3g (www.p3gconsortium.org), GenomEUtwin 
(www.genomeutwin.org), NCoEDG (www.ncoedg.org) and the PML 
(www.openpml.org). 
 
The data integration system developed for the GenomEUtwin project allows to federate 
data directly from seven twin centres using secure distributed database techniques. 
Currently the system provides access for phenotypic data of over 200 000 twins. In 
addition to GenomEUtwin, the GIUs expertice in data integration systems and standards 
are also used in other projects like Nordic Centre of Excellence in Disease Genetics and 
Centre of Excellence in Academy of Finland. GIU is also participating in multiple 
applications submitted for the 7th EU framework. The applications, sent as bids for six 
different calls, are related database and data integration systems and standards for 
molecular epidemiological studies, biobanking and medical genomics. 
 
GIU is also the home for public and open CanGEM (cancer genome mining) –database 
(www.cangem.org), which is developed in GIU. CanGEM is an integrative, systems 
biology oriented database for array CGH and gene expression data of cancer samples, 
bound to various international ontologies (eVOC, WHO ICD-10, TNM). Currently 
CanGEM contains data from about 1,500 samples. 
 
 
3.5. Funding 
About 90% of both the personnel and computer instrumentation and maintenance 
funding of GIU is coming from competitive research sources. The annual salary sum is 
about 600 000€ and the annual expense of the instrumentation is about 200 000€, as 
averaged over the five year period of GIU’s existence. 
 
Due to the nature of a substantial proportion of GIU being a high-performance computer 
and scientific software and database development unit, and thus not completely devoted 
to science, this is a quite problematic situation. In order to acknowledge the established 
and proven status of GIU as a bioinformatics and statistical computing unit, our 
suggestion would be that National Public Health Institute provide similar level of 
funding for the infrastructure part of GIU as it is providing the administrative ICT and 
data management units in KTL, and thus only the research persons in GIU would be 
funded from the research grants. This would also have a great impact on the quality of 
service in GIU due to adequate sever maintenance agreements and more predictable 
budget for renewal and upgrade of the instrumentation. 
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Figure 3. Funding of the high-performance computing instrumentation in GIU. 
About 85% of the funding has come from competitive sources. 
 
 
Background material                                                                       3 BIOINFORMATICS 
 
 58 
3.6. Scientific collaboration  
This list covers the list of scientific collaborations have taken place during 2003-2007. 
 
Global transcript profiles and pathways of adipose tissue in weight-discordant 
monozygotic twin pairs. Prof. A.Rissanen, Dr. M.Oresic, Prof. H.Yki-Järvinen, Prof. 
J.Kaprio, Prof. L.Peltonen (University of Helsinki, Helsinki University Central Hospital, 
KTL, VTT Technical Research Centre of Finland) 
Transcript profiles of brain in Cln1 and Cln5 deficient mice. Dr. A.Jalanko, Prof. L.Peltonen 
(University of Helsinki, KTL) 
Activating mutations in colorectal adenocarcinomas. Prof. L.Aaltonen (University of 
Helsinki) 
Comparative genomics analysis of genomic landscape and gene expression in vertebrates. 
Prof. H.Mannila, Prof. L.Peltonen (University of Helsinki, KTL, HIIT Helsinki Institute for 
Information Technology) 
Transcript profiles and pathways of dendritic cells of PLOSL patients link demyelinating 
CNS disorders. Prof. I.Julkunen, Prof. L.Peltonen (University of Helsinki, KTL) 
The federated database - a basis for biobank-based post-genome studies, integrating 
phenome and genome data. Prof. L.Peltonen, Prof. JE.Litton (University of Helsinki, KTL, 
Karolinska Institutet, Sweden) 
Indicative oligodendrocyte dysfunction in spinal cords of human fetuses suffering from a 
lethal motoneuron disease. Dr. M.Kestilä, Prof. L.Peltonen, Prof. H.Sariola, Dr. 
K.Wartiovaara (University of Helsinki, KTL) 
Gene expression and copy number profiling in asbestos-associated lung cancer. Dr. 
H.Wikman, Prof. J.Hollmen, Prof. S.Knuutila, Prof. S.Anttila (University of Helsinki) 
Infantile onset spinocerebellar ataxia caused by mitochondrial proteins Twinkle and 
Twinky. Prof. L.Peltonen, Prof. A.Suomalainen (University of Helsinki, KTL) 
Transcriptomal profiling of human lymphatic endothelial cells. Prof. K.Alitalo, Prof. 
D.Kerjaschki (University of Helsinki, University of Vienna, Austria) 
Cellular pathways and DNA copy number changes in primary uterine leiomyosarcoma. Dr. 
T.Böhling, Prof. S.Knuuttila (University of Helsinki, Helsinki University Central Hospital) 
Profiling genetic variation along the androgen biosynthesis and metabolism pathways in 
prostate cancer. Dr. J.Schleutker, Prof. O.Kallioniemi, Prof. M.Vihinen (University of 
Tampere, VTT Technical Research Centre of Finland) 
Batten disease (JNCL) linked to disturbances in mitochondrial, cytoskeletal, and synaptic 
compartments. Dr. A.Jalanko, Prof. L.Peltonen (University of Helsinki, KTL) 
Pathways regulating cell size and cell-cycle progression. Prof. J.Taipale (University of 
Helsinki, KTL) 
Cross-species analyses in human glucose metabolism. Prof. J.Kaprio, Prof. A.Rissanen, Prof. 
V.Salomaa, Prof. K.Kontula, Prof. MR.Taskinen, Prof. P.Pajukanta, Prof. L.Peltonen 
(University of Helsinki, Helsinki University Central Hospital, KTL, University of California, 
Los Angeles, USA) 
USF1 and dyslipidemias. Prof. P.Pajukanta, Prof. MR.Taskinen, Prof. L.Peltonen (University 
of Helsinki, Helsinki University Central Hospital, KTL, University of California, Los 
Angeles, USA) 
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3.7. Proposal for the future work and expected (social) benefits (next 
five years) 
Together with the establishment of the Finnish Institute for Molecular Medicine (FIMM) 
and integration of the Department of Molecular Medicine into FIMM the national role 
of GIU as a research oriented bioinformatics unit will be further emphasized and 
tentatively supported by increase of both personnel as well as computing hardware 
capacity. 
 
 
 
 
Figure 4. National access of the GIU bioinformatics database and software repositories. 
The goal is to build national system for access of the resources in GIU and allowing 
direct connections to these from all the Finnish Biocenters, in a way that supports 
systematic, high-performance and high-throughput analysis. CSC (National 
supercomputing resource in Finland) is planned to provide the peak computing capacity 
for most CPU intensive data analysis. 
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3.8. Personnel 
The personnel involved in GIU comprise postdoctoral and graduate level researchers, 
system administrators as well as students, emphasizing the role of GIU as an 
educational entity. The background education of the employees varies including 
biochemistry, computer science, mathematics and civil engineering. The co localization 
of the bioinformatics unit in the same building with the traditional wet lab laboratories 
has proven to be a key issue for a successful collaboration between the two disciplines 
and emphasized the status of bioinformatics being a cross-disciplinary field of science.  
 
Currently GIU employs 15 persons, 10 of them with the competitive external funding. 
The division of the GIU personnel into Infrastructure, Core (bioinformatics software 
and database development and management) and Science in depicted in Figure 5. 
 
 
Figure 5. Structure and personnel in GIU. 
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4 Large Scale DNA Extraction and Storage Facility 
National Biobank of Finland 
 
4.1. Background 
 
Numerous global efforts have been launched recently to establish biobanks. The word 
‘biobank’ is a little over a decade old. The first record in PubMed of its use appears in 
1996. A biobank has recently been defined by OECD as “a collection of biological 
material and the associated data and information stored in an organised system for a 
population or a large subset of a population“. KTL biobanking effort is older than most 
biobanks and importantly has been founded based on the epidemiological data 
collections. Already in early 1980s the large ATBC study had a strong biological 
sample arm and since 1990 all the epidemiological data collections of KTL have been 
accompanied by the systematic collection of biological samples, serum, plasma, blood 
for DNA extractions and biomarker determinations. MLO has been the centralized site 
for DNA and RNA extraction, storage, aliquoting and logistics for all KTL study 
samples. However, while individual collections can be well organised and accessible, 
there remains a need to harmonise between them by establishing networks. There also 
remains a need to ensure the longevity of the resources through appropriate funding 
mechanisms. Further, the DNA extraction and logistics laboratory has become a 
national site for biobanking materials, it holds numerous other large cohorts samples, 
including all the twin cohort samples and all Finnish birth cohorts samples 
(www.nationalbiobanks.fi). During past 10 years the KTL biobanking laboratory has 
also become the international DNA logistics site being in charge for DNA extraction 
and logistics for numerous EU funded studies. 
 
In the KTL biotechnology strategy biobanking was recognized as a key element for the 
future success of KTL. At the European level, many MLO investigators played a key 
role in biobanking-related discussions of the European Strategy Forum on Research 
Infrastructures (ESFRI) comprises representatives of EU Member States and Associated 
States and a representative of the European Commission. Its role is to support a 
coherent approach to policy-making on research infrastructures in Europe, and to act as 
an incubator for international negotiations about concrete initiatives. In 2006 its 
Roadmap for pan-European research infrastructure development across the sciences was 
published and then formally received by the Commission. ESFRI’s decision to include 
infrastructure to underpin research in the life sciences is significant because it indicates 
that there is for the first time a general recognition that the scale of life science research 
endeavours has increased to a point where separate research groups and various 
biobanking efforts need to pool resources. Europe’s national health care systems have 
facilitated collection of clinical samples and produced highly reliable health care 
records. Furthermore, Europe has strengths in epidemiological studies that have, over 
decades, accumulated data complemented often by biological samples. The diversity of 
European populations with well established but different histories is a beneficial feature 
for various research strategies. New biobanking initiatives have been launched and just 
like the older biobanks, they all rely on these strengths. The ministry of social and 
health affairs supported this effort as one of the major Finnish ESFRI initiatives and 
MLO investigators were in the critical position in producing the BBMRI bid for the 
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ESFRI call of FP7. MLO houses the website of BBMRI and Dr. Peltonen is the chair of 
the governance board of BBMRI (www.biobanks.eu). 
 
When the first DNA extraction facility was initiated in KTL in 1990, the DNA was 
extracted manually, and sample information was stored mainly by researchers working 
in distinct projects. As the number of collected samples increased yearly there was a 
growing need for centralized DNA extraction core unit; permanent staff, and automated 
DNA extraction and aliquoting machinery. During the evaluation period 1997-2007 the 
number of the staff has increased from two laboratory technicians to 11 persons. 
Autopure DNA extraction robot was purchased in 2001 and Tecan aliquoting robot in 
2002. The functioning of the unit has evolved from a DNA extraction laboratory into a 
coordinated biobank. The need for a large-scale DNA logistics facility in KTL has 
originally arisen from the needs of scientists working with large sample collections and 
this need still clearly exists. From the very early start we have seen the synergy of the 
Core working in close interaction with both the clinicians collecting the samples as well 
as geneticians utilizing the DNA in their studies. This has been a very fruitful approach 
ensuring both that the Core key personnel is closely following the front-line of genomic 
science and also realizes the importance of flexibility and rapid response to changing 
requests from biobank users. Accordingly, due to its good track record and the trust in 
our professional approach, the Core has been selected as the DNA biobank for several 
large international projects, funded by EU, pharma and different governmental and 
private entities. 
 
We have during the years of operation evaluated several commercially available 
database systems for the facility. However, after careful consideration, we have decided 
to develop the database interfaces in-house to ensure the flexibility and data protection 
needed in this kind of large cross-departmental facility. The database system of the 
facility works as a web - client to web - server connection to SQL server 2005 database. 
The web - client uses newest AJAX functionality offered by Microsoft to enable smooth 
UI. All operations to database are logged into transaction log, so it is possible to see 
what modifications have been done by whom. All operations can be rolled back using 
internal transaction handling mechanism. The sample receive, DNA extraction and 
DNA dilution are all combined to single web - client. There is large number of checks 
to make it possible to check to logical content of DB in any moment.  
 
 
4.2. Functioning of the unit and the main achievements 
Currently the biobank houses over 200 000 DNA samples, and some hundreds of RNA- 
and protein samples. Emphasis of the biobank is in DNA extraction, quality control and 
logistics. In 2006 over 15 000 DNA samples were extracted, and over 45 000 DNA 
aliquots were distributed to researchers worldwide. In addition to extraction and 
aliquoting robotics the facility is equipped with a state of the art bar coding system for 
sample tracking and confidentiality, and a tailor made database, SamWise, for data 
management, the full control of logistics, and on-line monitoring of the sample 
processing.  
 
The facility is responsible for sample management in several national and international 
research projects. The biggest national projects are Finrisk-studies (-87, -92, -97, -02, -
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07; approximately 60 000 DNA samples), Health2000 (15 000 DNA samples), and 
Finnish Twin cohort (over 13 000 DNA samples). The major international projects are 
EU-projects GenomEUTwin and Genetics of Healthy Ageing (GEHA) and the 
International MORGAM study. Except these large population cohorts, the unit also 
handles the DNA logistics or various study samples ascertained for major diseases like 
cardiovascular diseases, schizophrenia or autism. 
 
 
 
 
Data entry and recording of 
the sample
Extraction
Concentration 
measurement
Storing of samples 
and data
Aliquoting Shipping  
 
 
Figure 1. Handling of samples in the DNA isolation process 
 
 
4.3. Scientific and societal impact 
Human biological samples including associated medical data, and biomolecular research 
tools are a key resource in unravelling the interplay of genetic and environmental 
factors causing diseases and impact on their outcome, identification of new targets for 
therapy and reduction of attrition in drug discovery and development. The Finnish 
national biobanking effort has already biological samples from over 4% of the 
population and thanks to the KTL’s position as the national health monitoring authority, 
the linking of epidemiological data and vast amount of data collected via the national 
health care system with the information produced from biological samples is 
exceptionally feasible. KTL can build on existing sample collections, resources, 
technologies, and expertise, which is increasingly complemented with innovative 
components of the use of genome wide tools and properly embedded into Finnish 
scientific, ethical, legal and societal framework. The scientific impact of the Finnish 
biobank has already proven to be high, most of the frequently cited publications of 
MLO and KTL have been produced based on the biobank samples.  Further, several EU 
grants have been obtained thanks to this centralized, well organized effort of MLO. 
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Finally, most large scale national efforts in molecular epidemiology as well as the 
European BBMRI are heavily dependent on the sustainability and continuity of this 
national biobanking resource and the database and analytical structure integrated with it. 
 
 
4.4. Funding 
About 60% of the funding comes from the governmental budget covering salaries of 
technicians and a laboratory manager. The salaries of a project manager and another 
laboratory manager are paid by the competitive external funding (20% of total budget). 
Profits from services cover the rest of the funding, total budget being about 500 000€. 
About 35% of the budget is used for supplies and equipments. 
 
4.5. Scientific collaboration  
 
Figure 2. Collaborations of DNA extraction and storage facility/National Biobank of 
Finland 
 
 
4.6. Proposal for the future work and expected (social) benefits (next 
five years) 
The facility plans to stay in the fore-front of modern sample management. This will be a 
necessity given the large and significant international responsibilities taken up by us. 
We are key members in large EU-funded projects, such as GenomEUtwin, GEHA and 
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ENGAGE, in which especially the sample management issues have been dedicated to us. 
The facility personnel frequently visit the partner laboratories and groups to exchange 
ideas and experiences and takes also part in scientific meetings of the projects, when 
seen necessary or useful. We are also a member of P3G and ISBER-organizations and 
regularly participate in their meetings to get up-to-date information and share our 
experiences in modern sample management. The facility will be a Core Unit in the 
newly founded FIMM and clearly a necessity for the Institute to meet its mission. The 
greatest challenges in future are in keeping up with the increasing need for rapid large-
scale extraction and aliquotting of specific sample sets. This challenge will be faced 
with increasing automation of the facility and continuing development of the database 
tools in house. 
 
 
4.7. Personnel 
The facility has a highly qualified staff of a project manager (Päivi Laiho, Ph.D.), two 
laboratory managers (Outi Törnwall, M.Sc., Minttu Jussila, M.Sc.) for DNA extraction 
and aliquoting logistics, and eight laboratory technicians. In 2006, KTL/MLO recruited 
the expert in biobank-related societal and ethical issues, Professor Helena Kääriäinen, to 
emphasize the critical importance of the societal impact of this national effort. 
 
 
4.8. References 
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5 FINNISH DISEASE HERITAGE 
 
5.1. Research area and its significance 
In the beginning of 70’s a concept of the Finnish disease heritage (FDH, 
www.findis.org) was introduced by Jaakko Perheentupa and colleagues. Today FDH 
consists of 36 distinct monogenic disorders (Figure 1.), which are more common in 
Finland than in other countries. The reason for this enrichment is thought to be the 
founder effect/population bottlenecks, inbreeding and the relative isolation of Finnish 
population, because of linguistic, geopolitical and geographical reasons.  
 
 
 
Figure 1. Diseases of the Finnish disease heritage presented as so called Perheentupa’s 
steps. The vertical line shows the year when the phenotype was published for the first 
time.  
 
The search for the disease-causing genes started in the 1980’s. Some of the disease 
genes were characterized based on the knowledge about of a known protein that was 
found to be defective in a disease. However, this kind of information was not available 
in most disorders and different approach was needed.  
 
In the end of 1980’s Leena Peltonen and co-workers started to search for FDH genes by 
positional cloning. This is the method of choice to find the gene when the molecular 
pathogenesis of a disease is unknown. Initially, a locus was localized to a specific 
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chromosomal region by linkage analysis in families. Next the critical DNA-region was 
restricted by using linkage disequilibrium and monitoring for a shared haplotype among 
affected individuals. Finally regional candidate genes were analyzed in order to identify 
the disease-causing mutations.  
 
In general, the study of monogenic diseases has provided most valuable information on 
the molecular pathology of diseases, on the basic consequences of different mutations, 
as well as on the identification of the physiological functions of human genes. 
Furthermore, identification of the disease causing genes and respective proteins, have 
opened avenues to understand novel metabolic pathways and exposed new potential 
causative genes.  
 
The detection of the specific mutations has provided molecular tools for the diagnostics 
of FDH diseases. Consequently gene and mutation specific diagnostic methods have 
been developed and they are in use for prenatal and postnatal diagnostics. In principle, 
the high throughput methods developed for screening of the FDH disease mutations 
would enable us to effectively screen for the mutation carriers. We have tested a chip 
with 19 disease mutations in the random sample of Finnish population and established 
carrier frequencies varying regionally from 1:6-1:12 for all mutations. Perhaps even 
more importantly, identification of a disease gene has created also an excellent tool to 
study molecular and cell biology of the diseases, the final goal, yet mostly to be 
achieved, being the understanding of pathogenesis of a disease. In future, this 
information enables us to plan novel therapeutic approaches for FDH and other 
monogenic diseases, based on new potential therapeutic target molecules. 
 
Current investigations have revealed that there is not any clearcut difference between 
monogenic and complex polygenic diseases. Firstly, in a setting of Finland, representing 
a founder population molded by multiple bottlenecks, methods like homozygosity 
mapping or haplotype sharing combined with GWA genotyping platforms can be used 
to identify rare alleles of common disease loci facilitating shorcuts to genes, not 
identifiable by Hapmap-based GWA strategies. Consequently, the knowledge and 
paradigms of the Finnish population structure, established in the study of FDH diseases 
can be applied effectively for the efforts to expose and functionally analyse the allelic 
variants behind complex traits.  
 
 
5.2. The main achievements 
Genetics 
At the moment 35 FDH genes have been characterized. Nineteen of these have been 
identified and/or studied at the Department of Molecular Medicine (previously the 
Department of Human Molecular Genetics) in the National Public Health Institute or in 
the collaboration with MLO researchers (Table 1.). Our efforts in understanding the 
molecular genetics of the FDH genes have revealed the major mutation(s) as well as 
other minor mutations in the Finnish population as well as in some other populations. 
The geographical distribution of the disease alleles in Finland has indicated that this is 
the consequence of the population history and the age of the founder mutation of the 
disease.  
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Table 1. FDH genes that have been identified and/or studied at the Department of 
Molecular Medicine or in the collaboration with MLO researchers. Diseases marked in 
bold are discussed in more detail in this report. 
Disease [OMIM number] 
 
Defective protein/gene 
 
Fin-major mutation 
and its’ percentage 
value in Finnish 
patients 
Amyloidosis V [105120] (dominant) 
 
Gelsolin (GSN) D187N, 100% 
Aspartylglucosaminuria (AGU) [208400] Aspartylglucosaminidase 
(AGA) 
C163S, 98% 
Autoimmune polyendocrino-
pathycandidiasis ectodermal dystrophy 
(APECED) [240300] 
Autoimmune regulator (AIRE) 
 
R257X, 82% 
Juveline neuronal ceroid  
lipofuscinosis (JNCL) [204200] 
Novel transmembrane protein 
(CLN3) 
Genomic deletion of 
1.02 kb, 90% 
Congenital lactase deficiency (CLD) 
[223000] 
Lactase gene (LCT)  
 
Y1390X, 90% 
Congenital nephrotic syndrome of the 
Finnish type (CNF) [256300] 
Nephrin (NPHS1) 
 
c.121_122delCT 
(L41fs), 78% 
Free sialic acid storage disease (Salla 
disease) [604369] 
Solute carrier family 17, 
member 5 (SLC17A5) 
R39C, 95% 
Growth retardation, aminoaciduria,  
cholestasis, iron overload lactacidosis and 
early death (GRACILE) [603358] 
BCS1-like (BCS1L) S78G, 100% 
Hydrolethalus syndrome (HLS) 
[236680] 
Novel protein with unknown 
function (HYLS1) 
D211G, 100% 
Infantile neuronal  
ceroidlipofuscinosis (INCL) [256730] 
Palmitoyl protein thioesterase 1 
(PPT1) 
R122W, 98% 
Infantile onset spinocerebellar ataxia 
(IOSCA) [271245] 
Twinkle protein, mitochondrial 
precursor (PEO1) 
Y508C, 99% 
Lethal arthrogyposis with anterior horn 
cell disease (LAAHD) 
Gene identified, not yet 
published 
Mutation identified, not 
yet published 
Lethal congenital contracture  
syndrome (LCCS) [253310] 
Gene identified, not yet 
published 
Mutation identified, not 
yet published 
Meckel syndrome (MKS1) [249000] 
 
Novel cilia protein (MKS1) IVS15-7_35del 
(P470fs), 100%* 
Northern epilepsy (EPMR)  [600143] 
 
Novel TM protein (CLN8) 
 
R24G, 100% 
Polycystic lipomembranous 
osteodysplasia with sclerosing leuko-
encephalopathy (PLOSL) [221770] 
TYRO protein tyrosine kinase-
binding protein (TYROBP) and  
Triggering receptor expressed 
in myeloid cells-2 (TREM2) 
Genomic deletion of 
5.2 kb, 100%** 
RAPADILINO syndrome [266280] 
 
RecQ protein-like 4 (RECQL4) IVS7+2delT resulting 
in a in-frame skipping 
of exon 7, 85% 
Tibial muscle dystrophy (TMD) [600334] 
(dominant) 
 
Titin (TTN) 11 bp insertion/deletion 
resulting in a change of 
four amino acids, 100% 
Variant late infantile neuronal ceroid-
lipofuscinosis (vLINCL) [256731] 
Novel soluble/TM protein 
(CLN5) 
Y392X, 95% 
*Only about 70% of Finnish MKS-patients have a mutation in the MKS1 gene, but all of these have the 
same mutation. **All Finnish PLOSL patients have the same mutation in the TYROBP gene, but different 
mutations in the TREM2 and TYROBP genes have been identified from foreign PLOSL patients. 
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Development of strategies for analysis of gene function 
Identification of a disease gene and disease-causing mutations creates an excellent tool 
for future studies. Most of the novel genes of the FDH were originally of unknown 
function and this created the need to develop tools for molecular, cellular and tissue 
analyses for the characterization of gene function and disease mechanisms. Figure 2. 
illustrates the general outline of the strategy used to study the diseases the goal being to 
understand molecular pathogenesis of a disease. This approach has been successfully 
utilized for several genes of the FDH and the methodological expertise is currently 
being transferred for the analysis of gene function in complex diseases. 
            
 
Figure 2. Approaches to study pathogenesis of an inherited disease 
 
The research program of Finnish Disease Heritage has utilized different cellular models 
to analyze the intracellular localization, transport of normal and mutant disease proteins 
and these studies have brought us novel information about molecular functions of 
general importance. For example, in the case of Aspartylglucosaminuria, we could show 
the whole spectrum of analyses from gene characterization and cellular studies to 
protein crystallization, identification of a novel activation mechanism and determination 
of a phosphotransferase binding site for lysosomal targeting of the 
Aspartylglucosaminidase.  
 
In order to facilitate the initial characterization of exposed new pathways and to analyze 
the consequences of the gene elimination at organism level, we have produced knock-
out (KO) mouse models for six FDH and utilized a total of nine FDH mouse models 
(Table 2.), most of which have already been characterized in detail by us. The post-
genomics era has introduced demands to investigate and characterize the global 
variation evident within biological systems and we have routinely utilized transcript 
profiling to expose disturbed molecular pathways in our mouse models. Additionally, 
other systematic analysis methods are under development or utilized in collaborative 
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efforts. Importantly, the department has had the resources and excellent collaboration 
partners to conduct functional analyses based on findings form the genome-wide 
analyses, for example neurological dysfunction in the NCL and immunological 
functions in the APECED mouse models. In the case of the AGU mice, several 
therapeutic interventions have also been applied. The major findings based on the 
studies of the mouse models utilized by MLO are summarized in Table 3. 
 
Table 2. Mouse models at the Department of Molecular Medicine* 
Disease 
 
Gene Main phenotype 
Infantile neuronal  
ceroidlipofuscinosis (INCL) 
Palmitoyl Protein 
Thioesterase 1 (Ppt1) 
Early onset thalamocortical 
atrophy Blindness at 3-4 
months 
Motor abnormalities 
Early death at 5-6 months 
Juveline neuronal  
ceroidlipofuscinosis (JNCL)** 
Novel transmembrane 
protein (Cln3) 
Late onset thalamocortical 
atrophy Retinal degeneration 
White matter abnormalities 
Mild neurological phenotype 
Death at 18 months 
Variant late infantile  
neuronal ceroidlipofuscinosis 
(vLINCL) 
Novel soluble/TM 
protein (Cln5) 
Early onset reverse 
thalamocortical   
   atrophy  
Blindness 
Motor abnormalities 
Early aging 
Death at 8-10 months 
Northern epilepsy (EPMR)** 
 
Novel TM protein (Cln8) 
 
Late onset thalamocortical 
atrophy Retinal and motor 
degeneration Spastic paralysis 
Death at 10-12 months 
Autoimmune 
polyendocrinopathy-candidiasis-
ectodermal dystrophy 
(APECED) 
Autoimmune regulator 
(Aire) 
Mild autoimmune symptoms 
Autoantibodies, reduced 
fertility 
Growth retardation, 
aminoaciduria, cholestasis, iron 
overload lactacidosis and early 
death (GRACILE) 
Bcs1-like (Bcs1l) Not determined 
Aspartylglucosaminuria (AGU) 
 
 
Aspartylglucosaminidase 
(Aga) 
Thalamic atrophy 
Mild motor abnormalities 
Polycystic lipomembranous 
osteodysplasia with sclerosing 
leukoencephalopathy 
(PLOSL)** 
TYRO protein tyrosine 
kinase-binding protein  
(Tyrobp) and 
Triggering receptor 
expressed in myeloid 
cells 2 (Trem2) 
Thalamic atrophy 
Cortical changes          
Mild motor and sensory defects
Not determined 
 
*In addition, two KO mouse models are under the process of microinjection (Meckel syndrome 
and hydrolethalus). **These models were not initially produced by us but inbred into C57/BL 
congenic background. 
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Neuronal ceroid lipofuscinoses (INCL, vLINCL, JNCL, EPMR)  
The neuronal ceroid lipofuscinoses (NCLs) represent the most frequent group of 
inherited neurodegenerative diseases in children. These rare diseases, caused by 
mutations in eight known genes, provide a unique model to characterize the molecular 
pathways critical for normal neuronal development and involved in neurodegeneration. 
The research group of Peltonen has provided essential information by identification of 
two disease genes behind INCL (CLN1, PPT1) and vLINCLFin (CLN5) and contributing 
to the mapping/identification of genes behind JNCL (CLN3) and variant LINCL (CLN6). 
Groups Peltonen and Jalanko were in the key position in the analyses of the cellular 
localization of four NCL proteins PPT1, CLN3, CLN5 and CLN8, involved in the 
infantile, variant late infantile and juvenile NCLs and demonstrated that all of these 
except CLN8 are lysosomally located in non-neuronal cells. We have identified a 
considerable number of mutations resulting in these disorders and usually the disease 
mutations cause defects in the transport of these NCL proteins. The mRNA expression 
patterns of three NCL genes in mouse brain have been characterized and implicate 
important roles for CLN1, CLN3 and CLN5 in neuronal development. We have further 
analyzed the neuronal localization of PPT1, CLN3 and CLN8 proteins and showed that 
these proteins possess distinct properties in neurons. Additionally, we have defined 
novel targeting sequences and transport mechanisms of CLN3 protein.  
 
We have also provided the first clues to the functions of the NCL proteins in 
mammalian cells. PPT1 and CLN3 deficiencies were shown to be linked to endocytic 
abnormalities. For the CLN3 protein we have demonstrated interconnections with the 
microtubule-associated protein HOOK1 and CLN3 deficiency was shown to be linked 
to deregulated cytoskeletal function. To reveal the functional roles of NCL-proteins, we 
have systematically screened interaction partners for PPT1, CLN3 and CLN5 proteins. 
Our most recent unpublished findings show that PPT1 interacts with the F1 complex of 
ATP synthase and this interaction mediates neuronal lipid homeostasis. Additionally, 
we have revealed interactions between CLN3, and the cytoskeleton-related proteins 
fodrin, Na,K,ATPase and Grp78/BIP and shown that CLN3 participates in the 
endocytosis of the sodium pump. We have further identified novel interactions of CLN5 
protein with PPT1, CLN2, CLN3 and CLN6, implicating that CLN5 is a central player 
in a common NCL pathway. The molecular interactions of NCL proteins are 
summarized in Figure 3. 
 
 
                                
  
   Figure 3. NCL protein interactions  
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MLO investigators have produced KO mouse models mimicking human NCL mutations 
and they are in a good position to use these rare human diseases to characterize 
molecular pathways behind the associated neuronal degeneration. Each NCL mouse 
model exhibits a progressive NCL-like neurodegenerative phenotype that resembles the 
corresponding human disorder and these models are proving a valuable resource for 
understanding how the brain is affected. The mouse models of NCL display a selective 
neuronal loss early in pathogenesis with localized astrocytosis and neuronal loss in the 
thalamocortical system, detectable by quantitative immunohistochemical analyses and 
MRI. The Cln5-/- mice show distinct properties by exhibiting a “corticothalamic” neuron 
loss, first observed very early in cortex and only subsequently within the thalamus. In the 
context of the EU consortium NCL models, coordinated by A. Jalanko, we have 
backcrossed the Cln1/Ppt1ex4, Cln3, Cln5 and Cln8/mnd mouse models into the C57Bl6 
genetic background. This will make the NCL mouse models an invaluable source for the 
research community.  
 
We have utilized global transcript profiling to expose dysregulated pathways in NCL 
mouse models and demonstrated that Cln3 deficient cortical neurons exhibit disturbances 
in mitochondrial, cytoskeletal and synaptic functions and similar analysis of Cln1 
deficient cortical neurons revealed dysregulated lipid homeostasis, substantiated by 
biochemical measurements. We have also performed transcript profiling for the cortices 
of 1 and 4 month old Cln1 and Cln5 models and analysed these data comparatively to 
reveal a common affected pathway involving the neuronal cytoskeleton and growth cone 
assembly. The production of the congenic mouse strains for five NCL disorders has 
opened a new avenue to explore and compare affected pathways in NCL. We have 
initiated comparative global analyses utilising transcript and lipid profiling in four mouse 
models of NCL and aim at further understanding of the NCL biology.  
 
Autoimmune polyendocrinopathycandidiasis-ectodermal dystrophy (APECED)  
Autoimmune disease APECED is another example of the value of detailed 
characterization of a rare FDH diseases, which has exposed a novel and fundamental 
biological pathway by providing fundamental pieces of information to understand the 
mechanisms of immunological tolerance and autoimmunity in general. After reporting 
the locus for APECED in Finnish families, our laboratory and a Japanese group 
independently in the same issue of Nature Genetics 1997 reported the causative gene 
AIRE. We have subsequently chracterized the functional defects of patient mutations 
resulting in the increased understanding of the domains of the AIRE protein and their 
functions. We have used yeast two-hybrid assay to identify nuclear proteins which 
interact with AIRE protein. Most interesting finding was the interaction of AIRE with 
PIAS proteins PIAS1, PIASxα and PIAS3, representing E3 SUMO ligase proteins. We 
have studied in detail the cellular and functional consequences of the AIRE-PIAS1 
interaction. These results implied that this interaction was able to modulate transcription 
in gene specific fashion, linking AIRE transcription regulation with the SUMO-
pathways.  
 
Furthermore our group was the first one to construct and characterize Aire KO-mouse, 
which have been intensively used by us and in collaborations to reveal the central role 
of AIRE in the regulation of gene expression in thymus medullary epithelial cells. These 
studies have established the importance of AIRE in the development and maintenance 
of central tolerance. By comparing the immunological properties of the mouse model 
and APECED patients we could demonstrate that that the immunopathology in the two 
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organisms was far from identical. Thus for instance the functionality of regulatory T 
cells was impaired in patients but not in knock-out mice. Furthermore, the pattern of 
autoantibodies was mostly different. These results complied nicely with the observation 
that our mouse model displayed generally much milder autoimmune symptoms than 
APECED patients. The important conclusion was that results obtained from the mouse 
model should be critically applied for man. Further studies are in progress to reveal the 
role of AIRE in peripheral tolerance. Figure 4. illustrates important milestones of our 
APECED research project at MLO.          
 
Figure 4. The most important milestones in the APECED research project 
 
 
Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 
(PLOSL) 
PLOSL, also known as Nasu-Hakola disease, is a recessively inherited disease 
characterized by combination of osteoporosis and early-onset progressive dementia. 
This disease has been considered of special interest as a monogenic model of dementia 
with complex phenotype. We have characterized the molecular background of PLOSL 
by identifying mutations in two genes, namely TYROBP and TREM2, implicating that 
the same disease can be caused by mutations both in the ligand and receptor of an 
immunomodulating complex. The disease phenotype is identical regardless of which 
one of the genes is mutated. Interestingly, patients with PLOSL do not clinically 
manifest immunological defects, but the symptoms appear in brain and bone and the 
function of TYROBP and TREM2 have remained elusive in these tissues. 
 
TYROBP functions as a transmembrane adapter protein, which plays an important role 
in myeloid and natural killer (NK) cell activation and thus in triggering and amplifying 
inflammatory responses. TYROBP interacts with many different receptors depending on 
the cell type and together with TREM2 they are known to promote survival of human 
dendritic cells. We have shown that also microglial cells in the brain and osteoclasts in 
the bone, both target cells of the PLOSL, express the TYROBP/TREM2 receptor 
complex. More recently we have utilized global transcript profiling of dendritic cells of 
PLOSL patients and demonstrated dysregulation of actin bundling and immune 
response pathways. The pathological cascade induced by the lack of TYROBP/TREM2 
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is likely to trigger an inflammatory response in the CNS and our recent studies have 
implicated the importance of oligodendroglial cells in this event (Kiialainen, 
unpublished). To obtain deeper insight into the CNS pathology in TYROBP/TREM2 
deficiency, we have recently produced a TREM2 knockout mouse and aim to utilize it 
together with the existing TYROBP KO-mouse for further studies involving the 
interplay of TYROBP and TREM2 in the CNS. 
 
Lethal fetal syndromes (HLS, MKS, LCCS, LAAHD)   
The most recent studies of FDH have been focused to early birth defects enriched in 
Finland with the hypothesis that these rare diseases might contribute to our 
understanding of critical molecular pathways guiding human development. During the 
first year of life birth defects are the leading cause of death. These defects are defined as 
abnormalities of structure, function or body metabolism that are present at birth 
resulting in physical or mental disability or death. Birth defects can be caused by 
genetic or environmental factors, but in many cases reasons remain unknown. Four of 
the FDH diseases cause very severe birth defects that lead to death already in utero or 
immediately after birth. These syndromes - Meckel syndrome (MKS), Hydrolethalus 
syndrome (HLS), Lethal Congenital Contracture Syndrome (LCCS) and Lethal 
Arthrogryposis with Anterior Horn cell Disease (LAAHD) - will create shortcuts to the 
identification of new molecular mechanisms and events providing clues to 
understanding of organogenesis, dysmorphogenesis and human malformations generally. 
 
Meckel syndrome (MKS) represents the most common form of syndromic neural tube 
defects (NTDs). Main symptoms are polycystic kidneys, occipital 
meningoencephalocele, fibrotic changes of the liver and polydactyly. MKS is diagnosed 
worldwide and it is a heterogenous disorder; two genes (MKS1 and MKS3) and one 
locus (MKS2) are known, but these findings explain only a part of the MKS cases. We 
have recently characterized a novel MKS1 gene and a major mutation (29 bp intronic 
deletion) that has been found from 70% of Finnish MKS cases and from several 
Caucasian patients. We are currently searching for additional MKS loci using Finnish 
patients without mutations in the MKS1 or MKS3 genes or linkage to MKS2 locus. The 
comparative genomics in Chlamydomonas, Arabidopsis and human strongly support the 
role of MKS1 in flagellar (cilia in human) basal body proteome. Later, functional 
studies have shown that both MKS1 and meckelin (MKS3 protein) are linked to cilia, 
but the final function is not known yet. Meckel syndrome is the most severe one of 
known ciliopathies that is a very heterogenous group of disorders since the abnormal 
cilia function can be a cause for e.g. diabetes and overweight. 
 
Hydrolethalus syndrome (HLS) was discovered in Finland in the course of studying 
the Meckel syndrome (MKS). Like MKS, this disorder is characterized by central 
nervous system malformation and polydactyly, but unlike MKS, it does not show cystic 
kidney and liver, and the CNS derangement is hydrocephalus with absent midline 
structures not encephalocele. The pregnancy is characterized by hydramnios, which is 
often massive. The hydrolethalus syndrome is caused by the substitution of aspartic acid 
by glycine in a novel protein with an unknown function. Genome-wide expression 
arrays have revealed up-regulation of genes related to cell cycle regulation in patient 
cells. Studies by cultured neuronal progenitor cells obtained from an aborted HLS fetus 
and from normal fetuses (from pregnancies terminated for social reasons) have also 
shown patient cells having an increased cell proliferation rate. To identify the pathways 
associated with the function of the HYLS1 protein, we have created a transgenic knock-
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in D. melanogaster model expressing human HYLS1 and the detailed analysis of the fly 
model is in progress. 
 
Lethal arthrogryposes are a genetically and clinically heterogeneous group of 
disorders characterized by multiple contractures at birth. Today the diagnosis is often 
made based on the abnormal position of joints and diminished or lack of movements of 
a fetus in utero. Typical examples of these syndromes are Lethal Congenital Contracture 
Syndrome (LCCS) and Lethal Arthrogryposis with Anterior Horn cell Disease 
(LAAHD). Autopsies demonstrate the hallmarks of these diseases, muscular atrophy 
and paucity of anterior horn motor neurons. We have very recently identified mutations 
that cause both LCCS and LAAHD. These diseases are allelic and there is a distinct 
genotype-phenotype correlation. The study of these most severe motoneuron diseases 
will provide valuable information about the genes and pathways essential to normal 
motoneuron function and insight into the molecular mechanisms behind other 
motoneuron diseases such as ALS. 
 
Conclusion 
 
Table 3. The main results/achievements of the functional studies of FDH-genes at the 
Department of Molecular Medicine 
Cell models/ 
Cell phenotype 
Animal models General significance 
Infantile neuronal ceroidlipofuscinosis (INCL) 
 
Cellular localization and 
molecular interactions of 
PPT1. 
Novel features in brain 
pathology, functional 
analyses in knockout 
neurons. 
Novel metabolic pathways 
revealed. 
First clues to synaptic involvement 
in NCL. Cell and animal studies 
show that INCL is linked to 
dysregulated lipid homeostasis. 
Juveline neuronal ceroidlipofuscinosis (JNCL) 
 
Intracellular localization 
and molecular interactions 
of CLN3. 
Novel metabolic pathways, 
functional analyses in 
knockout neurons. 
First clues to CLN3 function in 
mammalian cells. JNCL linked to 
cytoskeleton-mediated 
dysregulation of ion transport. 
Variant late infantile neuronal ceroidlipofuscinosis (vLINCL) 
 
Intracellular localization 
and molecular interactions 
of CLN5. 
Novel features in brain 
pathology. Novel metabolic 
pathways revealed. 
First clues to common affected 
pathways in NCL. CLN5 may be 
the central player in NCL biology. 
Autoimmune polyendocrinopathycandidiasis-ectodermal dystrophy (APECED) 
 
Transient expression of 
AIRE and 13 different 
patient mutations. 
Mechanisms of 
immunological tolerance. 
Molecular mechanisms of central 
and peripheral tolerance. Cellular 
pathogenesis of AIRE mutations. 
Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL) 
 
Cellular localization and 
functional studies of 
dendritic signaling 
Novel metabolic pathways 
revealed 
Connection between actin 
bundling and demyelination. 
Oligodendrocyte phenotype 
revealed 
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5.3. Scientific impact  
 
Table 4. Summary of the scientific output during 1997-2007 
Scientific output N Comments 
 
Peer-review articles in international 
journals 
165 In addition 23 review articles/book chapters. 
See Appendix 1 
Invited lectures and chairmanships 
in international meetings 
15 e.g.  Chair - The 10th International Congress of 
Neuronal Ceroid Lipofuscinoses, Helsinki 2005 
Articles in domestic journals and 
text books 
5 See Appendix 1 
Lectures in domestic meetings and 
teaching lectures 
75  
Editorial tasks in international 
journals 
 
1 BBA Molecular Basis of Disease 2006 
Committee memberships: domestic 3 e.g. Board member of Finnish Gene Therapy 
Society, 1999–2005 Member 
Committee memberships: 
international (EU, WHO etc.) 
3 e.g. Member of the European Society of Gene 
Therapy Committee on gene therapy for genetic 
diseases 2000–2002 
International evaluation panels (EU 
etc.) 
2 e.g. Coordinator, EC FP6 STREP project NCL-
models LSHM-CT-2003-503051, 2004-2006 
Organizing committee of 
international meetings 
5 e.g. Member of the Scientific Advisory Board: 
The 9th International Congress of Neuronal 
Ceroid Lipofuscinoses, Chicago, USA, 2003; 
Member of the Scientific Advisory Board: The 
11th International Congress of Neuronal Ceroid 
Lipofuscinoses, Rochester, NY, USA, 2007 
Doctoral dissertations 
 
28 See Appendix 1 
Supervision of dissertations: 
Ongoing 
11  
Opponent of dissertations 
 
5  
Pre-examiner of  
- dissertations 
- adjunct professors 
- professorships 
 
23 
1 
 
 
Prizes 
 
1 The best Ph.D. thesis 2006 (Kaisu Luiro), 
Faculty of Medicine, University of Helsinki 
 
 
5.4. Societal impact  
About 60 newborn babies are born every year in Finland who suffer from FDH diseases 
already at birth or later in their lives. Most of the FDH mutations cause very severe or 
even lethal disease and the situation is always very hard for the whole family. The 
family wants to know if the disease is inherited, is there a risk for an affected child also 
in future pregnancies and is there any treament. Identification of disease-causing 
mutations has made DNA diagnostics possible. All mutations identified at MLO are 
available for diagnostic testing in the HUCH Laboratory Diagnostics (Helsinki, Finland). 
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The mutation analysis confirms the diagnosis and the best treatment, if available, can be 
planned.  
 
Charaterization of the molecular defect behind Finnish disease heritage has been a 
community effort linking experts in clinical medicine and genetic councelling with 
molecular geneticists, cell biologists and mouse experts. Total of 10 000 Finns have 
contributed to these studies with their biological samples and clinical data. The concept 
of Finnish genetics became world famous along with this national effort and this 
accomplishment has substantially increased the interest towards genetic research among 
the Finnish population. The impact of this legacy has already proven important in 
studies of common diseases, requiring active participation of even larger groups of the 
population.    
 
 
5.5. Research funding 
 
Table 5. Project funding during 1997-present 
Project name Funding agency*  
(PI)** 
Funding 
k€ 
Years 
Finnish disease heritage SA (LP) 
SA (OK) 
390 
35 
1997-2000 
1997-1999 
Molecular biology of Finnish 
diseases 
 
FO (LP, AJ, IU) 630 1997-2002 
Molecular and cellular biology of  
aspartylglucosaminuria and NCL 
SA (AJ) 376 1999-2007 
 
Center of Excellence, Academy 
of Finland 
SA (LP= coordin; AJ=PI) 423 
197 
2000-2005 
2006-2008 
Disease mechanisms in three 
NCL disorders 
FO (AJ) 
GS (AJ students) 
FO (AJ students) 
FO (OK) 
552 
190 
143 
30 
1997-2009 
2001-2007 
2002-2007 
2003-2005 
NCL-models EU STREP 
(AJ=coordinator, LP=PI) 
585 2004-2006 
Systematic analysis of gene 
function 
 
NCoE (AJ) 30 2007 
Molecular biology of 
autoimmune diseases 
 
SA (IU,LP) 84 2000-2001 
Molecular pathology of APECED 
 
SA (IU) 117 2000-2003 
Molecular biology and genetics of 
APECED 
 
FO (IU) 264 2000-2006 
Function of the APECED protein SA (IU) 
 
94 2001-2002 
APECED SA (HK) 
 
76 2001-2007 
Immunological tolerance 
 
SA (IU) 120 2004-2006 
EURAPS, Autoimmune 
Polyendocrine Syndrome Type I -
EU (LP) 276 2006-2008 
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- A Rare Disorder of Childhood 
as a Model for Autoimmunity 
Molecular genetics and biology of 
lethal fetal syndromes 
SA (MK) 
FO (MK) 
GS (MK students) 
720 
230 
57 
2003-2009 
2003-2010 
2005-2008 
Molecular genetics of 
RAPADILINO syndrome 
GS, FO (MK)  103 2004-2007 
 
Genetic and environmental 
determinants of craniofacial 
syndromes 
NIH (LP) 321 2005-2007 
*EU=European Union, SA=Academy of Finland, TEKES=Finnish Funding Agency for 
Technology and Innovation, FO=Foundations, GS=graduate schools. **PI=see senior scientific 
personnel in chapter 5.8 
 
 
5.6. Scientific collaboration  
Anu Jalanko 
Neuronal ceroid lipofuscinoses: Acad. Prof. Leena Peltonen (KTL), Prof. Anna-Elina 
Lehesjoki (Folkhälsän, Helsinki, Finland), Dr. Jonathan Cooper, (King’s College, London, 
UK), Dr. Matti Jauhiainen (KTL), Dr. Hannah Mitchison, (University College, London, UK), 
Prof. Elina Ikonen (University of Helsinki, Finland), Dr. Jaana Tyynelä (University of 
Helsinki, Finland), Dr. Juha Saharinen (KTL), Dr. Massimiliano Gentile (University of 
Helsinki, Finland), Dr. Leonard Khiroug (University of Helsinki, Finland), Dr. Nisse 
Kalkkinen (University of Helsinki, Finland),  Acad. Prof. Jussi Taipale (KTL), Dr. Liisa 
Myllykangas (Folkhälsän, Helsinki, Finland) 
Ismo Ulmanen 
APECED: Acad. Prof. Leena Peltonen (KTL), Prof. Ilkka Julkunen (KTL), Prof. Outi 
Vaarala (KTL), Dr. Juha Saharinen (KTL), Adj. Prof. Petteri Arstila (Haartman Institute, 
University of Helsinki, Finland), Prof. Jaakko Perheentupa (Helsinki University Hospital for 
Children and Adolescents, Finland), Prof. Jorma Palvimo (University of Kuopio, Finland), 
Prof. Olle Kämpe (Uppsala University, Sweden), Prof. Jacob Seeler (Institut Pasteur, Paris, 
France), Prof. Robyn Slattery (Monash University, Melbourne, Australia) 
Leena Peltonen 
PLOSL: Professor Panu Hakola (University of Kuopio, Finland), Dr. Lewis Lanier 
(University of San Fransisco, USA), Professor Ilkka Julkunen (KTL) 
Marjo Kestilä 
Lethal fetal syndromes: Acad. Prof. Leena Peltonen (KTL), Dr. Liisa Myllykangas 
(Folkhälsän, Helsinki. Finland), Adj. Prof. Riitta Herva (University Hospital of Oulu, 
Finland), Adj. Prof. Riitta Salonen (Family Federation, Helsinki, Finland), Adj. Prof. Anders 
Paetau (University Hospital of Helsinki, Finland), Dr. Kirmo Wartiovaara (University of 
Helsinki, Finland), Dr. Satu Kuure (University of Helsinki, Finland), Dr. Juha Saharinen 
(KTL), Prof. Brendan Lee (Baylor College of Medicine, Houston, Texas, USA) 
 
 
5.7. Proposal for the future work and expected (societal) benefits (next 
five years) 
Since the disease-causing genes and mutations behind diseases of the Finnish Disease 
Heritage have now been identified, the future studies will be focused on some special 
research problems facilitated by the resources we have built: Numerous mouse models 
will facilitate global analyses of target tissues and identification of involved molecular 
pathways behind critical disease processes e.g. neuronal degereration or aberrations of 
autoimmunity. Similarly, the produced cellular and Drosophila models will be used to 
identify pathways critical for normal development. Thus the ongoing investigations on 
the functional roles of the FDH gene products aim at the clarification of the molecular 
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pathology and novel therapeutic approaches for the respective diseases. Furthermore, 
this activity will be important for the maintenance and development of the skills and 
methods directly applicable for the functional studies of appearing genes behind the 
complex, polygenic diseases, which are intensively studied in MLO. In addition, we will 
develop the DNA-based diagnostic test panels for efficient carrier screening programs 
of FDH in the close collaboration with the clinical laboratory of the University Helsinki 
Central Hospital.  
 
 
5.8. Senior scientific personnel 
Leena Peltonen, M.D, Ph.D, Academy Professor 1987- 
Anu Jalanko, Ph.D., adjunct professor, group leader 1993- 
Ismo Ulmanen, Ph.D., adjunct professor, group leader 1998- 
Marjo Kestilä, Ph.D., adjunct professor, Academy research fellow, group leader 2002- 
Outi Kopra, Ph.D, adjunct professor, senior investigator 1996-1998, 1999-2006 
Irma Järvelä, M.D., Ph.D., adjunct professor, senior investigator 1997-1998 
Maarit Lehtovirta, Ph.D., post-doctoral fellow 1998-2000 
Meelis Kolmer, Ph.D., post-doctoral fellow 1998-2001 
Teppo Varilo, M.D, Ph.D, adjunct professor, senior investigator 1999- 
Petra Eskelin, M.D, Ph.D., post-doctoral fellow 2000-2003 
Minna Peltola-Laine, M.D., Ph.D., post-doctoral fellow 2000-2003 
Hannele Kangas, Ph.D., post-doctoral fellow 2001-2003, 2006-2007 
Aija Kyttälä, Ph.D, adjunct professor, senior investigator 2003- 
 
 
5.9. 15 key references  
 
Article 
 
IF 
No of 
citat.* 
Aaltonen J, Bjorses P, Perheentupa J, Horelli-Kuitunen N, Palotie A, 
Peltonen L, Lee YS, Francis F, Hennig S, Thiel C, Lehrach H, Yaspo 
ML. An autoimmune disease, APECED, caused by mutations in a 
novel gene featuring two PHD-type zinc-finger domains (1997) Nat 
Genet, 17:399-403 
25.797 307 
Jarvela I, Sainio M, Rantamaki T, Olkkonen VM, Carpen O, Peltonen L, 
Jalanko A. Biosynthesis and intracellular targeting of the CLN3 
protein defective in Batten disease (1998) Hum Mol Genet, 7:85-90 
7.764 114 
Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready P, Putaala 
H, Ruotsalainen V, Morita T, Nissinen M, Herva R, Kashtan CE, 
Peltonen L, Holmberg C, Olsen A, Tryggvason K. Positionally cloned 
gene for a novel glomerular protein--nephrin--is mutated in congenital 
nephrotic syndrome (1998) Mol Cell, 1:575-82 
14.971 505 
Savukoski M, Klockars T, Holmberg V, Santavuori P, Lander ES, 
Peltonen L. CLN5, a novel gene encoding a putative transmembrane 
protein mutated in Finnish variant late infantile neuronal ceroid 
lipofuscinosis (1998) Nat Genet, 19:286-8 
25.797 131 
Verheijen FW, Verbeek E, Aula N, Beerens CE, Havelaar AC, Joosse M, 
Peltonen L, Aula P, Galjaard H, van der Spek PJ, Mancini GM. A new 
gene, encoding an anion transporter, is mutated in sialic acid storage 
diseases (1999) Nat Genet, 23:462-5 
25.797 73 
Bjorses P, Halonen M, Palvimo JJ, Kolmer M, Aaltonen J, Ellonen P, 
Perheentupa J, Ulmanen I, Peltonen L. Mutations in the AIRE gene: 
effects on subcellular location and transactivation function of the 
12.649 108 
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autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy 
protein (2000) Am J Hum Genet, 66:378-92 
Paloneva J, Kestila M, Wu J, Salminen A, Bohling T, Ruotsalainen V, 
Hakola P, Bakker AB, Phillips JH, Pekkarinen P, Lanier LL, Timonen 
T, Peltonen L. Loss-of-function mutations in TYROBP (DAP12) 
result in a presenile dementia with bone cysts (2000) Nat Genet, 
25:357-61 
25.797 95 
Lehtovirta M, Kyttala A, Eskelinen EL, Hess M, Heinonen O, Jalanko A. 
Palmitoyl protein thioesterase (PPT) localizes into synaptosomes and 
synaptic vesicles in neurons: implications for infantile neuronal ceroid 
lipofuscinosis (INCL) (2001) Hum Mol Genet, 10:69-75 
7.764 40 
Ramsey C, Winqvist O, Puhakka L, Halonen M, Moro A, Kampe O, 
Eskelin P, Pelto-Huikko M, Peltonen L. Aire deficient mice develop 
multiple features of APECED phenotype and show altered immune 
response (2002) Hum Mol Genet, 11:397-409 
7.764 107 
Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, 
Adolfsson R, Bianchin M, Bird T, Miranda R, Salmaggi A, 
Tranebjaerg L, Konttinen Y, Peltonen L. Mutations in two genes 
encoding different subunits of a receptor signaling complex result in 
an identical disease phenotype (2002) Am J Hum Genet, 71:656-62 
12.649 57 
Visapaa I, Fellman V, Vesa J, Dasvarma A, Hutton JL, Kumar V, Payne 
GS, Makarow M, Van Coster R, Taylor RW, Turnbull DM, 
Suomalainen A, Peltonen L. GRACILE syndrome, a lethal metabolic 
disorder with iron overload, is caused by a point mutation in BCS1L 
(2002) Am J Hum Genet, 71:863-76 
12.649 34 
Paloneva J, Mandelin J, Kiialainen A, Bohling T, Prudlo J, Hakola P, 
Haltia M, Konttinen YT, Peltonen L. DAP12/TREM2 deficiency 
results in impaired osteoclast differentiation and osteoporotic features 
(2003) J Exp Med, 198:669-75 
13.965 44 
Kopra O, Vesa J, von Schantz C, Manninen T, Minye H, Fabritius AL, 
Rapola J, van Diggelen OP, Saarela J, Jalanko A, Peltonen L. A mouse 
model for Finnish variant late infantile neuronal ceroid lipofuscinosis, 
CLN5, reveals neuropathology associated with early aging (2004) 
Hum Mol Genet, 13:2893-906 
7.764 10 
Luiro K, Yliannala K, Ahtiainen L, Maunu H, Jarvela I, Kyttala A and 
Jalanko A. Interconnections of CLN3, Hook1 and Rab proteins link 
Batten disease to defects in the endocytic pathway (2004) Hum Mol 
Genet, 13:3017-27 
7.764 12 
Kyttala M, Tallila J, Salonen R, Kopra O, Kohlschmidt N, Paavola-Sakki 
P, Peltonen L, Kestila M. MKS1, encoding a component of the 
flagellar apparatus basal body proteome, is mutated in Meckel 
syndrome (2006) Nat Genet, 38:155-7 
25.797 23 
 
* based on Web of Science August 2007 
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6 GENETIC EPIDEMIOLOGY 
 
6.1. Research area and its significance 
The impressive development of genome projects has resulted in the availability of total 
genome sequence information for over 350 organisms, including over 50 mammals on 
the Web (www.ncbi.nlm.nih.gov). This progress and the generated genome resources 
and technologies have dramatically increased our possibilities to define the biology of 
any human disease, including those with polygenic complex background and provide 
the possibility to obtain a genome-wide view to common diseases and their trait 
components. Eventually this information will lead to improved understanding of genetic 
versus life style risk factors and, at least in well developed health care systems, improve 
our possibilities to treat and prevent human diseases. However, many research 
challenges remain before excessive genome information can be translated to better 
health care of our societies. Several approaches will be needed to discover and 
characterize every disease-susceptibility gene and there is a growing realization that the 
primary resource needed to address most of the above-mentioned issues are well defined 
collections of samples from human populations that include extensive clinical 
information (F. Collins, Nature, Vol. 429, July 27, 2004 p. 475).  
 
The goal of the research program is to capitalize the possibilities provided by the special 
population and well characterized study sample resources of Finland using updated 
molecular methods and new biocomputational strategies to collect genetic and 
molecular information of diseases with complex etiology. We aim to identify 
relationships between disease related phenotypes and genetic make up of individuals. 
We recognize that investigation of these relationships is hindered by 1) the imprecise 
definition and measurement of disease phenotypes 2) the heterogeneous genetic 
background, and 3) our limited knowledge about the mechanisms by which variations in 
DNA sequence can generate phenotypic effects and how these changes are related to 
other, life style risk factors or to the response of treatment.  Overcoming these factors 
requires a highly integrated application of genetic, genomic, and biocomputational 
approaches in studies of the best possible study samples collected.  
 
The Research Program on Genetic Epidemiology bridges the epidemiological, clinical 
and basic research, being well-rooted in the excellent clinical expertise and in the health 
care system of the special population of Finland and the great environment of 
Biomedicum Helsinki. Majority of our investigators also belong the prestigious, 
internationally evaluated National and Nordic centers of Excellence (www.aka.fi and 
www.ncoedg.org) as well as to the research program of Molecular Medicine of the 
Faculty of Medicine (research.med.helsinki.fi/molmed/), all multi-institutional 
organizations joining research group of KTL (both Department of Mental Health and 
Alcohol Research and with groups of the Department of Health and Functional 
Capacity), University, University hospital and Folkhälsan Research Center. These 
investigators occupy the 3rd floor of Biomedicum, making it really “the floor of 
molecular medicine” at Meilahti campus. The overall theme is to use excellent, 
clinically and epidemiologically well defined study samples to characterize the 
molecular background of diseases.  The target diseases represent common diseases with 
complex genetic and life style risk factors: cardiovascular, neuropsychiatric and 
immunological diseases. After initial characterization of the involved genes and alleles 
we are in an excellent position to define genetic and environmental/ life style risk 
Background material                                                        6 GENETIC EPIDEMIOLOGY 
 84 
factors for specific subtypes of the diseases and their trait components as well as to 
study the differences in drug response in patients with different genetic profiles. The 
molecular and biocomputational analyses needed in these efforts are greatly advanced 
by the expert infrastructure of the Biomedicum core facilities and the Finnish Genome 
Center in Biomedicum. The program takes a certain pride in significant support to their 
operations for all the investigators in Biomedicum, especially in biobanking, sequencing, 
biochip analyses, high throughput genotyping, bioinformatics and statistics and high 
throughput screening. 
 
This research program aims to produce novel understanding of the genetic and life style 
risk factors predisposing to common human diseases representing major public health 
problems. We build on the integrated strengths of Finnish molecular genetics, 
epidemiology, computer sciences and biostatistics. Using the special population 
structure of Finland and the large population cohorts at KTL we aim to create new 
understanding of the role of genetic profiles in human disease processes and to establish 
new intellectual paradigms to be tested in global populations in our numerous 
international networks and collaborations. In this era of genome-wide technologies and 
biobanks Finland offers unique potential for becoming one of the leading countries in 
biomedical research. Our well established population history, unique families and 
epidemiological study samples with vast amount of clinical and life style information 
facilitate detailed studies of the etiology and molecular pathogenesis of human diseases.  
 
The major goal of our current research is to identify predisposing genes and their risk 
alleles for major cardiovascular and neuropsychiatric diseases. We aim to capitalize the 
possibilities of the special population and epidemiological study sample resources of 
Finland in genome-wide analyses using molecular methods, across species comparisons 
and biocomputational strategies. Our special niche in the current era of genetics is based 
on the well defined Finnish study samples: Large pedigrees ascertained for specific 
diseases by our clinical collaborators and our access to the population cohorts, 
representing the whole population, collected during past 20 years from various 
geographical regions of Finland (Table 1.). The research will accelerate the discoveries 
of genetic profiles and gene-environment interactions leading to common human 
diseases. The research will pave the way to better understanding of complex diseases 
and their component traits, including the response to medications. 
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Table 1. Summary of our study samples, their genealogical origin and the clinical 
collaborators responsible for the study sample collection and characterization 
Phenotype Geography, 
populations 
Clinical  
collaborators 
Study 
samples 
FCHL,  
Low HDL 
Finland nationwide, 
Late settlement 
Eastern Finland, 
Dutch and UK study 
samples, MORGAM 
cohorts (Europe) 
Marja-Riitta Taskinen, 
Markku Laakso,  
Leif Groop,  
Markku Savolainen, 
Alun Evans,  
Veikko Salomaa,  
T.W.A de Bruin 
Large 
pedigrees, 
large 
populations 
cohorts 
Myocardial 
infarct 
Finland nationwide, 
Late settlement 
Eastern Finland, 
Canadian Quebec 
population 
Markku Laakso,  
Marja-Riitta Taskinen, 
Veikko Salomaa,  
Kari Kuulasmaa,  
Jorma Viikari,  
Claude Laberge 
Sib pair 
families, large 
population 
cohorts with 
identified 
cases 
Schizophrenia Finland nationwide; 
Late settlement 
Eastern Finland 
Jouko Lönnqvist,  
Matti Isohanni,  
Timo Partonen 
Nationwide 
collection of 
families, birth 
cohorts of 
1966,1986 
Autism and 
Asperger  
Finland nationwide, 
Central Finland, US 
(AGRE) family 
collections 
Lennart von Wendt, 
Taina Nieminen-von 
Wendt,  
Raija Vanhala,  
Irma Järvelä  
Nationwide 
collection of 
families, 
births cohorts 
of 1966,1986 
MS Finland, high risk 
Vaasa county, 
Canadian Quebec 
population, UK 
population 
Pentti Tienari,  
M-L. Sumelahti, 
George Ebers 
Nationwide 
collection of 
large 
pedigrees and 
trios 
Obesity  Finland, Late 
settlement Eastern 
Finland, Western 
Finland 
Kimmo Kontula, 
Veikko Salomaa,  
Marja-Riitta Taskinen 
Sibpairs, 
population 
cohorts 
 
Detailed analyses of our unique study samples in an efficient way requires the most 
updated high-throughput genotyping, sequencing and transcript profiling methodology. 
Further, system-biology based approaches relying on high-throughput biological 
experiments and computational analyses facilitate identification of critical pathways 
involved in the disease processes. The integrated expertise of the investigators of the 
Program and it’s collaborators both nationally and internationally provides a highly 
competitive setting for studies of molecular etiology of complex diseases. It should be 
emphasized that integrated analyses of complex data sets collected from human (and 
model orgnisms) requires construction and harmonization of databases and development 
of novel biocomputational and biostatistical strategies. During past 10 years MLO has 
made a special effort to recruite experts in databases and statistical analyses. We have 
become one of the leaders in databases related to biobanking in Europe and substantial 
amount of our external competitive research funding is used to these infrastructures 
(www.biobanks.eu). The graph below indicates the platforms and competences we have 
established for large study samples and data sets as well as the critical national and 
international links and collaborations related to these activities. 
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6.2. The main achievements 
Our research efforts during past 10 years in complex diseases has resulted in the 
mapping of total of 18 loci for complex traits with the genome-wide level of 
significance, the majority of these findings being replicated in other study samples from 
more heterogeneous populations. Further, we have established solid evidence of an 
associated allelic variant for seven complex disease genes in Finnish study samples and 
by our international collaborations in most cases replicated the findings in non-Finnish 
populations. Functional analyses have so far been focused on the specific allelic forms 
identified or on monogenic diseases providing information of pathways relevant for 
common diseases.  Special interest has been paid on the special complications or severe 
trait components of target traits. Specifically, the following accomplishments have been 
obtained during past ten years. 
Figure 1. The graph indicates the platforms and competences established for large study  
samples and data sets as well as the critical collaborations related to these activities. 
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• Tentative 18 disease or trait component loci have been mapped and further 
restricted using linkage disequilibrium and haplotype sharing strategy and dense 
SNP mapping.  New statistical analyses have been developed to maximize the 
use of information of the population structure. 
• Susceptibility loci have been mapped and at least some putative genes and their 
allelic variants identified for lactose intolerance, familial combined 
hyperlipidemia, MS, familial obesity, familial schizophrenia, autism and adult 
height. Additional susceptibility loci have been identified also in migraine, 
hypertension, height, BMI, nicotine addiction and preference for sweet.    
• The relationship between the mutation background and environmental/life style 
risk factors or treatment response has been analyzed in the collaborative effort 
with Finrisk investigators and within our GenomEUtwin project of European 
twins. This has resulted in the initial identification of some joint effects behind 
cardiovascular disease events. 
• Our in vitro (cellular) and/or in vivo (mouse) models for both numerous 
monogenic diseases, like APECED (autoimmune model), PLOSL, 
(demyelination and neuropsychiatric disease model), as well as for specific 
alleles of the USF1 gene (a risk gene behind dyslipidemias) and mouse crosses 
for anxiety are being used to study functional consequences of mutations in 
target tissues and have exposed putative defective pathways relevant for 
common diseases.  
 
Identification of complex disease genes  
Our major strategy for final gene identification has relied on the concept of shared 
haplotypes among affected individuals in exceptional families or regional collection of 
patients.  This is well exemplified by our reports on the associated genes in families 
with lactose intolerance, dyslipidemias, obesity, familial combined hyperlipidemia, 
schizophrenia. For all these traits, the involved gene was initially identified in 
exceptional families by positional cloning. For autism, multiple sclerosis and 
schizophrenia, an exceptional regional enrichment of cases or families exists in mid-
Finland (autism), in Vaasa region (MS), representing an early settlement region with 
high level of inbreeding, and in Kuusamo, an internal subisolate on the eastern boarder 
of Finland, inhabited in 1750’s (schizophrenia). These efforts have provided evidence 
except for the involved gene, but also identified allelic forms defined by common SNP 
variants, typically in non-coding or regulatory regions of these genes. The identified 
genes are remarkably interesting: a transcription factor USF1 for dyslipidemias, a 
protein kinase for MS and a novel gene, critical for neuronal development in Asperger 
syndrome and schizophrenia (DISC1).  
 
Many of our research efforts have been fundamental for international collaborations. Dr. 
Peltonen has co-ordinated an international collaboration within MS, which has 
replicated the PRKCA1 findings in Canadian, Swedish and Danish populations. Recent 
collaborative effort coordinated by Dr. William Hennah, currently in Edinburgh, tested 
the significance of DISC alleles in global study samples of schizophrenia and the EU 
funded GenomEUtwin (also coordinated by Dr. Peltonen) study has combined data from 
over 300 000 twin pairs (www.genomeutwin.org). Dr. Peltonen is also the head of the 
governance board of the recently funded ESFRI (European Strategic Forum for 
Research Infrastructures) effort for Biobanking and Biomolecular Resources (BBMRI). 
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Finally our tight collaborations with UCLA and the Broad Institute have facilitated a 
number of international projects funded by NIH (Dr. Peltonen as the P.I.) typically 
using Finnish population samples in GWA studies or deep sequencing efforts to 
characterize the genetic profiles behind cardiovascular or neuropsychiatric diseases). 
 
Some of the gene variants identified by us seem to be associated also with subtraits or 
quantitative features of these diseases. The risk allele of USF1 is correlated with high 
triglyceride levels in man and provides an increased risk for early cardiovascular events 
in women. DISC1 risk allele shows an association both with psychosis generally as well 
as with the QTL of specific neurobehavioural trait components, known to be associated 
with an increased risk of schizophrenia. 
 
Genetic loci identified for complex diseases in the Finnish study samples 
Following genome scans we have well defined loci for total of 12 diseases. Restriction 
of the critical, disease-associated regions for all these traits has been systematically 
carried out using linkage disequilibrium (LD) and allele sharing in disease alleles, 
relying on the dense set of single nucleotide polymorphisms and information of LD and 
haploblock intervals in Finns. 
  
Table 2. Summary of identified common disease loci and genes identified by us 
Phenotype 
 
Chromosome Gene Reference 
Three novel MS-loci 18q,5p,17q Myelin basic  
protein, C7, PRKCA 
Tienari et al. 1994 ,  
Kuokkanen et al. 1996, 1997, 
Saarela et al. 2002, 2006, 
Kallio et al. manuscript 
One major FCHL-
locus, two “modifying” 
loci 
Three loci for low 
HDL 
1q, 10q, 2q 
 
 
8q, 16q, 20q 
USF1 (1q) 
 
 
n.d. 
Pajukanta et al. 1998, 1999, 
2004 
 
Soro et al. 2002, Pajukanta et 
al. 2003 
One hypertension locus 3q AT Kainulainen et al. 1999,  
Perola et al. 2000 
One locus for 
osteoarthritis 
2q n.d. Leppavuori et al. 1999 
Three loci for 
schizophrenia 
1q,7q, 5q DISC1, Reelin, n.d. Hovatta et al. 1999, Ekelund 
et al. 2000, Paunio et al. 2001, 
Hennah et al. 2003, 2006, 
Peltonen et al. 2006 
Two loci for coronary 
heart disease 
 
2q,X n.d. Pajukanta et al. 2002 
Thee loci for migraine 4q, 17p, 18q n.d. Wessman et al. 2002, Anttila 
et al. 2006 
Multiple loci for stature 1q,7q,8q,X Col12A1 Perola et al. 2001, Sammalisto 
et al. 2006, Perola et al. 2007 
Two loci for obesity 18q,X n.d, SLC6A14 Ohman et al. 2000, Suviolahti 
et al. 2003 
Three loci for autism 
and Asperger 
syndrome 
3q, 1q, 15q n.d., DISC1 Auranen et al. 2002, 
Rehnstrom et al. 2006, 
Ylisaukko-oja et al. 2005, 
2006 
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Three loci for bipolar 
disease 
Locus for sweet 
preference  
Three loci for nicotine 
addiction  
Xq, 4q, 16p 
16p 
7q,10q,11p 
n.d. 
 
FTO 
 
n.d. 
Pekkarinen et al. 1995, 
Ekholm et al. 2003 
Keskitalo et al. manuscript 
 
Loukola et al. 2007 
 
Functional studies of identified disease alleles and characterization of their role in 
disease 
Although the major focus of our research effort so far has been in the identification of 
genes and genetic profiles behind common diseases, we here provide some examples of 
functional studies performed by us. For the USF1 behind dyslipidemias and early 
myocardial infarct, we have demonstrated that the risk allele shows allelic imbalance 
and abnormal reactivity to insulin both in fat and muscle as well as abnormal transcript 
profiles of the downstream genes for the USF1 in fat and muscle biopsies of individuals 
carrying the risk alleles. Further, to demonstrate the role of a specific allele at the level 
of the vessel wall of myocardial arteries we have shown in the Helsinki Sudden Death 
Study sample of 700 males that risk allele carriers show wide plaques and more 
advanced atherosclerosis. We have also produced a knockout mouse model for USF1 to 
address in detail the tissue specific functions of this dyslipidemia gene. For migraine, 
genome wide expression studies of rodent models with mutations in genes causing 
Mendelian forms of migraine have been used to identify common pathways and 
subsequently positional candidate genes for common forms of migraine. Even for 
behavioural traits rodent models have been useful: Mouse crosses have facilitated the 
unbiased search for aberrations in global transcript profiles and when combined with 
behavioral anxiety-measures, exposed 17 genes that regulate anxiety-like behavior by 
Dr. Hovatta. These results have been validated by local lentivirus-mediated gene 
transfer (overexpression and silencing by RNAi) experiments that have shown that 
glyoxalase 1 (Glo1) and glutathione reductase 1 (Gsr), regulate anxiety-related behavior 
in mouse in vivo. Allelic diversity of these genes is now being analyzed as part of the 
Finnish population-based Health 2000 study. A representative sample (n=6005) of 
Finland’s adult population was interviewed with CIDI (Composite International 
Diagnostic Interview) for the presence of anxiety disorders. The anxiety disorder sub-
cohort consists of 339 cases and 678 matched controls. 
 
Multiple studies have been performed to address the role and the population impact of 
identified variants for the disease or trait components of the disease in large nationwide 
family collections or population cohorts of KTL (Table 3.).   
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Table 3. Sample collections of the population cohorts  
Cohort Total 
cohort (n) 
DNA 
samples 
(n)(%) 
Average 
DNA 
yield** 
Serum 
(n) 
Other 
samples*** 
ATBC study 
 
29 000 2122 
(7.3)* 
144 29 000 n 
Finnish Twin Cohort 
 
42 000 12040 
(28.7) 
324 1 000 sess 
Finrisk 1992-2007 29 597 27150 
(89.5%) 
278 From 
all 
sess 
    92 6051 5784  154 6025 sess 
    97 8447 8791 285 7150 sess 
    02 8799 8758 300 8788 sess 
    07 6300 6300 300 6300 sess 
Helsinki Sudden Death 
Study 
1400 1400 (100) - 700 ft, pt(ss), 
u(ss) 
Health 2000 
 
7419 (8000) 6824 
(91.9) 
401 8000 sess 
KTL Psychiatric 
collections 
 
9728 2142 
(22.0) 
240 - c(ss) 
Northern Finland Birth 
Cohort 1966 & 1985-86 
~12 000 11652 300 From 
all 
p, sess 
Helsinki Sudden Death 
Study 
~1 000 000 0 0 0 pt, c(ss), 
ft(ss)  
Mobile Clinic Health 
Survey 
57 000 0 0 57 000 p 
Mini-Finland 
 
7217 0 0 7217 p, u 
Total 212 358 biological samples. ss=subsample; sess =several subsamples; *extraction 
unfinished, samples from all; **amount still left; ***plasma= p; frozen tissue = ft; tissue in 
paraffin =pt; urine= u; cells= c; nail clippings =n 
 
A good example of these efforts are the risk effects of 2.2-3.2 identified for the 
combination of risk alleles of USF1 and ApoA5 for cardiovascular risks in Finrisk 92 
and 97 with over 120 000 follow-up years total, as well as additive effect of 
combination of risk alleles for serum levels of cholesterol, TG, LDL and HDL observed 
in genotyping the risk variants of the full Finrisk 97 cohort (over 6000 individuals). To 
develop better tools to address the impact of risk alleles for disease outcomes we have 
collaborated with top level epidemiologists and mathematicians and adapted e.g. the 
decision tree models to identify how study how the risk alleles modify the disease risk 
in population groups with traditional risk alleles. In these efforts we are greatly helped 
by our collaborations with The Finnish Distinguished Professor of the Academy of 
Finland, Joel Terwilliger as well as the group of the Academy Professor Heikki Mannila 
in the Helsinki Institute of Information Technology. 
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Table 4. Association of pair-wise SNP combinations with the endpoints in time-to-
event analysis (covariates: age at baseline, (sex, cohort), smoking, hypertension, rchol, 
BMI, diabetes, CRP). The allele stated as the risk allele was coded as 1 and the other 
allele as 0.  
SNP Gene Inheritance 
Model 
Group FINRISK-92
HR (CI 
95%)         p   
FINRISK-97
HR (CI 95%) 
p 
Combined 
HR (CI 95%)  
p 
FDR 
c 
Rs7542281x 
Rs1042580 
F5 
THBD 
Recessive a 
Dominant a 
CHD, 
women 
4.51 (1.40-
14.54)  0.012 
7.14 (2.09-
24.36)  0.0017
4.45 (1.94-
10.19)    
0.00042 
+ 
Rs5030341x 
Rs1401296 
ICAM1
PROC 
Dominant a 
Dominant a 
Death, 
men 
2.53 (1.03-
6.20)    0.043 
2.68 (1.50-
4.76)    
0.00081 
1.63 (1.18-
2.24)      
0.0028 
+ 
Rs2269648x 
Rs1401296 
F5 
PROC 
Dominant b 
Dominant a 
Death, 
men 
1.20 (0.86-
1.66)    0.28  
1.07 (0.80-
1.44)    0.65  
1.80 (1.18-
2.76)      
0.0069 
+ 
Rs5030347x 
Rs1401296 
ICAM1
PROC 
Recessive a 
Dominant a 
CHD, 
women 
4.29 (0.38-
47.97)  0.24 
1.50 (0.22-
10.08)   0.68 
2.08 (1.21-
3.57)      
0.0083 
- 
Rs7542281x 
Rs1401296 
F5 
PROC 
Recessive a 
Dominant a 
CVD, all 1.51 (0.94-
2.44)    0.091 
1.50 (1.02-
2.21)     0.037
1.49 (1.11-
2.01)      0.009 
- 
Rs6025x 
Rs6048519 
F5 
THBD 
Dominant a 
Dominant a 
CVD, 
men 
1.53 (0.76-
3.08)    0.23  
5.09 (1.39-
18.68)   0.014
2.80 (1.42-
5.53)      
0.0029 
- 
Rs7542281x 
Rs1401296 
F5 
PROC 
Recessive a 
Dominant a 
Stroke, 
all 
3.00 (1.23-
7.31)    0.016 
2.00 (0.93-
4.32)     0.077
2.69 (1.35-
5.35)      
0.0050 
- 
Rs1401296x 
Rs6048519 
PROC 
THBD 
Recessive a 
Dominant a 
Stroke, 
men 
1.38 (0.33-
5.76)    0.66  
3.13 (1.06-
9.27)     0.039
3.42 (1.30-
8.99)      0.013 
- 
aMinor allele is the risk allele,  bMajor allele is the risk allele,  cFDR: Rejecting the null-
hypothesis for those with “+” assures that the false discovery rate <10% in the combined 
analysis. 
 
Systems Biology 
System biology was initiated with the recruitment of Dr. Jussi Taipale into KTL at 2005. 
His group has used cell cycle pathways as a proof of principle of the system biology 
approach to tackle molecular pathways in complex biological processes. The main 
achievements of the systems biology group, on board only in 2005-2007 are 1) 
identification of genes regulating cell size and cycle progression in Drosophila and in 
humans, 2) development of tools allowing prediction of regulation of genes based on 
sequence (including prediction of the effect of SNPs on gene expression), and 3) 
characterization of genes involved in mammalian Hedgehog signal transduction (a 
signalling pathway activated in several forms of human cancer). 
 
In genome-wide analyses of protein phosphorylation in regulation of the cell cycle in 
Drosophila S2 cells, and screened 14 000 dsRNAs in the Drosophila Gene Release I and 
II dsRNA libraries in multivariate flow cytometry assay in triplicate. This analysis 
resulted in the identification of a number of genes and pathways that have not 
previously been linked to regulation of the cell cycle. 
 
For analyzing organ specific growth control, a high-throughput assay was developed for 
analysis of transcription factor binding specificities, and this method was used to 
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measure the DNA binding profiles of GLIs 1-3, Tcf4 and c-ETS1, which mediate 
transcriptional responses to the Hedgehog, and Wnt and Ras/mitogen-activated protein 
kinase signaling pathways, respectively. To identify enhancer elements regulated by 
these pathways a novel computational tool EEL has been developed in collaboration 
with Dr. Kimmo Palin and Esko Ukkonen (University of Helsinki, Department of 
Computer Science) to align DNA sequence based on TF binding sites in all identified 
human and mouse genes. The resulting data was used to identify Hh and Wnt target 
genes, and to predict TFs that are activated in an experiment on the basis of changes in 
expression of a limited number of genes. Identification of tissue-specific enhancer 
elements has substantial potential significance for our understanding of complex disease 
genetics. 
 
 
6.3. Scientific impact  
 
Table 5. Summary of the scientific output during 1997-2007 
Scientific output  
 
N Comments 
Peer-review articles in 
international journals 
257 In addition 27 review articles/book chapters.  
See Appendix 2 
Invited lectures and 
chairmanships in 
international meetings 
>600 Examples of plenary and keynote lectures :  
- Leena Peltonen: “Story of My Roots: Disease Mutations 
of a Population”. Margaret Pittman Lecture, part of the 
NIH Director's Lecture series. Los Angeles, California, 
USA, January 28, 2004. 
- Leena Peltonen: “From families to populations: impact 
of disease genes” HGM 10th Human Genome Meeting, 
Kyoto, Japan, April 18-22, 2005.  
- Leena Peltonen: “Genome-wide view to human diseases 
and the special value of twin studies in the post-genome 
era”. ISTS (The International Society for Twin Studies) 
Mid-Congress Conference, Los Angeles, June 29, 2005. 
- Leena Peltonen: “From families to population: Lessons 
from disease genes of a genetic isolate”. ASHG 
Meeting, Salt Lake City, Utah, USA, October 25-29, 
2005.  
- Leena Peltonen: “European strengths in biomedical 
research in postgenome era”. From Biobanks to 
Biomarkers: Translating the potential of human 
population genetics research to improve the quality of 
health of the EU citizen, Hinxton, UK, September 20-
23, 2005.  
- Leena Peltonen: ”From Families to Population: 
Example of Finland”. Keystone Symposia, Genome 
Sequence Variation and the Inherited Basis of Common 
Disease and Complex Traits, Big Sky Resort, Big Sky, 
Montana, January 8-13, 2006  
- Leena Peltonen: “Human Disease Genes: From Families 
to Populations”. 11th International Congress of Human 
Genetics, Brisbane, Australia, August 6-10, 2006. 
- Leena Peltonen: “Low hanging fruits and beyond, 
genetics of common traits”. HGM 12th Human Genome 
Meeting, Montreal, Canada, May 19-25, 2007. 
- Leena Peltonen: “The GenomEUtwin project”. ICTS 
Meeting, Twin and multiples – a life course perspective, 
Ghent, Belgium, June 8-9, 2007.   
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Invited lectures and 
chairmanships in 
international meetings 
 - Leena Peltonen: “Genome-wide strategies to address 
molecular pathways of atherosclerosis”. European 
Atherosclerosis Society 76th Congress, Helsinki, Finland, 
June 10-13, 2007.  
- Leena Peltonen: “Beyond associations, understanding 
complex characters of common traits”. The Genomics of 
Common Diseases Conference, Wellcome Trust 
Conference Center, Hinxton, UK, July 7-10, 2007. 
Articles in domestic 
journals and text books 
18 See Appendix 2 
 
Lectures in domestic 
meetings and teaching 
lectures 
>300  
Editorial tasks in 
international journals 
 
14 
 
 
e.g. Psychiatric Genetics 1989–; European Journal of 
Human Genetics 1991 – 2004; American Journal of 
Medical Genetics 1992–; Current Opinion in Genetics & 
Development  2000– 
Committee memberships: 
domestic and gate keeper 
positions (domestic) 
12 e.g. Chairman of the Medical Research Council of 
Finland (Academy of Finland) 1997; Science and 
Technology Policy Council of Finland, Member 1997–
1998 
Committee memberships: 
international (EU, WHO 
etc.) 
 
16 e.g. EURESCO Scientific Steering Committee, Member 
1997–1998; International Bioethics Committee, 
UNESCO, Member 1998–2003; American Society of 
Human Genetics, Member, Board of Directors 2001–
2004; Chair, Populations and Public Health Strategy 
Committee, Wellcome Trust  
2004-; HUGO – President 2005– 
Membership of scientific 
organizations 
5 e.g. European Molecular Biology Organization (EMBO), 
Elected Member 1991- ; European Academy of Sciences 
(Academiae Europeae), Elected Member 1999– ; Foreign 
Associate Member in the Institute of Medicine of the  
National Academies, USA 2006– 
International evaluation 
panels (EU etc.) 
 
12 e.g. Scientific Advisory Board, Center for Molecular 
Medicine, Karolinska Institutet, Stockholm, Sweden, 
Member 1996– ; Scientific Advisory Board of the 
Genome Research Programme, Foundation for Strategic 
Research, Sweden, Member 1999–2005; International 
Advisory Board, SWEGENE, Sweden, Member 2000–
2004; Scientific Advisory Board of UK Biobanks, 
Member 2001– ; 
Scientific Advisory Board of the Shanghai Genome 
Center, Member 2002– ; Scientific Advisory Board, 
Genome Canada, Member 2002 – 2003 
Organizing committee of 
international meetings 
22 e.g.  EMBO Practical Course – SNP genotyping and 
Haploblock Analysis, August 2005, Helsinki, Finland; 
HGM2006 – Human Genome Meeting, May, 2006, 
Helsinki, Finland; GenomEUtwin Scientific Meeting, 
European network of twin registers and MORGAM 
cohorts, December, 2006, Rome, Italy 
Doctoral dissertations 
 
20 See Appendix 2 
Supervision of 
dissertations: ongoing 
44  
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Opponent of dissertations 
 
 National universities 6 
Foreign universities 10 
Pre-examiner of  
- dissertations 
- adjunct professors 
- professorships 
  
12 
6 
12 
Prizes 
 
11 e.g. EMBO Young Investigator 2006 (J.Taipale); 
European van Gysel Prize for Biomedical Research  2006 
(L.Peltonen); Eric K. Fernströms Stora Nordiska Priset 
2006 (L.Peltonen) 
 
 
6.4. Societal impact  
The final goal of genetic and genomic/system biology related research is to translate the 
wealth of data emerging from large-scale research efforts in genetic and genomic 
epidemiology conducted in well-characterized Finnish (and European) samples into 
information of relevance to future clinical and public health advances. The aspiration is 
to make use of large epidemiological datasets to help to define the precise aetiological 
DNA, RNA or protein variants, and to understand their joint effects (and interactions) 
with other variants and relevant life style exposures. We expect that the information 
gathered will be relevant to the practice of clinical medicine and public in two major 
respects: through advances in understanding of the pathogenesis of disease, and through 
the enhanced potential to use genetic and genomic information (including biomarkers) 
to stratify risk, monitor progression and predict therapeutic response to common health 
problems.  
 
Implementation of this new research date needs to be sensitive to the ethical, legal and 
social implications of such developments. Finland is in many ways an ideal setting for 
close integration between the scientific and clinical research and examination of the 
broader “societal” consequences of such research. In the setting of national health care 
system with a tradition of excellent communication with public and high acceptance of 
medical research the fruits of genome research can be expected to produce tangible 
benefits for Finnish (and European) citizens. Already now, the most commonly used 
DNA test in Nordic countries is the one detecting lactose intolerance, developed based 
on our innovation. Similar successes for DNA testing providing more accurate diagnosis 
and providing guidance to improved medication and intervention strategies in numerous 
old age diseases can be expected. The strength of Finnish genome research is more 
societal than technical. We can use the large clinical study samples and population 
cohorts at our disposal to understand the population-level effects of all biological 
variants identified by us and others. In the case of T2D for example, we can estimate 
based on published findings, that in Europeans, it is currently possible to achieve a 
discrimination index for a diagnosis of T2D of ~63%. This still lies some way short of 
the ~75-80% benchmark considered appropriate for clinical utility, but the potential for 
further discoveries in T2D genetics means that this benchmark is far from unattainable. 
Finnish study samples make it possible to evaluate the impact of common and rare 
alleles and their cross talk with traditional life style risk factors, improve the use of 
existing therapeutics and develop clinical diagnostics for prediction, prognostication, 
screening and “personalized” therapeutics.  
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6.5. Research funding 
 
Table 6. Project funding during 1997-present 
Project name Funding agency* 
(PI)** 
Funding 
k€ 
Years 
Limiting the immune response in adenoviral 
gene therapy in the brain -application to 
Parkinson’s disease 
EU (TP) 100 1997-1998 
Multiple Sclerosis 
 
EU (LP) 309 1997-2000 
Genetics of common diseases: integrated 
approach to genome-wide profiling of 
common traits 
FO (LP) 600 
 
1997-2006 
Several Ph.D. projects 
 
GS (LP students) 318 1997-2009 
Monica Cohort 
 
EU (LP) 78 
 
1998-2001 
Center of Excellence in Disease Genetics 
 
SA (LP) 900 2000-2005 
Molecular Genetic and neurocognitive 
profiles in autistic spectrum of disorders 
SA (LP) 96 
 
2000-2003 
GenomEUtwin, Genome-Wide Analysis of 
European Twin and Population Cohorts to 
Identify Genes in Common Diseases  
EU (LP) 3 336 2002-2007 
Genetic Loci Predisposing to Multiple 
Sclerosis (MS) 
FO (LP) 354 
 
2002-2007 
Characterization of genetic loci 
predisposing to multiple sclerosis 
HUS EVO (LP) 252 2002-2004 
Post Doctoral salary costs, genomewide 
analyses of background of common disease 
SA (LP) 204 2003-2007 
Research costs for acad. Prof., genomewide 
analyses of background of common disease 
SA (LP) 780 2003-2008 
Compgenome; New computational 
techniques for analysing the structural and 
functional landscape of the mammalian 
genomes 
SA (LP) 183 2004-2007 
Genetic analysis of schizophrenia 
phenotype clusters using advanced 
statistical approaches 
CO (LP)  120 
 
2004-2007 
Characterization of the genetic background 
of Multiple Sclerosis 
NIH (LP) 130 2004-2005 
Preparing funding for EU-project 
 
SA (LP) 50 2005,2007 
Neuropromise, Neuroprotective Stragegies 
for Multiple Sclerosis 
EU (LP) 471 
 
2005-2009 
GEHA, Genetics of Healthy Aging  EU (LP) 236 
 
2005-2010 
Genes and underlying metabolic pathways 
in MS 
 
HUS EVO (LP) 310 2005-2009 
Center of Excellence in Complex Disease 
Genetics 
SA (LP) 450 
 
2006-2008 
Population Biobanks, Promoting 
Harmonising of Epidemiological Biobanks 
in Europe  
EU (LP) 49 
 
2006-2008 
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Utilizing whole-genome association 
strategy to locate genetic variants 
predisposing for cardiovascular disease 
FO (LP) 180 
 
2006-2008 
Autism 
 
FO (LP) 120 2006-2007 
Molecular genetic study of schizophrenia 
and cognitive defects in Finnish family-
based sample 
HUS EVO (TP) 
FO (TP) 
66 
35 
2002-2003 
2005-2006 
Molecular genetic study of mood disorders: 
depressive and bipolar disorders and the 
seasonal pattern in Finland 
SA (TP) 120 2004-2006 
Molecular genetic study of mood disorders 
in Finland 
HUS EVO (TP) 
FO (TP) 
45 
20 
2005-2006 
2005 
Disorders of sleep regulation: basic 
mechanisms and therapeutic perspectives 
EU (TP) 120  2005-2008 
Genetic architecture of sleep and the role of 
sleep/sleep loss in development of mood 
disorders  
HUS EVO (TP) 90 2006-2008 
Utilizing whole-genome association 
strategy to locate genetic variants 
predisposing for cardiovascular disease. 
FO (MP) 40 
150 
2002-2004 
2005-2008 
Capturing and verifying the role of the 
genetic variation of functional and 
positional candidate loci in relation to 
cardiovascular disease in a Finnish 
population sample 
FO (MP) 40 
30 
2003-2005 
2007-2008 
Food preferences and chemosensory 
performance: genetic parameters addressed 
in twin and population cohorts 
SA (MP) 273 2004-2007 
Power tools for linkage and LD analysis for 
complex etiological models 
SA (MP) 100  2005-2007 
Growth control and Cancer 
 
FO (JT) 390 2005-2007 
Net2Drug EU (JT) 
 
82 
 
2007 
 
Genetics and neurobiology of anxiety SA (IH) 
FO (IH) 
182 
107 
2006-2009 
 
The effect of gene copy number variation 
on insulin resistance and related quantitative 
traits 
Novo Nordisk 
Fonden (KS) 
20 2006-2008 
*EU=European Union, SA=Academy of Finland, TEKES=Finnish Funding Agency for 
Technology and Innovation, FO=Foundations, HUS EVO=University Central Hospital. 
**PI=see senior scientific personnel in chapter 6.8 
 
 
6.6. Scientific collaboration  
Leena Peltonen 
Complex Disease Genetics: Prof. Mark Daly, Prof. David Altschuler (The Broad Institute, 
Cambridge, USA), Prof. Mark McCarthy (Oxford University, UK), Prof. Marja-Riitta 
Taskinen (University of Helsinki, Finland), Prof. Leif Groop (Lund University, Sweden), 
Prof. Jouko Lönnqvist (KTL), Professor David Porteous (Edinburgh University, UK) 
GenomEUtwin: Prof. Nick Martin (Queensland Institute of Medical Research, Brisbane, 
Australia), Prof. Tim Spector (King's College London, UK), Prof. Dorret Boomsma 
(Netherlands Twin Register, Amsterdam, Netherlands), Prof. Nancy Pedersen (Swedish 
Twin Registry, Stockholm, Sweden), Prof. Jaakko Karprio (University of Helsinki, Finland) 
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Population cohorts: Prof. Veikko Salomaa, Prof. Kari Kuulasmaa (KTL), Prof. Marjo-Riitta 
Järvelin (Imperial College, London, UK), Dr. Kari Stefansson (deCODE, Reykjavik, 
Iceland) 
Mathematic Modelling: Prof. Heikki Mannila (Helsinki Institute for Information 
Technology, Finland), Prof. Joe Terwilliger (University of Helsinki, Finland and Columbia 
University, New York, USA), Prof. Peter Donnelly (Oxford University, UK), Prof. Mark 
Daly (The Broad Institute, Cambridge, USA) 
Jussi Taipale 
Systems biology: Prof. Timothy Hughes (University of Toronto, Canada),  Prof. Joerg 
Hoheisel (German Cancer Research Center, Heidelberg, Germany), Prof. Olli Kallioniemi 
(Technical Research Centre, Turku, Finland), Prof. Juha M. Partanen (University of Helsinki, 
Finland), Prof. Lauri A. Aaltonen (University of Helsinki, Finland)  
Markus Perola 
Quantitative genetics: Prof. Pekka Karhunen (University of Tampere, Finland), Prof. 
Joseph Terwilliger (University of Helsinki, Finland and Columbia University, New York, 
USA), Prof. Hely Tuorila (University of Helsinki, Finland), Prof. Alun Evans (University 
of Belfast, UK), Prof. Claudio Francesci (University of Bologna, Italy), Dr. Harald Göring 
(Southwest Foundation of Biomedical Research, San Antonio, US) 
Tiina Paunio 
Disorders of mood and sleep: Prof. Erkki Isometsä (University of Helsinki, Finland), Adj. 
Prof. Timo Partonen, Adj. Prof. Annamari Tuulio-Henriksson (KTL), Adj. Prof. Tarja 
Stenberg (University of Helsinki, Finland), Prof. Jaakko Kaprio (University of Helsinki, 
Finland), Prof. Markku Koskenvuo (University of Helsinki, Finland), Prof. Reto Huber 
(University of Zurich, Switzerland), Prof. Tom de Boer (Leiden University Medical Center, 
The Netherlands), Prof. Nelson Freimer (University of California, Los Angeles, USA) 
Iiris Hovatta  
Molecular genetics and neurobiology of anxiety disorders: Acad. Prof. Leena Peltonen, 
Prof. Jouko Lönnqvist, Dr. Sami Pirkola (KTL), Prof. Joseph D. Terwilliger (University of 
Helsinki, Finland and Columbia University, New York, USA), Dr. Matthew Zapala, Prof. 
Nicholas Schork and Prof. Victoria Risbrough (UCSD, San Diego, USA), Dr. Dario Greco 
(University of Helsinki, Finland), Prof. Esa Korpi (University of Helsinki, Finland), Dr. Jin-
Hui Wang (Chinese Academy of Sciences, Beijing, China), Prof. Juha Kere (University of 
Helsinki, Finland), Adj. Prof. Sami Pirkola, Adj. Prof. Jaana Suvisaari (KTL) 
 
 
6.7. Proposal for the future work and expected (societal) benefits (next 
five years) 
With the rapidly emerging data from genome wide association studies in large case-
control study samples, new potentially associated genes will be identified. However, 
these “low hanging fruits”, typically representing common SNPs and showing the 
increased risk at the 1.05-1.2 level will not explain the complete genetic background of 
common diseases. The prestigious Finnish study samples and population resources 
available at KTL will be critical in the next phase of these studies: We need to fine-map 
the aetiological variants, identify full allelic spectrum behind the disease (both common 
and rare alleles) and to explore issues of pleiotropy and heterogeneity. Population-based 
cohorts will be central to efforts to understand the epidemiological characteristics of the 
variants we and others will identify in genome-wide association studies and to explore 
the scope of joint effects between risk alleles/haplotypes and between genes and 
environmental and lifestyle factors    
Based on our systematically built expertise, core facilities and collected study samples 
we are convinced that MLO, as a critical part of FIMM, will make a substantial and 
unique contribution to the identification and characterization of specific functional 
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variants and genetic profiles behind complex diseases and their trait components as well 
as in estimation of their relationship with lifestyle risk factors. 
 
We expect to be in a position where, at least for some of the variants, we can evaluate 
disease pathogenesis, explore population-based effects, evaluate the impact of common 
and rare alleles and their joint effects with traditional life style risk factors, improve the 
use of existing therapeutics and develop clinical diagnostics for prediction, 
prognostication, screening and ‘personalized’ therapeutics. If sufficient resources can be 
obtained, genetic epidemiological research at KTL would contribute significantly to the 
actions of our health care providers and public health officials and thus serve the 
betterment of the Finnish health care system and contribute to improved understanding 
of the background and causes of common diseases worldwide. 
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Li Song-Ping, Ph.D., post-doctoral fellow 2005- 
Päivi Laiho, Ph.D., head of the laboratory 2006- 
Teemu Kivioja, Ph.D., post-doctoral fellow 2006- 
Wei Gonghong, Ph.D., post-doctoral fellow 2006- 
Salim Mottagui-Tabar, senior investigator 2006-2007 
Eveliina Jakkula, MD, Ph.D., post-doctoral fellow 2006- 
Samuli Ripatti, Ph.D., senior investigator 2007- 
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7 MOLECULAR BIOLOGY OF CARDIOVASCULAR DISEASES 
 
7.1. Research area and its significance 
Atherosclerotic cardiovascular diseases are the major causes of death in western 
societies. The prevalence of coronary artery diseases (CAD), however, increases rapidly 
also in developing countries and formerly socialist economies of Europe. Thus, within 
the next 15 years, CAD are expected to be the main cause of death globally. Also in 
Finland, despite a considerable decrease in serum total cholesterol levels since the start 
of the North Karelia Project in the 1980’s, a large part of the population still has an 
increased risk of CAD and atherosclerosis. This mainly is due to a rising incidence of 
type 2 diabetes, obesity, and metabolic syndrome. Although the serum high-density 
(HDL) cholesterol levels have increased among a part of the Finnish population, about 
30 % of the population still has too high total as well as low-density lipoprotein (LDL) 
cholesterol concentrations. This data is based on the recent comprehensive health 
examination, the Health 2000 Health Examination Survey coordinated by National 
Public Health Institute. 
 
HDL and atherosclerosis  
An inverse correlation between the risk for developing premature CAD and the serum 
HDL cholesterol has been substantiated in a number of epidemiological and 
interventional studies. HDL protects against atherosclerosis via several mechanisms. It is 
a key mediator of reverse cholesterol transport, the process by which excess peripheral 
tissue cholesterol in lipid-laden macrophage-foam cells is shunted back to the liver for 
excretion. Additionally, HDL has anti-inflammatory, anti-oxidative, and anti-thrombotic 
activities that are suggested to contribute to its anti-atherogenic effects. The HDL in 
human plasma consists of several subpopulations of particles of distinct structure, 
composition and function. This heterogeneity, which is the result of continuous 
remodeling of HDL by plasma factors and specific membrane proteins such as ABCA1 
and G1, has important implications in terms of the cardioprotective functions of HDL. 
Lipid modifying drugs, especially modern statins, have successfully been used for the 
treatment of high LDL cholesterol levels in several large-scale clinical trials. However, 
statin monotherapy may have its limits in the inhibition of the development of 
atherosclerosis. Therefore, the treatment of CAD has recently been extended and 
targeted to low serum HDL cholesterol levels. However, elevated total HDL cholesterol 
levels may not reduce the progression of atherosclerosis as exemplified by a recent trial 
where the CETP inhibitor Torcetrapid failed to demonstrate reduction of atherosclerosis 
despite a large 50 % increase in HDL cholesterol levels. Considering the protective role 
of HDL it is of utmost importance to understand the formation of HDL as well as all the 
factors that modify the HDL subclass pattern. Our internationally recognized research 
programme has utilized various cohorts and characterized molecular mechanisms behind 
CAD. We have during the past ten years focused on several HDL-related aspects in 
atherosclerosis research, the major ones being:  i) lipid transfer proteins, especially 
phospholipid transfer protein (PLTP) and its role in HDL metabolism, ii) inflammation 
as a risk factor in atherosclerosis, iii) role of HDL-associated estrogens in protection 
against atherosclerosis, and iv) characteristics of low and high HDL subjects: Finnish 
low-HDL families and Health 2000 Health Examination Survey material. At the 
departmental level, our expertise is being utilized to reveal the molecular mechanisms 
behind novel gene variants connected to dyslipidemias. 
 
Background material                                                       7 MOLECULAR BIOLOGY OF  
                                                                                     CARDIOVASCULAR DISEASES 
 
 101
Regulation of cellular lipid homeostasis 
Rapid methodological development in the field of lipid cell biology has enabled us to 
obtain the first glimpses on how the complexity of the cellular lipidome is generated and 
how it is intimately and delicately connected with the machineries that regulate 
functions such as vesicle transport, cytoskeletal dynamics, and signalling cascades 
responsible for cell proliferation, differentiation, and apoptosis. Lipidous signalling 
molecules including phosphoinositides, ceramide, lysophospholipids, sphingosine-
related molecules, and oxysterols play key roles in these processes. Importantly, 
disturbances in these regulatory circuits are involved in the etiology of dyslipidemias, 
atherosclerosis, neurologic diseases, and possibly also cancer. The present activity aims 
to shed light on this area and has strong implications for both basic research and 
medicine. 
 
Oxysterols, 27-carbon oxygenated derivatives of cholesterol, are potent regulators of 
cellular lipid metabolism. Their functions have been divided in three main categories: 1) 
control of gene expression, 2) role as intermediates in the biosynthesis of bile acids and 
steroid hormones and 3) sterol efflux from cells. The best known functions of these 
compounds thus involve the regulation of body sterol homeostasis. Oxysterols are highly 
enriched in macrophage foam cells within arterial walls and in atherosclerotic lesions. 
They have cytotoxic, pro-apoptotic, and pro-inflammatory activities, and facilitate the 
differentiation of monocytes into macrophages. Therefore, oxysterols have been 
suggested to adversely affect the development and stability of atherosclerotic lesions. 
However, the first protein identified that binds oxysterols was oxysterol binding protein, 
OSBP. It binds several oxysterols with high affinity to its carboxy-terminal ligand 
binding domain, and acts as a sterol sensor that integrates the cellular sterol status with 
sphingomyelin metabolism by regulating ceramide transport form the endoplasmic 
reticulum (ER) to the Golgi apparatus. Interestingly, OSBP also acts as a sterol-
dependent regulator of extracellular signal regulated kinase (ERK) signalling pathways. 
Families of OSBP-related proteins (ORP) are found in eukaryotic organisms from yeast 
to man. Major activity in the group concentrates on characterizing the functional role of 
human ORP proteins in cellular lipid metabolism and membrane trafficking, as well as 
in the development of atherosclerosis. 
 
The work in the group is well integrated with the activity in Matti Jauhiainen’s group 
(see above); Work on cellular lipid homestasis closely tangents the study of HDL 
function. The group also acts as the cell biology expert center for the entire MLO 
department by providing help in methodology concerning cellular lipid metabolism and 
membrane trafficking. 
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Figure 1. Research topics of the research program. The top image illustrates an 
atherosclerotic lesion, and the bottom image a cell, e.g. a macrophage foam cell, within 
the lesion. Central pathways and molecules with potential to modify lesion development 
are indicated in the cell image. Abbreviations: PLTP, phospholipid transfer protein; 
HDL, high-density lipoprotein; LDL, low-density lipoprotein; apoA-I, apolipoprotein 
A-I; apoE, apolipoprotein E; ABC, ATP-binding cassette; LXR, liver X receptor; RXR, 
retinoid X receptor; ORP, oxysterol-binding protein related protein. 
 
 
7.2. The main achievements 
Participation in international epidemiological surveys 
The research program has participated in three large international multicenter studies. 
These are the Diabetes Atherosclerosis Intervention Study (DAIS), the Fenofibrate 
Intervention and Event Lowering in Diabates (FIELD) Trial, and the European 
Multicenter Study on Familial Dyslipidemias in Patients with Premature Coronary Heart 
Disease (EUFAM). Representative of the research program was member of the steering 
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committees of the DAIS and FIELD studies, and acted as coordinator of the EUFAM 
study funded by the EU. In addition to the steering, coordination, and data analysis tasks 
performed by the research program, the Analytical Biochemistry Laboratory that 
belonged to the research program until 2001, performed a major share of the 
biochemical analyses of patient samples in all three studies.  
 
Phospholipid transfer protein (PLTP): mechanisms of function and role in 
atherosclerosis 
The regulatory role of PLTP in HDL metabolism is achieved via its two main functions, 
phospholipid transfer activity and the capability to modulate HDL size and composition 
in a process called HDL conversion. PLTP is capable of generating a specific subgroup 
of HDL, preβ-HDL through HDL conversion, and these particles have been suggested to 
participate in the removal of cholesterol from macrophage foam cells. On the other hand, 
PLTP may regulate HDL levels in the circulation due to its ability to transport surface 
remnants after lipolysis of triglyceride-rich lipoproteins like VLDL and chylomicrons. 
Thus, PLTP can be envisioned to play an important role in the prevention of 
atherosclerosis. Expression of the PLTP gene is subject to regulation by nuclear 
receptors. Bile acids regulate PLTP expression through farnesoid X receptor, FXR, and 
oxysterols through liver X receptors, LXR. It is conceivable that PLTP expression may 
represent an attempt to further boost processes of reverse cholesterol transport, in which 
PLTP is suggested to play an important role. The LXR targets, in addition to PLTP, 
include a number of genes with key roles in the reverse cholesterol transport and HDL 
metabolism, including cholesteryl ester transfer protein (CETP), ABCA1, ABCG1, and 
apoE.  
 
PLTP seems to facilitate phospholipid transfer by acting as a true transfer protein 
between the donor (VLDL) and the acceptor (HDL) particles. In the second function 
associated with HDL conversion we have demonstrated that among the two lipid transfer 
proteins, PLTP is the major contributor to the generation of preβ-HDL particles in vitro 
and in vivo in a mouse model. During PLTP-mediated HDL conversion also large fused 
HDL particles are formed. Both preβ-HDL and large fused HDL particles enhance 
cholesterol removal from macrophages. In human plasma, PLTP exists in two forms, a 
high-activity (HA-PLTP) and a low-activity form (LA-PLTP). Using a subsample of the 
Health 2000 Health Examination Survey we showed that of the serum PLTP 
concentration, almost 50 % represented HA-PLTP. Altogether this population-based 
study revealed novel connections of the two PLTP forms not only to lipid but also 
carbohydrate metabolism. In addition to the antiatherogenic functions, PLTP may 
display also proatherogenic characteristics, and that these opposite features of PLTP 
could depend on the site of PLTP expression and action. We have shown that PLTP is 
present in human atherosclerotic lesions and is expressed by macrophages and foam 
cells. The role of macrophage-derived PLTP was investigated both in a macrophage cell 
culture system and in a mouse model. In a mouse model (bone-marrow transplantation 
technique), macrophage PLTP contributed significantly to total plasma phospholipid 
transfer activity but its deficiency in macrophages attenuated atherosclerotic lesion 
development. Similarly, macrophage CETP production in mouse promoted 
atherosclerotic lesion development. This data strongly suggest that the site of synthesis 
and function of the two lipid transfer proteins is important when assessing their role in 
atherosclerosis.  
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Inflammation as a risk factor in atherosclerosis 
Since infection and inflammation are appreciated as novel underlying risk factors for 
atherosclerosis during the past decade, interest in candidate pathogens has grown. 
Certain pathogens are currently linked with the pathogenesis of CAD and 
atherosclerosis. Of these agents, C. pneumoniae is most strongly associated with 
atherosclerosis. C. pneumoniae has been identified in macrophages and within aortic 
intima and more recently, viable bacteria have been isolated from atherosclerotic 
plaques and abdominal aortic aneurysms. We have studied C. pneumoniae infection in a 
mouse model as well as using human material. A new sensitive and specific enzyme 
immunoassay method for the measurement of serum chlamydial lipopolysaccharide 
(cLPS) concentration was developed and applied to quantitate cLPS in sera of patients 
with acute coronary syndrome (ACS). During acute coronary syndrome, both cLPS and 
hsCRP were elevated. These findings suggest that cLPS is liberated from the damaged 
tissue persistenly infected with C. pneumoniae during the ACS event. In mouse studies 
we investigated whether C. pneumoniae infection is responsive to statin treatment. 
Pravastatin accelerated host response to C. pneumoniae infection, but unlike simvastatin, 
was not able to decrease infection load in the lungs. Our results in the Chlamydia project 
not only strengthen the association between C. pneumoniae infection and cardiovascular 
disease but also highlight the role of C. pneumoniae LPS in the inflammatory process 
during acute coronary syndrome. 
 
Role of HDL-associated estrogens in protection against atherosclerosis 
Risk for cardiovascular disease among premenopausal women is lower as compared to 
men of same age. However, the incidence of CAD in women increases markedly after 
natural or surgical menopause. The protective role of hormone replacement therapy 
against CAD is controversial as many observational studies have shown beneficial 
effects, but clinical trials have failed to show any cardiovascular risk reduction. 
Endogenous estrogens exert favourable effects by increasing HDL and reducing LDL 
levels and improving endothelial function. Our focus has been estrogen fatty acyl esters, 
a unique class of hormones that are water insoluble and carried lipoprotein-bound in 
circulation. Our data demonstrate that lecithin-cholesterol acyltransferase (LCAT) in 
circulation facilitates synthesis of estrogen fatty acyl derivatives, and major 
esterification occurs in the HDL3 subfraction. The formed esterogen esters become 
incorporated in HDL particles where they protect the lipoprotein from oxidation. 
Estrogen esters can be transported to LDL in a process facilitated by CETP that could 
increase the anti-oxidative potential of LDL even after the particles have entered the 
vascular wall. This would ultimately hinder the foam cell formation. Current work 
indicates that HDL associated estrogen esters can be taken up at least via scavenger 
receptor B1 (SR-B1) into cells and the estrogen esters are hydrolyzed in the cell to 
generate free estradiol. Our data indicate that lipoprotein-bound estrogen fatty acyl 
esters, although existing at a low concentration level, may be physiologically important 
and affect the anti-atherogenic state in the cells to which HDL particles are targeted. 
 
Characteristics of low and high HDL subjects 
We have studied population-based samples utilizing the Health 2000 Survey study and 
Finnish low-HDL families. Our results suggest that the risk for the development of 
atherosclerosis measured as intima-media thickness in low-HDL family members is 
increased due to a decrease of HDL particle size and serum preβ-HDL concentration. 
Reduction of these HDL subspecies reflects a potentially efflux-deficient HDL pattern in 
the affected low-HDL family members. In addition, our recent data suggest that 
defective ABCA1 function in cholesterol-loaded macrophages is one potential 
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contributor to impaired reverse cholesterol transport process and the increased CAD risk 
in subjects with low HDL.  
 
Identification and characterization of human oxysterol binding protein homologues 
We carried out cDNA cloning and analysis of the gene structures of the entire human 
ORP family with 12 members. Thereafter, we have provided evidence for a role of 
OSBP and three ORPs, ORP1L, ORP2, ORP8, and ORP10 in cellular cholesterol and 
lipid metabolism, in endocytic membrane trafficking, in the development of 
atherosclerotic lesions in a mouse model, or in the control of human serum lipid levels. 
Our published data generated in collaboration with Dr. C.Thiele (Max-Planck-Institute, 
Dresden, Germany) suggests that at least 11 out of the 12 human ORPs bind 25-
hydroxycholesterol (25OHC), cholesterol, or both. We modelled the structure of human 
ORP2, and verified by site-directed mutagenesis that the protein binds sterols within a 
pocket in the C-terminal ligand binding domain similar to that of yeast Osh4p, 
suggesting that ORPs throughout the eukaryotic kingdom share a similar fold. 
According to our working hypothesis, members of the ORP family sense the 
intracellular concentrations of different sterols and relay information to machineries 
responsible for the control of cellular lipid homeostasis, intracellular vesicle transport, 
and cell signalling. 
 
Mechanisms of ORP function  
The mechanisms of ORP function have been pursued mainly in cultured cell models. We 
have shown that ORP1L interacts with Rab7, a central regulator of the late endocytic 
pathway, and acts as an effector of the small GTPase. This interaction has strong impact 
on the microtubule-dependent sub-cellular distribution of late endosomes/lysosomes as 
well as the functional properties of these organelles. Furthermore, we have shown that 
Rab7, another Rab7 effector called RILP, and ORP1L form a tripartite complex that 
recruits the dynein-dynactin motor on late endosome membranes. ORP1L, which binds 
both sterols and phosphoinositides, most likely regulates the partitioning of the motor 
complex to membrane domains in which it can interact with its membrane anchor, 
spectrin.  
 
ORP2 overexpression was found to have profound effects on the cholesterol metabolism 
in cell models, causing an increase of cellular cholesterol efflux and cell-type dependent 
effects on its storage in the form of cholesterol esters. The data suggests that excess 
ORP2 induces enhancement of intracellular cholesterol transport. Whether this involves 
function as a direct cholesterol carrier remains to be elucidated. ORP2 over-expression 
also leads to changes in the cellular phospholipid molecular species composition and a 
defect in neutral lipids (NL) and recycling of NL fatty acids. Our recent discovery of 
oxysterol-dependent localization of ORP2 on cytoplasmic NL droplets, and the finding 
that ORP2 silencing leads to increased triglyceride storage, suggest that ORP2 may 
execute a major function in NL metabolism. In an ongoing study we are, using site-
specific mutants, assessing the specific roles of ORP2 sterol binding, NL droplet 
localization, and ER association in the functions of the protein in cellular cholesterol and 
NL metabolism. 
 
In early 2006 we carried out in cultured cells a screen for ORPs that impact on the 
transcriptional regulation of cellular sterol homeostasis. Here, ORP8 came up as a 
promising candidate the overexpression and silencing of which had opposite effects on 
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the transcription of LXR and SREBP-2 target genes. ORP8 silencing was shown to 
induce upregulation of ABCA1 expression and cholesterol efflux to apoA-I, and its 
overexpression suppressed cholesterol biosynthesis. ORP8 was shown to bind 25OHC, 
to interact physically with SCAP, and to attenuate the enhancement of ABCA1 
expression by oxysterols. The effects of ORP8 overexpression were shown to be 
dependent on sterol binding. However, it seems that the effects of ORP8 on ABCA1 are 
not dependent on LXR, suggesting that an entirely novel sterol-dependent regulatory 
pathway has been revealed. Importantly, ORP8 is abundant in macrophages, and 
elevated ORP8 expression is detected in human coronary artery atherosclerotic lesions, 
suggesting a role in cardiovascular diseases.  
 
ORPs, lipid homeostasis in vivo, and atherosclerosis 
We have employed new mouse models to cast light on ORP functions in vivo. These 
include a transgenic model that expresses human ORP1L under a macrophage-specific 
promoter, and adenovirus-mediated hepatic overexpression of OSBP, ORP1L, and 
ORP3. To reveal ORP functions in hepatic lipid metabolism, we determined the effects 
of adenovirus-mediated hepatic ORP overexpression in mice on serum and liver tissue 
lipids. OSBP expression was found to result in a strong elevation of both liver and serum 
VLDL triglyceride levels, due to up-regulation of SREBP-1c and its lipogenic target 
genes. This was connected with the down-regulation of extracellular signal regulated 
kinase (ERK) phosphorylation in the OSBP-transduced liver. Furthermore, we showed 
that silencing of OSBP expression by RNA interference in cultured hepatocytes 
suppressed the insulin stimulation of SREBP-1c expression and activity, as well as 
triglyceride synthesis. This study revealed a new, crucially important role of OSBP in 
the control of hepatic lipogenesis.  
 
To approach ORP functions in the development of atherosclerosis we generated a 
transgenic (TG) mouse model expressing human ORP1L under a macrophage-specific 
promoter, that of scavenger receptor A. The mice were used as bone marrow (BM) 
donors to LDL receptor deficient animals, which were fed a Western-type diet. As 
compared to recipients of control bone marrow, the ORP1L BM recipients displayed a 
110% increase of aortic root atherosclerotic lesion size. The TG macrophages displayed 
a decrease of ABCG1 and apolipoprotein E mRNA and protein levels, as well as 
impaired cholesterol efflux. Further, they displayed increased phospholipid transfer 
protein (PLTP) mRNA expression and activity in serum, all changes that provide 
explanations to the increased lesion size. ORP1L overexpression was shown to attenuate 
the stimulation of ABCG1 expression by the LXR agonist 22(R)-hydroxycholesterol, 
bringing up the possibility that the effects may be due to modulation of LXR activity. 
This work demonstrated for the first time the potential of ORPs as modulators of 
atherosclerosis and motivated further work to assess the role of the entire gene/protein 
family in cardiovascular diseases. 
 
The analysis of linkage/association of ORP gene single nucleotide polymorphisms (SNP) 
with human dyslipidemias in collaboration with prof. L. Peltonen revealed linkage and 
association of certain ORP10 SNP alleles with HDL-cholesterol and TG levels in 
Finnish low-HDL and familial combined hyperlipidemia (FCHL) family materials. 
Functional characterization of ORP10 in order to clarify the mechanisms underlying the 
genetic findings is underway. 
  
Background material                                                       7 MOLECULAR BIOLOGY OF  
                                                                                     CARDIOVASCULAR DISEASES 
 
 107
7.3. Scientific impact  
 
Table 1. Summary of the scientific output during 1997-2007 
Scientific output 
 
N Comments 
Peer-review papers in international 
journals 
201 In addition 36 review articles/book chapters.  
See Appendix 3 
Invited lectures and chairmanships 
in international meetings 
58  
Articles in domestic journals and 
text books 
4 See Appendix 3 
Lectures in domestic meetings and 
teaching lectures 
60  
Editorial tasks in international 
journals 
4 M.J., Clinical Chemistry and Laboratory 
Medicine; C.E., Current Opinion in Lipidology, 
CCLM, Atherosclerosis 
Committee memberships: domestic 
 
5  
Committee memberships: 
international (EU, WHO etc.) 
6  
International evaluation panels (EU 
etc.) 
9  
Organizing committee of 
international meetings 
28 e.g. 76th Conference of the European 
Atherosclerosis Society, EAS, Helsinki, June 
2007 
Doctoral dissertations 
 
13 See Appendix 3 
Supervision of dissertations: 
ongoing 
6  
Opponent of dissertations 
 
13  
Pre-examiner of  
- dissertations 
- adjunct professors 
- professorships 
 
43 
14 
1 
 
Prizes 
 
1 Aurator Asset Management Ltd (Turku, Finland) 
Stipendium in Research of Biotechnology and 
Medicine 2002 (V.O.)   
 
 
7.4. Societal impact  
Representatives of the Unit have served in the boards of foundations supporting 
research, the Finnish Atherosclerosis Society, the Finnish Society of Sciences of Letters 
and the Minerva medical Foundation, as well as consultants for the Medix Laboratories 
and Medix Biochemica Inc. The researchers have given a number of lectures at 
domestic scientific meetings (16) and, importantly, also layman lectures, e.g. to high 
school pupils and the senior citizens. Furthermore, information on lipid metabolism has 
been distributed to clinicians through articles published in domestic medical journals (5). 
Importantly, representative of the Unit has been member of the steering committee for 
Cardiovascular diseases and diabetes in the Health 2000 Health examination Survey. 
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Representatives of the Unit have also served in the executive boards of major 
international societies focusing on the basic and clinical aspects of atherosclerosis, the 
European Atherosclerosis Society (EAS) and the International Atherosclerosis Society 
(IAS), as well as in the council of Scandinavian Society for Atherosclerosis Research 
(SSAR) and European Lipoprotein Club.  
 
 
7.5. Research funding 
 
Table 2. Project funding during 1997-present 
Project name Funding 
agency* (PI)** 
Funding 
k€ 
Years 
Antiatherogenic function of HDL 
 
FO (MJ) 177 1997-2007 
EUFAM 
 
EU (CE) 420 1997-2000 
FIELD study 
 
CO (CE) 1 012 1997-2005 
Role of PLTP in HDL metabolism 
 
FO (CE) 200 2001-2004 
Cholesterol removal from cells: role of transfer 
proteins and HDL-associated estradiol esters 
FO (MJ) 69 2001-2007 
Structure, function, and animal models of PLTP  
 
FO (MJ) 151 2003-2007 
Chlamydia pneumoniae and atherosclerosis 
 
TEKES, SA (MJ) 23 2004-2006 
PLTP: role in atherosclerosis 
 
GS (MJ student) 56 2006-2009 
PLTP: mechanisms of function and role in the 
reverse cholesterol transport process 
SA (MJ) 180 2007-2009 
Lipolytic and lipid transfer activities in the 
development of chicken ovarian follicles and 
the embryo 
SA (JS) 180 2007-2009 
Mechanisms of intracellular membrane 
trafficking 
SA (VO) 217 1997-2000 
2001-2003 
Intracellular protein transport  EU TMR 
programme (VO) 
205 1997-2000 
Function of human OSBP-related proteins SA (VO)  
SA (VO, ML) 
1054 1999-2007 
Human oxysterol-bind. proteins in lipid 
metabolism and atherosclerosis 
FO (VO) 349 2000-2007 
Integration of cellular lipid dynamics and 
signalling 
SA (VO) 121 2000-2002 
Functional analysis of the OSBP homologue 
ORP1L 
GS (VO student) 105 2002-2005 
Human oxysterol binding proteins 
 
FO (VO) 34 2002, 2007 
Oxysterol binding and PL transfer proteins 
 
FO (VO) 57 2004-2007 
Role of ORP2 in cellular lipid metabolism GS (VO student) 
 
56 2006-2009 
*EU=European Union, SA=Academy of Finland, TEKES=Finnish Funding Agency for Technology and 
Innovation, FO=Foundations, CO=company. **PI=see senior scientific personnel in chapter 7.8 
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7.6. Scientific collaboration 
Matti Jauhiainen  
Antiatherogenic mechanims of HDL: structural, functional and clinical studies: Prof. 
Petri Kovanen (Wihuri Research Institute, Helsinki), Prof. Marja-Riitta Taskinen (University 
of Helsinki, Helsinki), Prof. Elina Ikonen (University of Helsinki, Helsinki), Acad. Prof. 
Leena Peltonen (KTL), Prof. Matti Tikkanen (University of Helsinki, Helsinki),  Prof. 
Markku Savolainen (University of Oulu, Oulu), Adj. Prof. Mika Ala-Korpela (Technical 
University of Helsinki, Helsinki), Prof. Philip Barter (The Heart Research Institute, Sydney, 
Australia), Prof. Arie van Tol (Erasmus University, Rotterdam, The Netherlands), Prof. 
Kerry-Anne Rye (The Heart Research Institute, Sydney, Australia), Prof. Björn Dahlbäck 
(University Hospital, Malmö, Sweden), Prof. Jacques Genest (McGill University, 
Canada),  Prof. Alice Lichtenstein (Tufts University, Boston, USA), Adj. Prof. Juha 
Holopainen (University of Helsinki, Helsinki), Prof. Wolfgang J. Schneider (Medical 
University of Vienna, Vienna, Austria). 
Vesa Olkkonen 
Role of OSBP-related proteins (ORP) in lipid metabolism and in the development of 
athetrosclerosis: Dr. Gerd Wohlfahrt (Orion Pharmaceutical Corporation, Espoo, Finland), 
Prof. Seppo Ylä-Herttuala (AIV-Institute, University of Kuopio, Finland), Prof. Petri 
Kovanen (Wihuri Research Institute, Helsinki, Finland), Acad. Prof. Leena Peltonen (KTL), 
Dr. Christoph Thiele (Max-Planck-Institute of Molecular Cell Biology and Genetics, 
Dresden, Germany), Prof. Bart Staels (Pasteur Institute, Lille, France), Dr. Andrew Brown 
(University of New South Wales, Sydney, Australia), Dr. Miranda van Eck 
(Leiden/Amsterdam Center for Drug Research, Gorlaeus Laboratories, Leiden, The 
Netherlands), Prof. Jacques Neefjes (The Netherlands Cancer Institute, Amsterdam, The 
Netherlands) 
 
 
7.7. Proposal for the future work and expected (societal) benefits (next 
five years) 
During the next five years the research programme will focus on: 1) The anti-
atherogenic mechanisms of high-density lipoproteins, 2) The role of fasting-induced 
adipose factor (FIAF) in regulation of lipoprotein metabolism, 3) The relationship 
between inflammation and atherosclerosis, 4) New regulatory mechanisms integrating 
the cellular sterol status with metabolism of other lipid classes and with signalling 
processes, 5) The role of OSBP-related proteins and their interaction partners in the 
complex genetic background of common diseases. Additionally, we will contribute to 
the biotechnology strategy of KTL by 6) Development and utilization of new 
approaches and methods which allow maximal extraction of relevant information from 
the nationwide epidemiologic population cohorts. The projects are outlined below in 
more detail. 
  
1) The mechanisms by which anti-atherogenic pre-HDL are generated are poorly 
known. To elucidate the interplay between phospholipid transfer prorein (PLTP) 
and the new apolipoprotein, apoM, and its importance for HDL metabolism, we 
will utilize apoM mouse models and subsamples from different epidemiological 
cohorts. Furthermore, we aim to gain a more clear definition of the mechanisms 
by which structural modifications of HDL, PLTP and CETP by proteolytic and 
lipolytic enzymes present in the arterial intima modify their function in the 
reverse cholesterol transport. We believe that prevention of these proteolytic 
processes would significantly decelerate atherogenesis, and thus prevent 
atherothrombotic complications such as premature myocardial infarction. A 
second HDL-related research topic is the mechanisms of HDL-associated 
estrogens in protection against atherosclerosis. The future research aims to 
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investigate in detail the receptor-associated pathways of cellular uptake of HDL-
associated female hormone estradiol and its fatty acyl derivatives. Moreover, the 
mechanisms of intracellular hydrolysis of the estradiol esters to generate 
biologically active, free estrogen will be investigated. This will further add to 
our knowledge of the antiatherogenic abilities of estrogen and HDL. 
2) Obesity is currently a major public health problem. At least one out of five obese 
people develops type 2 (adult-onset) diabetes, and many more develop 
abnormalities of carbohydrate metabolism called impaired glucose tolerance, a 
pre-diabetic state. One group of recently emerged factors having a major impact 
on lipid and possibly glucose metabolism are the ANGPTL (angiopoietin-like 
proteins). Our aim is to study one of these, Fasting-Induced Adipose Factor, 
FIAF. The composite literature data suggest that via physical association with 
plasma lipoproteins, FIAF acts as a powerful signal from fat and other tissues to 
prevent fat storage and stimulate fat mobilization, especially under conditions of 
fasting. This suggests that disturbance in FIAF signalling might be involved in 
dyslipidemia. We will develop a realiable method for quantification of FIAF in 
plasma samples and determine the response of FIAF levels to fibrate treatment. 
Furthermore, we will study whether changes in lipoprotein profiles and other 
clinical parameters correlate with changes in FIAF levels. The study material is 
the Finnish arm of the FIELD study, and a subsample of the Health 2000 Health 
Examination Survey is used as “normal” population. 
3) We will, as a large collaborative effort, clarify the role of periodontal pathogens 
and C. pneumoniae as risk factors for cardiovascular diseases. Animal models 
and human samples will be used to analyze lipoprotein levels and degree of 
atherosclerosis. It has been suggested that chronic infections may have a role in 
both the initiation and progression of atherosclerosis. So far only single 
pathogens have been studied as risk factors for CAD. However, the frequency of 
C. pneumoniae and oral pathogen infection in Finland is rather high. For this 
reason it is important to study their combined effect in atherosclerosis since 
there may be differences launched by them for instance in the degree of liver 
steatosis, dyslipidemia, and inflammation signalling. We expect to reach break-
thoughs in understanding the role of chronic inflammation in the development of 
atherosclerotic cardiovascular diseases. 
4) To gain insight into the novel regulatory pathways that OSBP-related proteins 
(ORPs) form part of, we will create animal models in which expression of ORPs 
is silenced, or genes encoding the proteins are disrupted. Here, we aim to clarify 
the roles of these proteins especially in hepatic lipid metabolism and in 
macrophages. Simultaneously with the animal model work, cell models are 
employed to investigate (i) the individual ORP functions and (ii) the effects of 
simultaneous silencing of multiple ORPs, which are likely to execute partially 
overlapping tasks. The phenotypic analysis of the models focuses on lipid 
metabolism, gene expression analysis, and functional assays monitoring 
intracellular vesicle transport and signalling cascades. Special effort is invested 
on identifying connections between the ORP effector pathways and the 
signalling pathways playing central roles in obesity, type 2 diabetes, and 
atherosclerosis. 
5) We aim to elucidate the role of OSBP-related proteins and other components in 
their effector pathways, in the complex genetic background of common lipid 
disorders and atherosclerosis. The linkage and association of SNP 
polymorphisms in these genes with serum lipid parameters and other clinical 
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phenotypes will be investigated. The genetic studies are complemented by 
functional analysis in relevant cell and animal models. As the ultimate goal, we 
aim to elucidate the possibilities of using these novel factors as targets for the 
development of new therapies to prevent and treat dyslipidemias, atherosclerotic 
cardiovascular diseases, and type 2 diabetes. 
6) In all of the above projects we will maximally utilize the nationwide 
epidemiological cohorts. Furthermore, we aim to develop new approaches and 
methods which allow maximal extraction of relevant information from the 
population cohorts by using modern technologies. As an example, we have 
successfully started a collaboration in which NMR metabonomics is applied to 
analyze plasma lipoprotein subclasses. This high-throughput method will be 
used to make clinically relevant lipoprotein subclass profiles available for use 
e.g. in the evaluation of an individual’s risk for coronary heart disease.   
 
 
7.8. Senior scientific personnel 
Christian Ehnholm, M.D., Ph.D., research professor 1977-2005, Emeritus Professor  
    2005- 
Matti Jauhiainen, Ph.D., adjunct professor, group leader 1988- 
Vesa Olkkonen, Ph.D., adjunct professor, group leader 1993- 
Elina Ikonen, M.D., Ph.D., adjunct professor, group leader 1997-2004 
Jouko Sundvall, M.Sc., head chemist, analytical biochemistry 1997-2001 
Marjatta Antikainen, M.D., Ph.D., senior investigator 1997-1999 
Markku Lehto, Ph.D., senior investigator 1999-2007 
Daoguang Yan, M.D., Ph.D., senior investigator 2005-2007 
Julia Perttilä, Ph.D., post-doctoral fellow 2006- 
Jani Saarela, Ph.D., post-doctoral fellow 2007- 
 
 
7.9. 15 key references 
 
Article 
 
IF 
No of 
citat.* 
Tahvanainen E, Syvanne M, Frick MH, Murtomaki-Repo S, Antikainen M, 
Kesaniemi YA, Kauma H, Pasternak A, Taskinen MR, Ehnholm C. 
Association of variation in hepatic lipase activity with promoter 
variation in the hepatic lipase gene. The LOCAT Study Investigators 
(1998)  J Clin Invest, 101:956-60 
15.053 74 
Syvanne M, Nieminen MS, Frick MH, Kauma H, Majahalme S, Virtanen 
V, Kesaniemi YA, Pasternack A, Ehnholm C, Taskinen MR. 
Associations between lipoproteins and the progression of coronary and 
vein-graft atherosclerosis in a controlled trial with gemfibrozil in men 
with low baseline levels of HDL cholesterol (1998) Circulation, 
98:1993-9 
11.632 37 
Ghosh S, Watanabe RM, Hauser ER, Valle T, Magnuson VL, Erdos MR, 
Langefeld CD, Balow J, Jr., Ally DS, Kohtamaki K, Chines P, Birznieks 
G, Kaleta HS, Musick A, Te C, Tannenbaum J, Eldridge W, Shapiro S, 
Martin C, Witt A, So A, Chang J, Shurtleff B, Porter R, Kudelko K, 
Unni A, Segal L, Sharaf R, Blaschak-Harvan J, Eriksson J, Tenkula T, 
Vidgren G, Ehnholm C, Tuomilehto-Wolf E, Hagopian W, Buchanan 
TA, Tuomilehto J, Bergman RN, Collins FS, Boehnke M. Type 2 
diabetes: evidence for linkage on chromosome 20 in 716 Finnish 
10.231 137 
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Holtta-Vuori M, Maatta J, Ullrich O, Kuismanen E, Ikonen E. Mobilization 
of late-endosomal cholesterol is inhibited by Rab guanine nucleotide 
dissociation inhibitor (2000) Curr Biol, 10:95-8 
11.732 35 
Heino S, Lusa S, Somerharju P, Ehnholm C, Olkkonen VM, Ikonen E. 
Dissecting the role of the golgi complex and lipid rafts in biosynthetic 
transport of cholesterol to the cell surface (2000) Proc Natl Acad Sci U S 
A, 97:8375-80 
10.231 95 
Olkkonen VM, Ikonen E. Genetic defects of intracellular-membrane 
transport (2000) N Engl J Med, 343:1095-104 (review) 
44.016 26 
Vehkavaara S, Hakala-Ala-Pietila T, Virkamaki A, Bergholm R, Ehnholm 
C, Hovatta O, Taskinen MR, Yki-Jarvinen H. Differential effects of oral 
and transdermal estrogen replacement therapy on endothelial function in 
postmenopausal women (2000) Circulation, 102:2687-93 
11.632 51 
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Staels B, Olkkonen VM. The two variants of oxysterol binding protein-
related protein-1 display different tissue expression patterns, have 
different intracellular localization, and are functionally distinct (2003) 
Mol Biol Cell, 14:903-15 
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Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai 
A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, 
Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M. Effects of 
long-term fenofibrate therapy on cardiovascular events in 9795 people 
with type 2 diabetes mellitus (the FIELD study): randomised controlled 
trial (2005) Lancet, 366:1849-61 
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Johansson M, Lehto M, Tanhuanpaa K, Cover TL, Olkkonen VM. The 
oxysterol-binding protein homologue ORP1L interacts with Rab7 and 
alters functional properties of late endocytic compartments (2005) Mol 
Biol Cell, 16:5480-92 
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Watanabe H, Soderlund S, Soro-Paavonen A, Hiukka A, Leinonen E, 
Alagona C, Salonen R, Tuomainen TP, Ehnholm C, Jauhiainen M, 
Taskinen MR. Decreased high-density lipoprotein (HDL) particle size, 
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families: relationship with intima-media thickness (2006) Arterioscler 
Thromb Vasc Biol, 26:897-902 
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assembly of Rab7-RILP-p150Glued, ORP1L, and the receptor betalll 
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Yan D, Lehto M, Rasilainen L, Metso J, Ehnholm C, Yla-Herttuala S, 
Jauhiainen M, Olkkonen VM. Oxysterol Binding Protein Induces 
Upregulation of SREBP-1c and Enhances Hepatic Lipogenesis (2007) 
Arterioscler Thromb Vasc Biol, 27:1108-14 
7.053 - 
Vikstedt R, Ye D, Metso J, Hildebrand RB, Van Berkel TJ, Ehnholm C, 
Jauhiainen M, Van Eck M. Macrophage phospholipid transfer protein 
contributes significantly to total plasma phospholipid transfer activity 
and its deficiency leads to diminished atherosclerotic lesion 
development (2007) Arterioscler Thromb Vasc Biol, 27:578-86 
7.053 - 
Yan D, Jauhiainen M, Hildebrand RB, Willems van Dijk K, Van Berkel TJ, 
Ehnholm C, Van Eck M, Olkkonen VM. Expression of Human OSBP-
Related Protein 1L in Macrophages Enhances Atherosclerotic Lesion 
Development in LDL Receptor-Deficient Mice (2007) Arterioscler 
Thromb Vasc Biol, 27:1618-24 
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8 PATERNITY TESTING LABORATORY 
Mission and personnel of the laboratory  
Paternity testing laboratory performs paternity and other related testing applying reliable, 
up-to-date and quality controlled DNA-based methods. We aim to direct our services to 
satisfy our customer’s needs and constantly improve the quality of our work. At present 
the personnel consists of four full time and one half time workers.  The head of the 
laboratory is M.Sc. Matti Lukka. In addition three of the researchers of MLO work part-
time in PTL (Ismo Ulmanen, Marjo Kestilä, Pekka Ellonen). 
 
Legal framework  
The official paternity testing is based on the paternity law from 1975 and on the law on 
forensic genetic paternity testing and additional statutes from 2005. Based on this 
legislation paternity testing is performed, if necessary, to establish the paternity for a 
child born out of marriage or in the cases of annulment of paternity. The law from 2005 
states that paternity testing is based on genes, inherited DNA or gene products. 
Moreover the law rules that if the father candidate is dead, or cannot be reached, his 
parents or other relatives can be tested. According to the 2005 law the official paternity 
testing is carried out in PTL of National Public Health Institute or in Department of 
Forensic Medicine, University of Helsinki. In addition the law on alien immigrants from 
2000 orders that the biological relatedness within immigrating families is verified by 
testing in PTL or in Department of Forensic Medicine, University of Helsinki.  
 
Volume of paternity testing in 1997-2007  
During the inspected period of time the number of investigated paternity cases has 
increased from about 1100 to about 1400 cases per year. About 75 percent of the 
investigations are ordered by municipal child welfare officials. Our next biggest 
customers are private persons and courts. The proportions of different customer 
categories have stayed rather stable. The number of other relatedness testing but direct 
paternity was about 30 in 2006. 
 
 
Figure 1. Development of the paternity cases analysed in the PTL starting from 1995 to 
2006. The numbers of cases are indicated according to the different categories of the 
customers. 
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Development of paternity testing methodology  
The methodology of testing in PTL has been based on PCR amplification of short 
tandem repeat (STR) DNA. Since year the 2000 the electrophoretic separation of 
DNA fragments has been performed, instead of gel electrophoresis, by using ABI310 
capillary electrophoresis equipment. Four commonly used commercial DNA-marker 
kits have been introduced as they have come to market. Our analysis resources of 
today are composed of 19 autosomal and 12 Y-chromosomal STR DNA-markers. 
 
Development of quality   
Paternity testing laboratory has been accredited since 2002. Accreditation is based on 
internationally agreed criteria and it's goal is to recognize a body's competence to 
carry out specific tasks. When the laboratory is accredited clients can trust that the 
independent third part has evaluated the activities and found them to be competent, 
reliable and credible. In Finland accreditation is performed by FINAS (Finnish 
accreditation service) and it carries out assessments annually. The purpose of 
assessments is to consolidate the quality management and technical competence and 
encourage the continuous development of their activities. Scope of accreditation in 
paternity testing laboratory is paternity testing in forensic genetics, including DNA 
isolation, DNA amplification and DNA typing. PTL also participates in the yearly 
international quality control test carried out by the English Speaking Working Group 
of International Society of Forensic Genetics. 
 
Scientific and international activities  
The goal of the PTL is and has been to follow and participate scientific and 
international activities in the field of forensic genetics. During 1997-2007 period the 
researchers of the laboratory have published four scientific reports. The laboratory 
personell participate actively the events, like meeting and courses, of the International 
Society of Forensic Genetics (ISFG). In 2006 PTL personell arranged together with 
Dept. of Forensic Genetics, University of Helsinki, the international conference on 
forensic genetics in Tuusula, Finland. This was one of the main international events of 
the field in 2006 and was attended by 100 participants from 28 different countries. 
 
Paternity testing in the future  
It is most likely that the present paternity testing methodology, applied also in PTL, 
will be based on PCR of STRs at least in the near future. However, the laboratory 
processes will be developed to be more automated. The DNA marker resources and 
calculation methods will be further developed to produce information more effectively 
in the complicated paternity and kinship cases. We predict that the volume of 
paternity testing is likely to rather increase than to decrease in the near future. 
 
References 
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9 APPENDIXES 
 
Appendix 1: The Finnish disease heritage - Dissertations and 
publications in 1997-2007 
 
Dissertations 1997-2007 
1. Aaltonen J: Molecular genetics of APECED (Autoimmune PolyEndocrinopathy 
Candidiasis Ectodermal Dystrophy). 1998. (Publications of National Public Health 
Institute A3/1998) 
2. Klockars T: Positional cloning of the CLN5 gene. 1998. (Publications of the National 
Public Health Institute A22/1998) 
3. Nikali K: Molecular Genetics of Infantile Onset Spinocerebellar Ataxia. 1998. 
(Publications of the National Public Health Institute A14/1998, University of Helsinki, 
Helsinki) 
4. Paavola P: Molecular genetics of Meckel syndrome. 1998. (Publications of the National 
Public Health Institute A21/1998) 
5. Peltola M: Aspartylglucosaminuria (AGU): lysosomal targeting of AGA, the cellular 
consequences of mutations and an attempt at gene therapy. 1998. (Publications of the 
National Public Health Institute A12/1998) 
6. Tenhunen K: Mouse aspartylglucosaminidase gene and mouse model for 
aspartylglucosaminuria. 1998. (Publications of the National Public Health Institute 
A17/1998) 
7. Uusitalo A: Aspartylglucosaminuria: disease pathogenesis, developmental expression and 
regulation of the aspartylglucosaminidase gene. 1998. (Publications of the National 
Public Health Institute A15/1998) 
8. Björses P: Autoimmune polyendocrinopathy - candidiasis - ectodermal dystrophy 
(APECED): from locus to defective protein. 1999. (Publications of the National Public 
Health Institute A24/1999) 
9. Savukoski M: Molecular genetics of the late infantile neuronal ceroid lipofuscinosis 
(LINCL). 1999. (Publications of the National Public Health Institute A25/1999) 
10. Varilo T: The age of the mutations in the Finnish disease heritage: a genealogical and 
linkage disequilibrium study. 1999. (Publications of the National Public Health Institute 
A21/1999) 
11. Kangas H: Familial amyloidosis of the Finnish type (FAF) - consequences of 
amyloidosis-associated mutation for gelsolin processing and function. 2000. (Publications 
of the National Public Health Institute A9/2000) 
12. Salomäki P: Free sialic acid storage diseases: same gene - different mutations. 2001. 
(Annales Universitatis Turkuensis A I:451) 
13. Salonen T: Molecular and cellular biology of infantile neuronal ceroid lipofuscinosis. 
2001. (Publications of the National Public Health Institute A3/2001) 
14. Visapää I: Molecular genetics of the GRACILE syndrome. 2002. (Publications of the 
National Public Health Institute A28/2002) 
15. Aula N: Molecular pathogenesis of Salla disease. 2003. (Publications of the National 
Public Health Institute A19/2003) 
16. Halonen M: Monogenic model for autoimmune diseases: molecular basis of autoimmune 
polyendocrinopathy - candidiasis - ectodermal dystrophy (APECED). 2003 (Publications 
of the National Public Health Institute A4/2003)  
17. Haravuori H: Molecular genetics of tibial muscular dystrophy (TMD) and a novel distal 
myopathy. 2003. (Publications of the National Public Health Institute A24/2003)  
18. Isosomppi J: Molecular and cell biology of infantile (CLN1) and variant late infantile 
(CLN5) neuronal ceroid lipofuscinoses. 2003. (Publications of the National Public Health 
Institute A3/2003) 
19. Paloneva J: Defective genes behind PLOSLO: molecular and neuropathological 
characteristics of the disease. 2003. (Publications of the National Public Health Institute 
A8/2003) 
20. Ramsey C: A link between the Autoimmune Regulator gene (AIRE) and peripheral self-
tolerance. 2003. (UCLA David Geffen School of Medicine and the National Public 
Health Institute) 
21. Holmberg V: CLN5 - from mutation to defective protein and clinical phenotype. 2004. 
(Publications of the National Public Health Institute A2/2004)  
Background material                                                                                    APPENDIX 1 
 116
22. Saarela J: Characterization of aspartylglucosaminidase activation and 
aspartylglucosaminuria mutations. 2004. (Publications of the National Public Health 
Institute A1/2004)  
23. Lonka L: Neuronal ceroid lipofuscinosis CLN8 – from gene to protein. 2004. 
(ethesis.helsinki.fi) 
24. Lanyi-Mee L: The identification and characterization of the hydrolethalus syndrome gene, 
HYLS on 11q24. 2005. UCLA David Geffen School of Medicine and the National Public 
Health Institute) 
25. Pakkasjärvi N: Investigations on molecular aspects of lethal congenital contracture 
syndrome. 2005. (Publications of the National Public Health Institute A28/2005) 
26. Kyttälä M: Identification of the Meckel syndrome gene (MSK1) exposes a novel 
ciliopathy. 2006. (Publications of the National Public Health Institute A5/2006) 
27. Luiro K: Molecular and cellular mechanisms behind juvenile neuronal ceroid 
lipofuscinosis (JNCL, Batten disease). 2006. (Publications of the National Public Health 
Institute A4/2006)  
28. Ahtiainen L: Unravelling Molecular and Cellular Disease Mechanisms in Infantile 
Neuronal Ceroid Lipofuscinosis (INCL). 2007 (Publications of the National Public Health 
Institute A5/2007) 
 
 
Publications 1997-2007 
 
International peer review articles 
1. Aaltonen, J., Bjorses, P., Perheentupa, J., HorelliKuitunen, N., Palotie, A., Peltonen, L., 
Lee, Y.S., Francis, F., Hennig, S., Thiel, C. et al. (1997) An autoimmune disease, 
APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger 
domains. Nat Genet, 17, 399-403. 25.797 
2. Aaltonen, J., Horelli-Kuitunen, N., Fan, J.B., Bjorses, P., Perheentupa, J., Myers, R., 
Palotie, A. and Peltonen, L. (1997) High-resolution physical and transcriptional mapping 
of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy locus on 
chromosome 21q22.3 by FISH. Genome Res, 7, 820-9. 10.139 
3. Jarvela, I., Autti, T., Lamminranta, S., Aberg, L., Raininko, R. and Santavuori, P. (1997) 
Clinical and magnetic resonance imaging findings in Batten disease: analysis of the major 
mutation (1.02-kb deletion). Ann Neurol, 42, 799-802. 8.051 
4. Klockars, T., Isosomppi, J., Laan, M., Kakko, N., Palotie, A. and Peltonen, L. (1997) The 
visual assignment of genes by fiber-fish: BTF3 protein homologue gene (BTF3) and a 
novel pseudogene of human RNA helicase A (DDX9P) on 13q22. Genomics, 44, 355-7. 
3.181 
5. Mannikko, M., Kestila, M., Lenkkeri, U., Alakurtti, H., Holmberg, C., Leisti, J., Salonen, 
R., Aula, P., Mustonen, A., Peltonen, L. et al. (1997) Improved prenatal diagnosis of the 
congenital nephrotic syndrome of the Finnish type based on DNA analysis. Kidney Int, 51, 
868-72. 4.927 
6. Mikkola, H., Muszbek, L., Haramura, G., Hamalainen, E., Jalanko, A. and Palotie, A. 
(1997) Molecular mechanisms of mutations in factor XIII A-subunit deficiency: In vitro 
expression in COS-cells demonstrates intracellular degradation of the mutant proteins. 
Thromb Haemost, 77, 1068-1072. 3.056 
7. Munroe, P.B., Orawe, A.M., Mitchison, H.M., Jarvela, I.E., Santavuori, P., Lerner, T.J., 
Taschner, P.E.M., Gardiner, R.M. and Mole, S.E. (1997) Strategy for mutation detection 
in CLN3: Characterisation of two Finnish mutations. Neuropediatrics, 28, 15-17. 1.377 
8. Nikali, K., Isosomppi, J., Lonnqvist, T., Mao, J.I., Suomalainen, A. and Peltonen, L. 
(1997) Toward cloning of a novel ataxia gene: refined assignment and physical map of 
the IOSCA locus (SCA8) on 10q24. Genomics, 39, 185-91. 3.181 
9. Paavola, P., Salonen, R., Baumer, A., Schinzel, A., Boyd, P.A., Gould, S., Meusburger, 
H., Tenconi, R., Barnicoat, A., Winter, R. et al. (1997) Clinical and genetic heterogeneity 
in Meckel syndrome. Hum Genet, 101, 88-92. 4.331 
10. Paunio, T., Kangas, H., Kiuru, S., Palo, J., Peltonen, L. and Syvanen, A.C. (1997) Tissue 
distribution and levels of gelsolin mRNA in normal individuals and patients with 
gelsolin-related amyloidosis. FEBS Lett, 406, 49-55. 3.415 
11. Pirttila, T., Soininen, H., Mehta, P.D., Heinonen, O., Lehtimaki, T., Bogdanovic, N., 
Paljarvi, L., Kim, K.S., Kosunen, O., Winblad, B. et al. (1997) Apolipoprotein E 
genotype and amyloid load in Alzheimer disease and control brains. Neurobiol Aging, 18, 
121-7. 5.599 
Background material                                                                                    APPENDIX 1 
 117
12. Ruottinen, H.M., Rinne, J.O., Haaparanta, M., Solin, O., Bergman, J., Oikonen, V.J., 
Jarvela, I. and Santavuori, P. (1997) [F-18]fluorodopa PET shows striatal dopaminergic 
dysfunction in juvenile neuronal ceroid lipofuscinosis. J Neurol Neurosurg Psychiatry, 62, 
622-625. 3.122 
13. Sharp, J.D., Wheeler, R.B., Lake, B.D., Savukoski, M., Jarvela, I.E., Peltonen, L., 
Gardiner, R.M. and Williams, R.E. (1997) Loci for classical and a variant late infantile 
neuronal ceroid lipofuscinosis map to chromosomes 11p15 and 15q21-23. Hum Mol 
Genet, 6, 591-5. 7.764 
14. Syvanen, A.C., Jarvela, I., Paunio, T. and Vesa, J. (1997) DNA diagnosis and 
identification of carriers of infantile and juvenile neuronal ceroid lipofuscinoses. 
Neuropediatrics, 28, 63-6. 1.366 
15. Syvanen, A.C., Tilgmann, C., Rinne, J. and Ulmanen, I. (1997) Genetic polymorphism of 
catechol-O-methyltransferase (COMT): correlation of genotype with individual variation 
of S-COMT activity and comparison of the allele frequencies in the normal population 
and parkinsonian patients in Finland. Pharmacogenetics, 7, 65-71. 5.882 
16. Tikkanen, R., Peltola, M., Oinonen, C., Rouvinen, J. and Peltonen, L. (1997) Several 
cooperating binding sites mediate the interaction of a lysosomal enzyme with 
phosphotransferase. EMBO J, 16, 6684-93. 10.053 
17. Uusitalo, A., Tenhunen, K., Tenhunen, J., Matikainen, S., Peltonen, L. and Jalanko, A. 
(1997) Expression and regulation of the human and mouse aspartylglucosaminidase gene. 
J Biol Chem, 272, 9524-30. 5.854 
18. Wartiovaara, K., Paavola, P., Suvanto, P., Paulin, L., Saarma, M., Peltonen, L. and 
Sariola, H. (1997) Exclusion of the p75 neurotrophin receptor gene as a candidate gene 
for Meckel syndrome. Clin Dysmorphol, 6, 213-7. 0.667 
19. Aberg, L., Jarvela, I., Rapola, J., Autti, T., Kirveskari, E., Lappi, M., Sipila, L. and 
Santavuori, P. (1998) Atypical juvenile neuronal ceroid liposfuscinosis with granular 
osmiophilic deposit-like inclusions in the autonomic nerve cells of the gut wall. Acta 
Neuropathol (Berl), 95, 306-312. 2.527 
20. Barlund, M., Nupponen, N.N., Karhu, R., Tanner, M.M., Paavola, P., Kallioniemi, O.P. 
and Kallioniemi, A. (1998) Molecular cytogenetic mapping of 24 CEPH YACs and 24 
gene-specific large insert probes to chromosome 17. Cytogenet Cell Genet, 82, 189-191. -  
21. de Seze, J., Udd, B., Haravuori, H., Sablonniere, B., Maurage, C.A., Hurtevent, J.F., 
Boutry, N., Stojkovic, T., Schraen, S., Petit, H. et al. (1998) The first European family 
with tibial muscular dystrophy outside the Finnish population. Neurology, 51, 1746-1748. 
5.065 
22. Fellman, V., Rapola, J., Pihko, H., Varilo, T. and Raivio, K.O. (1998) Iron-overload 
disease in infants involving fetal growth retardation, lactic acidosis, liver haemosiderosis, 
and aminoaciduria. Lancet, 351, 490-3. 23.878 
23. Haravuori, H., Makela-Bengs, P., Udd, B., Partanen, J., Pulkkinen, L., Somer, H. and 
Peltonen, L. (1998) Assignment of the tibial muscular dystrophy locus to chromosome 
2q31. Am J Hum Genet, 62, 620-6. 12.649 
24. Jalanko, A., Tenhunen, K., McKinney, C.E., LaMarca, M.E., Rapola, J., Autti, T., 
Joensuu, R., Manninen, T., Sipila, I., Ikonen, S. et al. (1998) Mice with an 
aspartylglucosaminuria mutation similar to humans replicate the pathophysiology in 
patients. Hum Mol Genet, 7, 265-72. 7.764 
25. Jarvela, I., Enattah, N.S., Kokkonen, J., Varilo, T., Savilahti, E. and Peltonen, L. (1998) 
Assignment of the locus for congenital lactase deficiency to 2q21, in the vicinity of but 
separate from the lactase-phlorizin hydrolase gene. Am J Hum Genet, 63, 1078-85. 12.649 
26. Jarvela, I., Sainio, M., Rantamaki, T., Olkkonen, V.M., Carpen, O., Peltonen, L. and 
Jalanko, A. (1998) Biosynthesis and intracellular targeting of the CLN3 protein defective 
in Batten disease. Hum Mol Genet, 7, 85-90. 7.764 
27. Jarvela, I., Savukoski, M., Ammala, P. and Von Koskull, H. (1998) Prenatally detected 
paternal uniparental chromosome 13 isodisomy. Prenat Diagn, 18, 1169-1173. 1.640 
28. Kestila, M., Lenkkeri, U., Mannikko, M., Lamerdin, J., McCready, P., Putaala, H., 
Ruotsalainen, V., Morita, T., Nissinen, M., Herva, R. et al. (1998) Positionally cloned 
gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic 
syndrome. Mol Cell, 1, 575-82. 14.971 
29. Kyttala, A., Heinonen, O., Peltonen, L. and Jalanko, A. (1998) Expression and 
endocytosis of lysosomal aspartylglucosaminidase in mouse primary neurons. J Neurosci, 
18, 7750-6. 7.506 
30. Makela-Bengs, P., Jarvinen, N., Vuopala, K., Suomalainen, A., Ignatius, J., Sipila, M., 
Herva, R., Palotie, A. and Peltonen, L. (1998) Assignment of the disease locus for lethal 
Background material                                                                                    APPENDIX 1 
 118
congenital contracture syndrome to a restricted region of chromosome 9q34, by genome 
scan using five affected individuals. Am J Hum Genet, 63, 506-16. 12.649 
31. McLeod, H.L., Syvanen, A.C., Githang'a, J., Indalo, A., Ismail, D., Dewar, K., Ulmanen, 
I. and Sludden, J. (1998) Ethnic differences in catechol O-methyltransferase 
pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan 
than Caucasian or South-west Asian individuals. Pharmacogenetics, 8, 195-9. 5.882 
32. Myhre, A.G., Bjorses, P., Dalen, A. and Husebye, E.S. (1998) Three sisters with 
Addison's disease. J Clin Endocrinol Metab, 83, 4204-4206. 6.020 
33. Paunio, T., Kangas, H., Heinonen, O., Buc-Caron, M.H., Robert, J.J., Kaasinen, S., 
Julkunen, I., Mallet, J. and Peltonen, L. (1998) Cells of the neuronal lineage play a major 
role in the generation of amyloid precursor fragments in gelsolin-related amyloidosis. J 
Biol Chem, 273, 16319-24. 5.854 
34. Pekkarinen, P., Hovatta, I., Hakola, P., Jarvi, O., Kestila, M., Lenkkeri, U., Adolfsson, R., 
Holmgren, G., Nylander, P.O., Tranebjaerg, L. et al. (1998) Assignment of the locus for 
PLO-SL, a frontal-lobe dementia with bone cysts, to 19q13. Am J Hum Genet, 62, 362-72. 
12.649 
35. Pekkarinen, P., Kestila, M., Paloneva, J., Terwillign, J., Varilo, T., Jarvi, O., Hakola, P. 
and Peltonen, L. (1998) Fine-scale mapping of a novel dementia gene, PLOSL, by 
linkage disequilibrium. Genomics, 54, 307-15. 3.181 
36. Peltola, M., Kyttala, A., Heinonen, O., Rapola, J., Paunio, T., Revah, F., Peltonen, L. and 
Jalanko, A. (1998) Adenovirus-mediated gene transfer results in decreased lysosomal 
storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse. 
Gene Ther, 5, 1314-21. 4.836 
37. Saarela, J., Laine, M., Tikkanen, R., Oinonen, C., Jalanko, A., Rouvinen, J. and Peltonen, 
L. (1998) Activation and oligomerization of aspartylglucosaminidase. J Biol Chem, 273, 
25320-8. 5.854 
38. Salonen, T., Hellsten, E., Horelli-Kuitunen, N., Peltonen, L. and Jalanko, A. (1998) 
Mouse palmitoyl protein thioesterase: gene structure and expression of cDNA. Genome 
Res, 8, 724-30. 10.139 
39. Savukoski, M., Klockars, T., Holmberg, V., Santavuori, P., Lander, E.S. and Peltonen, L. 
(1998) CLN5, a novel gene encoding a putative transmembrane protein mutated in 
Finnish variant late infantile neuronal ceroid lipofuscinosis. Nat Genet, 19, 286-8. 25.797 
40. Tenhunen, K., Uusitalo, A., Autti, T., Joensuu, R., Kettunen, M., Kauppinen, R.A., 
Ikonen, S., LaMarca, M.E., Haltia, M., Ginns, E.I. et al. (1998) Monitoring the CNS 
pathology in aspartylglucosaminuria mice. J Neuropathol Exp Neurol, 57, 1154-63. 4.471 
41. Udd, B., Haravuori, H., Kalimo, H., Partanen, J., Pulkkinen, L., Paetau, A., Peltonen, L. 
and Somer, H. (1998) Tibial muscular dystrophy - from clinical description to linkage on 
chromosome 2q31. Neuromuscul Disord, 8, 327-332. 3.340 
42. Visapaa, I., Fellman, V., Varilo, T., Palotie, A., Raivio, K.O. and Peltonen, L. (1998) 
Assignment of the locus for a new lethal neonatal metabolic syndrome to 2q33-37. Am J 
Hum Genet, 63, 1396-403. 12.649 
43. Yaspo, M.L., Aaltonen, J., Horelli-Kuitunen, N., Peltonen, L. and Lehrach, H. (1998) 
Cloning of a novel human putative type Ia integral membrane protein mapping to 21q22.3. 
Genomics, 49, 133-6. 3.181 
44. Bjorses, P., Pelto-Huikko, M., Kaukonen, J., Aaltonen, J., Peltonen, L. and Ulmanen, I. 
(1999) Localization of the APECED protein in distinct nuclear structures. Hum Mol 
Genet, 8, 259-66. 7.764 
45. Horelli-Kuitunen, N., Aaltonen, J., Yaspo, M.L., Eeva, M., Wessman, M., Peltonen, L. 
and Palotie, A. (1999) Mapping ESTs by fiber-FISH. Genome Res, 9, 62-71. 10.139 
46. Horelli-Kuitunen, N., Gahmberg, N., Eeva, M., Palotie, A. and Jarvela, I. (1999) 
Interstitial deletion of bands 11q21 -> 22.3 in a three-year-old girl defined using 
fluorescence in situ hybridization on metaphase chromosomes. Am J Med Genet, 86, 416-
419. 1.913 
47. Isosomppi, J., Heinonen, O., Hiltunen, J.O., Greene, N.D., Vesa, J., Uusitalo, A., 
Mitchison, H.M., Saarma, M., Jalanko, A. and Peltonen, L. (1999) Developmental 
expression of palmitoyl protein thioesterase in normal mice. Dev Brain Res, 118, 1-11. 
1.508 
48. Jarvela, I., Lehtovirta, M., Tikkanen, R., Kyttala, A. and Jalanko, A. (1999) Defective 
intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL). Hum Mol 
Genet, 8, 1091-8. 7.764 
49. Kangas, H., Ulmanen, I., Paunio, T., Kwiatkowski, D.J., Lehtovirta, M., Jalanko, A. and 
Peltonen, L. (1999) Functional consequences of amyloidosis mutation for gelsolin 
Background material                                                                                    APPENDIX 1 
 119
polypeptide -- analysis of gelsolin-actin interaction and gelsolin processing in gelsolin 
knock-out fibroblasts. FEBS Lett, 454, 233-9. 3.415 
50. Klockars, T., Holmberg, V., Savukoski, M., Lander, E.S. and Peltonen, L. (1999) 
Transcript identification on the CLN5 region on chromosome 13q22. Hum Genet, 105, 
51-6. 4.331.  
51. Klockars, T., Savukoski, M., Isosomppi, J. and Peltonen, L. (1999) Positional cloning of 
the CLN5 gene defective in the Finnish variant of the LINCL. Mol Genet Metab, 66, 324-
8. 2.678 
52. Laine, M., Richter, J., Fahlman, C., Rapola, J., Renlund, M., Peltonen, L., Karlsson, S. 
and Jalanko, A. (1999) Correction of peripheral lysosomal accumulation in mice with 
aspartylglucosaminuria by bone marrow transplantation. Exp Hematol, 27, 1467-74. 
4.019 
53. Lauronen, L., Munroe, P.B., Jarvela, I., Autti, T., Mitchison, H.M., O'Rawe, A.M., 
Gardiner, R.M., Mole, S.E., Puranen, J., Hakkinen, A.M. et al. (1999) Delayed classic 
and protracted phenotypes of compound heterozygous juvenile neuronal ceroid 
lipofuscinosis. Neurology, 52, 360-5. 5.690 
54. Lauteala, T., Mykkanen, J., Horelli-Kuitunen, N., Aaltonen, J., Paavola, P., Savontaus, 
M.L., Simell, O. and Aula, P. (1999) Characterization of the lysinuric protein intolerance 
(LPI) region within T-cell receptor alpha/delta gene cluster on chromosome site 14q11. 
Hereditas, 130, 19-24. 0.596 
55. Paavola, P., Avela, K., Horelli-Kuitunen, N., Barlund, M., Kallioniemi, A., Idanheimo, N., 
Kyttala, M., de la Chapelle, A., Palotie, A., Lehesjoki, A.E. et al. (1999) High-resolution 
physical and genetic mapping of the critical region for Meckel syndrome and Mulibrey 
Nanism on chromosome 17q22-q23. Genome Res, 9, 267-76. 10.139 
56. Paavola, P., Horelli-Kuitunen, N., Palotie, A. and Peltonen, L. (1999) Characterization of 
a novel gene, PNUTL2, on human chromosome 17q22-q23 and its exclusion as the 
Meckel syndrome gene. Genomics, 55, 122-5. 3.181 
57. Rapola, J., Lahdetie, J., Isosomppi, J., Helminen, P., Penttinen, M. and Jarvela, I. (1999) 
Prenatal diagnosis of variant late infantile neuronal ceroid lipofuscinosis 
(vLINCL[Finnish]; CLN5). Prenat Diagn, 19, 685-8. 1.514 
58. Uusitalo, A., Tenhunen, K., Heinonen, O., Hiltunen, J.O., Saarma, M., Haltia, M., Jalanko, 
A. and Peltonen, L. (1999) Toward understanding the neuronal pathogenesis of 
aspartylglucosaminuria: expression of aspartylglucosaminidase in brain during 
development. Mol Genet Metab, 67, 294-307. 2.678 
59. Verheijen, F.W., Verbeek, E., Aula, N., Beerens, C.E., Havelaar, A.C., Joosse, M., 
Peltonen, L., Aula, P., Galjaard, H., van der Spek, P.J. et al. (1999) A new gene, encoding 
an anion transporter, is mutated in sialic acid storage diseases. Nat Genet, 23, 462-5. 
25.797 
60. Visapaa, I., Salonen, R., Varilo, T., Paavola, P. and Peltonen, L. (1999) Assignment of 
the locus for hydrolethalus syndrome to a highly restricted region on 11q23-25. Am J 
Hum Genet, 65, 1086-95. 12.649 
61. Aula, N., Salomaki, P., Timonen, R., Verheijen, F., Mancini, G., Mansson, J.E., Aula, P. 
and Peltonen, L. (2000) The spectrum of SLC17A5-gene mutations resulting in free sialic 
acid-storage diseases indicates some genotype-phenotype correlation. Am J Hum Genet, 
67, 832-40. 12.649 
62. Bjorses, P., Halonen, M., Palvimo, J.J., Kolmer, M., Aaltonen, J., Ellonen, P., 
Perheentupa, J., Ulmanen, I. and Peltonen, L. (2000) Mutations in the AIRE gene: effects 
on subcellular location and transactivation function of the autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy protein. Am J Hum Genet, 66, 378-
92. 12.649 
63. Forsman, T., Lautala, P., Lundstrom, K., Monastyrskaia, K., Ouzzine, M., Burchell, B., 
Taskinen, J. and Ulmanen, I. (2000) Production of human UDP-glucuronosyltransferases 
1A6 and 1A9 using the Semliki Forest virus expression system. Life Sci, 67, 2473-2484. 
2.512 
64. Heinonen, O., Kyttala, A., Lehmus, E., Paunio, T., Peltonen, L. and Jalanko, A. (2000) 
Expression of palmitoyl protein thioesterase in neurons. Mol Genet Metab, 69, 123-9. 
2.678 
65. Heinonen, O., Salonen, T., Jalanko, A., Peltonen, L. and Copp, A. (2000) CLN-1 and 
CLN-5, genes for infantile and variant late infantile neuronal ceroid lipofuscinoses, are 
expressed in the embryonic human brain. J Comp Neurol, 426, 406-12. 3.855 
Background material                                                                                    APPENDIX 1 
 120
66. Holmberg, V., Lauronen, L., Autti, T., Santavuori, P., Savukoski, M., Uvebrant, P., 
Hofman, I., Peltonen, L. and Jarvela, I. (2000) Phenotype-genotype correlation in eight 
patients with Finnish variant late infantile NCL (CLN5). Neurology, 55, 579-81. 5.065 
67. Klemetti, P., Bjorses, P., Tuomi, T., Perheentupa, J., Partanen, J., Rautonen, N., 
Hinkkanen, A., Ilonen, J. and Vaarala, O. (2000) Autoimmunity to glutamic acid 
decarboxylase in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal 
dystrophy (APECED). Clin Exp Immunol, 119, 419-25. 2.805 
68. Lonka, L., Kyttala, A., Ranta, S., Jalanko, A. and Lehesjoki, A.E. (2000) The neuronal 
ceroid lipofuscinosis CLN8 membrane protein is a resident of the endoplasmic reticulum. 
Hum Mol Genet, 9, 1691-1697. 7.764 
69. Paloneva, J., Kestila, M., Wu, J., Salminen, A., Bohling, T., Ruotsalainen, V., Hakola, P., 
Bakker, A.B., Phillips, J.H., Pekkarinen, P. et al. (2000) Loss-of-function mutations in 
TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet, 25, 357-61. 
25.797 
70. Salonen, T., Jarvela, I., Peltonen, L. and Jalanko, A. (2000) Detection of eight novel 
palmitoyl protein thioesterase (PPT) mutations underlying infantile neuronal ceroid 
lipofuscinosis (INCL;CLN1). Hum Mutat, 15, 273-9. 7.923 
71. Soderbergh, A., Rorsman, F., Halonen, M., Ekwall, O., Bjorses, P., Kampe, O. and 
Husebye, E.S. (2000) Autoantibodies against aromatic L-amino acid decarboxylase 
identifies a subgroup of patients with Addison's disease. J Clin Endocrinol Metab, 85, 
460-463. 6.020 
72. Halonen, M., Pelto-Huikko, M., Eskelin, P., Peltonen, L., Ulmanen, I. and Kolmer, M. 
(2001) Subcellular location and expression pattern of autoimmune regulator (Aire), the 
mouse orthologue for human gene defective in autoimmune polyendocrinopathy 
candidiasis ectodermal dystrophy (APECED). J Histochem Cytochem, 49, 197-208. 2.208 
73. Haravuori, H., Vihola, A., Straub, V., Auranen, M., Richard, I., Marchand, S., Voit, T., 
Labeit, S., Somer, H., Peltonen, L. et al. (2001) Secondary calpain3 deficiency in 2q-
linked muscular dystrophy: titin is the candidate gene. Neurology, 56, 869-77. 5.065 
74. Holopainen, J.M., Saarikoski, J., Kinnunen, P.K.J. and Jarvela, I. (2001) Elevated 
lysosomal pH in neuronal ceroid lipofuscinoses (NCLs). Eur J Biochem, 268, 5851-5856. 
3.164 
75. Lautala, P., Ulmanen, I. and Taskinen, J. (2001) Molecular mechanisms controlling the 
rate and specificity of catechol O-methylation by human soluble catechol O-
methyltransferase. Mol Pharmacol, 59, 393-402. 4.612 
76. Lee, M.S., Lyoo, C.H., Ulmanen, I., Syvanen, A.C. and Rinne, J.O. (2001) Genotypes of 
catechol-O-methyltransferase and response to levodopa treatment in patients with 
Parkinson's disease. Neurosci Lett, 298, 131-4. 1.898 
77. Lehtovirta, M., Kyttala, A., Eskelinen, E.L., Hess, M., Heinonen, O. and Jalanko, A. 
(2001) Palmitoyl protein thioesterase (PPT) localizes into synaptosomes and synaptic 
vesicles in neurons: implications for infantile neuronal ceroid lipofuscinosis (INCL). Hum 
Mol Genet, 10, 69-75. 7.764 
78. Li, F.Y., Nikali, K., Gregan, J., Leibiger, I., Leibiger, B., Schweyen, R., Larsson, C. and 
Suomalainen, A. (2001) Characterization of a novel human putative mitochondrial 
transporter homologous to the yeast mitochondrial RNA splicing proteins 3 and 4. FEBS 
Lett, 494, 79-84. 3.415 
79. Luiro, K., Kopra, O., Lehtovirta, M. and Jalanko, A. (2001) CLN3 protein is targeted to 
neuronal synapses but excluded from synaptic vesicles: new clues to Batten disease. Hum 
Mol Genet, 10, 2123-31. 7.764 
80. Mole, S.E., Zhong, N.A., Sarpong, A., Logan, W.P., Hofmann, S., Yi, W., Franken, P.F., 
van Diggelen, O.P., Breuning, M.H., Moroziewicz, D. et al. (2001) New mutations in the 
neuronal ceroid lipofuscinosis genes. Eur J Paediatr Neurol, 5 Suppl A, 7-10. 1.364 
81. Monni, O., Barlund, M., Mousses, S., Kononen, J., Sauter, G., Heiskanen, M., Paavola, P., 
Avela, K., Chen, Y.D., Bittner, M.L. et al. (2001) Comprehensive copy number and gene 
expression profiling of the 17q23 amplicon in human breast cancer. Proc Natl Acad Sci U 
S A, 98, 5711-5716. 10.231 
82. Myhre, A.G., Halonen, M., Eskelin, P., Ekwall, O., Hedstrand, H., Rorsman, F., Kampe, 
O. and Husebye, E.S. (2001) Autoimmune polyendocrine syndrome type 1 (APS I) in 
Norway. Clin Endocrinol (Oxf), 54, 211-217. 3.412 
83. Paloneva, J., Autti, T., Raininko, R., Partanen, J., Salonen, O., Puranen, M., Hakola, P. 
and Haltia, M. (2001) CNS manifestations of Nasu-Hakola disease - A frontal dementia 
with bone cysts. Neurology, 56, 1552-1558. 5.065 
Background material                                                                                    APPENDIX 1 
 121
84. Saarela, J., Laine, M., Oinonen, C., Schantz, C., Jalanko, A., Rouvinen, J. and Peltonen, L. 
(2001) Molecular pathogenesis of a disease: structural consequences of 
aspartylglucosaminuria mutations. Hum Mol Genet, 10, 983-95. 7.764 
85. Salomaki, P., Aula, N., Juvonen, V., Renlund, M. and Aula, P. (2001) Prenatal detection 
of free sialic acid storage disease: genetic and biochemical studies in nine families. 
Prenat Diagn, 21, 354-358. 1.640 
86. Salonen, T., Heinonen-Kopra, O., Vesa, J. and Jalanko, A. (2001) Neuronal trafficking of 
palmitoyl protein thioesterase provides an excellent model to study the effects of different 
mutations which cause infantile neuronal ceroid lipofuscinocis. Mol Cell Neurosci, 18, 
131-140. 4.641 
87. Aula, N., Jalanko, A., Aula, P. and Peltonen, L. (2002) Unraveling the molecular 
pathogenesis of free sialic acid storage disorders: altered targeting of mutant sialin. Mol 
Genet Metab, 77, 99-107. 2.678 
88. Bondestam, J., Kaivo-oja, N., Kallio, J., Groome, N., Hyden-Granskog, C., Fujii, M., 
Moustakas, A., Jalanko, A., ten Dijke, P. and Ritvos, O. (2002) Engagement of activin 
and bone morphogenetic protein signaling pathway Smad proteins in the induction of 
inhibin B production in ovarian granulosa cells. Mol Cell Endocrinol, 195, 79-88. 2.918 
89. Erikson, A., Aula, N., Aula, P. and Mansson, J.E. (2002) Free sialic acid storage (Salla) 
disease in Sweden. Acta Paediatr, 91, 1324-1327. 1.277 
90. Fellman, V., Visapaa, I., Vujic, M., Wennerholm, U.B. and Peltonen, L. (2002) Antenatal 
diagnosis of hereditary fetal growth retardation with aminoaciduria, cholestasis, iron 
overload, and lactic acidosis in the newborn infant. Acta Obstet Gynecol Scand, 81, 398-
402. 1.549 
91. Hackman, P., Vihola, A., Haravuori, H., Marchand, S., Sarparanta, J., De Seze, J., Labeit, 
S., Witt, C., Peltonen, L., Richard, I. et al. (2002) Tibial muscular dystrophy is a 
titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle 
protein titin. Am J Hum Genet, 71, 492-500. 12.649 
92. Halonen, M., Eskelin, P., Myhre, A.G., Perheentupa, J., Husebye, E.S., Kampe, O., 
Rorsman, F., Peltonen, L., Ulmanen, I. and Partanen, J. (2002) AIRE mutations and 
human leukocyte antigen genotypes as determinants of the autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy phenotype. J Clin Endocrinol 
Metab, 87, 2568-74. 6.020 
93. Isosomppi, J., Vesa, J., Jalanko, A. and Peltonen, L. (2002) Lysosomal localization of the 
neuronal ceroid lipofuscinosis CLN5 protein. Hum Mol Genet, 11, 885-91. 7.764 
94. Kallijarvi, J., Avela, K., Lipsanen-Nyman, M., Ulmanen, I. and Lehesjoki, A.E. (2002) 
The TRIM37 gene encodes a peroxisomal RING-B-box-coiled-coil protein: Classification 
of mulibrey nanism as a new peroxisomal disorder. Am J Hum Genet, 70, 1215-1228. 
12.649 
95. Kangas, H., Seidah, N.G. and Paunio, T. (2002) Role of proprotein convertases in the 
pathogenic processing of the amyloidosis-associated form of secretory gelsolin. Amyloid, 
9, 83-7. 1.910 
96. Meng, X.J., Wahlstrom, G., Immonen, T., Kolmer, M., Tirronen, M., Predel, R., 
Kalkkinen, N., Heino, T.I., Sariola, H. and Roos, C. (2002) The Drosophila hugin gene 
codes for myostimulatory and ecdysis-modifying neuropeptides. Mech Dev, 117, 5-13. 
3.838 
97. Nikali, K., Saharinen, J. and Peltonen, L. (2002) cDNA cloning, expression profile and 
genomic structure of a novel human transcript on chromosome 10q24, and its analyses as 
a candidate gene for infantile onset spinocerebellar ataxia. Gene, 299, 111-5. 2.694 
98. Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., 
Bianchin, M., Bird, T., Miranda, R., Salmaggi, A. et al. (2002) Mutations in two genes 
encoding different subunits of a receptor signaling complex result in an identical disease 
phenotype. Am J Hum Genet, 71, 656-62. 12.649 
99. Ramsey, C., Bukrinsky, A. and Peltonen, L. (2002) Systematic mutagenesis of the 
functional domains of AIRE reveals their role in intracellular targeting. Hum Mol Genet, 
11, 3299-308. 7.764 
100. Ramsey, C., Winqvist, O., Puhakka, L., Halonen, M., Moro, A., Kampe, O., Eskelin, P., 
Pelto-Huikko, M. and Peltonen, L. (2002) Aire deficient mice develop multiple features 
of APECED phenotype and show altered immune response. Hum Mol Genet, 11, 397-409. 
7.764 
101. Vesa, J., Chin, M.H., Oelgeschlager, K., Isosomppi, J., DellAngelica, E.C., Jalanko, A. 
and Peltonen, L. (2002) Neuronal ceroid lipofuscinoses are connected at molecular level: 
interaction of CLN5 protein with CLN2 and CLN3. Mol Biol Cell, 13, 2410-20. 6.520 
Background material                                                                                    APPENDIX 1 
 122
102. Visapaa, I., Fellman, V., Lanyi, L. and Peltonen, L. (2002) ABCB6 (MTABC3) excluded 
as the causative gene for the growth retardation syndrome with aminoaciduria, cholestasis, 
iron overload, and lactacidosis. Am J Med Genet, 109, 202-5. 1.913 
103. Visapaa, I., Fellman, V., Vesa, J., Dasvarma, A., Hutton, J.L., Kumar, V., Payne, G.S., 
Makarow, M., Van Coster, R., Taylor, R.W. et al. (2002) GRACILE syndrome, a lethal 
metabolic disorder with iron overload, is caused by a point mutation in BCS1L. Am J 
Hum Genet, 71, 863-76. 12.649 
104. Ahtiainen, L., Van Diggelen, O.P., Jalanko, A. and Kopra, O. (2003) Palmitoyl protein 
thioesterase 1 is targeted to the axons in neurons. J Comp Neurol, 455, 368-77. 3.831 
105. Conceicao, I., Sales-Luis, M.L., De Carvalho, M., Evangelista, T., Fernandes, R., Paunio, 
T., Kangas, H., Coutinho, P., Neves, C. and Saraiva, M.J. (2003) Gelsolin-related familial 
amyloidosis, Finnish type, in a Portuguese family: clinical and neurophysiological studies. 
Muscle Nerve, 28, 715-21. 2.458 
106. Gylling, M., Kaariainen, E., Vaisanen, R., Kerosuo, L., Solin, M.L., Halme, L., Saari, S., 
Halonen, M., Kampe, O., Perheentupa, J. et al. (2003) The hypoparathyroidism of 
autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protective effect of 
male sex. J Clin Endocrinol Metab, 88, 4602-4608. 6.020 
107. Harkke, S., Laine, M. and Jalanko, A. (2003) Aspartylglucosaminidase (AGA) is 
efficiently produced and endocytosed by glial cells: implication for the therapy of a 
lysosomal storage disorder. J Gene Med, 5, 472-82. 3.916 
108. Liston, A., Lesage, S., Wilson, J., Peltonen, L. and Goodnow, C.C. (2003) Aire regulates 
negative selection of organ-specific T cells. Nat Immunol, 4, 350-4.27.011. 27.596 
109. Mahjneh, I., Haravuori, H., Paetau, A., Anderson, L.V.B., Saarinen, A., Udd, B. and 
Somer, H. (2003) A distinct phenotype of distal myopathy in a large Finnish family. 
Neurology, 61, 87-92. 5.065 
110. Paloneva, J., Mandelin, J., Kiialainen, A., Bohling, T., Prudlo, J., Hakola, P., Haltia, M., 
Konttinen, Y.T. and Peltonen, L. (2003) DAP12/TREM2 deficiency results in impaired 
osteoclast differentiation and osteoporotic features. J Exp Med, 198, 669-75. 13.965 
111. Rinne, J.O., Ulmanen, I. and Lee, M.S. (2003) Catechol-O-methyl transferase (COMT) 
inhibitors in patients with Parkinson's disease: is COMT genotype a useful indicator of 
clinical efficacy? Am J Pharmacogenomics, 3, 11-5. - 
112. Salmaggi, A., Maccagnano, E., Musso, A., Di Lena, L., Paloneva, J. and Boiardi, A. 
(2003) An Italian family with Nasu-Hakola disease. J Neurol, 250, 878-880. 2.844 
113. Siitonen, H.A., Kopra, O., Kaariainen, H., Haravuori, H., Winter, R.M., Saamanen, A.M., 
Peltonen, L. and Kestila, M. (2003) Molecular defect of RAPADILINO syndrome 
expands the phenotype spectrum of RECQL diseases. Hum Mol Genet, 12, 2837-44. 
7.764 
114. Aula, N., Kopra, O., Jalanko, A. and Peltonen, L. (2004) Sialin expression in the CNS 
implicates extralysosomal function in neurons. Neurobiol Dis, 15, 251-61. 4.048 
115. Halonen, M., Kangas, H., Ruppell, T., Ilmarinen, T., Ollila, J., Kolmer, M., Vihinen, M., 
Palvimo, J., Saarela, J., Ulmanen, I. et al. (2004) APECED-causing mutations in AIRE 
reveal the functional domains of the protein. Hum Mutat, 23, 245-57. 7.923 
116. Haravuori, H., Siitonen, H.A., Mahjneh, I., Hackman, P., Lahti, L., Somer, H., Peltonen, 
L., Kestila, M. and Udd, B. (2004) Linkage to two separate loci in a family with a novel 
distal myopathy phenotype (MPD3). Neuromuscul Disord, 14, 183-7. 3.340 
117. Hentges, K.E., Kyttala, M., Justice, M.J. and Peltonen, L. (2004) Comparative physical 
maps of the human and mouse Meckel syndrome critical regions. Mamm Genome, 15, 
252-64. 2.747 
118. Holmberg, V., Jalanko, A., Isosomppi, J., Fabritius, A.L., Peltonen, L. and Kopra, O. 
(2004) The mouse ortholog of the neuronal ceroid lipofuscinosis CLN5 gene encodes a 
soluble lysosomal glycoprotein expressed in the developing brain. Neurobiol Dis, 16, 29-
40. 4.048 
119. Kopra, O., Vesa, J., von Schantz, C., Manninen, T., Minye, H., Fabritius, A.L., Rapola, J., 
van Diggelen, O.P., Saarela, J., Jalanko, A. et al. (2004) A mouse model for Finnish 
variant late infantile neuronal ceroid lipofuscinosis, CLN5, reveals neuropathology 
associated with early aging. Hum Mol Genet, 13, 2893-906. 7.764 
120. Kuusniemi, A.M., Kestila, M., Patrakka, J., Lahdenkari, A.T., Ruotsalainen, V., 
Holmberg, C., Karikoski, R., Salonen, R., Tryggvason, K. and Jalanko, H. (2004) Tissue 
expression of nephrin in human and pig. Pediatr Res, 55, 774-781. 2.875 
121. Lahdenkari, A.T., Kestila, M., Holmberg, C., Koskimies, O. and Jalanko, H. (2004) 
Nephrin gene (NPHS1) in patients with minimal change nephrotic syndrome (MCNS). 
Kidney Int, 65, 1856-1863. 4.927 
Background material                                                                                    APPENDIX 1 
 123
122. Lahdenkari, A.T., Lounatmaa, K., Patrakka, J., Holmberg, C., Wartiovaara, J., Kestila, M., 
Koskimies, O. and Jalanko, H. (2004) Podocytes are firmly attached to glomerular 
basement membrane in kidneys with heavy proteinuria. J Am Soc Nephrol, 15, 2611-18. 
7.240 
123. Laine, M., Ahtiainen, L., Rapola, J., Richter, J. and Jalanko, A. (2004) Bone marrow 
transplantation in young aspartylglucosaminuria mice: improved clearance of lysosomal 
storage in brain by using wild type as compared to heterozygote donors. Bone Marrow 
Transplant, 34, 1001-1003. 2.643 
124. Liston, A., Gray, D.H., Lesage, S., Fletcher, A.L., Wilson, J., Webster, K.E., Scott, H.S., 
Boyd, R.L., Peltonen, L. and Goodnow, C.C. (2004) Gene dosage--limiting role of Aire 
in thymic expression, clonal deletion, and organ-specific autoimmunity. J Exp Med, 200, 
1015-26. 13.965 
125. Lonka, L., Salonen, T., Siintola, E., Kopra, O., Lehesjoki, A.E. and Jalanko, A. (2004) 
Localization of wild-type and mutant neuronal ceroid lipofuscinosis CLN8 proteins in 
non-neuronal and neuronal cells. J Neurosci Res, 76, 862-871. 3.239 
126. Luiro, K., Yliannala, K., Ahtiainen, L., Maunu, H., Jarvela, I., Kyttala, A. and Jalanko, A. 
(2004) Interconnections of CLN3, Hook1 and Rab proteins link Batten disease to defects 
in the endocytic pathway. Hum Mol Genet, 13, 3017-27. 7.764 
127. Moreau, S.J.M., Cherqui, A., Doury, G., Dubois, F., Fourdrain, Y., Sabatier, L., Bulet, P., 
Saarela, J., Prevost, G. and Giordanengo, P. (2004) Identification of an 
aspartylglucosaminidase-like protein in the venom of the parasitic wasp Asobara tabida 
(Hymenoptera : Braconidae). Insect Biochem Mol Biol, 34, 485-492. 2.733 
128. Saarela, J., Oinonen, C., Jalanko, A., Rouvinen, J. and Peltonen, L. (2004) 
Autoproteolytic activation of human aspartylglucosaminidase. Biochem J, 378, 363-71. 
4.224 
129. Saarela, J., von Schantz, C., Peltonen, L. and Jalanko, A. (2004) A novel 
aspartylglucosaminuria mutation affects translocation of aspartylglucosaminidase. Hum 
Mutat, 24, 350-1. 7.923 
130. Soderbergh, A., Myhre, A.G., Ekwall, O., Gebre-Medhin, G., Hedstrand, H., Landgren, 
E., Miettinen, A., Eskelin, P., Halonen, M., Tuomi, T. et al. (2004) Prevalence and 
clinical associations of 10 defined autoantibodies in autoimmune polyendocrine 
syndrome type I. J Clin Endocrinol Metab, 89, 557-562. 6.020 
131. Tyynismaa, H., Sembongi, H., Bokori-Brown, M., Granycome, C., Ashley, N., Poulton, J., 
Jalanko, A., Spelbrink, J.N., Holt, I.J. and Suomalainen, A. (2004) Twinkle helicase is 
essential for mtDNA maintenance and regulates mtDNA copy number. Hum Mol Genet, 
13, 3219-3227. 7.764 
132. Anttonen, A.K., Mahjneh, I., Hamalainen, R.H., Lagier-Tourenne, C., Kopra, O., Waris, 
L., Anttonen, M., Joensuu, T., Kalimo, H., Paetau, A. et al. (2005) The gene disrupted in 
Marinesco-Sjogren syndrome encodes SIL1, an HSPA5 cochaperone. Nat Genet, 37, 
1309-11. 25.797 
133. Ilmarinen, T., Eskelin, P., Halonen, M., Ruppell, T., Kilpikari, R., Torres, G.D., Kangas, 
H. and Ulmanen, I. (2005) Functional analysis of SAND mutations in AIRE supports 
dominant inheritance of the G228W mutation. Hum Mutat, 26, 322-331. 7.923 
134. Jalanko, A., Vesa, J., Manninen, T., von Schantz, C., Minye, H., Fabritius, A.L., Salonen, 
T., Rapola, J., Gentile, M., Kopra, O. et al. (2005) Mice with Ppt1Deltaex4 mutation 
replicate the INCL phenotype and show an inflammation-associated loss of interneurons. 
Neurobiol Dis, 18, 226-41. 4.048 
135. Kellermayer, R., Siitonen, H.A., Hadzsiev, K., Kestila, M. and Kosztolanyi, G. (2005) A 
patient with Rothmund-Thomson syndrome and all features of RAPADILINO. Arch 
Dermatol, 141, 617-620. 3.434 
136. Kiialainen, A., Hovanes, K., Paloneva, J., Kopra, O. and Peltonen, L. (2005) Dap12 and 
Trem2, molecules involved in innate immunity and neurodegeneration, are co-expressed 
in the CNS. Neurobiol Dis, 18, 314-22. 4.048 
137. Klunemann, H.H., Ridha, B.H., Magy, L., Wherrett, J.R., Hemelsoet, D.M., Keen, R.W., 
De Bleecker, J.L., Rossor, M.N., Marienhagen, J., Klein, H.E. et al. (2005) The genetic 
causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. 
Neurology, 64, 1502-7. 5.065 
138. Kyttala, A., Yliannala, K., Schu, P., Jalanko, A. and Luzio, J.P. (2005) AP-1 and AP-3 
facilitate lysosomal targeting of Batten disease protein CLN3 via its dileucine motif. J 
Biol Chem, 280, 10277-83. 5.854 
Background material                                                                                    APPENDIX 1 
 124
139. Lahdenkari, A.T., Suvanto, M., Kajantie, E., Koskimies, O., Kestila, M. and Jalanko, H. 
(2005) Clinical features and outcome of childhood minimal change nephrotic syndrome: 
is genetics involved? Pediatr Nephrol, 20, 1073-1080. 1.620 
140. Mee, L., Honkala, H., Kopra, O., Vesa, J., Finnila, S., Visapaa, I., Sang, T.K., Jackson, 
G.R., Salonen, R., Kestila, M. et al. (2005) Hydrolethalus syndrome is caused by a 
missense mutation in a novel gene HYLS1. Hum Mol Genet, 14, 1475-88. 7.764 
141. Nikali, K., Suomalainen, A., Saharinen, J., Kuokkanen, M., Spelbrink, J.N., Lonnqvist, T. 
and Peltonen, L. (2005) Infantile onset spinocerebellar ataxia is caused by recessive 
mutations in mitochondrial proteins Twinkle and Twinky. Hum Mol Genet, 14, 2981-90. 
7.764 
142. Pakkasjarvi, N., Gentile, M., Saharinen, J., Honkanen, J., Herva, R., Peltonen, L. and 
Kestila, M. (2005) Indicative oligodendrocyte dysfunction in spinal cords of human 
fetuses suffering from a lethal motoneuron disease. J Neurobiol, 65, 269-81. 4.170 
143. Tyynismaa, H., Mjosund, K.P., Wanrooij, S., Lappalainen, I., Ylikallio, E., Jalanko, A., 
Spelbrink, J.N., Paetau, A. and Suomalainen, A. (2005) Mutant mitochondrial helicase 
Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in mice. 
Proc Natl Acad Sci U S A, 102, 17687-17692. 10.231 
144. Ahtiainen, L., Luiro, K., Kauppi, M., Tyynela, J., Kopra, O. and Jalanko, A. (2006) 
Palmitoyl protein thioesterase 1 (PPT1) deficiency causes endocytic defects connected to 
abnormal saposin processing. Exp Cell Res, 312, 1540-53. 3.777 
145. Brannstrom, J., Hassler, S., Peltonen, L., Herrmann, B. and Winqvist, O. (2006) Defect 
internalization and tyrosine kinase activation in Aire deficient antigen presenting cells 
exposed to Candida albicans antigens. Clin Immunol, 121, 265-73. 3.217 
146. Collins, S.M., Dominguez, M., Ilmarinen, T., Costigan, C. and Irvine, A.D. (2006) 
Dermatological manifestations of autoimmune polyendocrinopathy-candidiasis-
ectodermal dystrophy syndrome. Br J Dermatol, 154, 1088-93. 2.978 
147. Dominguez, M., Crushell, E., Ilmarinen, T., McGovern, E., Collins, S., Chang, B., 
Fleming, P., Irvine, A.D., Brosnahan, D., Ulmanen, I. et al. (2006) Autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in the Irish population. 
J Pediatr Endocrinol Metab, 19, 1343-52. 0.841 
148. Hassler, S., Ramsey, C., Karlsson, M.C., Larsson, D., Herrmann, B., Rozell, B., 
Backheden, M., Peltonen, L., Kampe, O. and Winqvist, O. (2006) Aire deficient mice 
develop hematopoetic irregularities and marginal zone B cell lymphoma. Blood, 108, 
1941-8. 10.131 
149. Kyttala, M., Tallila, J., Salonen, R., Kopra, O., Kohlschmidt, N., Paavola-Sakki, P., 
Peltonen, L. and Kestila, M. (2006) MKS1, encoding a component of the flagellar 
apparatus basal body proteome, is mutated in Meckel syndrome. Nat Genet, 38, 155-7. 
25.797 
150. Luiro, K., Kopra, O., Blom, T., Gentile, M., Mitchison, H.M., Hovatta, I., Tornquist, K. 
and Jalanko, A. (2006) Batten disease (JNCL) is linked to disturbances in mitochondrial, 
cytoskeletal, and synaptic compartments. J Neurosci Res, 84, 1124-38. 3.476 
151. Meager, A., Visvalingam, K., Peterson, P., Moll, K., Murumagi, A., Krohn, K., Eskelin, 
P., Perheentupa, J., Husebye, E., Kadota, Y. et al. (2006) Anti-interferon autoantibodies 
in autoimmune polyendocrinopathy syndrome type 1. Plos Medicine, 3, 1152-1164. 8.389 
152. Pakkasjarvi, N., Ritvanen, A., Herva, R., Peltonen, L., Kestila, M. and Ignatius, J. (2006) 
Lethal congenital contracture syndrome (LCCS) and other lethal arthrogryposes in 
Finland--an epidemiological study. Am J Med Genet A, 140, 1834-9. 1.913 
153. Pontynen, N., Miettinen, A., Petteri Arstila, T., Kampe, O., Alimohammadi, M., Vaarala, 
O., Peltonen, L. and Ulmanen, I. (2006) Aire deficient mice do not develop the same 
profile of tissue-specific autoantibodies as APECED patients. J Autoimmun, 27, 96-104. 
2.491 
154. Ramsey, C., Hassler, S., Marits, P., Kampe, O., Surh, C.A., Peltonen, L. and Winqvist, O. 
(2006) Increased antigen presenting cell-mediated T cell activation in mice and patients 
without the autoimmune regulator. Eur J Immunol, 36, 305-317. 4.876 
155. Srivastava, T., Garola, R.E., Kestila, M., Tryggvason, K., Ruotsalainen, V., Sharma, M., 
Savin, V.J., Jalanko, H. and Warady, B.A. (2006) Recurrence of proteinuria following 
renal transplantation in congenital nephrotic syndrome of the Finnish type. Pediatr 
Nephrol, 21, 711-718. 1.620 
156. Turunen, J.A., Wessman, M., Forsblom, C., Kilpikari, R., Parkkonen, M., Pontynen, N., 
Ilmarinen, T., Ulmanen, I., Peltonen, L. and Groop, P.H. (2006) Association analysis of 
the AIRE and insulin genes in Finnish type 1 diabetic patients. Immunogenetics, 58, 331-
8. 2.976 
Background material                                                                                    APPENDIX 1 
 125
157. Van Maldergem, L., Siitonen, H.A., Jalkh, N., Chouery, E., De Roy, M., Delague, V., 
Muenke, M., Jabs, E.W., Cai, J., Wang, L.L. et al. (2006) Revisiting the craniosynostosis-
radial ray hypoplasia association: Baller-Gerold syndrome caused by mutations in the 
RECQL4 gene. J Med Genet, 43, 148-152. 4.330 
158. Virta, S., Rapola, J., Jalanko, A. and Laine, M. (2006) Use of nonviral promoters in 
adenovirus-mediated gene therapy: reduction of lysosomal storage in the 
aspartylglucosaminuria mouse. J Gen Med, 8, 699-706. 3.699 
159. Ahtiainen L, Kolikova J, Mutka A-L, Luiro K, Gentile M, Ikonen E, Khiroug L, Jalanko 
A, Kopra O. (2007) Palmitoyl protein thioesterase 1 (Ppt1) deficient mouse neurons show 
alterations in cholesterol metabolism and calcium homeostasis prior to synaptic 
dysfunction. Neurobiol Dis, in press. 4.048 
160. Gillard, G.O., Dooley, J., Erickson, M., Peltonen, L. and Farr, A.G. (2007) Aire-
dependent alterations in medullary thymic epithelium indicate a role for Aire in thymic 
epithelial differentiation. J Immunol, 178, 3007-15. 6.387 
161. Kiialainen, A., Veckman, V., Saharinen, J., Paloneva, J., Gentile, M., Hakola, P., 
Hemelsoet, D.M., Ridha, B.H., Kopra, O., Julkunen, I. et al. (2007) Transcript profiles of 
dendritic cells of PLOSL patients link demyelinating CNS disorders with abnormalities in 
pathways of actin bundling and immune response. J Mol Med, Epub May 26. 2.090 
162. Lambe, T., Leung, J.C., Ferry, H., Bouriez-Jones, T., Makinen, K., Crockford, T.L., Jiang, 
H.R., Nickerson, J.M., Peltonen, L., Forrester, J.V. et al. (2007) Limited peripheral T cell 
anergy predisposes to retinal autoimmunity. J Immunol, 178, 4276-83. 6.387 
163. Lyly, A., von Schantz, C., Salonen, T., Kopra, O., Saarela, J., Jauhiainen, M., Kyttala, A. 
and Jalanko, A. (2007) Glycosylation, transport, and complex formation of palmitoyl 
protein thioesterase 1 (PPT1) - distinct characteristics in neurons. BMC Cell Biology, in 
press. 2.742 
164. Pakkasjarvi, N., Kerosuo, L., Nousiainen, H., Gentile, M., Saharinen, J., Suhonen, J., 
Sariola, H., Peltonen, L., Kestila, M. and Wartiovaara, K. (2007) Neural precursor cells 
from a fatal human motoneuron disease differentiate despite aberrant gene expression. 
Dev Neurobiol, 67, 270-84. 4.170 
165. Ruan, Q.-G., Tung, K., Eisenman, D., Setiady, Y., Eckenrode, S., Yi, B., S, P., Zheng, 
W.-P., Zhang, Y., Peltonen, L. et al. (2007) The autoimmune regulator directly controls 
the expression of genes critical for thymic epithelial function. J Immunol, 178, 00-00. 
6.387 
 
International review articles 
1. Hellsten, E., Vesa, J., Jalanko, A. and Peltonen, L. (1997) From locus to cellular 
disturbances: Positional cloning of the infantile neuronal ceroid lipofuscinosis gene. 
Neuropediatrics, 28, 9-11. 1.377 
2. Peltonen, L. (1997) Molecular background of the Finnish disease heritage. Ann Med, 29, 
553-556.3.848 
3. Peltonen, L. and Uusitalo, A. (1997) Rare disease genes - Lessons and challenges. 
Genome Res, 7, 765-767. 10.139 
4. Bjorses, P., Aaltonen, J., Horelli-Kuitunen, N., Yaspo, M.L. and Peltonen, L. (1998) 
Gene defect behind APECED: a new clue to autoimmunity. Hum Mol Genet, 7, 1547-
1553. 7.764 
5. Salonen, R. and Paavola, P. (1998) Meckel syndrome. J Med Genet, 35, 497-501. 4.330 
6. Udd, B., Haravuori, H., Kalimo, H., Partanen, J., Pulkkinen, L., Paetau, A., Peltonen, L. 
and Somer, H. (1998) Tibial muscular dystrophy--from clinical description to linkage on 
chromosome 2q31. Neuromuscul Disord, 8, 327-32. 2.615 
7. Aaltonen, J. and Bjorses, P. (1999) Cloning of the APECED gene provides new insight 
into human autoimmunity. Ann Med, 31, 111-116. 3.848 
8. Klockars, T., Savukoski, M., Isosomppi, J. and Peltonen, L. (1999) Positional cloning of 
the CLN5 gene defective in the Finnish variant of the LINCL. Mol Genet Metab, 66, 324-
8. 2.371 
9. Peltonen, L., Jalanko, A. and Varilo, T. (1999) Molecular genetics of the Finnish disease 
heritage. Hum Mol Genet, 8, 1913-1923. 7.764 
10. Peltonen, L., Savukoski, M. and Vesa, J. (2000) Genetics of the neuronal ceroid 
lipofuscinoses. Curr Opin Genet Dev, 10, 299-305. 9.361 
11. Meriluoto, T., Halonen, M., Pelto-Huikko, M., Kangas, H., Korhonen, J., Kolmer, M., 
Ulmanen, I. and Eskelin, P. (2001) The autoimmune regulator: a key toward 
understanding the molecular pathogenesis of autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy. Keio J Med, 50, 225-39 
Background material                                                                                    APPENDIX 1 
 126
12. Vesa, J. and Peltonen, L. (2002) Mutated genes in juvenile and variant late infantile 
neuronal ceroid lipofuscinoses encode lysosomal proteins. Curr Mol Med, 2, 439-44. 
4.850 
13. Peterson, P. and Peltonen, L. (2005) Autoimmune polyendocrinopathy syndrome type 1 
(APS1) and AIRE gene: New views on molecular basis of autoimmunity. J Autoimmun, 
25, 49-55. 2.491 
14. Ulmanen, I., Halonen, M., Ilmarinen, T. and Peltonen, L. (2005) Monogenic autoimmune 
diseases - lessons of self-tolerance. Curr Opin Immunol, 17, 609-15. 9.422 
15. Jalanko, A., Tyynela, J. and Peltonen, L. (2006) From genes to systems: new global 
strategies for the characterization of NCL biology. Biochim Biophys Acta - Molecular 
Basis of Disease, 1762, 934-44. 3.298 
16. Kyttala, A., Lahtinen, U., Braulke, T. and Hofmann, S.L. (2006) Functional biology of 
the neuronal ceroid lipofuscinoses (NCL) proteins. Biochim Biophys Acta - Molecular 
Basis of Disease, 1762, 920-933. 3.298 
 
International book chapters 
1. Jarvinen, N., Makela-Bengs, P., Suomalainen, Vuopala, K., Herva, R., Palotie, A. and 
Peltonen, L. (1998) LCCS: A lethal motoneuron disease of the fetus maps to chromosome 
9q34. Morphogenesis: Cellular Interactions, 857, 260-262 
2. Hofman, S. and Peltonen, L. (2001) The neuronal ceroid lipofuscinoses. The Metabolic & 
Molecular bases of inherited disease, 8th; III, 3877-3894  
3. Aula, P., Jalanko, A. and Peltonen, L. (2001) Aspartylglucosaminuria. The Metabolic & 
Molecular bases of inherited disease, 8, 141; 3535-3550 
4. Ranta, S., Savukoski, M., Santavuori, P. and Haltia, M. (2001) Studies of homogenous 
populations: CLN5 and CLN8. Batten Disease: Diagnosis, Treatment, and Research, 45, 
123-140 
5. Peltonen, L. (2002) Aspartylglucosaminuria. Encyclopedia of Molecular Medicine, 5, 
272-274 
6. Kestila, M. and Peltonen, L. (2007) MKS genes and Meckel syndrome: New revelations 
of cilial function in human development. Inborn Errors of Development, in press  
7. Van Maldergem, L., Siitonen, HA., Jabs, EW. (2007) RECQL4 and the Baller-Gerold, 
RAPADILINO and Rothmund-Thomson Syndromes. Inborn Errors of Development, in 
press 
 
Domestic articles  
1. Ulmanen, I., Tenhunen, J. and Savola, J.-M. (1997) [Gene technology in drug 
development]. Suomen Lääkärilehti, 20-21, 2381-2387 
2. Kestila, M. and Varilo, T. (2003) Suomalaisten omien tautien geenit melkein selvitetty. 
Kansanterveyslehti, 3/2003 
 
Domestic book chapters 
1. Ulmanen, I., Tenhunen, J., Ylänne, J., Valste, J. and Viitanen, P. (1997) [Gene]. A 
textbook on microbiology and applications of genetics 
2. Ulmanen, I., Tenhunen, J. and Ylänne, J. (2004) [Gene and biotechnology]. A textbook on 
microbiology and applications of genetics, pp 180 
3. Kestilä, M. and Aula, P. (2007) Suomalainen tautiperintö. Perinnöllisyyslääketiede, pp. 221-
239 
 
 
Background material                                                                                   APPENDIX 2 
 127
Appendix 2: Genetic epidemiology - Dissertations and publications in 
1997-2007 
 
Dissertations 1997-2007  
1. Hovatta I: Molecular genetics of familial schizophrenia and PLO-SL. 1998. (Publications 
of the National Public Health Institute A20/1998) 
2. Pekkarinen P: Genetic mapping of the loci for a monogenic and a multifactorial 
neuropsychiatric disorder: PLO-SL and familial bipolar disorder. 1998. (Publications of 
the National Public Health Institute A19/1998) 
3. Kuokkanen S: Search for gene loci predisposing to multiple sclerosis in the Finnish 
population. 1998. (Publications of the National Public Health Institute A13/1998) 
4. Lönnqvist L: Molecular genetics of type I fibrillinopathies. 1998. (Publications of the 
National Public Health Institute A16/1998)  
5. Pajukanta P: Search for familial combined hyperlipidemia susceptibility genes. 1998. 
(Publications of the National Public Health Institute A26/1998) 
6. Rantamäki-Häkkinen T: Fibrillin defects in Marfan syndrome: impact on DNA diagnosis 
and molecular pathogenesis. 1998. (Publications of the National Public Health Institute 
A5/1998)  
7. Perola M: Finnish genes of hypertension. 1999. (Publications of the National Public 
Health Institution A8/1999)  
8. Kaukonen J: Autosomal dominant progressive external ophthalmoplegia (adPEO): A tale 
of two genomes. 2000. (Publications of the National Public Health A4/2000)  
9. Pastinen T: Scoring human genomic SNPs and mutations: multiplexed primer extension 
with manifolds and microarrays as solid-support. 2000. (Publications of the National 
Public Health Institute A5/2000).  
10. Ekelund J: Molecular genetics of schizophrenia and comorbid and related traits. 2001. 
(Publications of the National Public Health Institute A17/2001).  
11. Öhman M: The Search for genes predisposing to obesity. 2001. (Publications of the 
National Public Health Institution A3/2001)  
12. Auranen M: Molecular genetics of autism spectrum disorders in the Finnish population. 
2002. (Publications of the National Public Health Institute A23/2002) 
13. Chen D: Identification of Gene Variations on Chromosome 17 Associated with Multiple 
Sclerosis. 2003. (UCLA David Geffen School of Medicine and the National Public 
Health Institution) 
14. Lilja H: Searching for genes predisposing to common dyslipidemias. 2004. (Publications 
of the National Public Health Institute A16/2004) 
15. Bronnikov D: Identification of multiple sclerosis susceptibility genes in Finnish 
Population. 2005. (UCLA David Geffen School of Medicine and the National Public 
Health Institution) 
16. Ekholm J: Molecular genetics of bipolar disorder and related traits. 2005. (Publications of 
the National Public Health Institution A26/2005) 
17. Enattah N: Molecular Genetics of Lactase Persistence. 2005. (Publications of the National 
Public Health Institute A4/2005) 
18. Hennah W: Genetics of schizophrenia: the 1q42 locus in Finnish Families. 2005. 
(Publications of the National Public Health Institution A22/2005) 
19. Suviolahti E: Search for genetic variants conferring the susceptibility to obesity and 
related metabolic traits. 2005. (Publications of the National Public Health Institution 
A25/2005) 
20. Ylisaukko-oja T: Search for susceptibility genes in autism spectrum disorders. 2005. 
(Publications of the National Public Health Institution A21/2005) 
 
 
Publications 1997-2007 
 
International peer review articles 
1. Aro, A.R., Hakonen, A., Hietala, M., Lonnqvist, J., Niemela, P., Peltonen, L. and Aula, P. 
(1997) Acceptance of genetic testing in a general population: age, education and gender 
differences. Patient Educ Couns, 32, 41-9. 1.356 
2. Collod-Beroud, G., Beroud, C., Ades, L., Black, C., Boxer, M., Brock, D.J., Godfrey, M., 
Hayward, C., Karttunen, L., Milewicz, D. et al. (1997) Marfan Database (second edition): 
Background material                                                                                   APPENDIX 2 
 128
software and database for the analysis of mutations in the human FBN1 gene. Nucleic 
Acids Res, 25, 147-50. 7.552 
3. Hovatta, I., Terwilliger, J.D., Lichtermann, D., Makikyro, T., Suvisaari, J., Peltonen, L. 
and Lonnqvist, J. (1997) Schizophrenia in the genetic isolate of Finland. Am J Med Genet, 
74, 353-60. 1.913 
4. Kuokkanen, S., Gschwend, M., Rioux, J.D., Daly, M.J., Terwilliger, J.D., Tienari, P.J., 
Wikstrom, J., Palo, J., Stein, L.D., Hudson, T.J. et al. (1997) Genomewide scan of 
multiple sclerosis in Finnish multiplex families. Am J Hum Genet, 61, 1379-87. 12.649 
5. Mikkola, H., Muszbek, L., Laiho, E., Syrjala, M., Hamalainen, E., Haramura, G., Salmi, 
T., Peltonen, L. and Palotie, A. (1997) Molecular mechanism of a mild phenotype in 
coagulation factor XIII (FXIII) deficiency: a splicing mutation permitting partial correct 
splicing of FXIII A-subunit mRNA. Blood, 89, 1279-87.10.131 
6. Mustajoki, S., Kauppinen, R., Mustajoki, P., Suomalainen, A. and Peltonen, L. (1997) 
Steady-state transcript levels of the porphobilinogen deaminase gene in patients with 
acute intermittent porphyria. Genome Res, 7, 1054-60. 10.139 
7. Oksanen, L., Ohman, M., Heiman, M., Kainulainen, K., Kaprio, J., Mustajoki, P., 
Koivisto, V., Koskenvuo, M., Janne, O.A., Peltonen, L. et al. (1997) Markers for the gene 
ob and serum leptin levels in human morbid obesity. Hum Genet, 99, 559-64. 4.331 
8. Pajukanta, P., Porkka, K.V., Antikainen, M., Taskinen, M.R., Perola, M., Murtomaki-
Repo, S., Ehnholm, S., Nuotio, I., Suurinkeroinen, L., Lahdenkari, A.T. et al. (1997) No 
evidence of linkage between familial combined hyperlipidemia and genes encoding 
lipolytic enzymes in Finnish families. Arterioscler Thromb Vasc Biol, 17, 841-50. 7.053 
9. Pastinen, T., Kurg, A., Metspalu, A., Peltonen, L. and Syvanen, A.C. (1997) 
Minisequencing: a specific tool for DNA analysis and diagnostics on oligonucleotide 
arrays. Genome Res, 7, 606-14. 10.139 
10. Porkka, K.V., Nuotio, I., Pajukanta, P., Ehnholm, C., Suurinkeroinen, L., Syvanne, M., 
Lehtimaki, T., Lahdenkari, A.T., Lahdenpera, S., Ylitalo, K. et al. (1997) Phenotype 
expression in familial combined hyperlipidemia. Atherosclerosis, 133, 245-53. 3.777 
11. Savolainen, V.T., Pajarinen, J., Perola, M., Penttila, A. and Karhunen, P.J. (1997) 
Polymorphism in the cytochrome P450 2E1 gene and the risk of alcoholic liver disease. J 
Hepatol, 26, 55-61. 4.931 
12. Sitbon, G., Hurtig, M., Palotie, A., Lonngren, J. and Syvanen, A.C. (1997) A colorimetric 
minisequencing assay for the mutation in codon 506 of the coagulation factor V gene. 
Thromb Haemost, 77, 701-703. 3.056 
13. Suomalainen, A., Majander, A., Wallin, M., Setala, K., Kontula, K., Leinonen, H., Salmi, 
T., Paetau, A., Haltia, M., Valanne, L. et al. (1997) Autosomal dominant progressive 
external ophthalmoplegia with multiple deletions of mtDNA: clinical, biochemical, and 
molecular genetic features of the 10q-linked disease. Neurology, 48, 1244-53. 5.065 
14. Wansen, K., Pastinen, T., Kuokkanen, S., Wikstrom, J., Palo, J., Peltonen, L. and Tienari, 
P.J. (1997) Immune system genes in multiple sclerosis: genetic association and linkage 
analyses on TCR beta, IGH, IFN-gamma and IL-1ra/IL-1 beta loci. J Neuroimmunol, 79, 
29-36. 2.824 
15. Ylitalo, K., Porkka, K.V., Meri, S., Nuotio, I., Suurinkeroinen, L., Vakkilainen, J., 
Pajukanta, P., Viikari, J.S., Peltonen, L., Ehnholm, C. et al. (1997) Serum complement 
and familial combined hyperlipidemia. Atherosclerosis, 129, 271-7. 3.777 
16. Clark, A.G., Weiss, K.M., Nickerson, D.A., Taylor, S.L., Buchanan, A., Stengard, J., 
Salomaa, V., Vartiainen, E., Perola, M., Boerwinkle, E. et al. (1998) Haplotype structure 
and population genetic inferences from nucleotide-sequence variation in human 
lipoprotein lipase. Am J Hum Genet, 63, 595-612. 12.649 
17. Collod-Beroud, G., Beroud, C., Ades, L., Black, C., Boxer, M., Brock, D.J., Holman, K.J., 
de Paepe, A., Francke, U., Grau, U. et al. (1998) Marfan Database (third edition): new 
mutations and new routines for the software. Nucleic Acids Res, 26, 229-3. 7.552 
18. Hovatta, I., Lichtermann, D., Juvonen, H., Suvisaari, J., Terwilliger, J.D., Arajarvi, R., 
Kokko-Sahin, M.L., Ekelund, J., Lonnqvist, J. and Peltonen, L. (1998) Linkage analysis 
of putative schizophrenia gene candidate regions on chromosomes 3p, 5q, 6p, 8p, 20p and 
22q in a population-based sampled Finnish family set. Mol Psychiatry, 3, 452-7. 9.335 
19. Jallinoja, P., Hakonen, A., Aro, A.R., Niemela, P., Hietala, M., Lonnqvist, J., Peltonen, L. 
and Aula, P. (1998) Attitudes towards genetic testing: analysis of contradictions. Soc Sci 
Med, 46, 1367-74.- 
20. Karttunen, L., Ukkonen, T., Kainulainen, K., Syvanen, A.C. and Peltonen, L. (1998) Two 
novel fibrillin-1 mutations resulting in premature termination codons but in different 
mutant transcript levels and clinical phenotypes. Hum Mutat, Suppl 1, S34-7. 7.923 
Background material                                                                                   APPENDIX 2 
 129
21. Kittles, R.A., Perola, M., Peltonen, L., Bergen, A.W., Aragon, R.A., Virkkunen, M., 
Linnoila, M., Goldman, D. and Long, J.C. (1998) Dual origins of Finns revealed by Y 
chromosome haplotype variation. Am J Hum Genet, 62, 1171-9. 12.649 
22. Libert, F., Cochaux, P., Beckman, G., Samson, M., Aksenova, M., Cao, A., Czeizel, A., 
Claustres, M., de la Rua, C., Ferrari, M. et al. (1998) The deltaccr5 mutation conferring 
protection against HIV-1 in Caucasian populations has a single and recent origin in 
Northeastern Europe. Hum Mol Genet, 7, 399-406. 7.764 
23. Lichtermann, D., Hovatta, I., Terwilliger, J.D., Peltonen, L. and Lonnqvist, J. (1998) 
Concordance for sex and the pseudoautosomal gene hypothesis revisited: no evidence of 
increased sex concordance in a nationwide Finnish sample of siblings with paternally 
derived schizophrenia. Am J Psychiatry, 155, 1365-75. 8.286 
24. Lonnqvist, L., Reinhardt, D., Sakai, L. and Peltonen, L. (1998) Evidence for furin-type 
activity-mediated C-terminal processing of profibrillin-1 and interference in the 
processing by certain mutations. Hum Mol Genet, 7, 2039-44. 7.764 
25. Pajukanta, P., Nuotio, I., Terwilliger, J.D., Porkka, K.V.K., Ylitalo, K., Pihlajamaki, J., 
Suomalainen, A.J., Syvanen, A.C., Lehtimaki, T., Viikari, J.S.A. et al. (1998) Linkage of 
familial combined hyperlipidaemia to chromosome 1q21-q23. Nat Genet, 18, 369-373. 
25.797 
26. Pastinen, T., Liitsola, K., Niini, P., Salminen, M. and Syvanen, A.C. (1998) Contribution 
of the CCR5 and MBL genes to susceptibility to HIV type 1 infection in the Finnish 
population. AIDS Res Hum Retroviruses, 14, 695-698. 2.531 
27. Pastinen, T., Perola, M., Niini, P., Terwilliger, J., Salomaa, V., Vartiainen, E., Peltonen, L. 
and Syvanen, A. (1998) Array-based multiplex analysis of candidate genes reveals two 
independent and additive genetic risk factors for myocardial infarction in the Finnish 
population. Hum Mol Genet, 7, 1453-62. 7.764 
28. Tahvanainen, E., Pajukanta, P., Porkka, K., Nieminen, S., Ikavalko, L., Nuotio, I., 
Taskinen, M.R., Peltonen, L. and Ehnholm, C. (1998) Haplotypes of the ApoA-I/C-III/A-
IV gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol, 18, 
1810-7. 7.053 
29. Tienari, P.J., Kuokkanen, S., Pastinen, T., Wikstrom, J., Sajantila, A., Sandberg-
Wollheim, M., Palo, J. and Peltonen, L. (1998) Golli-MBP gene in multiple sclerosis 
susceptibility. J Neuroimmunol, 81, 158-67. 2.824 
30. Vakkilainen, J., Porkka, K.V., Nuotio, I., Pajukanta, P., Suurinkeroinen, L., Ylitalo, K., 
Viikari, J.S., Ehnholm, C. and Taskinen, M.R. (1998) Glucose intolerance in familial 
combined hyperlipidaemia. EUFAM study group. Eur J Clin Invest, 28, 24-32. 2.684 
31. Valanne, L., Ketonen, L., Majander, A., Suomalainen, A. and Pihko, H. (1998) 
Neuroradiologic findings in children with mitochondrial disorders. Am J Neuroradiol, 19, 
369-377. 2.525 
32. Videman, T., Leppavuori, J., Kaprio, J., Battie, M.C., Gibbons, L.E., Peltonen, L. and 
Koskenvuo, M. (1998) Intragenic polymorphisms of the vitamin D receptor gene 
associated with intervertebral disc degeneration. Spine, 23, 2477-85. 2.187 
33. Williams, J., Spurlock, G., Holmans, P., Mant, R., Murphy, K., Jones, L., Cardno, A., 
Asherson, P., Blackwood, D., Muir, W. et al. (1998) A meta-analysis and transmission 
disequilibrium study of association between the dopamine D3 receptor gene and 
schizophrenia. Mol Psychiatry, 3, 141-149. 9.335 
34. Ekelund, J., Lichtermann, D., Jarvelin, M.R. and Peltonen, L. (1999) Association between 
novelty seeking and the type 4 dopamine receptor gene in a large Finnish cohort sample. 
Am J Psychiatry, 156, 1453-5. 8.286 
35. Gecz, J., Barnett, S., Liu, J., Hollway, G., Donnelly, A., Eyre, H., Eshkevari, H.S., 
Baltazar, R., Grunn, A., Nagaraja, R. et al. (1999) Characterization of the human 
glutamate receptor subunit 3 gene (GRIA3), a candidate for bipolar disorder and 
nonspecific X-linked mental retardation. Genomics, 62, 356-68. 3.181 
36. Hovatta, I., Varilo, T., Suvisaari, J., Terwilliger, J.D., Ollikainen, V., Arajarvi, R., 
Juvonen, H., Kokko-Sahin, M.L., Vaisanen, L., Mannila, H. et al. (1999) A genomewide 
screen for schizophrenia genes in an isolated Finnish subpopulation, suggesting multiple 
susceptibility loci. Am J Hum Genet, 65, 1114-24. 12.649 
37. Ilveskoski, E., Perola, M., Lehtimaki, T., Laippala, P., Savolainen, V., Pajarinen, J., 
Penttila, A., Lalu, K.H., Mannikko, A., Liesto, K.K. et al. (1999) Age-dependent 
association of apolipoprotein E genotype with coronary and aortic atherosclerosis in 
middle-aged men: an autopsy study. Circulation, 100, 608-13. 11.632 
Background material                                                                                   APPENDIX 2 
 130
38. Kainulainen, K., Perola, M., Terwilliger, J., Kaprio, J., Koskenvuo, M., Syvanen, A.C., 
Vartiainen, E., Peltonen, L. and Kontula, K. (1999) Evidence for involvement of the type 
1 angiotensin II receptor locus in essential hypertension. Hypertension, 33, 844-9. 6.331 
39. Kajander, O.A., Kunnas, T.A., Perola, M., Lehtinen, S.K., Karhunen, P.J. and Jacobs, 
H.T. (1999) Long-extension PCR to detect deleted mitochondrial DNA molecules is 
compromized by technical artefacts. Biochem Biophys Res Commun, 254, 507-14. 3.000 
40. Kaukonen, J., Zeviani, M., Comi, G.P., Piscaglia, M.G., Peltonen, L. and Suomalainen, A. 
(1999) A third locus predisposing to multiple deletions of mtDNA in autosomal dominant 
progressive external ophthalmoplegia. Am J Hum Genet, 65, 256-61. 12.649 
41. Mikkelsson, J., Perola, M., Kauppila, L.I., Laippala, P., Savolainen, V., Pajarinen, J., 
Penttila, A. and Karhunen, P.J. (1999) The GPIIIa Pl(A) polymorphism in the progression 
of abdominal aortic atherosclerosis. Atherosclerosis, 147, 55-60. 3.777 
42. Mikkelsson, J., Perola, M., Laippala, P., Savolainen, V., Pajarinen, J., Lalu, K., Penttila, 
A. and Karhunen, P.J. (1999) Glycoprotein IIIa Pl(A) polymorphism associates with 
progression of coronary artery disease and with myocardial infarction in an autopsy series 
of middle-aged men who died suddenly. Arterioscler Thromb Vasc Biol, 19, 2573-8. 
7.053 
43. Ohman, M., Oksanen, L., Kainulainen, K., Janne, O.A., Kaprio, J., Koskenvuo, M., 
Mustajoki, P., Kontula, K. and Peltonen, L. (1999) Testing of human homologues of 
murine obesity genes as candidate regions in Finnish obese sib pairs. Eur J Hum Genet, 7, 
117-24. 3.251 
44. Pajukanta, P., Terwilliger, J.D., Perola, M., Hiekkalinna, T., Nuotio, I., Ellonen, P., 
Parkkonen, M., Hartiala, J., Ylitalo, K., Pihlajamaki, J. et al. (1999) Genomewide scan 
for familial combined hyperlipidemia genes in finnish families, suggesting multiple 
susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels. Am J 
Hum Genet, 64, 1453-63. 12.649 
45. Rantamaki, T., Kaitila, I., Syvanen, A.C., Lukka, M. and Peltonen, L. (1999) Recurrence 
of Marfan syndrome as a result of parental germ-line mosaicism for an FBN1 mutation. 
Am J Hum Genet, 64, 993-1001. 12.649 
46. Rovio, A., Tiranti, V., Bednarz, A.L., Suomalainen, A., Spelbrink, J.N., Lecrenier, N., 
Melberg, A., Zeviani, M., Poulton, J., Foury, F. et al. (1999) Analysis of the trinucleotide 
CAG repeat from the human mitochondrial DNA polymerase gene in healthy and 
diseased individuals. Eur J Hum Genet, 7, 140-146. 3.251 
47. Souery, D., Lipp, O., Rivelli, S.K., Massat, I., Serretti, A., Cavallini, C., Ackenheil, M., 
Adolfsson, R., Aschauer, H., Blackwood, D. et al. (1999) Tyrosine hydroxylase 
polymorphism and phenotypic heterogeneity in bipolar affective disorder: A multicenter 
association study. Am J Med Genet, 88, 527-532. 1.913 
48. Wartiovaara, U., Perola, M., Mikkola, H., Totterman, K., Savolainen, V., Penttila, A., 
Grant, P.J., Tikkanen, M.J., Vartiainen, E., Karhunen, P.J. et al. (1999) Association of 
FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. 
Atherosclerosis, 142, 295-300. 3.777 
49. Weidenbach, M., Brenner, R., Rantamaki, T. and Redel, D.A. (1999) Acute mitral 
regurgitation due to chordal rupture in a patient with neonatal Marfan syndrome caused 
by a deletion in exon 29 of the FBN1 gene. Pediatr Cardiol, 20, 382-385. 0.986 
50. Auranen, M., Nieminen, T., Majuri, S., Vanhala, R., Peltonen, L. and Jarvela, I. (2000) 
Analysis of autism susceptibility gene loci on chromosomes 1p, 4p, 6q, 7q, 13q, 15q, 16p, 
17q, 19q and 22q in Finnish multiplex families. Mol Psychiatry, 5, 320-2. 9.335 
51. Auranen, M., Villanova, M., Muntoni, F., Fardeau, M., Scherer, S.W., Kalino, H. and 
Minassian, B.A. (2000) X-linked vacuolar myopathies: Two separate loci and refined 
genetic mapping. Ann Neurol, 47, 666-669. 7.571 
52. Ekelund, J., Lichtermann, D., Hovatta, I., Ellonen, P., Suvisaari, J., Terwilliger, J.D., 
Juvonen, H., Varilo, T., Arajarvi, R., Kokko-Sahin, M.L. et al. (2000) Genome-wide scan 
for schizophrenia in the Finnish population: evidence for a locus on chromosome 7q22. 
Hum Mol Genet, 9, 1049-57. 7.764 
53. Fullerton, S.M., Clark, A.G., Weiss, K.M., Nickerson, D.A., Taylor, S.L., Stengard, J.H., 
Salomaa, V., Vartiainen, E., Perola, M., Boerwinkle, E. et al. (2000) Apolipoprotein E 
variation at the sequence haplotype level: implications for the origin and maintenance of a 
major human polymorphism. Am J Hum Genet, 67, 881-900. 12.649 
54. Kaukonen, J., Juselius, J.K., Tiranti, V., Kyttala, A., Zeviani, M., Comi, G.P., Keranen, S., 
Peltonen, L. and Suomalainen, A. (2000) Role of adenine nucleotide translocator 1 in 
mtDNA maintenance. Science, 289, 782-5. 30.927 
Background material                                                                                   APPENDIX 2 
 131
55. Lindqvist, A.K., Lahdetie, J., Tienari, P.J., Wikstrom, J., Palo, J., Allen, M., Peltonen, L. 
and Gyllensten, U. (2000) Mapping of the HLA class II susceptibility haplotype for 
multiple sclerosis in Finland. Hereditas, 132, 89-94. 0.596 
56. Luoto, R., Kaprio, J., Rutanen, E.M., Taipale, P., Perola, M. and Koskenvuo, M. (2000) 
Heritability and risk factors of uterine fibroids--the Finnish Twin Cohort study. Maturitas, 
37, 15-26. 2.004 
57. Massat, I., Souery, D., Lipp, O., Blairy, S., Papadimitriou, G., Dikeos, D., Ackenheil, M., 
Fuchshuber, S., Hilger, C., Kaneva, R. et al. (2000) A European multicenter association 
study of HTR2A receptor polymorphism in bipolar affective disorder. Am J Med Genet, 
96, 136-140. 1.913 
58. Mikkelsson, J., Perola, M., Laippala, P., Penttila, A. and Karhunen, P.J. (2000) 
Glycoprotein IIIa Pl(A1/A2) polymorphism and sudden cardiac death. J Am Coll Cardiol, 
36, 1317-23. 9.200 
59. Mikkelsson, J., Perola, M., Wartiovaara, U., Peltonen, L., Palotie, A., Penttila, A. and 
Karhunen, P.J. (2000) Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, 
coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died 
suddenly. Thromb Haemost, 84, 78-82. 3.056 
60. Mustajoki, S., Laine, M., Lahtela, M., Mustajoki, P., Peltonen, L. and Kauppinen, R. 
(2000) Acute intermittent porphyria: expression of mutant and wild-type porphobilinogen 
deaminase in COS-1 cells. Mol Med, 6, 670-9. 3.349 
61. Ohman, M., Oksanen, L., Kaprio, J., Koskenvuo, M., Mustajoki, P., Rissanen, A., Salmi, 
J., Kontula, K. and Peltonen, L. (2000) Genome-wide scan of obesity in Finnish sibpairs 
reveals linkage to chromosome Xq24. J Clin Endocrinol Metab, 85, 3183-90. 6.020 
62. Pajukanta, P., Cargill, M., Viitanen, L., Nuotio, I., Kareinen, A., Perola, M., Terwilliger, 
J.D., Kempas, E., Daly, M., Lilja, H. et al. (2000) Two loci on chromosomes 2 and X for 
premature coronary heart disease identified in early- and late-settlement populations of 
Finland. Am J Hum Genet, 67, 1481-93. 12.649 
63. Pastinen, T., Raitio, M., Lindroos, K., Tainola, P., Peltonen, L. and Syvanen, A.C. (2000) 
A system for specific, high-throughput genotyping by allele-specific primer extension on 
microarrays. Genome Res, 10, 1031-42. 10.139 
64. Perola, M., Kainulainen, K., Pajukanta, P., Terwilliger, J.D., Hiekkalinna, T., Ellonen, P., 
Kaprio, J., Koskenvuo, M., Kontula, K. and Peltonen, L. (2000) Genome-wide scan of 
predisposing loci for increased diastolic blood pressure in Finnish siblings. J Hypertens, 
18, 1579-85. 5.218 
65. Varilo, T., Laan, M., Hovatta, I., Wiebe, V., Terwilliger, J.D. and Peltonen, L. (2000) 
Linkage disequilibrium in isolated populations: Finland and a young sub-population of 
Kuusamo. Eur J Hum Genet, 8, 604-12.3.251 
66. Virolainen, E., Wessman, M., Hovatta, I., Niemi, K.M., Ignatius, J., Kere, J., Peltonen, L. 
and Palotie, A. (2000) Assignment of a novel locus for autosomal recessive congenital 
ichthyosis to chromosome 19p13.1-p13.2. Am J Hum Genet, 66, 1132-7. 12.649 
67. Ylitalo, K., Large, V., Pajukanta, P., Reynisdottir, S., Porkka, K.V.K., Vakkilainen, J., 
Nuotio, I., Taskinen, M.R. and Arner, P. (2000) Reduced hormone-sensitive lipase 
activity is not a major metabolic defect in Finnish FCHL families. Atherosclerosis, 153, 
373-381. 3.777 
68. Auranen, M., Ala-Mello, S., Turunen, J.A. and Jarvela, I. (2001) Further evidence for 
linkage of autosomal-dominant medullary cystic kidney disease on chromosome 1q21. 
Kidney Int, 60, 1225-1232. 4.927 
69. Auranen, M., Vanhala, R., Vosman, M., Levander, M., Varilo, T., Hietala, M., Riikonen, 
R., Peltonen, L. and Jarvela, I. (2001) MECP2 gene analysis in classical Rett syndrome 
and in patients with Rett-like features. Neurology, 56, 611-7. 5.065 
70. Ekelund, J., Hovatta, I., Parker, A., Paunio, T., Varilo, T., Martin, R., Suhonen, J., 
Ellonen, P., Chan, G., Sinsheimer, J.S. et al. (2001) Chromosome 1 loci in Finnish 
schizophrenia families. Hum Mol Genet, 10, 1611-7. 7.764 
71. Ekelund, J., Suhonen, J., Jarvelin, M.R., Peltonen, L. and Lichtermann, D. (2001) No 
association of the -521 C/T polymorphism in the promoter of DRD4 with novelty seeking. 
Mol Psychiatry, 6, 618-9. 9.335 
72. Feng, J., Yan, J., Michaud, S., Craddock, N., Jones, I.R., Cook, E.H., Jr., Goldman, D., 
Heston, L.L., Peltonen, L., Delisi, L.E. et al. (2001) Scanning of estrogen receptor alpha 
(ERalpha) and thyroid hormone receptor alpha (TRalpha) genes in patients with 
psychiatric diseases: four missense mutations identified in ERalpha gene. Am J Med 
Genet, 105, 369-74. 1.913 
Background material                                                                                   APPENDIX 2 
 132
73. Gong, Y., Slee, R.B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A.M., Wang, 
H., Cundy, T., Glorieux, F.H., Lev, D. et al. (2001) LDL receptor-related protein 5 (LRP5) 
affects bone accrual and eye development. Cell, 107, 513-23. 29.431 
74. Haukka, J., Suvisaari, J., Varilo, T. and Lonnqvist, J. (2001) Regional variation in the 
incidence of schizophrenia in Finland: a study of birth cohorts born from 1950 to 1969. 
Psychol Med, 31, 1045-53.3.476 
75. Jarvelainen, H.A., Orpana, A., Perola, M., Savolainen, V.T., Karhunen, P.J. and Lindros, 
K.O. (2001) Promoter polymorphism of the CD14 endotoxin receptor gene as a risk 
factor for alcoholic liver disease. Hepatology, 33, 1148-53. 9.792 
76. Johansson, C., Smedh, C., Partonen, T., Pekkarinen, P., Paunio, T., Ekholm, J., Peltonen, 
L., Lichtermann, D., Palmgren, J., Adolfsson, R. et al. (2001) Seasonal affective disorder 
and serotonin-related polymorphisms. Neurobiol Dis, 8, 351-7. 4.048 
77. Kajander, O.A., Kupari, M., Perola, M., Pajarinen, J., Savolainen, V., Penttila, A. and 
Karhunen, P.J. (2001) Testing genetic susceptibility loci for alcoholic heart muscle 
disease. Alcohol Clin Exp Res, 25, 1409-13. 2.636 
78. Keso, T., Perola, M., Laippala, P., Ilveskoski, E., Kunnas, T.A., Mikkelsson, J., Penttila, 
A., Hurme, M. and Karhunen, P.J. (2001) Polymorphisms within the tumor necrosis 
factor locus and prevalence of coronary artery disease in middle-aged men. 
Atherosclerosis, 154, 691-7. 3.777 
79. Lichtermann, D., Ekelund, J., Pukkala, E., Tanskanen, A. and Lonnqvist, J. (2001) 
Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen 
Psychiatry, 58, 573-578. 12.642 
80. Lofberg, M., Lindholm, H., Naveri, H., Majander, A., Suomalainen, A., Paetau, A., 
Sovijarvi, A., Harkonen, M. and Somer, H. (2001) ATP, phosphocreatine and lactate in 
exercising muscle in mitochondrial disease and McArdle's disease. Neuromuscul Disord, 
11, 370-375. 3.340 
81. Mikkelsson, J., Perola, M., Penttila, A., Goldschmidt-Clermont, P.J. and Karhunen, P.J. 
(2001) The GPIIIa (beta3 integrin) PlA polymorphism in the early development of 
coronary atherosclerosis. Atherosclerosis, 154, 721-7. 3.777 
82. Mikkelsson, J., Perola, M., Penttila, A. and Karhunen, P.J. (2001) Platelet glycoprotein 
Ibalpha HPA-2 Met/VNTR B haplotype as a genetic predictor of myocardial infarction 
and sudden cardiac death. Circulation, 104, 876-80. 11.632 
83. Pajukanta, P., Bodnar, J.S., Sallinen, R., Chu, M., Airaksinen, T., Xiao, Q., Castellani, 
L.W., Sheth, S.S., Wessman, M., Palotie, A. et al. (2001) Fine mapping of Hyplip1 and 
the human homolog, a potential locus for FCHL. Mamm Genome, 12, 238-45. 2.747 
84. Pastinen, T., Perola, M., Ignatius, J., Sabatti, C., Tainola, P., Levander, M., Syvanen, A.C. 
and Peltonen, L. (2001) Dissecting a population genome for targeted screening of disease 
mutations. Hum Mol Genet, 10, 2961-72. 7.764 
85. Paunio, T., Ekelund, J., Varilo, T., Parker, A., Hovatta, I., Turunen, J.A., Rinard, K., Foti, 
A., Terwilliger, J.D., Juvonen, H. et al. (2001) Genome-wide scan in a nationwide study 
sample of schizophrenia families in Finland reveals susceptibility loci on chromosomes 
2q and 5q. Hum Mol Genet, 10, 3037-48. 7.764 
86. Perola, M., Ohman, M., Hiekkalinna, T., Leppavuori, J., Pajukanta, P., Wessman, M., 
Koskenvuo, M., Palotie, A., Lange, K., Kaprio, J. et al. (2001) Quantitative-trait-locus 
analysis of body-mass index and of stature, by combined analysis of genome scans of five 
Finnish study groups. Am J Hum Genet, 69, 117-23. 12.649 
87. Pirinen, S., Kentala, A., Nieminen, P., Varilo, T., Thesleff, I. and Arte, S. (2001) 
Recessively inherited lower incisor hypodontia. J Med Genet, 38, 551-6. 4.330 
88. Pollanen, P.J., Karhunen, P.J., Mikkelsson, J., Laippala, P., Perola, M., Penttila, A., 
Mattila, K.M., Koivula, T. and Lehtimaki, T. (2001) Coronary artery complicated lesion 
area is related to functional polymorphism of matrix metalloproteinase 9 gene: an autopsy 
study. Arterioscler Thromb Vasc Biol, 21, 1446-50. 7.053 
89. Rahman, S., Poulton, J., Marchington, D. and Suomalainen, A. (2001) Decrease of 3243 
A -> G mtDNA mutation from blood in MELAS syndrome: A longitudinal study. Am J 
Hum Genet, 68, 238-240. 12.649 
90. Raitio, M., Lindroos, K., Laukkanen, M., Pastinen, T., Sistonen, P., Sajantila, A. and 
Syvanen, A.C. (2001) Y-chromosomal SNPs in Finno-Ugric-speaking populations 
analyzed by minisequencing on microarrays. Genome Res, 11, 471-482. 10.139 
91. Spelbrink, J.N., Li, F.Y., Tiranti, V., Nikali, K., Yuan, Q.P., Tariq, M., Wanrooij, S., 
Garrido, N., Comi, G., Morandi, L. et al. (2001) Human mitochondrial DNA deletions 
associated with mutations in the gene encoding Twinkle, a phage T7 gene LF-like protein 
localized in mitochondria. Nat Genet, 28, 223-231. 25.797 
Background material                                                                                   APPENDIX 2 
 133
92. Stengard, J.H., Salomaa, V., Rasi, V., Vahtera, E., Ehnholm, C., Krusius, T., Perola, M. 
and Vartiainen, E. (2001) Utility of the Arg/Gln polymorphism of the factor VII (FVII) 
gene, serum lipid levels and body mass index in the prediction of the FVII:C and FVII:Ag 
in North Karelia; a cross-sectional and prospective study. Blood Coagul Fibrinolysis, 12, 
445-52. 1.657 
93. Allayee, H., Krass, K.L., Pajukanta, P., Cantor, R.M., van der Kallen, C.J., Mar, R., 
Rotter, J.I., de Bruin, T.W., Peltonen, L. and Lusis, A.J. (2002) Locus for elevated 
apolipoprotein B levels on chromosome 1p31 in families with familial combined 
hyperlipidemia. Circ Res, 90, 926-31. 9.408 
94. Auranen, M., Vanhala, R., Varilo, T., Ayers, K., Kempas, E., Ylisaukko-Oja, T., 
Sinsheimer, J.S., Peltonen, L. and Jarvela, I. (2002) A genomewide screen for autism-
spectrum disorders: evidence for a major susceptibility locus on chromosome 3q25-27. 
Am J Hum Genet, 71, 777-90. 12.649 
95. Berloff, N., Perola, M. and Lange, K. (2002) Spline methods for the comparison of 
physical and genetic maps. J Comput Biol, 9, 465-75. 2.446 
96. Ekholm, J.M., Pekkarinen, P., Pajukanta, P., Kieseppa, T., Partonen, T., Paunio, T., 
Varilo, T., Perola, M., Lonnqvist, J. and Peltonen, L. (2002) Bipolar disorder 
susceptibility region on Xq24-q27.1 in Finnish families. Mol Psychiatry, 7, 453-9. 9.335 
97. Enattah, N.S., Sahi, T., Savilahti, E., Terwilliger, J.D., Peltonen, L. and Jarvela, I. (2002) 
Identification of a variant associated with adult-type hypolactasia. Nat Genet, 30, 233-7. 
25.797 
98. Fuentes, R.M., Perola, M., Nissinen, A. and Tuomilehto, J. (2002) ACE gene and 
physical activity, blood pressure, and hypertension: a population study in Finland. J Appl 
Physiol, 92, 2508-12. 3.037 
99. Hu, G., Modrek, B., Riise Stensland, H.M., Saarela, J., Pajukanta, P., Kustanovich, V., 
Peltonen, L., Nelson, S.F. and Lee, C. (2002) Efficient discovery of single-nucleotide 
polymorphisms in coding regions of human genes. Pharmacogenomics J, 2, 236-42. 
3.957 
100. Keltikangas-Jarvinen, L., Elovainio, M., Kivimaki, M., Ekelund, J. and Peltonen, L. 
(2002) Novelty seeking as a mediator in relationships between type 4 dopamine receptor 
gene polymorphism and predisposition to higher education. Learning and Individual 
Differences, 14, 23-30. - 
101. Korkko, J., Kaitila, I., Lonnqvist, L., Peltonen, L. and Ala-Kokko, L. (2002) Sensitivity 
of conformation sensitive gel electrophoresis in detecting mutations in Marfan syndrome 
and related conditions. J Med Genet, 39, 34-41. 4.330 
102. Kunnas, T.A., Ilveskoski, E., Niskakangas, T., Laippala, P., Kajander, O.A., Mikkelsson, 
J., Goebeler, S., Penttila, A., Perola, M., Nikkari, S.T. et al. (2002) Association of the 
endothelial nitric oxide synthase gene polymorphism with risk of coronary artery disease 
and myocardial infarction in middle-aged men. J Mol Med, 80, 605-9. 2.090 
103. Lehtimaki, T., Kunnas, T.A., Mattila, K.M., Perola, M., Penttila, A., Koivula, T. and 
Karhunen, P.J. (2002) Coronary artery wall atherosclerosis in relation to the estrogen 
receptor 1 gene polymorphism: an autopsy study. J Mol Med, 80, 176-80. 2.090 
104. Lilja, H.E., Soro, A., Ylitalo, K., Nuotio, I., Viikari, J.S., Salomaa, V., Vartiainen, E., 
Taskinen, M.R., Peltonen, L. and Pajukanta, P. (2002) A candidate gene study in low 
HDL-cholesterol families provides evidence for the involvement of the APOA2 gene and 
the APOA1C3A4 gene cluster. Atherosclerosis, 164, 103-11. 3.777 
105. Massat, I., Souery, D., Del-Favero, J., Van Gestel, S., Serretti, A., Macciardi, F., Smeraldi, 
E., Kaneva, R., Adolfsson, R., Nylander, P.O. et al. (2002) Positive association of 
dopamine D2 receptor polymorphism with bipolar affective disorder in a European 
Multicenter Association Study of affective disorders. Am J Med Genet, 114, 177-85. 
1.913 
106. Mikkelsson, J., Perola, M., Penttila, A. and Karhunen, P.J. (2002) Platelet collagen 
receptor GPIa (C807T/HPA-5) haplotype is not associated with an increased risk of fatal 
coronary events in middle-aged men. Atherosclerosis, 165, 111-8. 3.777 
107. Minassian, B.A., Aiyar, R., Alic, S., Banwell, B., Villanova, M., Fardeau, M., Mandell, 
J.W., Juel, V.C., Rafii, M., Auranen, M. et al. (2002) Narrowing in on the causative 
defect of an intriguing X-linked myopathy with excessive autophagy. Neurology, 59, 596-
601. 5.065 
108. Mohlke, K.L., Erdos, M.R., Scott, L.J., Fingerlin, T.E., Jackson, A.U., Silander, K., 
Hollstein, P., Boehnke, M. and Collins, F.S. (2002) High-throughput screening for 
evidence of association by using mass spectrometry genotyping on DNA pools. Proc Natl 
Acad Sci U S A, 99, 16928-33. 10.231 
Background material                                                                                   APPENDIX 2 
 134
109. Palmer, C.G., Turunen, J.A., Sinsheimer, J.S., Minassian, S., Paunio, T., Lonnqvist, J., 
Peltonen, L. and Woodward, J.A. (2002) RHD maternal-fetal genotype incompatibility 
increases schizophrenia susceptibility. Am J Hum Genet, 71, 1312-9. 12.649 
110. Pollanen, P.J., Lehtimaki, T., Ilveskoski, E., Mikkelsson, J., Kajander, O.A., Laippala, P., 
Perola, M., Goebeler, S., Penttila, A., Mattila, K.M. et al. (2002) Coronary artery 
calcification is related to functional polymorphism of matrix metalloproteinase 3: the 
Helsinki Sudden Death Study. Atherosclerosis, 164, 329-35. 3.777 
111. Reunanen, K., Finnila, S., Laaksonen, M., Sumelahti, M.L., Wikstrom, J., Pastinen, T., 
Kuokkanen, S., Saarela, J., Uimari, P., Ruutiainen, J. et al. (2002) Chromosome 19q13 
and multiple sclerosis susceptibility in Finland: a linkage and two-stage association study. 
J Neuroimmunol, 126, 134-42. 2.824 
112. Saarela, J., Schoenberg Fejzo, M., Chen, D., Finnila, S., Parkkonen, M., Kuokkanen, S., 
Sobel, E., Tienari, P.J., Sumelahti, M.L., Wikstrom, J. et al. (2002) Fine mapping of a 
multiple sclerosis locus to 2.5 Mb on chromosome 17q22-q24. Hum Mol Genet, 11, 2257-
67. 7.764 
113. Soro, A., Pajukanta, P., Lilja, H.E., Ylitalo, K., Hiekkalinna, T., Perola, M., Cantor, R.M., 
Viikari, J.S., Taskinen, M.R. and Peltonen, L. (2002) Genome scans provide evidence for 
low-HDL-C loci on chromosomes 8q23, 16q24.1-24.2, and 20q13.11 in Finnish families. 
Am J Hum Genet, 70, 1333-40. 12.649 
114. Terwilliger, J.D., Haghighi, F., Hiekkalinna, T.S. and Goring, H.H. (2002) A bias-ed 
assessment of the use of SNPs in human complex traits. Curr Opin Genet Dev, 12, 726-
734. 9.361 
115. Tuulio-Henriksson, A., Haukka, J., Partonen, T., Varilo, T., Paunio, T., Ekelund, J., 
Cannon, T.D., Meyer, J.M. and Lonnqvist, J. (2002) Heritability and number of 
quantitative trait loci of neurocognitive functions in families with schizophrenia. Am J 
Med Genet, 114, 483-90. 1.913 
116. Vakkilainen, J., Pajukanta, P., Cantor, R.M., Nuotio, I.O., Lahdenpera, S., Ylitalo, K., 
Pihlajamaki, J., Kovanen, P.T., Laakso, M., Viikari, J.S. et al. (2002) Genetic influences 
contributing to LDL particle size in familial combined hyperlipidaemia. Eur J Hum Genet, 
10, 547-52. 3.251 
117. Wessman, M., Kallela, M., Kaunisto, M.A., Marttila, P., Sobel, E., Hartiala, J., Oswell, 
G., Leal, S.M., Papp, J.C., Hamalainen, E. et al. (2002) A susceptibility locus for 
migraine with aura, on chromosome 4q24. Am J Hum Genet, 70, 652-62. 12.649 
118. Alfthan, G., Laurinen, M.S., Valsta, L.M., Pastinen, T. and Aro, A. (2003) Folate intake, 
plasma folate and homocysteine status in a random Finnish population. Eur J Clin Nutr, 
57, 81-88. 2.163 
119. Auranen, M., Varilo, T., Alen, R., Vanhala, R., Ayers, K., Kempas, E., Ylisaukko-Oja, T., 
Peltonen, L. and Jarvela, I. (2003) Evidence for allelic association on chromosome 3q25-
27 in families with autism spectrum disorders originating from a subisolate of Finland. 
Mol Psychiatry, 8, 879-84. 9.335 
120. Chen, D.C., Saarela, J., Nuotio, I., Jokiaho, A., Peltonen, L. and Palotie, A. (2003) 
Comparison of GenFlex Tag array and Pyrosequencing in SNP genotyping. J Mol Diagn, 
5, 243-9. 2.885 
121. Collod-Beroud, G., Le Bourdelles, S., Ades, L., Ala-Kokko, L., Booms, P., Boxer, M., 
Child, A., Comeglio, P., De Paepe, A., Hyland, J.C. et al. (2003) Update of the UMD-
FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat, 
22, 199-208. 7.923 
122. Ekelund, J., Wahlbeck, K. and Back, N. (2003) No association between micrometer-sized 
particles in human cerebrospinal fluid and schizophrenia. Neurosci Lett, 349, 68-70. 
1.898 
123. Ekholm, J.M., Kieseppa, T., Hiekkalinna, T., Partonen, T., Paunio, T., Perola, M., 
Ekelund, J., Lonnqvist, J., Pekkarinen-Ijas, P. and Peltonen, L. (2003) Evidence of 
susceptibility loci on 4q32 and 16p12 for bipolar disorder. Hum Mol Genet, 12, 1907-15. 
7.764 
124. Forsman, E., Lemmela, S., Varilo, T., Kristo, P., Forsius, H., Sankila, E.M. and Jarvela, I. 
(2003) The role of TIGR and OPTN in Finnish glaucoma families: a clinical and 
molecular genetic study. Mol Vis, 9, 217-222. 2.239 
125. Gasperoni, T.L., Ekelund, J., Huttunen, M., Palmer, C.G.S., Tuulio-Henriksson, A., 
Lonnqvist, J., Kaprio, J., Peltonen, L. and Cannon, T.D. (2003) Genetic linkage and 
association between chromosome 1q and working memory function in schizophrenia. Am 
J Med Genet B Neuropsychiatr Genet, 116B, 8-16. 3.521 
Background material                                                                                   APPENDIX 2 
 135
126. Harris, J.R., Willemsen, G., Aitlahti, T., Petrini, C., Evans, A., Silander, K., Cirrincione, 
L. and Kyvik, K.O. (2003) Ethical issues and GenomEUtwin. Twin Res, 6, 455-63. 1.664 
127. Hennah, W., Varilo, T., Kestila, M., Paunio, T., Arajarvi, R., Haukka, J., Parker, A., 
Martin, R., Levitzky, S., Partonen, T. et al. (2003) Haplotype transmission analysis 
provides evidence of association for DISC1 to schizophrenia and suggests sex-dependent 
effects. Hum Mol Genet, 12, 3151-9. 7.764 
128. Johansson, C., Willeit, M., Levitan, R., Partonen, T., Smedh, C., Del Favero, J., Bel 
Kacem, S., Praschak-Rieder, N., Neumeister, A., Masellis, M. et al. (2003) The serotonin 
transporter promoter repeat length polymorphism, seasonal affective disorder and 
seasonality. Psychol Med, 33, 785-92. 3.476 
129. Johansson, C., Willeit, M., Smedh, C., Ekholm, J., Paunio, T., Kieseppa, T., Lichtermann, 
D., Praschak-Rieder, N., Neumeister, A., Nilsson, L.G. et al. (2003) Circadian clock-
related polymorphisms in seasonal affective disorder and their relevance to diurnal 
preference. Neuropsychopharmacology, 28, 734-9. 5.369 
130. Kaminen, N., Hannula-Jouppi, K., Kestila, M., Lahermo, P., Muller, K., Kaaranen, M., 
Myllyluoma, B., Voutilainen, A., Lyytinen, H., Nopola-Hemmi, J. et al. (2003) A 
genome scan for developmental dyslexia confirms linkage to chromosome 2p11 and 
suggests a new locus on 7q32. J Med Genet, 40, 340-345. 4.330 
131. Keltikangas-Jarvinen, L., Elovainio, M., Kivimaki, M., Lichtermann, D., Ekelund, J. and 
Peltonen, L. (2003) Association between the type 4 dopamine receptor gene 
polymorphism and novelty seeking. Psychosom Med, 65, 471-6. 3.642 
132. Koivisto, M., Perola, M., Varilo, T., Hennah, W., Ekelund, J., Lukk, M., Peltonen, L., 
Ukkonen, E. and Mannila, H. (2003) An MDL method for finding haplotype blocks and 
for estimating the strength of haplotype block boundaries. Pac Symp Biocomput, 502-13. 
- 
133. Kunnas, T.A., Mikkelsson, J., Ilveskoski, E., Tanner, M.M., Laippala, P., Penttila, A., 
Perola, M., Nikkari, S.T. and Karhunen, P.J. (2003) A functional variant of the iNOS 
gene flanking region is associated with LAD coronary artery disease: an autopsy study. 
Eur J Clin Invest, 33, 1032-7. 2.684 
134. Kuokkanen, M., Enattah, N.S., Oksanen, A., Savilahti, E., Orpana, A. and Jarvela, I. 
(2003) Transcriptional regulation of the lactase-phlorizin hydrolase gene by 
polymorphisms associated with adult-type hypolactasia. Gut, 52, 647-652. 7.692 
135. Lewis, C.M., Levinson, D.F., Wise, L.H., DeLisi, L.E., Straub, R.E., Hovatta, I., 
Williams, N.M., Schwab, S.G., Pulver, A.E., Faraone, S.V. et al. (2003) Genome scan 
meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum 
Genet, 73, 34-48. 12.649 
136. Makela, R., Karhunen, P.J., Kunnas, T.A., Ilveskoski, E., Kajander, O.A., Mikkelsson, J., 
Perola, M., Penttila, A. and Lehtimaki, T. (2003) Myeloperoxidase gene variation as a 
determinant of atherosclerosis progression in the abdominal and thoracic aorta: an 
autopsy study. Lab Invest, 83, 919-25. 3.859 
137. Mannila, H., Koivisto, M., Perola, M., Varilo, T., Hennah, W., Ekelund, J., Lukk, M., 
Peltonen, L. and Ukkonen, E. (2003) Minimum description length block finder, a method 
to identify haplotype blocks and to compare the strength of block boundaries. Am J Hum 
Genet, 73, 86-94. 12.649 
138. Pajukanta, P., Allayee, H., Krass, K.L., Kuraishy, A., Soro, A., Lilja, H.E., Mar, R., 
Taskinen, M.R., Nuotio, I., Laakso, M. et al. (2003) Combined analysis of genome scans 
of dutch and finnish families reveals a susceptibility locus for high-density lipoprotein 
cholesterol on chromosome 16q. Am J Hum Genet, 72, 903-17. 12.649 
139. Pettersson-Fernholm, K., Forsblom, C., Hudson, B.I., Perola, M., Grant, P.J. and Groop, 
P.H. (2003) The functional -374 T/A RAGE gene polymorphism is associated with 
proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes, 52, 891-4. 
8.028 
140. Pettersson-Fernholm, K., Forsblom, C., Perola, M. and Groop, P.H. (2003) 
Polymorphisms in the nephrin gene and diabetic nephropathy in type 1 diabetic patients. 
Kidney Int, 63, 1205-10. 4.927 
141. Pihlaja, H., Rantamaki, T., Wikstrom, J., Sumelahti, M.L., Laaksonen, M., Ilonen, J., 
Ruutiainen, J., Pirttila, T., Elovaara, I., Reunanen, M. et al. (2003) Linkage 
disequilibrium between the MBP tetranucleotide repeat and multiple sclerosis is restricted 
to a geographically defined subpopulation in Finland. Genes Immun, 4, 138-46. 3.779 
142. Rontu, R., Karhunen, P.J., Ilveskoski, E., Mikkelsson, J., Kajander, O., Perola, M., 
Penttila, A., Koivisto, A.M. and Lehtimaki, T. (2003) Smoking-dependent association 
Background material                                                                                   APPENDIX 2 
 136
between paraoxonase 1 M/L55 genotype and coronary atherosclerosis in males: an 
autopsy study. Atherosclerosis, 171, 31-7. 3.777 
143. Segurado, R., Detera-Wadleigh, S.D., Levinson, D.F., Lewis, C.M., Gill, M., Nurnberger, 
J.I., Jr., Craddock, N., DePaulo, J.R., Baron, M., Gershon, E.S. et al. (2003) Genome scan 
meta-analysis of schizophrenia and bipolar disorder, part III: Bipolar disorder. Am J Hum 
Genet, 73, 49-62. 12.649 
144. Silander, K., Axelsson, T., Widen, E., Dahlgren, A., Palotie, A. and Syvanen, A.C. (2003) 
Analysis of genetic variation in the GenomEUtwin project. Twin Res, 6, 391-8. 1.664 
145. Silventoinen, K., Sammalisto, S., Perola, M., Boomsma, D.I., Cornes, B.K., Davis, C., 
Dunkel, L., De Lange, M., Harris, J.R., Hjelmborg, J.V. et al. (2003) Heritability of adult 
body height: a comparative study of twin cohorts in eight countries. Twin Res, 6, 399-408. 
1.664 
146. Snapir, A., Mikkelsson, J., Perola, M., Penttila, A., Scheinin, M. and Karhunen, P.J. 
(2003) Variation in the alpha2B-adrenoceptor gene as a risk factor for prehospital fatal 
myocardial infarction and sudden cardiac death. J Am Coll Cardiol, 41, 190-4. 9.200 
147. Suviolahti, E., Oksanen, L.J., Ohman, M., Cantor, R.M., Ridderstrale, M., Tuomi, T., 
Kaprio, J., Rissanen, A., Mustajoki, P., Jousilahti, P. et al. (2003) The SLC6A14 gene 
shows evidence of association with obesity. J Clin Invest, 112, 1762-72. 15.053 
148. Tahvanainen, P., Tahvanainen, E., Reijonen, H., Halme, L., Kaariainen, H. and 
Hockerstedt, K. (2003) Polycystic liver disease is genetically heterogeneous: clinical and 
linkage studies in eight Finnish families. J Hepatol, 38, 39-43. 4.931 
149. Tuulio-Henriksson, A., Arajarvi, R., Partonen, T., Haukka, J., Varilo, T., Schreck, M., 
Cannon, T. and Lonnqvist, J. (2003) Familial loading associates with impairment in 
visual span among healthy siblings of schizophrenia patients. Biol Psychiatry, 54, 623-
628. 6.779 
150. Urbanek, M., Du, Y., Silander, K., Collins, F.S., Steppan, C.M., Strauss, J.F., 3rd, Dunaif, 
A., Spielman, R.S. and Legro, R.S. (2003) Variation in resistin gene promoter not 
associated with polycystic ovary syndrome. Diabetes, 52, 214-7. 8.028 
151. Varilo, T., Paunio, T., Parker, A., Perola, M., Meyer, J., Terwilliger, J.D. and Peltonen, L. 
(2003) The interval of linkage disequilibrium (LD) detected with microsatellite and SNP 
markers in chromosomes of Finnish populations with different histories. Hum Mol Genet, 
12, 51-9. 7.764 
152. Alanne, M., Salomaa, V., Saarela, J., Peltonen, L. and Perola, M. (2004) DNA extraction 
yield is associated with several phenotypic characteristics: results from two large 
population surveys. J Thromb Haemost, 2, 2069-71. 5.262 
153. Alfthan, G., Tapani, K., Nissinen, K., Saarela, J. and Aro, A. (2004) The effect of low 
doses of betaine on plasma homocysteine in healthy volunteers. Br J Nutr, 92, 665-669. 
2.967 
154. Arajarvi, R., Haukka, J., Varilo, T., Suokas, J., Juvonen, H., Suvisaari, J., Muhonen, M., 
Suominen, K., Tuulio-Henriksson, A., Schreck, M. et al. (2004) Clinical phenotype of 
schizophrenia in a Finnish isolate. Schizophr Res, 67, 195-205. 4.231 
155. Bonetti, A., Reunanen, K., Finnila, S., Koivisto, K., Wikstrom, J., Sumelahti, M.L., 
Pirttila, T., Elovaara, I., Reunanen, M., Saarela, J. et al. (2004) A two-stage study on 
multiple sclerosis susceptibility and chromosome 2q33. Genes Immun, 5, 142-6. 3.779 
156. Chen, D.C., Saarela, J., Clark, R.A., Miettinen, T., Chi, A., Eichler, E.E., Peltonen, L. and 
Palotie, A. (2004) Segmental duplications flank the multiple sclerosis locus on 
chromosome 17q. Genome Res, 14, 1483-92. 10.139 
157. Churchill, G. and Airey, D.C. and Allayee, H. and Angel, J.M. and Attie, A.D. and Beatty, 
J. and Beavis, W.D. and Belknap, J.K. and Bennett, B. and Berrettini, W. et al. (2004) 
The Collaborative Cross, a community resource for the genetic analysis of complex traits. 
Nat Genet, 36, 1133-1137. 25.797 
158. Conneely, K.N., Silander, K., Scott, L.J., Mohlke, K.L., Lazaridis, K.N., Valle, T.T., 
Tuomilehto, J., Bergman, R.N., Watanabe, R.M., Buchanan, T.A. et al. (2004) Variation 
in the resistin gene is associated with obesity and insulin-related phenotypes in Finnish 
subjects. Diabetologia, 47, 1782-8. 5.337 
159. Davila, S., Furu, L., Gharavi, A.G., Tian, X., Onoe, T., Qian, Q., Li, A.R., Cai, Y.Q., 
Kamath, P.S., King, B.F. et al. (2004) Mutations in SEC63 cause autosomal dominant 
polycystic liver disease. Nat Genet, 36, 575-577. 25.797 
160. Do Thi, N.A., Saillour, P., Ferrero, L., Dedieu, J.F., Mallet, J. and Paunio, T. (2004) 
Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP 
promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's 
disease. Gene Ther, 11, 746-56. 4.836 
Background material                                                                                   APPENDIX 2 
 137
161. Drenth, J.P.H., Tahvanainen, E., Morsche, R., Tahvanainen, P., Kaariainen, H., 
Hockerstedt, K., van de Kamp, J.M., Breuning, M.H. and Jansen, J. (2004) Abnormal 
hepatocystin caused by truncating PRKCSH mutations leads to autosomal dominant 
polycystic liver disease. Hepatology, 39, 924-931. 9.792 
162. Ekelund, J., Hennah, W., Hiekkalinna, T., Parker, A., Meyer, J., Lonnqvist, J. and 
Peltonen, L. (2004) Replication of 1q42 linkage in Finnish schizophrenia pedigrees. Mol 
Psychiatry, 9, 1037-41. 9.335 
163. Enattah, N.S., Forsblom, C., Rasinpera, H., Tuomi, T., Groop, P.H. and Jarvela, I. (2004) 
The genetic variant of lactase persistence C(-13910)T as a risk factor for type I and II 
diabetes in the Finnish population. Eur J Clin Nutr, 58, 1319-1322. 2.163 
164. Jarvinen, A.K., Hautaniemi, S., Edgren, H., Auvinen, P., Saarela, J., Kallioniemi, O.P. 
and Monni, O. (2004) Are data from different gene expression microarray platforms 
comparable? Genomics, 83, 1164-1168.3.181 
165. Johansson, C., Willeit, M., Aron, L., Smedh, C., Ekholm, J., Paunio, T., Kieseppa, T., 
Lichtermann, D., Praschak-Rieder, N., Neumeister, A. et al. (2004) Seasonal affective 
disorder and the G-protein beta-3-subunit C825T polymorphism. Biol Psychiatry, 55, 
317-9. 6.779 
166. Keltikangas-Jarvinen, L., Raikkonen, K., Ekelund, J. and Peltonen, L. (2004) Nature and 
nurture in novelty seeking. Mol Psychiatry, 9, 308-11. 9.335 
167. Koivisto, M. and Sood, K. (2004) Exact Bayesian structure discovery in Bayesian 
networks. J Mach Learn Res, 5, 549-573. 4.027 
168. Koivukoski, L., Fisher, S.A., Kanninen, T., Lewis, C.M., von Wowern, F., Hunt, S., 
Kardia, S.L., Levy, D., Perola, M., Rankinen, T. et al. (2004) Meta-analysis of genome-
wide scans for hypertension and blood pressure in Caucasians shows evidence of 
susceptibility regions on chromosomes 2 and 3. Hum Mol Genet, 13, 2325-32. 7.764 
169. Kraft, P., Palmer, C.G., Woodward, A.J., Turunen, J.A., Minassian, S., Paunio, T., 
Lonnqvist, J., Peltonen, L. and Sinsheimer, J.S. (2004) RHD maternal-fetal genotype 
incompatibility and schizophrenia: extending the MFG test to include multiple siblings 
and birth order. Eur J Hum Genet, 12, 192-8. 3.251 
170. Lemmela, S., Ylisaukko-oja, T., Forsman, E. and Jarvela, I. (2004) Exclusion of 14 
candidate loci for primary open angle glaucoma in Finnish families. Mol Vis, 10, 260-264. 
2.239 
171. Lilja, H.E., Suviolahti, E., Soro-Paavonen, A., Hiekkalinna, T., Day, A., Lange, K., Sobel, 
E., Taskinen, M.R., Peltonen, L., Perola, M. et al. (2004) Locus for quantitative HDL-
cholesterol on chromosome 10q in Finnish families with dyslipidemia. J Lipid Res, 45, 
1876-84. 3.909 
172. Luoma, P., Melberg, A., Rinne, J.O., Kaukonen, J.A., Nupponen, N.N., Chalmers, R.M., 
Oldfors, A., Rautakorpi, I., Peltonen, L., Majamaa, K. et al. (2004) Parkinsonism, 
premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical 
and molecular genetic study. Lancet, 364, 875-82. 23.878 
173. Miettunen, J., Kantojarvi, L., Ekelund, J., Veijola, J., Karvonen, J.T., Peltonen, L., 
Jarvelin, M.R., Freimer, N., Lichtermann, D. and Joukamaa, M. (2004) A large 
population cohort provides normative data for investigation of temperament. Acta 
Psychiatr Scand, 110, 150-7. 2.968 
174. Ollikainen, E., Mikkelsson, J., Perola, M., Penttila, A. and Karhunen, P.J. (2004) Platelet 
membrane collagen receptor glycoprotein VI polymorphism is associated with coronary 
thrombosis and fatal myocardial infarction in middle-aged men. Atherosclerosis, 176, 95-
9. 3.777 
175. Pajukanta, P., Lilja, H.E., Sinsheimer, J.S., Cantor, R.M., Lusis, A.J., Gentile, M., Duan, 
X.J., Soro-Paavonen, A., Naukkarinen, J., Saarela, J. et al. (2004) Familial combined 
hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet, 36, 
371-6. 25.797 
176. Paunio, T., Tuulio-Henriksson, A., Hiekkalinna, T., Perola, M., Varilo, T., Partonen, T., 
Cannon, T.D., Lonnqvist, J. and Peltonen, L. (2004) Search for cognitive trait 
components of schizophrenia reveals a locus for verbal learning and memory on 4q and 
for visual working memory on 2q. Hum Mol Genet, 13, 1693-702. 7.764 
177. Pettersson-Fernholm, K.J., Forsblom, C.M., Perola, M., Fagerudd, J.A. and Groop, P.H. 
(2004) Dopamine D3 receptor gene polymorphisms, blood pressure and nephropathy in 
type 1 diabetic patients. Nephrol Dial Transplant, 19, 1432-6. 2.976 
178. Rontu, R., Lehtimaki, T., Ilveskoski, E., Mikkelsson, J., Kajander, O., Goebeler, S., 
Perola, M., Penttila, A. and Karhunen, P.J. (2004) Association of paraoxonase-1 M55L 
Background material                                                                                   APPENDIX 2 
 138
genotype and alcohol consumption with coronary atherosclerosis: the Helsinki Sudden 
Death Study. Pharmacogenetics, 14, 479-85. 5.882 
179. Silander, K., Mohlke, K.L., Scott, L.J., Peck, E.C., Hollstein, P., Skol, A.D., Jackson, 
A.U., Deloukas, P., Hunt, S., Stavrides, G. et al. (2004) Genetic variation near the 
hepatocyte nuclear factor-4 alpha gene predicts susceptibility to type 2 diabetes. Diabetes, 
53, 1141-9. 8.028 
180. Silander, K., Scott, L.J., Valle, T.T., Mohlke, K.L., Stringham, H.M., Wiles, K.R., Duren, 
W.L., Doheny, K.F., Pugh, E.W., Chines, P. et al. (2004) A large set of Finnish affected 
sibling pair families with type 2 diabetes suggests susceptibility loci on chromosomes 6, 
11, and 14. Diabetes, 53, 821-9. 8.028 
181. Solovieva, S., Kouhia, S., Leino-Arjas, P., Ala-Kokko, L., Luoma, K., Raininko, R., 
Saarela, J. and Riihimaki, H. (2004) Interleukin 1 polymorphisms and intervertebral disc 
degeneration. Epidemiology, 15, 626-633. 4.043 
182. Solovieva, S., Leino-Arjas, P., Saarela, J., Luoma, K., Raininko, R. and Riihimaki, H. 
(2004) Possible association of interleukin 1 gene locus polymorphisms with low back 
pain. Pain, 109, 8-19. 4.309 
183. Ylisaukko-oja, T., Nieminen-von Wendt, T., Kempas, E., Sarenius, S., Varilo, T., von 
Wendt, L., Peltonen, L. and Jarvela, I. (2004) Genome-wide scan for loci of Asperger 
syndrome. Mol Psychiatry, 9, 161-8. 9.335 
184. Ylisaukko-oja, T., Rehnstrom, K., Vanhala, R., Tengstrom, C., Lahdetie, J. and Jarvela, I. 
(2004) Identification of two AGTR2 mutations in male patients with non-syndromic 
mental retardation. Hum Genet, 114, 211-213. 4.331 
185. Bennett, A., Sovio, U., Ruokonen, A., Martikainen, H., Pouta, A., Taponen, S., 
Hartikainen, A.L., Franks, S., Peltonen, L., Elliott, P. et al. (2005) No association 
between insulin gene variation and adult metabolic phenotypes in a large Finnish birth 
cohort. Diabetologia, 48, 886-91. 5.337 
186. Cannon, T.D., Hennah, W., van Erp, T.G., Thompson, P.M., Lonnqvist, J., Huttunen, M., 
Gasperoni, T., Tuulio-Henriksson, A., Pirkola, T., Toga, A.W. et al. (2005) Association 
of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and 
impaired short- and long-term memory. Arch Gen Psychiatry, 62, 1205-13. 12.642 
187. Ekelund, J., Johansson, E., Jarvelin, M.R. and Lichtermann, D. (2005) Self-employment 
and risk aversion - evidence from psychological test data. Labour Economics, 12, 649-
659. - 
188. Elovainio, M., Kivimaki, M., Viikari, J., Ekelund, J. and Keltikangas-Jarvinen, L. (2005) 
The mediating role of novelty seeking in the association between the type 4-dopamine 
receptor gene polymorphism and cigarette-smoking behavior. Pers Individ Dif, 38, 639-
645. - 
189. Enattah, N.S., Sulkava, R., Halonen, P., Kontula, K. and Jarvela, I. (2005) Genetic variant 
of lactase-persistent C/T-13910 is associated with bone fractures in very old age. J Am 
Geriatr Soc, 53, 79-82. 3.479 
190. Hakonen, A.H., Heiskanen, S., Juvonen, V., Lappalainen, I., Luoma, P.T., Rantamaki, M., 
Goethem, G.V., Lofgren, A., Hackman, P., Paetau, A. et al. (2005) Mitochondrial DNA 
polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient 
European origin. Am J Hum Genet, 77, 430-41. 12.649 
191. Hennah, W., Tuulio-Henriksson, A., Paunio, T., Ekelund, J., Varilo, T., Partonen, T., 
Cannon, T.D., Lonnqvist, J. and Peltonen, L. (2005) A haplotype within the DISC1 gene 
is associated with visual memory functions in families with a high density of 
schizophrenia. Mol Psychiatry, 10, 1097-103. 9.335 
192. Hiekkalinna, T., Terwilliger, J.D., Sammalisto, S., Peltonen, L. and Perola, M. (2005) 
AUTOGSCAN: powerful tools for automated genome-wide linkage and linkage 
disequilibrium analysis. Twin Res Hum Genet, 8, 16-21. 1.481 
193. Johnson, L., Luke, A., Adeyemo, A., Deng, H.W., Mitchell, B.D., Comuzzie, A.G., Cole, 
S.A., Blangero, J., Perola, M. and Teare, M.D. (2005) Meta-analysis of five genome-wide 
linkage studies for body mass index reveals significant evidence for linkage to 
chromosome 8p. Int J Obes (Lond), 29, 413-9. 4.482 
194. Kuokkanen, M., Butzow, R., Rasinpera, H., Medrek, K., Nilbert, M., Malander, S., 
Lubinski, J. and Jarvela, I. (2005) Lactase persistence and ovarian carcinoma risk in 
Finland, Poland and Sweden. Int J Cancer, 117, 90-94. 4.700 
195. Kwasnicka-Crawford, D.A., Carson, A.R., Roberts, W., Summers, A.M., Rehnstrom, K., 
Jarvela, I. and Scherer, S.W. (2005) Characterization of a novel cation transporter 
ATPase gene (ATP13A4) interrupted by 3q25-q29 inversion in an individual with 
language delay. Genomics, 86, 182-194.3.181 
Background material                                                                                   APPENDIX 2 
 139
196. Lahti, J., Raikkonen, K., Ekelund, J., Peltonen, L., Raitakari, O.T. and Keltikangas-
Jarvinen, L. (2005) Novelty seeking: interaction between parental alcohol use and 
dopamine D4 receptor gene exon III polymorphism over 17 years. Psychiatr Genet, 15, 
133-9. 2.366 
197. Lincoln, M.R., Montpetit, A., Cader, M.Z., Saarela, J., Dyment, D.A., Tiislar, M., Ferretti, 
V., Tienari, P.J., Sadovnick, A.D., Peltonen, L. et al. (2005) A predominant role for the 
HLA class II region in the association of the MHC region with multiple sclerosis. Nat 
Genet, 37, 1108-12. 25.797 
198. Mikkelsson, J., Perola, M. and Karhunen, P.J. (2005) Genetics of platelet glycoprotein 
receptors: risk of thrombotic events and pharmacogenetic implications. Clin Appl Thromb 
Hemost, 11, 113-25. 1.183 
199. Naukkarinen, J., Gentile, M., Soro-Paavonen, A., Saarela, J., Koistinen, H.A., Pajukanta, 
P., Taskinen, M.R. and Peltonen, L. (2005) USF1 and dyslipidemias: converging 
evidence for a functional intronic variant. Hum Mol Genet, 14, 2595-605. 7.764 
200. Pollanen, P.J., Lehtimaki, T., Mikkelsson, J., Ilveskoski, E., Kunnas, T., Perola, M., 
Penttila, A., Mattila, K.M., Nikkari, S.T., Syrjakoski, K. et al. (2005) Matrix 
metalloproteinase3 and 9 gene promoter polymorphisms: joint action of two loci as a risk 
factor for coronary artery complicated plaques. Atherosclerosis, 180, 73-8. 3.777 
201. Rasinpera, H., Forsblom, C., Enattah, N.S., Halonen, P., Salo, K., Victorzon, M., Mecklin, 
J.P., Jarvinen, H., Enholm, S., Sellick, G. et al. (2005) The C/C-13910 genotype of adult-
type hypolactasia is associated with an increased risk of colorectal cancer in the Finnish 
population. Gut, 54, 643-647. 7.692 
202. Rasinpera, H., Kuokkanen, M., Kolho, K.L., Lindahl, H., Enattah, N.S., Savilahti, E., 
Orpana, A. and Jarvela, I. (2005) Transcriptional downregulation of the lactase (LCT) 
gene during childhood. Gut, 54, 1660-1661. 7.692 
203. Riise Stensland, H.M., Saarela, J., Bronnikov, D.O., Parkkonen, M., Jokiaho, A.J., Palotie, 
A., Tienari, P.J., Sumelahti, M.L., Elovaara, I., Koivisto, K. et al. (2005) Fine mapping of 
the multiple sclerosis susceptibility locus on 5p14-p12. J Neuroimmunol, 170, 122-33. 
2.824 
204. Sammalisto, S., Hiekkalinna, T., Suviolahti, E., Sood, K., Metzidis, A., Pajukanta, P., 
Lilja, H.E., Soro-Paavonen, A., Taskinen, M.R., Tuomi, T. et al. (2005) A male-specific 
quantitative trait locus on 1p21 controlling human stature. J Med Genet, 42, 932-9. 4.330 
205. Silander, K., Komulainen, K., Ellonen, P., Jussila, M., Alanne, M., Levander, M., Tainola, 
P., Kuulasmaa, K., Salomaa, V., Perola, M. et al. (2005) Evaluating whole genome 
amplification via multiply-primed rolling circle amplification for SNP genotyping of 
samples with low DNA yield. Twin Res Hum Genet, 8, 368-75. 1.481 
206. Ylisaukko-Oja, T., Peyrard-Janvid, M., Lindgren, C.M., Rehnstrom, K., Vanhala, R., 
Peltonen, L., Jarvela, I. and Kere, J. (2005) Family-based association study of DYX1C1 
variants in autism. Eur J Hum Genet, 13, 127-30. 3.251 
207. Ylisaukko-oja, T., Rehnstrom, K., Auranen, M., Vanhala, R., Alen, R., Kempas, E., 
Ellonen, P., Turunen, J.A., Makkonen, I., Riikonen, R. et al. (2005) Analysis of four 
neuroligin genes as candidates for autism. Eur J Hum Genet, 13, 1285-92. 3.251 
208. Ylisaukko-Oja, T., Rehnstrom, K., Vanhala, R., Kempas, E., von Koskull, H., Tengstrom, 
C., Mustonen, A., Ounap, K., Lahdetie, J. and Jarvela, I. (2005) MECP2 mutation 
analysis in patients with mental retardation. Am J Med Genet A, 132A, 121-124. 1.913 
209. Anttila, V., Kallela, M., Oswell, G., Kaunisto, M.A., Nyholt, D.R., Hamalainen, E., 
Havanka, H., Ilmavirta, M., Terwilliger, J., Sobel, E. et al. (2006) Trait components 
provide tools to dissect the genetic susceptibility of migraine. Am J Hum Genet, 79, 85-99. 
12.649 
210. Arajarvi, R., Varilo, T., Haukka, J., Suvisaari, J., Suokas, J., Juvonen, H., Muhonen, M., 
Suominen, K., Hintikka, J., Schreck, M. et al. (2006) Affective flattening and alogia 
associate with the familial form of schizophrenia. Psychiatry Res, 141, 161-72. 1.957 
211. Auro, K., Komulainen, K., Alanne, M., Silander, K., Peltonen, L., Perola, M. and 
Salomaa, V. (2006) Thrombomodulin gene polymorphisms and haplotypes and the risk of 
cardiovascular events: a prospective follow-up study. Arterioscler Thromb Vasc Biol, 26, 
942-7. 7.053 
212. Bjorklund, M., Taipale, M., Varjosalo, M., Saharinen, J., Lahdenpera, J. and Taipale, J. 
(2006) Identification of pathways regulating cell size and cell-cycle progression by RNAi. 
Nature, 439, 1009-1013. 29.273 
213. Chin, R.K., Zhu, M., Christiansen, P.A., Liu, W., Ware, C., Peltonen, L., Zhang, X., Guo, 
L., Han, S., Zheng, B. et al. (2006) Lymphotoxin pathway-directed, autoimmune 
Background material                                                                                   APPENDIX 2 
 140
regulator-independent central tolerance to arthritogenic collagen. J Immunol, 177, 290-7. 
6.387 
214. Fan, Y.M., Lehtimaki, T., Rontu, R., Ilveskoski, E., Goebeler, S., Kajander, O., 
Mikkelsson, J., Perola, M. and Karhunen, P.J. (2006) Age-dependent association between 
hepatic lipase gene C-480T polymorphism and the risk of pre-hospital sudden cardiac 
death: The Helsinki Sudden Death Study. Atherosclerosis. 3.777 
215. Hallikas, O. and Taipale, J. (2006) High-throughput assay for determining specificity and 
affinity of protein-DNA binding interactions. Nat Protoc, 1, 215-22. - 
216. Karhunen, V., Forss, H., Goebeler, S., Huhtala, H., Ilveskoski, E., Kajander, O., 
Mikkelsson, J., Penttila, A., Perola, M., Ranta, H. et al. (2006) Radiographic assessment 
of dental health in middle-aged men following sudden cardiac death. J Dent Res, 85, 89-
93. 3.192 
217. Komulainen, K., Alanne, M., Auro, K., Kilpikari, R., Pajukanta, P., Saarela, J., Ellonen, 
P., Salminen, K., Kulathinal, S., Kuulasmaa, K. et al. (2006) Risk alleles of USF1 gene 
predict cardiovascular disease of women in two prospective studies. PLoS Genet, 2, e69. 
7.671 
218. Kuokkanen, M., Kokkonen, J., Enattah, N.S., Ylisaukko-Oja, T., Komu, H., Varilo, T., 
Peltonen, L., Savilahti, E. and Jarvela, I. (2006) Mutations in the Translated Region of the 
Lactase Gene (LCT) Underlie Congenital Lactase Deficiency. Am J Hum Genet, 78, 339-
44. 12.649 
219. Kuokkanen, M., Myllyniemi, M., Vauhkonen, M., Heske, T., Kaariainen, I., Karesvuori, 
S., Linnala, A., Harkonen, M., Jarvela, I. and Sipponen, P. (2006) A biopsy-based quick 
test in the diagnosis of duodenal hypolactasia in upper gastrointestinal endoscopy. 
Endoscopy, 38, 708-712. 4.072 
220. Lahermo, P., Liljedahl, U., Alnaes, G., Axelsson, T., Brookes, A.J., Ellonen, P., Groop, 
P.H., Hallden, C., Holmberg, D., Holmberg, K. et al. (2006) A quality assessment survey 
of SNP genotyping laboratories. Hum Mutat, 27, 711-714. 7.923 
221. Lahti, J., Raikkonen, K., Ekelund, J., Peltonen, L., Raitakari, O.T. and Keltikangas-
Jarvinen, L. (2006) Socio-demographic the association between characteristics moderate 
DRD4 and novelty seeking. Pers Individ Dif, 40, 533-543. - 
222. Minarik, M., Benesova, L., Fantova, L., Horacek, J., Heracek, J. and Loukola, A. (2006) 
Parallel optimization and genotyping of multiple single-nucleotide polymorphism 
markers by sample pooling approach using cycling-gradient CE with multiple injections. 
Electrophoresis, 27, 3856-63. 3.850 
223. Minassian, S.L., Palmer, C.G., Turunen, J.A., Paunio, T., Lonnqvist, J., Peltonen, L., 
Woodward, J.A. and Sinsheimer, J.S. (2006) Incorporating serotypes into family based 
association studies using the MFG test. Ann Hum Genet, 70, 541-53. 3.192 
224. Mononen, N., Seppala, E.H., Duggal, P., Autio, V., Ikonen, T., Ellonen, P., Saharinen, J., 
Saarela, J., Vihinen, M., Tammela, T.L.J. et al. (2006) Profiling genetic variation along 
the androgen biosynthesis and metabolism pathways implicates several single nucleotide 
polymorphisms and their combinations as prostate cancer risk factors. Cancer Res, 66, 
743-747. 7.616 
225. Palin, K., Taipale, J. and Ukkonen, E. (2006) Locating potential enhancer elements by 
comparative genomics using the EEL software. Nat Protoc, 1, 368-74. - 
226. Palmer, C.G., Hsieh, H.J., Reed, E.F., Lonnqvist, J., Peltonen, L., Woodward, J.A. and 
Sinsheimer, J.S. (2006) HLA-B maternal-fetal genotype matching increases risk of 
schizophrenia. Am J Hum Genet, 79, 710-5. 12.649 
227. Rehnstrom, K., Ylisaukko-oja, T., Nieminen-von Wendt, T., Sarenius, S., Kallman, T., 
Kempas, E., von Wendt, L., Peltonen, L. and Jarvela, I. (2006) Independent replication 
and initial fine mapping of 3p21-24 in Asperger syndrome. J Med Genet, 43, e6. 4.330 
228. Saarela, J., Kallio, S.P., Chen, D., Montpetit, A., Jokiaho, A., Choi, E., Asselta, R., 
Bronnikov, D., Lincoln, M.R., Sadovnick, A.D. et al. (2006) PRKCA and multiple 
sclerosis: association in two independent populations. PLoS Genet, 2, e42. 7.671 
229. Service, S., DeYoung, J., Karayiorgou, M., Roos, J.L., Pretorious, H., Bedoya, G., Ospina, 
J., Ruiz-Linares, A., Macedo, A., Palha, J.A. et al. (2006) Magnitude and distribution of 
linkage disequilibrium in population isolates and implications for genome-wide 
association studies. Nat Genet, 38, 556-60. 25.797 
230. Suviolahti, E., Reue, K., Cantor, R.M., Phan, J., Gentile, M., Naukkarinen, J., Soro-
Paavonen, A., Oksanen, L., Kaprio, J., Rissanen, A. et al. (2006) Cross-species analyses 
implicate Lipin 1 involvement in human glucose metabolism. Hum Mol Genet, 15, 377-
86. 7.764 
Background material                                                                                   APPENDIX 2 
 141
231. Terwilliger, J.D. and Hiekkalinna, T. (2006) An utter refutation of the 'Fundamental 
Theorem of the HapMap'. Eur J Hum Genet, 14, 426-437. 3.251 
232. Trikalinos, T.A., Karvouni, A., Zintzaras, E., Ylisaukko-oja, T., Peltonen, L., Jarvela, I. 
and Ioannidis, J.P. (2006) A heterogeneity-based genome search meta-analysis for 
autism-spectrum disorders. Mol Psychiatry, 11, 29-36. 9.335 
233. Valli-Jaakola, K., Palvimo, J.J., Lipsanen-Nyman, M., Salomaa, V., Peltonen, L., Kontula, 
K. and Schalin-Jantti, C. (2006) A two-base deletion -439delGC in the melanocortin-4 
receptor promoter associated with early-onset obesity. Horm Res, 66, 61-9. 1.386 
234. Wang, H., Lin, C.H., Service, S., Chen, Y., Freimer, N. and Sabatti, C. (2006) Linkage 
disequilibrium and haplotype homozygosity in population samples genotyped at a high 
marker density. Hum Hered, 62, 175-89. 3.645 
235. Varjosalo, M., Li, S.P. and Taipale, J. (2006) Divergence of hedgehog signal transduction 
mechanism between Drosophila and mammals. Dev Cell, 10, 177-186. 14.609 
236. Ylisaukko-oja, T., Alarcon, M., Cantor, R.M., Auranen, M., Vanhala, R., Kempas, E., 
von Wendt, L., Jarvela, I., Geschwind, D.H. and Peltonen, L. (2006) Search for autism 
loci by combined analysis of Autism Genetic Resource Exchange and Finnish families. 
Ann Neurol, 59, 145-55. 7.571 
237. Antila, M., Tuulio-Henriksson, A., Kieseppa, T., Eerola, M., Partonen, T. and Lonnqvist, 
J. (2007) Cognitive functioning in patients with familial bipolar I disorder and their 
unaffected relatives. Psychol Med, 37, 679-87. 2.366 
238. Antila, M., Tuulio-Henriksson, A., Kieseppa, T., Soronen, P., Palo, O.M., Paunio, T., 
Haukka, J., Partonen, T. and Lonnqvist, J. (2007) Heritability of cognitive functions in 
families with bipolar disorder. Neuropsychiatr Genet, in press. - 
239. Do Thi, N.A., Saillour, P., Ferrero, L., Paunio, T. and Mallet, J. (2007) Does neuronal 
expression of GDNF effectively protect dopaminergic neurons in a rat model of 
Parkinson's disease? Gene Ther, 14, 441-50. 4.836 
240. Hennah, W., Tomppo, L., Hiekkalinna, T., Palo, O.M., Kilpinen, H., Ekelund, J., Tuulio-
Henriksson, A., Silander, K., Partonen, T., Paunio, T. et al. (2007) Families with the risk 
allele of DISC1 reveal a link between schizophrenia and another component of the same 
molecular pathway, NDE1. Hum Mol Genet, 16, 453-62. 7.764 
241. Hovatta, I., Zapala, M.A., Broide, R.S., Schadt, E.E., Libiger, O., Schork, N.J., Lockhart, 
D.J. and Barlow, C. (2007) DNA variation and brain region-specific expression profiles 
exhibit different relationships between inbred mouse strains: implications for eQTL 
mapping studies. Genome Biol, 8, R25. 9.712 
242. Keskitalo, K., Knaapila, A., Kallela, M., Palotie, A. and Wessman, M. (2007) Sweet taste 
preferences are partly genetically determined; identification of a trait locus on 
chromosome 16. Am J Clin Nutr, 86, 55-63. 5.853 
243. Knaapila, A., Keskitalo, K., Kallela, M., Wessman, M., Sammalisto, S., Hiekkalinna, T., 
Palotie, A., Peltonen, L., Tuorila, H. and Perola, M. (2007) Genetic component of 
identification, intensity and pleasantness of odours: a Finnish family study. Eur J Hum 
Genet, 15, 596-602. 3.251 
244. Knaapila, A., Tuorila, H., Silventoinen, K., Keskitalo, K., Kallela, M., Wessman, M., 
Peltonen, L., Cherkas, L.F., Spector, T.D. and Perola, M. (2007) Food neophobia shows 
heritable variation in humans. Physiol Behav, in press. 2.183 
245. Muilu, J., Peltonen, L. and Litton, J.-E. (2007) The federated database - basis for 
biobank-based post-genome studies, integrating phenome and genome data from 600 000 
twin pairs in Europe. Eur J Hum Genet, 15, 718-23. 3.251 
246. Nussbaum, R. and Peltonen, L. (2007) Genetics of disease Recent advances in the 
genetics of human disease offer something new for every scientific interest. Curr Opin 
Genet Dev, 17, 163-5. 9.361 
247. Nyman, E.S., Ogdie, M.N., Loukola, A.Varilo, T., Taanila, A., Hurtig, T., Moilanen, I.K., 
Loo, S.K., McGough, J.J., Järvelin, M.-R., Smalley, S.L. et al. (2007) Finnish ADHD 
Special Section - ADHD candidate gene study in a population-based birth cohort: 
Association with BDH and DRD. Am Acad Child Psy, in press. 4.113 
248. Partonen, T., Treutlein, J., Alpman, A., Frank, J., Johansson, C., Depner, M., Aron, L., 
Rietschel, M., Wellek, S., Soronen, P. et al. (2007) Three circadian clock genes Per2, 
Arntl, and Npas2 contribute to winter depression. Ann Med, 39, 229-38. 3.848 
249. Perola, M., Sammalisto, S., Hiekkalinna, T., Martin, N., Visscher, P.M., Montgomery, 
G.W., Benyamin, B., Harris, J.R., Boomsma, D.I., Willemsen, G. et al. (2007) Combined 
genome scans for body stature in 6602 European twins: evidence for common Caucasian 
loci. PLoS Genet, 3, e97. 7.671 
Background material                                                                                   APPENDIX 2 
 142
250. Saccone, S.F., Pergadia, M.L., Loukola, A., Broms, U., Montgomery, G.W., Wang, J.C., 
Agrawal, A., Dick, D.M., Heath, A.C., Todorov, A.A. et al. (2007) Genetic linkage to 
chromosome 22q12 for a heavy-smoking quantitative trait in two independent samples. 
Am J Hum Genet, 80, 856-66.12.649 
251. Shtir, C., Nagakawa, I.S., Duren, W.L., Conneely, K.N., Scott, L.J., Silander, K., Valle, 
T.T., Tuomilehto, J., Buchanan, T.A., Bergman, R.N. et al. (2007) Subsets of Finns with 
high HDL to total cholesterol ratio show evidence for linkage to type 2 diabetes on 
chromosome 6q. Hum Hered, 63, 17-25. 3.645 
252. Soro-Paavonen, A., Naukkarinen, J., Lee-Rueckert, M., Watanabe, H., Rantala, E., 
Soderlund, S., Hiukka, A., Kovanen, P.T., Jauhiainen, M., Peltonen, L. et al. (2007) 
Common ABCA1 variants, HDL levels and cellular cholesterol efflux in subjects with 
familial low-HDL. J Lipid Res, 48, 1409-16. 3.909 
253. Suominen, S., Mantere, O., Valtonen, H., Arvilommi, P., Leppamaki, S., Paunio, T. and 
Isometsa, E. (2007) Early age at onset of bipolar disorder is associated with more severe 
clinical features but delayed treatment seeking. Bipolar Disord, in press. 4.812 
254. Tikka-Kleemola, P., Hamalainen, E., Tuomainen, K., Suvela, M., Artma, A., Kahre, O., 
Wessman, M., Palotie, A. and Silander, K. (2007) The enhancement of homogenous mass 
extension reaction: Comparison of two enzymes. Mol Cell Probes, 21, 216-21. 1.634 
255. Turunen, J.A., Peltonen, J.O., Pietilainen, O.P., Hennah, W., Loukola, A., Paunio, T., 
Silander, K., Ekelund, J., Varilo, T., Partonen, T. et al. (2007) The role of DTNBP1, 
NRG1, and AKT1 in the genetics of schizophrenia in Finland. Schizophr Res, 91, 27-36. 
4.231 
256. Wick, N., Saharinen, P., Saharinen, J., Gurnhofer, E., Steiner, C.W., Raab, I., Stokic, D., 
Giovanoli, P., Buchsbaum, S., Burchard, A. et al. (2007) Transcriptomal comparison of 
human dermal lymphatic endothelial cells ex vivo and in vitro. Physiol Genomics, 28, 
179-92. 4.636 
257. Wikman, H., Ruosaari, S., Nymark, P., Sarhadi, V.K., Saharinen, J., Vanhala, E., 
Karjalainen, A., Hollmen, J., Knuutila, S. and Anttila, S. (2007) Gene expression and 
copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-
associated lung cancer. Oncogene, 26, 4730-7. 6.872 
 
International review articles 
1. Burn, J., Camm, J., Davies, M.J., Peltonen, L., Schwartz, P.J. and Watkins, H. (1997) The 
phenotype/genotype relation and the current status of genetic screening in hypertrophic 
cardiomyopathy, Marfan syndrome, and the long QT syndrome. Heart, 78, 110-6. 3.078 
2. Pajukanta, P. and Peltonen, L. (1997) How to tackle genetic loci predisposing to 
atherosclerosis? Curr Opin Lipidol, 8, 95-100. 5.314 
3. Rantamaki, T., Karttunen, L. and Peltonen, L. (1997) Badly engineered fibrillin - Lessons 
from molecular studies of Marfan syndrome. Trends Cardiovasc Med, 7, 282-288. 4.771 
4. Aouizerat, B.E., Allayee, H., Bodnar, J., Krass, K.L., Peltonen, L., de Bruin, T.W., Rotter, 
J.I. and Lusis, A.J. (1999) Novel genes for familial combined hyperlipidemia. Curr Opin 
Lipidol, 10, 113-22. 5.314 
5. Peltonen, L. (2000) Positional cloning of disease genes: advantages of genetic isolates. 
Hum Hered, 50, 66-75. 2.051 
6. Peltonen, L., Palotie, A. and Lange, K. (2000) Use of population isolates for mapping 
complex traits. Nat Rev Genet, 1, 182-90. 22.947 
7. Peltonen, L. (2001) The molecular dissection of human diseases after the human genome 
project. Pharmacogenomics J, 1, 5-6. 3.603 
8. Peltonen, L. and McKusick, V.A. (2001) Genomics and medicine. Dissecting human 
disease in the postgenomic era. Science, 291, 1224-9. 30.028 
9. Boomsma, D., Busjahn, A. and Peltonen, L. (2002) Classical twin studies and beyond. 
Nat Rev Genet, 3, 872-882. 22.947 
10. Peltonen, L. (2003) GenomEUtwin: A strategy to identify genetic influences on health 
and disease. Twin Res, 6, 354-360. 1.664 
11. Hennah, W., Varilo, T., Paunio, T. and Peltonen, L. (2004) Haplotype analysis and 
identification of genes for a complex trait: examples from schizophrenia. Ann Med, 36, 
322-31. 3.848 
12. Varilo, T. and Peltonen, L. (2004) Isolates and their potential use in complex gene 
mapping efforts - Commentary. Curr Opin Genet Dev, 14, 316-323. 9.361 
13. Evans, A., Salomaa, V., Kulathinal, S., Asplund, K., Cambien, F., Ferrario, M., Perola, 
M., Peltonen, L., Shields, D., Tunstall-Pedoe, H. et al. (2005) MORGAM (an 
international pooling of cardiovascular cohorts). Int J Epidemiol, 34, 21-7. 4.045 
Background material                                                                                   APPENDIX 2 
 143
14. Hennah, W., Thomson, P., Peltonen, L. and Porteous, D. (2006) Beyond schizophrenia: 
The role of DISC1 in major mental illness. Schizophr Bull, 32, 409-416. 2.871 
15. Naukkarinen, J., Ehnholm, C. and Peltonen, L. (2006) Genetics of familial combined 
hyperlipidemia. Curr Opin Lipidol, 17, 285-90. 5.314 
16. Peltonen, L., Perola, M., Naukkarinen, J. and Palotie, A. (2006) Lessons from studying 
monogenic disease for common disease. Hum Mol Genet, 15 Spec No 1, R67-74. 7.764 
17. Enattah, N. and Peltonen, L. (2007) Evidence for still ongoing convergence evolution of 
the lactase persistance T-13910 alleles in humans. Am J Hum Genet, in press. 12.649 
18. Franceschi, C., Bezrukov, V., Blanche, H., Bolund, L., Christensen, K., de Benedictis, G., 
Deiana, L., Gonos, E., Hervonen, A., Yang, H. et al. (2007) Genetics of healthy aging in 
Europe: the EU-integrated project GEHA (GEnetics of Healthy Aging). Ann NY Acad Sci, 
1100, 21-45. 1.930 
19. Varjosalo, M. and Taipale, J. (2007) Hedgehog signaling. J Cell Sci, 120, 3-6. 6.543 
 
International book chapters 
1. Peltonen, L. (1997) The Molecular background of human disease. Epilepsy and 
pregnancy, 159-166  
2. Pajukanta, P., Ehnholm, C., Taskinen, M-R., Peltonen, L. (2000) Evidence of linkage in 
familial combined hyperlipidemia to chromosome 1q21-q23. Lipoprotein metabolism and 
atherogenesis, pp. 56-58  
3. Peltonen, L., Saarela, J. and Kuokkanen, S. (2002) Multiple sclerosis. The genetic basis of 
common disease, 44  
4. Varilo, T. and Peltonen, L. (2005) Population selection in complex disease gene mapping. 
Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics 
5. Lahti, J., Räikkönen, K., Ekelund, J., Peltonen, L., Raitakari, O.T. and Keltikangas-
Järvinen, L. (2006) Socio-demographic characteristics moderate the association between 
DRD4 and novelty seeking. Personality and Individual Differences, 40, 533-534 
6. Peltonen, L. (2007) Consequences of the Genome Project for Understanding 
Development. Inborn Errors of Development, in press 
7. Hovatta, I. Genetic influence on mammalian CNS gene expression: impact on behavior. 
New Encyclopedia of Neuroscience, accepted for publication 
8. Zapala, M.A., Barlow, C. and Hovatta, I. Molecular anatomy of the mammalian brain. 
New Encyclopedia of Neuroscience, accepted for publication 
 
Domestic articles  
1. Jarvela, I. and Palotie, L. (1998) [Suggestions from Department of Health and Security's 
genetic screening advisory committee have been published]. Duodecim, 22, 2287-9 
2. Pajukanta, P. and Palotie, L. (1998) [Genetics of hereditary dyslipidemia now becoming 
clear]. Duodecim, 114, 1447-1449 
3. Pastinen, T. and Perola, M. (1998) [DNA chips--a new diagnostic revolution?]. Duodecim, 
114, 829-831 
4. Kontula, K., Perola, M., Hiltunen, T., Kainulainen, K. and Palotie, L. (2000) [Genes and 
hypertension]. Duodecim, 116, 1751-8 
5. Palotie, L. (2000) [Where is the genome project leading to?]. Duodecim, 116, 1731-3 
6. Peltonen-Palotie, L. (2001) Miten perimähankkeen valmistuminen vaikuttaa 
mahdollisuuksiimme selvittää sairauksien patogeneesiä? Duodecim, 117, 939-44  
7. Paunio, T. and Saarela, J. (2003) Neuropsykiatriset sairaudet osin geneettisiä. 
Kansanterveyslehti, 3/2003 
8. Perola, M. (2003) Sydän- ja verisuonitaudeille lukuisia alttiusgeenejä. Kansanterveyslehti, 
3/2003 
9. Palotie, L., Saarela, J., Saharinen, J. (2003) Geneettisen tutkimuksen 
menetelmäarsenaalin uutuuksia. Kansanterveyslehti, 3/2003 
10. Palotie, A. and Peltonen-Palotie, L. (2004) [Do we need a Finnish biobank? Availability 
of epidemiologic data should benefit everybody]. Duodecim, 120, 1710-2 
11. Paunio, T. (2006) [DISC1 and liability to psychosis]. Duodecim, 122, 2431-3 
12. Paunio, T. (2006) [Epigenetic mechanism underlying psychiatric disorders]. Duodecim, 
122, 489-90 
 
Domestic book chapters 
1. Palotie, A., Palotie L. (1998) LUKU XIV Perinnöllisten sairauksien DNA-diagnostiikka. 
Kliininen kemia ja hematologia, 6:52 
2. Palotie, L. (1998) Ihmisen geenikartta.  Perinnöllisyyslääketiede, 3, 63-73 
Background material                                                                                   APPENDIX 2 
 144
3. Palotie, L., Aula, P. (1998)  Periytyvien tautien hoito.  Perinnöllisyyslääketiede 19, 280-
287 
4. Ala-Kokko, L., Kuivaniemi, H., Palotie, L. (2001) Perinnölliset sidekudoksen sairaudet. 
Reumataudit 
5. Palotie, L. (2002) Ihmisen perimän kartoitus. Perinnöllisyyslääketiede, 65-76 
6. Palotie, L., Palotie, A. (2007) Geenikartoituksesta tautien syiden ymmärtämiseen. 
Perinnöllisyyslääketiede, 48-59 
Background material                                                                                    APPENDIX 3 
 145
Appendix 3: Molecular biology of cardiovascular diseases - 
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PREAMBLE  
 
Introduction  
The mission of the National Public Health Institute (KTL) in Finland is to protect and 
promote the health of the Finnish people. As a research and expert institute belonging to 
the Ministry of Social Affairs and Health, KTL is responsible for providing decision-
makers, professionals and citizens with the best possible health-related information for 
their choices. A general strategy for the Institute was prepared in 2001, while detailed 
objectives for the work are agreed upon annually with the Ministry. Ultimate 
responsibility of leading and managing the whole Institute rests on the Director General 
of KTL. The three main areas of work in KTL have traditionally been: 1) infectious 
diseases and immunizations, 2) chronic diseases and health promotion, and 3) 
environmental health. In all these areas, both research and public health functions are 
carried out. Activities of the Institute include basic research, ranging from detailed 
analysis of the molecular mechanisms of pathogenesis to large scale epidemiological 
and preventive studies and research into factors influencing health. 
 
KTL’s main facilities are located in Helsinki and three other facilities in Kuopio, Oulu 
and Turku. The Institute with the total personnel of 980 has 12 departments, each of 
which is built of various laboratories and units. The Department of Molecular Medicine 
of KTL is located in Helsinki. It lists as its goals characterization of the molecular 
background of human diseases and production of new data on the relationship between 
the genetic and life style risk factors that result in the health problems of Finns. Current 
research programs of the Department focus on the characterization of the molecular 
background of the Finnish disease heritage, cardiovascular diseases, genetic 
epidemiology of common diseases and systems biology. 
 
The task of the Evaluation Panel 
The objective of the review was to provide an evaluation of the work of the Department 
of Molecular Medicine of KTL for the Ministry of Social Affairs and Health. The 
evaluation was to examine the functions, strategic importance, scientific merits and 
value for money of the scientific and expert work undertaken, and to make proposals for 
future work. A special emphasis was to be placed on the evaluation of the relevance and 
effectiveness of the work and of its impact on the health of Finnish people. 
 
Composition of the Evaluation Panel 
The Evaluation Panel consisted of Professor Albert Hofman (Erasmus MC, Rotterdam, 
The Netherlands), Professor Alan Wright (MRC Human Genetics Unit, Edinburgh, UK), 
Professor Mart Saarma (University of Helsinki, Helsinki, Finland) and Chancellor Eero 
Vuorio (University of Turku, Turku, Finland), who acted as the Chair of the Panel. 
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1 REVIEW OF THE ACTIVITIES OF THE DEPARTMENT OF 
MOLECULAR MEDICINE (MLO) 
1.1. Background information 
The current department of Molecular Medicine is a result of a merge of two previous 
departments of KTL: Department of Human Molecular Genetics and Department of 
Biochemistry. This administrative reconstruction was based on the recommendation by 
the previous international evaluation of 1995, and took place in 2001. Since June 1, 
2007 the research programs and core facilities of MLO were strategically joined as a 
part of the Institute for Molecular Medicine Finland (FIMM). At the same time the 
Paternity Testing Laboratory was integrated into the Department of Research and 
Expertise Support Services. 
 
Department of Human Molecular Genetics (founded in 1988, Director Professor 
Leena Peltonen) exploited the unique opportunities of the genetic isolation of Finland to 
analyse the genetic background of human disease. The main goal of the department was 
to characterize the molecular background of the diseases of Finnish disease heritage and 
via this effort to develop tools and analytical strategies for the identification of genetic 
and life style risk profiles in common multifactorial diseases, representing public health 
problems. Additionally, the department developed specific DNA test panels of disease 
mutations based on findings made in population based studies. The department served 
investigators both within KTL and nationwide as a knowledge centre for human 
genetics-related molecular biology techniques. Unlike the other Departments at KTL, 
the main mission of the Department of Human Molecular Genetics was research and it 
had no public health responsibilities beyond being in charge of the DNA-based national 
paternity testing.  
 
The 1995 Evaluation Panel concluded that the department had exploited effectively the 
Finnish disease heritage and in the field of common diseases had produced studies of 
the highest standard, especially in multiple sclerosis and bipolar disease. Specifically, 
this was attributed to the good collaborations with the FINRISK study and the 
Department of Mental Health. The research in human genetics was considered of major 
potential significance for public health. The panel recommended that (i) there should be 
further investment in this group in view of the potential public health importance of 
research in human genetics, (ii) the KTL should consider developing mechanisms 
through further investment in collaborations to extend the range of studies on the 
structure and function of gene products, including the use of transgenic animals and (iii) 
these studies should be developed further through the development of screening and 
other programmes – particularly through collaborations with other groups in KTL which 
have the necessary skills in epidemiology and behavioural sciences. 
 
Department of Biochemistry (which functioned until 2001 under the directorship of 
Professor Christian Ehnholm) has concentrated on three major research topics: 
Lipoprotein metabolism, lipoprotein genetics and cell biology. The major focus was on 
lipoprotein metabolism and genetic factors influencing the risk of cardiovascular disease. 
The cell biology research was directed to the study of intracellular membrane traffic and 
microsomal triglyceride transfer. The department was specialized also in extensive 
biomarker analyses of lipid metabolism supporting research projects nationwide. In the 
1995 Evaluation Report the research on lipoprotein metabolism was considered of high 
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quality and the lipoprotein genetics of good quality. The quality of the cell biology 
research was considered impressive. The panel recommended that (i) a strategic 
reappraisal of the role of the KTL in cardiovascular research should be undertaken 
covering particularly the departments of Epidemiology and Health Promotion, Human 
Molecular Genetics, Nutrition and Biochemistry with possibly some reconfiguration of 
departmental boundaries to meet the needs of the strategy more effectively and enhance 
critical mass in the key areas, and that (ii) the professional staff of the Department 
should be encouraged to develop their own high quality research programmes within an 
overall strategic framework; and that (iii) the cell biology group should be strengthened. 
 
Department of Molecular Medicine (MLO) was founded in 2001 by merging the 
Departments of Human Molecular Genetics and Biochemistry. The first director was 
Christian Ehnholm (2001-2002), followed by Leena Peltonen (2002-2004) and Anu 
Jalanko (2004-). The MLO moved to the new biomedical research building: 
Biomedicum Helsinki, located on the Meilahti medical campus housing preclinical 
departments of the Medical Faculty of the University of Helsinki, next to the University 
Hospital. The research activities of the MLO have been since organized into 
programmes that were identified as the most relevant areas from the public health and 
scientific perspectives.  
 
1.2. Department of Molecular Medicine today 
Organization. The department consists of three research programs (Genetic 
Epidemiology, Finnish Disease Heritage, and Molecular Biology of Cardiovascular 
Diseases) with eight research groups) and three core facilities (Large Scale DNA 
Extraction and Storage Facility, Bioinformatics and Biotechnology). Until 31.5.2007 the 
Paternity Testing Laboratory was also part of the MLO. Since June 1, 2007, the research 
programs and core facilities of MLO have been strategically joined as a part of the 
Institute for Molecular Medicine Finland (FIMM), which signed (together with similar 
institutes in Umeå, Sweden, and Oslo, Norway) a partnership agreement with European 
Molecular Biology Laboratory (EMBL) on Oct 3, 2007.  
 
Research programme on genetic epidemiology (Programme Director Leena 
Peltonen) 
The research programme on genetic epidemiology is based on the access of KTL to well 
defined Finnish study samples including large pedigrees of specific diseases and 
nationwide epidemiological cohorts. The major research projects involve molecular 
characterization of hyperlipidemias, metabolic syndrome, multiple sclerosis and severe 
psychiatric disorders. Utilization of genome-wide marker maps, transcript analyses 
combined with new tools in biocomputing and biostatistics has resulted in the initial 
identification of several genes and loci associated with common diseases. This success 
is based on efficient use of the special population structure of Finland and has provided 
new paradigms for the use of founder populations in disease gene identification. This 
research area has also remarkably contributed to the development of new technologies 
for the collection and analysis of massive genome-wide information. 
 
The systems biology research area was initiated within the Genetic epidemiology 
programme of the MLO with the recruitment of Professor Jussi Taipale in 2005. J. 
Taipale has the joint appointment from the KTL and the University of Helsinki. The 
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research of his group aims at understanding disease mechanisms and development of 
high content screening methods to facilitate identification of new cancer disease genes 
and characterization of the functions of genes and their regulatory elements. 
Development of novel methodologies has already resulted in internationally recognized 
success. 
 
Research programme on the molecular biology of cardiovascular diseases 
(Programme Director Matti Jauhiainen) 
The genetic findings in lipid metabolism constitute the basis for the functional analyses 
aimed at understanding the molecular mechanisms behind cardiovascular diseases. This 
research area utilizes biochemical, cellular and animal models to tackle basic lipid 
metabolism. Life style and nutritional risk factors are tackled utilizing nationwide 
sample cohorts and functional analyses. 
 
Research programme on Finnish disease heritage (Programme Director Marjo 
Kestilä) 
The Finnish disease heritage consists of over 30, typically recessive inherited diseases, 
enriched in this founder population. They have provided a proof of principle for the 
efficient use of the unique population structure and sample resources in identification 
and characterization of disease genes, development of DNA-based diagnostics and 
elucidation of metabolic pathways important for human health in general. This research 
utilizes cell and animal models and genome-wide functional analyses to follow the 
disease process in cells and tissues.  
 
Core facilities and technology platforms 
Most of the core facilities and technology platforms have been developed in a close 
collaboration and by joint funding with the University of Helsinki/Biomedicum 
Helsinki. This activity of KTL is a wonderful example of the fruitful collaboration 
between the institutions working under different ministries. Many of the key scientists 
working in the core facilities have also joint appointments at the KTL and University of 
Helsinki. KTL and Biomedicum Helsinki are to be congratulated for their success in the 
development of these very important units. It is important to note that MLO scientists 
working at Biomedicum Helsinki have free access also to other important core facilities 
at the University of Helsinki. These include various imaging techniques, protein 
chemistry, electron microscopy etc. In addition, KTL scientists have also used the 
services of the Finnish Genome Centre that has currently been fused with the FIMM.  
 
The bioinformatics unit (Head Juha Saharinen) utilizes and develops genome-wide 
computational analyses for the research purposes of molecular medicine. 
The biotechnology core facility (Head Janna Saarela) develops and provides easy 
access for investigators to genome-wide methods in transcript profiling and 
characterization of copy-number and functional variations using DNA microarray 
technology. The DNA sequencing facility (Project manager Pekka Ellonen) is part of 
the biotechnology core offering high quality sequencing and genotyping services for the 
research community also outside KTL.  
Large Scale DNA Extraction and Storage Facility/National Biobank of Finland 
(Project manager Päivi Laiho) serves the research groups of KTL and universities in 
DNA biobanking. It is equipped with state of the art sample tracking system, automated 
DNA extraction equipment, liquid handling robots, storage facilities and data 
management tools for sample logistics and optimal confidentiality and quality control. 
Evaluation report 
 
This core facility is a joint operation of KTL, FIMM and several Finnish and foreign 
collaborators (universities, hospitals and national public health institutes). 
 
As its goal the Department of Molecular Medicine lists the use of the unique Finnish 
study samples and population cohorts to characterize the molecular background of 
human diseases. This includes efforts to produce new data on the relationship between 
the genetic and life style risk factors that result in public health problems. The resulting 
genome-wide information is further utilized to develop intervention strategies and more 
biology-related classification for diseases, which are potentially valuable for developing 
diagnostics. The research programs are especially focused on characterization of the 
molecular background of Finnish disease heritage, cardiovascular diseases and 
neuropsychiatric diseases. The Department provides expertise in a wide range of 
genomic and biocomputational analyses for the national and international scientific 
community, for national health care officials, for decision makers and for the general 
public. 
 
To guarantee its top level of expertise in modern genetic and biological analyses, MLO 
has built an infrastructure that facilitates the collection of genome-wide information on 
the genetic background of diseases as well as functional information on the molecules 
that are critical in the disease process. Furthermore, the department has established 
necessary database and computational resources for the expert analyses of the massive 
amount of collected biological information. MLO reports that its scientific expertise, 
technology platforms and large nationwide sample collections facilitate a highly 
competitive environment for research and education in molecular medicine for the 21st 
century. 
 
1.3. Staff and resources  
The development of personnel of the MLO has increased steadily from 1997 to 2007, 
and currently comprises 44 permanent and 139 externally funded positions. The annual 
governmental budget has varied between 1.6-2.7 million euros including also the 
salaries of the permanent personnel (currently 2.06 million euros), and the external 
funding has increased from 0.6 million euros in 1997 to a stable 2.6 million euros, 
which represents 55% of the total funding including rents and equipment, but excluding 
internal services (management help, animal facility support, media kitchen, library 
services).  
 
1.4. Strategic planning and management  
The Director General of the KTL distributes the overall resources between departments 
after acceptance of the annual strategic plan of each department. The steering group of 
MLO (program leaders and core facility leaders) meets the Director General once a year 
to present the yearly achievements and strategic plans for the next year. The internal 
allocation of resources takes place upon the acceptance of the strategic plan and the 
Director General does not interfere with the internal allocation of resources. At the 
beginning of each year the director of the Department makes a proposal for the 
allocation of the institutional funds to the steering group of the Department that 
provides feedback and then the budget is finalized by the Department director. Once a 
year, the steering group of MLO holds a strategic brainstorming session to discuss 
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future developmental needs of the Department. All research programs have their own 
strategy days also at least once a year.  
 
The steering group of the Department meets once a week to discuss urgent matters and 
plans. MLO has a weekly departmental meeting for all personnel, at which the director 
of the Department briefly informs everyone about important current issues. These 
meetings also contain presentations by invited lecturers, and by postdoctoral and junior 
researchers of the MLO. These monthly meetings end with a free discussion on 
pertinent scientific and administrative matters. The meetings are held in English to 
facilitate participation of the non-Finnish speaking scientists. 
 
Each research program has a weekly meeting on managerial subjects. In these meetings 
the research progress of each project is followed thoroughly. Research core facilities 
usually have their meetings once a month, assessing mostly managerial issues. Each 
core facility also has a supervisory group of scientists and stakeholders that meets at 
least once a year. Additionally, graduate students and postdoctoral researchers have 
regular strategic planning meetings with the supervisors and members of collaborating 
research groups.  
 
As part of the new Finnish salary and support system, every employee has a discussion 
once a year with his/her supervisor where they discuss personal achievements, future 
plans, needs for further education etc. Additionally, salary agreement is discussed once 
a year between each employee and the immediate supervisor or unit head, within the 
limitations of the general rules of KTL and the budget available. To make the process 
transparent, the overall ranking of the different personnel groups are discussed in the 
Department board meeting.   
 
2 SCOPE AND PURPOSE OF THE EVALUATION  
The objective of the review was to provide an evaluation of the work of the Department 
of Molecular Medicine of KTL for the Ministry of Social Affairs and Health. The 
evaluation was to examine the functions, strategic importance, scientific merits and 
value for money of the scientific and expert work undertaken, and to make proposals for 
future work. A special emphasis was to be placed on the evaluation of the relevance and 
effectiveness of the work and of its impact on the health of Finnish people. 
 
The evaluation and the Evaluation Report aimed to address the following main issues: 
 
h. National relevance and effectiveness of the activities 
i. Appropriateness and adequacy of the research, expert functions and services  
j. Output and quality of research activities 
k. National and international co-operation  
l. Resource allocation 
m. Research fund raising 
n. Development needs, especially regarding processes and organization 
  
The evaluation panel was advised that the main purpose of the evaluation was to guide 
the Ministry of Social Affairs and Health in its strategic management of KTL. The 
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practical implementation of the results, based on the decisions made at the Ministry, is 
the responsibility of the Director General of KTL.  
 
This evaluation is based on the written documentation provided for the panel prior to the 
site visit on September 26, 2007, and on the presentations given and interviews 
conducted during the site visit. The document prepared by Dr. Anu Jalanko, Director of 
the MLO, included 1) a report on progress in research over period 1997-2007 and 
research plans for the period 2007-2011, 2) the arrangement for governance and 
management, and 3) allocation of staff and resources, and 4) her plans for the future 
development of the Department. The document also included self evaluation of the 
Department regarding 1) the appropriateness of its work to the national public health 
needs, 2) its role in the dissemination of research results and knowledge and technology 
transfer, 3) a description of the interfaces between the Department and the key players 
in Finland and abroad. The panel was also informed of the Report of the 1995 
Evaluation Panel of the National Public Health Institute. During the site visit panel 
members had an opportunity to interview group leaders, investigators and the staff of 
MLO and discuss with representatives of the University of Helsinki.  
 
3 ASSESSMENT OF THE MLO BY THE EVALUATION PANEL 
3.1. National relevance and effectiveness of the activities 
The MLO section of KTL is in a unique position among biomedical research groups in 
Finland in that it is comparatively free of teaching or clinical commitments and can 
almost entirely focus on basic biomedical research. It can recruit good quality staff and 
students and has good core facilities, allowing it to make a disproportionate contribution 
to international research in molecular medicine. Only about 45% of its funding comes 
from the Ministry of Social Affairs and Health so that MLO researchers have competed 
well in obtaining external funds, which is reflected in their strong publication record, 
wide range of high quality collaborators and major success with EU program funding. 
At both national and international levels, they are in a good position to become even 
more effective by the formation of FIMM, formally linking scientists in MLO with 
others at the University of Helsinki and the University of Helsinki Hospitals, further 
strengthening the research infrastructure and links with clinical and academic medicine. 
Several individuals have shared professorships/adjunct professorships with other 
Institutions, indicating an existing high level of national integration, which is set to be 
strengthened further. We would therefore rate the overall effectiveness of MLO as very 
high, in both national and international contexts, in terms of value for money, research 
output and overall impact in molecular medicine.  
 
Although the MLO has continued to fulfil its important role of developing novel 
approaches in biomedical research its role and achievements in implementing new 
biotechnologies, in patenting, licensing and technology transfer have been rather modest. 
In addition, although several findings at the Department have been published in top 
biomedical journals the Department has very little research and development 
agreements with domestic and international pharmaceutical and biotech companies. The 
Department has been an important environment for the development of talented 
individuals, but very few people have moved to biotech industry or started their own 
start-up companies. 
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3.2. Appropriateness and adequacy of the research, expert functions 
and services 
The research output of MLO staff is very impressive, with a steady average of 50-60 
publications per year, and mean impact factors of around 6. The standard is well 
maintained across the major MLO sections, namely the genetic epidemiology of 
common diseases, which produces about one-half of the above papers, the Finnish 
disease heritage and molecular biology of cardiovascular disease sections. The research 
activities of each section will be considered in more detail below (section 3). The expert 
functions of MLO staff are wide ranging, from international functions (HUGO, ESFRI, 
GenomEUtwin, UCLA, Broad Institute, Sanger Centre, Nordic Centre of Excellence) to 
national functions, such as the activities of the various Finnish population cohorts, 
provision of bioinformatic, sequencing, genotyping and microarray services for external 
researchers.  In should be noted, however, that most of these contacts have been 
established and developed by Dr. L.Peltonen, whereas other senior researchers have 
been less active. Finally, the training of PhD students is a vital part of MLO activities 
which appears to be very successful. An average of about 6 PhD theses is completed per 
year, making an excellent and major contribution to training of the next generation of 
biomedical scientists. The committee met with the graduate students and found them to 
be quite satisfied with the level of support, interactions and research activity within 
MLO.  MLO has also a significant number of postdoctoral fellows, but as in almost 
all Finnish research units, their number should be increased.  
  
3.3. Output and quality of research activities 
The genetic epidemiology section is led by Professor Peltonen (she also has 
appointment at the University of Helsinki), who must be congratulated on her 
achievements both at a personal level (President of HUGO, Leader of GenomEUtwin 
etc.) and as a leader and external fundraiser within MLO. The transition from 
monogenic disorders, exemplified by past and present Finnish disease heritage work, 
which is widely recognized internationally as being of very high quality, to that of 
common and genetically complex disorders has raised questions as to whether the 
historical advantages of Finnish resources – such as unique population isolates, access 
to nationwide disease and control cohorts, relative genetic uniformity – would carry 
over to common disorders. There is a continuing debate as to the advantages and 
disadvantages of founder populations such as Finland in elucidating the genetic basis of 
complex disorders. The answers will emerge over the next 5 years but it is already clear 
that the Peltonen group at MLO is strongly placed to make an impact in this area. This 
arises firstly from their current success rate in elucidating genetic influences in common 
disorders, best exemplified by their discovery of genetic variation within USF1 and 
ORP10 in dyslipidemias, in GPRA in asthmatics and in several genes influencing 
multiple sclerosis (MHC class II, MBP, PRKCA, C7). The international competition has 
been intense and they have made excellent use of regional enrichment of cases, such as 
in autism, schizophrenia and multiple sclerosis. The results clearly show that the group 
of Professor Peltonen is internationally highly competitive. Secondly, the availability of 
large and well characterised Finnish population cohorts (e.g. Finnish Birth Cohort, 
Finrisk, EU twin cohorts) will stand MLO and other researchers in very good stead for 
both finding and replicating genetic associations, unbiased assessment of genetic effect 
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sizes and of allele frequencies, and further characterisation of identified susceptibility 
variants.  
 
Two research groups within the genetic epidemiology section of Professor Peltonen 
deserve special comment. Firstly, the group of Professor Taipale working on systems 
biology appears to be innovative and highly competitive internationally. Their use of 
bioinformatics to predict regulatory sites within the genome, using transcription factors 
involved in cancer and cell cycle regulation as a model is likely to provide extremely 
useful skills and software for other groups within and outside of MLO, since the 
majority of SNPs associated with common diseases appear to be regulatory, although it 
has proved difficult to establish this unequivocally. A systems biology approach is well 
suited to the analysis of complex traits involved in human disease and is seen to be a 
major strength within MLO. Secondly, the quantitative or statistical genetics component 
under Dr. Perola is an integral part of the genetic epidemiology team, which has 
increased to 8-10 people due to their success in obtaining external funding, although 
core funding for this group is limited. Strong statistical genetics is seen to be an 
essential ingredient in the use of genome-wide association studies and in all future 
studies of the large epidemiological and twin cohorts.  
 
The majority of the Finnish disease heritage genes have now been identified, which is a 
major achievement and continues to bear fruit in terms of carrier screening and 
elucidation of both normal physiological and disease-associated mechanisms. In some 
cases the studies have continued to elucidate the molecular mechanisms of pathogenesis 
of the disease. A good example is the APECED gene which has elucidated auto-immune 
mechanisms relevant to a wide range of such diseases. This work has helped to foster 
the skills and resources required to characterise genetic variants within disease 
susceptibility genes that are often of unknown function. This will stand MLO staff in 
good stead in the future. The identification of 35/36 Finnish disease heritage genes 
signals the opening rather than the closure of the chapter in which these disorders are 
elucidated in molecular detail and the public health implications are established for the 
Finnish population.  
 
Cardiovascular disease remains a major problem in Finland largely due to its association 
with obesity and metabolic syndrome.  The molecular biology of cardiovascular 
diseases section plays an important role in elucidating such disease mechanisms and 
links well with the genetic epidemiology studies within MLO. Currently under the 
leadership of Matti Jauhiainen and Vesa Olkkonen, the section has published a good 
number of high profile papers and has appropriate international collaborations as well as 
a prominent role in a variety of clinical trials. They are also well placed to make 
maximum use of the national epidemiological cohorts with regard to cardiovascular and 
lipid disorders. Thus the section cardiovascular disease fits very well with the overall 
profile of MLO. 
 
3.4. National and international co-operation 
The level of national and international co-operation is seen to be very high, suggesting 
that MLO staff is fulfilling the need to interact with other groups to maximize their 
effectiveness and provide best value for money. In the field of genetic epidemiology, 
two examples are the linking of national twin cohorts in the GenomEUtwin study, led 
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by Professor Peltonen, and the Centre of Excellence in Complex Disease Genetics. In 
cardiovascular disease, the links with University of Oxford (Professor Mark McCarthy) 
and with the MIT/Broad Institute clearly strengthen MLO research. In the area of “gene 
to function” there is often the greatest need to develop external collaborations since it is 
impossible to have all the necessary skills in-house. In some cases, such as the analysis 
of USF1, in-house expertise in cardiovascular biochemistry and bioinformatics has 
clearly been a major advantage but MLO have developed a large number of 
collaborations with national and international partners and so appear to have been very 
effective in this respect. The move of Professor Peltonen to the Sanger Institute is 
clearly going to strengthen the links with KTL. 
 
3.5. Resource allocation 
The areas of research covered by MLO staff are, in general, receiving strong support by 
other national governments, often with specific focused initiatives, such as in 
biobanking and case-control association studies. The latter has proved successful to date 
in the majority of common disorders investigated with sufficiently large cohorts (e.g. 
Wellcome Trust Case-Control studies). There would seem to be scope for centring one 
or more targeted initiatives around MLO activities where Finland has advantages over 
more diverse populations and health care systems. For example, the availability of good 
longitudinal data from the population cohorts may lead to better characterised case and 
control cohorts, with more and better quality quantitative risk factor data. Example 
might be hypertension or metabolic syndrome, which has become a global epidemic 
within recent years. Another possible area where there is special Finnish expertise and 
resources might be in neuropsychiatric disorders. In both cases, very large scale 
association studies are required with controls that are as well characterised as cases, 
which has sometimes been the weak link in other such studies (e.g. WTCC studies).  
 Regardless of whether specific Finnish initiatives are launched in common disorders, 
association studies are likely to form the backbone of much of the research in genetic 
epidemiology, cardiovascular and neuropsyciatric disease research over the next 5 years 
and require suitable core resources. Foremost among such resources must be the 
availability of high quality statistical genetics and bioinformatics. At the present time 
the former are largely supported by external short-term funds. The availability of 
resources to perform high throughput sequencing and animal model studies are 
expensive but are also essential requirements for future research in this area.  
 
3.6. Research fund raising 
MLO staff has been exceptionally successful in raising funds for research, with 55% 
(see page 5) of research funding being provided by external awards. This reflects very 
well on MLO staff but also raises some questions about the future. About one-third of 
external funds came from EU funded projects and it is not clear that this is sustainable 
in the future.  Participation in new ERC funding schemes, licensing of MLO 
innovations and collaborative agreements with industry are encouraged. 
 
There is a clear plan that FIMM will provide a new building, a high turnover of young 
group leaders, and a limited number of permanent staff positions, which should 
maximize research effectiveness, but there appears to be no new funding stream to 
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support MLO activities. It is therefore essential that the core staff positions discussed 
below is secured or it could disproportionately compromise much of the work of MLO. 
It is also very important that MLO continues to develop core facilities and as a member 
of FIMM participates in the development of new core technologies critically important 
for the modern biomedical and translational research. 
 
3.7. Development needs, especially regarding processes and 
organization 
The future infrastructure needs of both FIMM and MLO need to be carefully considered. 
In MLO, the available KTL infrastructure appears to supply many of the needs 
effectively at the present time but the research environment in molecular medicine is 
changing rapidly, so that some important changes may need to be considered to 
maintain international competitiveness. The core MLO infrastructures include 
genotyping using Sequenom and Affymetrix gene chip platforms; gene expression 
profiling using Affymetrix gene arrays; and sequencing, currently using an ABI 3730 
machine although discussions are underway to obtain a high throughput sequencer such 
as Solexa; finally, bioinformatic and statistical support. One concern is the need for 
greater statistical genetic and bioinformatics resources specifically to deal with whole 
genome and focused SNP association scans in the large national epidemiological 
cohorts. At the present time, Dr. Perola leads a small group of statistical geneticists 
about 90% of whom are externally funded and there appears to be a need for core 
support for database managers, statistical geneticists and programmers, and 
bioinformaticians in order to cope with the expected deluge of association data. The 
report refers to the present bottleneck in functional characterisation of locally 
discovered disease susceptibility genes but we anticipate that a further and severe 
bottleneck will be in database management, statistical and bioinformatics analysis of 
association and other gene mapping data. External collaborations with international and 
national researchers in this area are already in place but it is recommended that in-house 
expertise be strengthened in this area, perhaps including appointment of a senior figure 
in statistical genetics.  
  
The issue of the gene characterisation bottleneck in complex disease genetics also needs 
to be addressed. There appears to be useful synergy between the cardiovascular and 
complex genetics sections, which links gene discovery with characterisation in this area 
but the way forward is less clear in neuropsychiatric genetics and other areas where ad 
hoc arrangements can only be made subsequent to gene discovery. In addition, animal 
models, mainly mouse and Drosophila, are being used effectively to complement other 
functional studies. The continued subsidisation of small animal costs is strongly 
supported since many researchers at other institutions can no longer afford this type of 
work and are turning to cheaper models that can be less useful. The use of zebrafish is 
increasingly used for characterisation of regulatory sequences but this is locally 
available to MLO researchers. In summary, the future requirements for gene 
characterisation are both very diverse and impossible to predict in advance so that ad 
hoc arrangements will continue to be necessary.  
 
The appointment of Dr. Kallioniemi as Director of FIMM is likely to change the 
infrastructure requirements, with some shift in the direction of cancer research. High 
quality biomicroscopy and confocal imaging, fluorescence activated cell sorting and 
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laser capture microdissection underpins an increasing amount of modern molecular 
medicine research so that allowance for purchase and maintenance of such core 
equipment should be in place to maintain competitiveness. The proposal to purchase 
high throughput sequencing capacity for genotyping is strongly supported and is more 
easily justified in the wider context of FIMM. In large scale genomic sequencing FIMM 
and MLO should collaborate with the Sequencing Center at the Institute of 
Biotechnology that are using the Roche 454 technology.  However, overall sequencing 
costs are likely to increase with the increased capacity despite substantial reductions in 
cost per base pair. It is not clear how this will be financed. Sequencing of large, often 
megabase sized regions is increasingly necessary to identify low frequency variants, to 
identify signatures of selection and to identify variants underlying linkage or association 
peaks, all of which are both labour-intensive and costly.  
 
The departure of Professor Peltonen to the Sanger Institute raises questions as to the 
continuing leadership within the research programme on genetic epidemiology. She will 
continue in a part-time (20%) capacity at FIMM but it seems to the external evaluators 
that full-time leadership may be required to ensure the continued success and growth of 
this area within MLO. Appointment of an internationally recognised human molecular 
or statistical geneticist would appear to be an important goal.  
  
3.8. Summary of the main recommendations of the evaluation panel 
1. Recognizing the many scientific achievements of researchers working at MLO, the 
panel strongly recommends continuous strong support for all research programmes 
(genetic epidemiology, systems biology, cardiovascular diseases and Finnish disease 
heritage) of MLO.  
 
2. As access to up-to-date research equipment and infrastructures is vital for continuous 
success of MLO the panel strongly recommends KTL to continue its strong support for 
core facilities required by MLO scientists (in collaboration with the University of 
Helsinki and FIMM). 
 
3. The panel encourages MLO scientists to increase their participation in technology 
transfer (patenting, licensing etc.) activities and in research and development 
agreements with domestic and international pharmaceutical and biotech companies.  
 
4. The panel emphasises that the directorship of the research programme on genetic 
epidemiology at MLO needs to be solved now that Professor Leena Peltonen will only 
devote 20 % of her time to the newly organised MLO under FIMM.  
 
